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Abstract
Background: Electronic health records are invaluable for studying clinically recorded
biomarkers and outcomes, but conversion of raw datasets to a research-ready format
and replication of analyses can be challenging. The differential white cell count is a
common blood test which may reflect inflammation and cardiovascular risk, but previous
epidemiological studies have been small or in selected populations.
Aim: To develop methods to assist in using electronic health record databases for re-
search, and apply them to an exemplar study investigating differential white cell counts
and onset of cardiovascular diseases.
Methods: The data source was CALIBER: linked electronic health records from primary
care, hospitalisation, acute coronary syndrome registry and death registry. Software was
developed to assist selection of relevant diagnostic codes, data manipulation, and mul-
tiple imputation of missing data. Individuals in CALIBER without prior cardiovascular
disease were followed up for a range of specific initial cardiovascular presentations. Sur-
vival models were used to investigate the associations of type 2 diabetes and differential
white cell counts with initial cardiovascular presentations. The association of total white
cell count with mortality was investigated in CALIBER and replicated in the New Zealand
PREDICT cohort.
Results: Add-on software packages for the R statistical system were developed and
published in an open access repository. Type 2 diabetes was associated with higher risk
of coronary disease and ischaemic stroke but lower risk of abdominal aortic aneurysm
and subarachnoid haemorrhage. Among 775 231 individuals with a record of differential
leukocyte count followed up for median 3.8 years, 54 980 experienced an initial presen-
tation of cardiovascular disease. High neutrophil counts were strongly associated with
heart failure and myocardial infarction, but not angina. Low eosinophil counts were asso-
ciated with heart failure and unheralded coronary death. Total white cell count showed a
‘J’ shaped association with mortality in both CALIBER and PREDICT.
Conclusions: White cell subtypes are differentially associated with specific initial car-
diovascular presentations. A range of tools were developed to assist researchers using
CALIBER and other electronic health record data sources.
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1 Introduction
1.1 Outline of thesis
Electronic health records and advances in computing technology provide an exciting
opportunity for improving health and healthcare by harnessing the power of big data.
This thesis explores the use of electronic health record databases for investigating blood
biomarkers and patient outcomes, with the example of differential white blood cell count
and onset of different cardiovascular diseases in initially healthy people.
Electronic health record data are ‘big data’ in every sense of the phrase and can yield
useful insights into every aspect of health and care, from aetiologic studies to clinical trial
design to monitoring the quality and safety of healthcare. In this thesis, as well as using
electronic health records to answer a set of clinical questions, I examine the research
process itself from raw data to results. The thesis describes new tools I have developed
to assist in data preparation, variable definition and statistical analysis.
The first chapter of this thesis introduces the use of electronic health records for re-
search, the cardiovascular diseases of interest, the biological roles of white blood cells,
and why white blood cell counts are relevant to the development of cardiovascular dis-
eases. Chapter 2 reviews previous epidemiological studies investigating white blood cell
counts and incidence of cardiovascular diseases. Chapter 3 describes CALIBER [1], a
research platform comprised of linked primary care, hospitalisation, mortality and acute
coronary syndrome registry data in England. CALIBER was the main database used for
the studies that comprise this thesis. Chapter 4 describes validation work and methods I
have developed to assist in the use of CALIBER data for epidemiological studies. Chap-
ter 5 describes the identification of the initial presentation of cardiovascular diseases in
a cohort of individuals in CALIBER. In this chapter, I investigate type 2 diabetes and the
blood marker of diabetic control, HbA1c, as risk factors for cardiovascular diseases.
Chapter 6, describes the extraction and exploration of differential white blood cell
counts recorded in CALIBER. The main study is reported in chapters 7 and 8. This is
an investigation of the association of the differential white blood cell count with the onset
of twelve cardiovascular diseases, particularly focussing on neutrophil count and eosin-
ophil count. Replication of study findings in other populations is important to verify the
generalisability of the conclusions, so the following chapter (chapter 9) reports an analysis
of total white blood cell count and mortality in CALIBER and the New Zealand PREDICT
cohort.
The final discussion (chapter 10) brings together the findings of this thesis and in-
cludes recommendations for clinical practice, research and future development of elec-
tronic health records.
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1.2 Electronic health records for epidemiology
Electronic health records (EHR) are being increasingly used in many countries around the
world. Research databases based on electronic health records are invaluable for studying
disease epidemiology, pharmacoepidemiology and quality of care [2]. They record ‘real-
world’ clinical information and treatments, outside the formal structure of clinical trials or
bespoke cohort studies. EHR will become increasingly important in the era of precision
medicine [3], where detailed genotype and phenotype information will inform the develop-
ment of new specialised therapies. Non-healthcare data (such as geographic data, social
care data and data from mobile devices) are increasingly being linked to healthcare data
in order to answer new questions and inform public health interventions [2].
1.2.1 Electronic health record data sources
Information in these ‘real-world’ data sources can be generated in a number of ways:
Information entered by clinicians. Symptoms, diagnoses, examination findings, let-
ters, prescriptions and reports of investigations are examples of reports generated by
clinicians, which may be entered into electronic health records in a variety of formats.
Typically diagnoses and prescribed medication are coded using a dictionary, but much
information is entered as unstructured free text, and some is available only as scanned
text or handwriting. In the UK, general practices have been using computers for over
20 years [4], and pseudonymised patient data have been compiled into a number of re-
search databases. The Clinical Practice Research Datalink (CPRD, www.cprd.com), for-
merly known as the General Practice Research Database, is owned by the Medicines
and Healthcare products Regulatory Agency and is described in more detail in sub-
section 3.3.1 on page 53. The Health Improvement Network (THIN, www.thin-uk.net),
QResearch (www.qresearch.org) and ResearchOne (www.researchone.org) are collab-
orations between academic groups and the system manufacturer. These databases gen-
erally include only coded and numerical data; limited amounts of free text are available
for research use in CPRD and THIN but they have to be manually anonymised before
being released to researchers. CALIBER contains data from a subset of CPRD practices
which consented to linkage of patient records with other data sources.
Because general practitioners (GPs) look after patients over the long term and receive
letters from other care providers, the GP record is the most complete longitudinal health
care record that exists for most people in the UK. However, it does not include details of
acute conditions or investigations performed in secondary care, such as acute hospital
care or mental health care.
In contrast to general practice, adoption of electronic health record systems in UK
hospitals has been slow [5], and studies using hospital electronic records rarely in-
volve multiple sites. This is in contrast with the US, where research studies can draw
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on the electronic health records of multiple hospitals, such as the eMERGE Network
https://emerge.mc.vanderbilt.edu/ [6]. An initiative by the National Institute for Health
Research, the ‘Health Informatics Collaborative’ aims to addess this by setting up a
collaboration between five hospitals in England with large biomedical research centres
(www.nihr.ac.uk/about/nihr-hic.htm) in order to share patient data for research.
Laboratory results. Local and regional databases of laboratory results can be invalu-
able for research when linked to other data sources, as has been done for the Test Safe
database in New Zealand [7]. Where laboratory results are electronically transferred into
electronic health records, such as in UK general practice, this information can be conve-
niently extracted for research alongside detailed clinical information.
Prescribing information. Electronic prescribing systems can provide detailed infor-
mation on drug prescription and drug administration, and will be increasingly useful for
research as more hospitals adopt electronic prescribing. Individual level data on pre-
scriptions dispensed in the community are available in some countries such as New
Zealand [8], and can form a useful research resource when linked to other individual
patient data sources such as hospitalisation, laboratory results and mortality.
Registries, audits, mandatory reporting databases There are numerous registries,
audits and mandatory patient-level reports collected on a regional or national level in the
UK and other countries. Linkage of these data sources to outcomes such as mortality
can be a vital component of clinical audit to improve the quality of care. CALIBER con-
tains data from MINAP, the Myocardial Ischaemia National Audit Project, which collects
information on acute coronary syndromes in England and Wales; it is described in more
detail in subsection 3.3.3 on page 57.
Registries can collect information in a variety of ways, and information submitted to the
registry may or may not also be part of the patient’s medical record as used for clinical
decision making. Information can be abstracted from the clinical record by clerks or audit
nurses (as in MINAP [9]), submitted directly by clinicians using a web-based form (e.g.
SWEDEHEART, the Swedish heart attack register [10]) or extracted automatically from
the electronic health record (e.g. the English National Diabetes Audit [11]). National death
registries, while not part of the EHR themselves, are an important data source for many
long-term studies using EHR or registry data sources.
Secondary use data Many countries maintain databases of hospital admission data
for administrative and billing purposes, such as Hospital Episode Statistics (HES) in Eng-
land (www.hscic.gov.uk/hes), Patient Episode Database in Wales (www.infoandstats.
wales.nhs.uk/page.cfm?orgid=869&pid=40977), the Scottish Morbidity Record (www.
ndc.scot.nhs.uk/Data-Dictionary/SMR-Datasets/), and the SPARCS database in
New York State (https://www.health.ny.gov/diseases/chronic/hospdata.htm). HES
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submissions from hospitals contain admission dates, purpose of admission (emergency
or elective), specialty, coded primary and secondary diagnoses, and procedures per-
formed. Hospitals in England are reimbursed according to tariffs associated with the
diagnoses and procedures coded. However, the information in the HES submissions is
not used for direct patient care, and involvement of clinicians in the coding process is
variable [12].
1.2.2 Linkage of data sources
Patient records in different data sources can be linked in order to provide a richer dataset
for research and overcome some of the limitations of an individual data source. For
example, linkage of a general practice database to a cancer registry can allow detailed
clinical information about the cancer to be combined with longitudinal information on a
patient’s other medical conditions [13]. For some research questions, outcomes and
exposures may be recorded in different datasets, so linkage is the only way to answer
the question, whereas in other cases linkage may enrich the main data source or enable
validation of the data.
Linkage algorithms aim to identify which records in different datasets (or within a single
dataset) belong to the same patient, using identifiers such as NHS number, sex, date
of birth and address or postcode [14]. If strong identifiers are well recorded in both
source datasets the linkage may be considered ‘deterministic’, with matches considered
to be ‘exact’. However, if each record may have a number of potential matches with
different probabilities, records can be linked probabilistically in order to take into account
the uncertainty in the linkage and obtain unbiased results [15].
Linkage of data sources has to be performed carefully to ensure that linkage errors
(missed matches and false matches) do not bias the results [16]. Where different datasets
are used for numerator and denominator, bias can be caused by variations in the proba-
bility of linkage between subgroups, such as between ethnic groups [17]. It is important
to cross-reference linked datasets and try to understand the reasons why clinical events
may not be recorded in one or more of the data sources [18]. New statistical approaches
allow the uncertainty in matches to be propagated into analysis results, for example us-
ing multiple imputation [19], in order to obtain unbiased results even in the presence of
linkage error.
1.2.3 Electronic health records versus bespoke studies
Historically, many epidemiological findings have been based on bespoke cohort studies,
as this was the only way to obtain reliable follow-up data on a large number of people.
However, if the study only requires information about a person’s health which is already
captured in usual clinical practice, EHR databases may be preferable to a bespoke cohort
study, for the following reasons:
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• Larger size – EHR databases can potentially contain many more patients than any
consented cohort, and this will grow with time. This is essential for comparing
the strength of association of risk factors with rare outcomes. As an illustration I
carried out a sample size simulation for a cohort study investigating an endpoint
with incidence 8 per 100 000 patient-years, described in more detail in section 6.3
(Table 6.1 on page 134). In this example, a sample size of 700 000 with mean 3
year follow-up is required to detect with 80% power that hazard ratios 1.2 and 1.8
are significantly different.
• More diseases – Comprehensive EHR systems record information about all dis-
eases and conditions affecting a patient, rather than the limited set of conditions or
information that an investigator decides to collect.
• Less selection bias – EHR databases based on usual clinical care are more repre-
sentative of the general population than a bespoke study cohort, which may have a
low response rate for recruitment [20].
• Lower cost – Re-using information which is already collected for clinical care allows
data on large numbers of people to be aggregated cheaply.
• Wide coverage – EHR data sources can potentially cover entire regions or coun-
tries. In contrast, cohort studies may be geographically isolated to facilitate recruit-
ment and follow-up of participants. For example, one of the best-known cohorts
for investigating the onset of cardiovascular diseases was based in Framingham, a
small town of 28 000 inhabitants in the US state of Massachusetts [21].
• Contemporary – EHR cohorts provide information on current patterns of morbidity
and healthcare, compared to historical cohort studies.
• General population denominator – UK general practice databases such as CPRD
can provide a population denominator, because the majority of the UK population
is registered with a general practitioner and the entire population is eligible for care
within the same system (the NHS) [22].
• Link with clinical care – EHR captures information on ‘real-world’ clinical events,
and can provide valuable insights into the quality of care. There is also the exciting
potential for clinical trials to be performed within EHR cohort populations, although
there are still many challenges to overcome [23].
EHR data sources also have some disadvantages, which means that consented cohort
studies are necessary for answering some research questions. A key disadvantage is that
the completeness of data and granularity of clinical information in EHR can be variable.
Some information may be ‘missing’ in the sense that it was generated but not recorded
in the EHR in a way that can be extracted (e.g. as free text instead of a coded value), but
much information is ‘missing’ because it was never generated in the first place, if it was
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not clinically relevant. Clinical parameters may be measured only for a subset of patients
and at variable times; this needs to be considered carefully when planning studies using
these data sources in order to avoid introducing bias. For example, HbA1c, a blood test
for diagnosing diabetes and assessing disease control, is measured only in patients who
already have diabetes, those with suspected diabetes and those in whom the clinician
wishes to rule out diabetes (see chapter 5).
1.3 The CALIBER research platform – electronic health records for
cardiovascular research
In this thesis, I used linked data from CALIBER (Cardiovascular Research using Linked
Bespoke Studies and Electronic Records). The CALIBER research platform includes
primary care data from CPRD, hospitalisation data from HES, detailed information on
acute coronary syndromes from MINAP and date and cause of death from the national
death registry [1]. CALIBER contains data from 244 CPRD general practices in England
which consented to the linkage, covering about 4% of the English population in 2006
[18], and is curated by the Clinical Epidemiology Group in the UCL Institute of Health
Informatics. The data sources and validation studies for CALIBER are described in detail
in the next two chapters. This section compares CALIBER with primary care data sources
available in other countries.
CALIBER has a number of unique features that set it apart internationally from other
cardiovascular research datasets, and make it the ideal data source for this thesis [1].
England has detailed electronic primary care records, national cardiovascular registries,
a national database of hospitalisation records and a national mortality registry, with a
unique person identifier (the NHS number) facilitating linkage between the data sources.
There are a number of general practice databases in England based on different EHR
system manufacturers, but currently CPRD is the only one linked to a cardiovascular
registry and other data sources (the CALIBER platform).
Scotland and Wales also have strong primary care data sources, with some prac-
tices contributing to CPRD. They also have their own primary care databases which
include a large proportion of practices in the country: the Welsh SAIL databank
www.saildatabank.com and the Scottish Primary Care Information Resource www.spire.
scot.nhs.uk/. There is ongoing work to link these databases to other data sources, but
at the time of writing this thesis, CALIBER was the only primary care database linked to
a cardiovascular registry, hospitalisation and mortality records.
Small collections of primary care data have been used for research in a number of
countries, but the only large database (with over a million patients) outside the UK is in
the Netherlands: the Integrated Primary Care Information (IPCI) database [24]. IPCI con-
tains records of diagnoses (coded using the International Classification of Primary Care,
ICPC), referrals, laboratory test results, surgical procedures, medication and hospitaliza-
tions, and is used for postmarketing surveillance [25] and epidemiology [26]. However it
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is not linked to other data sources. In New Zealand, the PREDICT programme gathers
information on cardiovascular risk assessments in primary care and links them with labo-
ratory values, dispensed medication, hospitalisation and mortality data. Full longitudinal
general practice records are not available in PREDICT, but for this thesis the information
on cardiovascular risk factors and outcomes was valuable for a replication study (chapter
9).
Differences in the way healthcare is organised in other countries may preclude aggre-
gation of ambulatory care information into a research database. Unlike the UK and Scan-
dinavian countries, in many countries it is usual for patients to present directly to a spe-
cialist, bypassing the gatekeeper role of primary care providers, meaning that they may
not have a comprehensive longitudinal patient record curated in a single place. Some US
managed care organisations (e.g. Kaiser Permanente) curate research databases span-
ning primary and secondary care, but the lack of a national healthcare system means that
US healthcare databases are limited to a selected segment of society, such as persons
with a particular health insurance plan, older persons or veterans.
A strength of UK primary care data is that it can provide a population denominator
for calculation of incidence rates, as the majority of people are registered with a general
practitioner [22] and it is only possible to register permanently with a single practice (tem-
porary registrations are excluded from research databases). It is not possible to obtain a
population denominator from primary care data in countries that allow people to register
with more than one primary care practice. Deficiencies in primary care information sys-
tems are another source of limitation; a conference workshop in 2006 noted that some
countries had a multitude of incompatible primary care systems (e.g. Germany, Croatia)
and some used free text extensively rather than coded data (e.g. Czech republic) [27].
In contrast, the Netherlands and the UK have almost complete coverage of primary care
with only a few EHR systems covering the entire country [27].
Scandinavian countries have extensively linked disease registries and other health-
care datasets, but lack large primary care research databases. For example, the CopDiff
database in Copenhagen (http://almenpraksis.ku.dk/english/research/copdiff/)
links differential white cell counts performed in general practice for any reason with out-
comes including cancer, hospitalisations and mortality [28]. The absence of primary care
data limits the utility of these databases for cardiovascular research, as important risk
factors such as smoking and body mass index are not recorded [29].
In summary, for research purposes UK primary care data sources have a number of
key advantages over data from other countries:
• Population-based – most people are registered with a general practice, and pa-
tients are permitted to register with only one primary care practice (e.g. UK, the
Netherlands, Scandinavian countries)
• Strong primary care – the GP maintains a longitudinal care record and is gatekeeper
for secondary care (e.g. UK, the Netherlands, Scandinavian countries)
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• Small number of clinical systems used in primary care – this facilitates data extrac-
tion for research (e.g. UK, the Netherlands)
• Important diagnoses recorded using a coding system (e.g. UK, the Netherlands)
• Linkage of primary care data to other sources – as far as I know, this is only done
in the UK at scale
Only the UK and the Netherlands have population-based primary care data available
on over a million patients. The CPRD database in England is much larger than IPCI, and
is linked to other data sources to form the CALIBER research platform. The richness of
the source datasets make CALIBER ideal for the studies in this thesis.
1.4 Recording of blood biomarkers in electronic health records
Many blood tests are performed in clinical practice, and they are commonly stored in
a structured electronic format in electronic patient records, making them amenable to
research. Research on blood biomarkers is important for understanding how they are
associated with disease and how they can best be used to assist clinical decision making.
For a number of years UK general practices have received results electronically from
the laboratory, and CPRD contains these results. However, tests requested by hospital
clinicians are generally not included, only tests requested by the GP.
The differential leukocyte count is a component of the full blood count, one of the most
common blood tests in medical practice. A wide range of parameters are reported by
blood count analysers and are included as part of the report, but clinicians are typically
interested in only a handful of parameters, or may be interested only in gross perturba-
tions of some of the parameters. The richness of the continuous values of these parame-
ters are not fully used clinically. This thesis will explore the associations of the differential
leukocyte count with cardiovascular diseases, and seeks to contribute to discussions on
how these tests should be interpreted and used clinically.
1.5 Initial presentation of cardiovascular diseases
Cardiovascular disease is the most common cause of death worldwide and a significant
cause of morbidity [30] and healthcare costs (21% of overall NHS expenditure in the
UK in 2004 [31]). Myocardial infarction and stroke are acute cardiovascular events re-
sponsible for much of this morbidity and mortality, but they have declined in incidence in
developed countries [32, 33]. Chronic cardiovascular conditions such as stable angina
and heart failure comprise a significant proportion of the contemporary cardiovascular
disease burden [34]. These conditions have in common cardiovascular risk factors such
as smoking [35] and hypertension [36], and many of them also share aetiological mech-
anisms, such as atherosclerosis.
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Atherosclerosis is a pathological process in which lipid-laden deposits in arterial walls
cause arteries to become narrower, restricting the blood flow and increasing the risk of
thrombosis. In coronary arteries this can lead to myocardial infarction (MI); in the cere-
bral circulation it can cause strokes and in the peripheral arteries it can cause intermittent
claudication, ischaemic legs and gangrene [37]. Damage to arterial walls is another im-
portant pathological process which can lead to arterial stiffness, weakness and propen-
sity to rupture [38]. The myocardium can also be affected – chronic hypertension can lead
to left ventricular hypertrophy, with increased stiffness and impaired function, eventually
leading to heart failure [39].
For this thesis I chose to study the following twelve initial presentations of cardiovascu-
lar diseases: stable angina, unstable angina, non-fatal myocardial infarction, unheralded
coronary death (fatal myocardial infarction as the initial presentation of cardiovascular
disease), transient ischaemic attack, ischaemic stroke, haemorrhagic stroke, subarach-
noid haemorrhage, a composite of ventricular arrhythmia or sudden cardiac death, heart
failure, peripheral arterial disease and abdominal aortic aneurysm.
These diseases are responsible for much morbidity and mortality, and share a number
of pathological processes that involve leukocytes; they are summarised in Table 1.1 on
page 29 and described in more detail in the rest of this chapter.
Table 1.1: Summary of key pathological processes involving leukocytes that may con-
tribute to the twelve cardiovascular diseases of interest
Initial presentation of
cardiovascular disease
Pathological process
Atherosclerosis Inflammation Thrombosis
Coronary artery disease presentations
Stable angina • •
Unstable angina • • ◦
Non-fatal myocardial infarction • • •
Unheralded coronary death • • •
Cerebrovascular disease presentations
Transient ischaemic attack ◦ ◦ •
Ischaemic stroke ◦ ◦ •
Haemorrhagic stroke ? ?
Subarachnoid haemorrhage ? ?
Other cardiovascular diseases
Ventricular arrhythmia /
sudden cardiac death
◦ ◦ ◦
Heart failure ◦ ◦
Peripheral arterial disease • • ◦
Abdominal aortic aneurysm •
Legend: • always, ◦ sometimes, ? possibly
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Coronary artery disease presentations. Narrowing of coronary arteries without
thrombosis causes stable angina. Few studies estimate separate associations for sub-
types of coronary disease, but I wished to do so because the processes of atherosclerosis
and thrombosis may have differential importance in these presentations and the under-
lying risk factors may be differentially associated with angina and myocardial infarction.
I separated stable and unstable angina, and for myocardial infarction I differentiated be-
tween fatal and non-fatal events, as they give rise to very different patient experiences.
Dropping dead with a heart attack ‘out of the blue’ (‘unheralded coronary death’), in a per-
son with no known history of cardiovascular disease, is a particularly devastating event
which deserves special consideration.
Cerebrovascular disease presentations. Among cerebrovascular diseases, I sought
to differentiate between different causes of stroke, namely ischaemic, haemorrhagic (in-
tracerebral haemorrhage) and subarachnoid haemorrhage.
Subarachnoid haemorrhage is usually due to rupture of an intracranial arterial
aneurysm [40], but it has been suggested that inflammation and atherosclerosis also
play a role. One cohort study found an association between total leukocyte counts
and incidence of subarachnoid haemorrhage [40], and histological studies of ruptured
aneurysms found inflammatory infiltrates near the site of rupture as well as atheroscle-
rotic lesions [41].
I included transient ischaemic attack as a separate endpoint because it commonly
leads to ischaemic stroke but the patient experience is very different, as they receive
an initial warning rather than an unheralded disabling stroke.
Other cardiovascular diseases. I included a composite of ventricular arrhythmias and
sudden cardiac death (presumably due to ventricular fibrillation) as an ‘arrhythmia’ end-
point, in order to differentiate between mechanisms acting via atherosclerosis and is-
chaemic heart disease versus those increasing the risk of arrhythmias by direct influence
on the myocardium. Heart failure was another endpoint; as the initial presentation of
cardiovascular disease, it may be due to chronic hypertension or silent ischaemic heart
disease. Abdominal aortic aneurysms are characterised by an inflammatory process in
the aortic wall with leukocyte infiltration, destruction of elastin and collagen and loss of
smooth muscle [42,43]; ruptured or leaking aneurysms can be fatal [44]. Peripheral arte-
rial disease commonly presents initially with chronic symptoms (intermittent claudication)
but can progress to critical limb ischaemia and gangrene; smoking is a strong risk fac-
tor [35].
I included non-specific stroke and non-specific coronary disease as additional end-
points, as some patients did not have a more specific cardiovascular diagnosis recorded
in the EHR. For some analyses these endpoints may be grouped with the specific end-
point they are most similar to; I have described these decisions in chapter 5 where I report
the phenotype definitions in CALIBER for these cardiovascular diseases.
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Cardiovascular diseases not included. I did not include infective conditions such as
endocarditis or inflammatory conditions such as vasculitis as initial presentations of car-
diovascular disease, as the risk factors and preventative strategies are different. Similarly
I chose not to include congenital or degenerative conditions such as valve disease. I
also excluded conditions that may be asymptomatic and are predominantly cardiovascu-
lar risk factors rather than diseases in their own right, such as diabetes, hypertension
and obesity. As I was studying only the initial presentation of cardiovascular disease
in this project, I disregarded events occurring after the initial presentation, and patient’s
follow-up ended at that point.
1.6 Cardiovascular diseases and inflammation
Many cohort studies have demonstrated that total white blood cell counts are associated
with greater incidence [45] and worse prognosis [46] of coronary disease [47]. White
blood cells play a major role in atherosclerosis, which is an inflammatory process [48],
and some cardiovascular diseases such as abdominal aortic aneurysms are a result of
other inflammatory processes which weaken blood vessel walls [44]. However, although
leukocyte counts are included in the full blood count (complete blood count), one of the
most commonly performed blood tests, these numbers are not currently used in cardio-
vascular decision making or risk prediction [30]. Part of the reason might be that differ-
ential leukocyte counts were not widely available at the time that many of the risk factors
for atherosclerosis were being discovered. In 1948, when the Framingham heart study
commenced, automated cell counters were not available so leukocyte counts could only
be obtained by laborious manual counting [21]. Regression dilution bias due to impreci-
sion in manual counting may have resulted in under-estimation of associations between
leukocyte components and coronary heart disease [49].
Why focus on leukocyte counts, when there are other inflammatory biomarkers avail-
able to measure? C reactive protein (CRP) and interleukin-6 (IL-6) are associated with
cardiovascular disease [50, 51] and measurable in peripheral blood. However, the ad-
vantage of studying leukocyte counts is that they are already measured in a large num-
ber of patients, making the study possible in clinically collected data. Associations of
leukocyte counts can be studied in relation to the large number of diseases recorded in
clinical data, rather than a narrow subset chosen as endpoints of a bespoke study. If
a risk prediction model based on leukocyte counts were found to be clinically useful, it
could be incorporated in risk prediction models for minimal cost. A further reason is that
the leukocyte subtypes have well-known biological roles which are potentially causal in
atherosclerotic disease, unlike CRP, for which Mendelian randomisation studies suggest
it is not causative in cardiovascular disease [52].
Manipulation of the immune system is now considered a potentially useful therapeu-
tic mechanism in cardiovascular disease, and leukocyte counts could be important for
guiding or monitoring such therapy. Trials are currently underway to examine whether
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Figure 1.1: Simplified diagram of haematopoiesis
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anti-inflammatory agents such as methotrexate can prevent cardiovascular disease in
high risk individuals [53]. This is described further in section 1.8 on page 36.
1.7 Leukocyte biology
1.7.1 Leukocyte production and differentiation
All blood cells are derived from haematopoetic stem cells which reside in the bone mar-
row. Pluripotent stem cells give rise to lymphoid and myeloid lineages (Figure 1.1 on
page 32). Lymphocytes are derived from a lymphoid progenitor; basophils, neutrophils,
monocytes and eosinophils are derived from a granulocyte / myeloid progenitor. Mono-
cytes migrate into tissues and differentiate into macrophages. ‘Granulocytes’ include
neutrophils, basophils, eosinophils and mast cells [54]. Neutrophils comprise the ma-
jority of granulocytes and are also the most numerous type of white blood cell in most
patients.
Lymphocytes, monocytes, basophils, eosinophils and neutrophils are measured in pe-
ripheral blood of patients as part of full blood count analyses. This test is performed for a
variety of indications including suspected disorders of erythrocytes (e.g. anaemia, bleed-
ing, haemolysis or polycythaemia), platelets (e.g. bruising) or leukocytes (e.g. infection,
leukaemia), or any general medical condition.
32
1.7. Leukocyte biology
Leukocyte counts can be affected by many factors such as acute and chronic infections,
autoimmune disease, medication and haematological conditions. Knowing whether a pa-
tient is clinically unwell at the time of a blood test is important in clinical decision making,
and is likely to be important for interpreting tests in a research context. EHR data sources
that record a wide range of general medical conditions (such as infections) are essential
to identify tests performed when a patient was clinically ‘stable’.
The underlying stable leukocyte count for a patient is thought to be genetically deter-
mined. The eMERGE consortium has developed standardised phenotypic definitions for
identifying acute conditions at the time of blood testing in order to identify stable leukocyte
count values that can be correlated with genotype [55,56].
1.7.2 Physiological roles of leukocytes
Neutrophils
Neutrophils are the most abundant type of white blood cell in humans and are an es-
sential part of the innate immune system. They are essential for defence against bac-
terial infection, and have several modes of action: they can phagocytose pathogens,
they can release cytotoxic free radicals and proteolytic enzymes [57], or they can destroy
pathogens using ‘extracellular traps’ consisting of chromatin and granules which form an
extracellular fibril matrix [58].
Neutrophils become activated during myocardial ischaemia [57]. Neutrophils have
been detected in atherosclerotic plaques [59] and might increase the risk of atheroscle-
rotic plaque rupture and thrombosis by damaging or obstructing blood vessels, or by
activating the coagulation system [60]. Overactive neutrophil extracellular traps and
neutrophil-platelet interactions can also play a part in causing thrombosis [58].
Neutrophils are thought to be involved in the development of abdominal aortic
aneurysms, which are characterised by an inflammatory process in the aortic wall with
leukocyte infiltration, destruction of elastin and collagen and loss of smooth muscle
[42, 43]. Evidence for the importance of neutrophils comes from experiments in mice,
in which neutrophil depletion reduced the formation of aortic aneurysms [61].
Higher neutrophil counts are associated with smoking [62] and increased incidence of
type 2 diabetes [63]. Hence it seems likely that they are associated with cardiovascular
diseases, and their roles in inflammation and thrombosis suggest that this may be a
causal relationship rather than merely a marker of an inflammatory state.
Lymphocytes
Lymphocytes comprise T, B and natural killer (NK) cells, each of which consists of a
number of subclasses with different functions. B lymphocytes include B2 cells, which
are associated with adaptive immunity. They respond to antigen presentation in a T-cell
dependent manner and produce antibodies against foreign pathogens [64]. B1 cells are
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a component of the innate immune system, and are thought to be protective in athero-
sclerosis because they spontaneously produce natural antibodies that bind to oxidised
LDL cholesterol and apoptotic cells [64]. Regulatory B lymphocytes can suppress the
immune response [64].
T lymphocytes include a range of different subtypes. T helper cells are required for
the promotion of certain types of immune response. T regulatory cells induce immune
tolerance and may be atheroprotective. CD8+ cytotoxic T cells infiltrate atherosclerotic
plaques and promote cell death [65].
NK cells are a component of the innate immune system. Their function is to cause lysis
of virally infected cells and tumour cells [66], but they have been detected in atheroscle-
rotic plaques, suggesting that they may play a role in atherosclerosis [67].
Associations between lymphocyte count and cardiovascular disease may not be as
straightforward as for the other cell types because different lymphocyte subtypes are in-
volved in different immune responses and may have opposing influences on atheroscler-
osis and inflammation. Lymphocyte subsets and their association with cardiovascular
diseases have been investigated only in small studies (several hundred patients) [65],
and are measured only for specific indications rather than in usual care.
Lymphocyte counts may be relevant to cardiovascular diseases by mechanisms other
than atherosclerosis. Low total lymphocyte count is associated with malnutrition and im-
mune suppression [68] and observational studies have shown that it is a poor prognostic
factor in patients with heart failure [69] and ST elevation myocardial infarction [70].
Monocytes
Monocytes migrate across the epithelium of the blood vessel into the atheroma and differ-
entiate into macrophages [71]. Macrophages phagocytose and accumulate lipids, secrete
cytokines that attract other leukocytes, digest the extracellular matrix, disturb smooth
muscle cell function, and can influence vasodilatation [71]. After myocardial infarction
in a mouse model, increased sympathetic nervous signalling leads to increased produc-
tion of leukocytes including monocytes and acceleration of atherosclerotic plaque growth,
which may contribute to reinfarction [37].
There are two subsets of monocytes: CD14hiCD16- monocytes are inflammatory and
have been associated with myocardial infarction and stroke in patients undergoing elec-
tive angiography [72], whereas CD14+CD16+ monocytes are thought to be primarily
reparative. In the ApoE-/- mouse model of hypercholesterolaemia, mice fed a high-fat
diet had increased monocyte and granulocyte counts and increased aortic atheroscler-
osis [73].
Eosinophils
Eosinophils are multifunctional leukocytes which are more abundant in parasitic infesta-
tions [74] but their main role is thought to be in maintaining tissue homeostasis through
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‘Local Immune And Remodelling / Repair’ activities [75]. Eosinophil counts increase
acutely after myocardial infarction [76] and histological studies found large numbers of
eosinophils in coronary thrombi [77] and post-mortem hearts with cardiac rupture [78].
Genome wide association studies found that a non-synonymous single nucleotide poly-
morphism (SNP) in SH2B3 was associated both with eosinophil count and myocardial
infarction [79], suggesting a potential causal link.
Interleukin-5 (IL-5) is the principal cytokine mediating the release of eosinophils into
the bloodstream [80], and is strongly associated with eosinophil counts in cross-sectional
studies [81]. Eosinophil counts are raised in diseases characterised by an overactive
immune response such as asthma [82], for which anti-IL5 monoclonal antibodies are
being investigated as a potential therapy [83].
There is some evidence that IL-5 may be atheroprotective – a cross-sectional study
found that higher IL-5 was correlated with decreased subclinical atherosclerosis [84] and
variants in the IL-5 gene are associated with coronary artery disease [85]. In mouse
studies, macrophage-specific overexpression of IL-5 led to increased secretion of IgM
antibodies that inhibit uptake of oxidized low-density lipoprotein, with consequent inhibi-
tion of atherosclerosis [86].
Basophils
Basophils are involved in allergic and other inflammatory reactions. They release a num-
ber of biologically active mediator substances (such as histamine) in response to IgE
receptor activation. Cerivastatin and atorvastatin inhibit IgE-mediated histamine release
in human basophils in vitro [87], and it is thought that this may contribute to their anti-
inflammatory effect.
1.7.3 Leukocytes and atherosclerosis
The process of atherosclerosis involves the accumulation of low-density lipoproteins con-
taining cholesterol in the artery wall. These deposits activate the endothelium, triggering
the recruitment of monocytes and T cells. Monocytes migrate into the intima and differ-
entiate into macrophages, which internalise the lipoproteins to form large ‘foam cells’. T
lymphocytes in lesions recognize local antigens and secrete pro-inflammatory cytokines
that contribute to local inflammation and growth of the plaque. Inflammation may lead to
local proteolysis, plaque rupture, and thrombus formation, which causes ischaemia and
infarction [88].
These processes may give rise to causal relationships between circulating leukocytes
and specific cardiovascular diseases, which I have illustrated in Figure 1.2 on page
36. Smoking causes atherosclerosis and thrombosis by a variety of mechanisms [89],
and is associated with higher neutrophil, lymphocyte and monocyte counts [62]. Higher
neutrophil count is associated with increased incidence of type 2 diabetes [63]. Death
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Figure 1.2: Directed acyclic graph showing how neutrophils, monocytes and lymphocytes
may be involved in causal pathways for coronary artery disease
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following myocardial infarction is considered to occur either via heart failure or arrhythmia
[90], although there are other less common causes such as myocardial rupture.
1.8 Effects of drugs on leukocytes
There are many drugs such as steroids, chemotherapy agents and biologic agents which
can affect leukocyte activity or counts. Most of these drugs are not currently used thera-
peutically in atherosclerotic cardiovascular disease, except for statins. Statins may have
greater benefit in patients with higher total leukocyte counts, as shown in the LIPID study
of pravastatin [91]. The differential leukocyte count was not measured in this study, but
the total leukocyte count is largely a reflection of neutrophil count as they are the most
numerous type of white blood cell.
Statins are commonly used for treatment of hypercholesterolemia and prevention of
atherosclerotic diseases, but they have pleiotropic effects, one of which is to reduce
inflammation. Their primary mechanism of action in lowering cholesterol is competi-
tive inhibition of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reduc-
tase which catalyses a rate-limiting step in cholesterol biosynthesis [92]. Mevalonate,
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the product of HMG-CoA reductase, is also the the precursor of isoprenoid compounds
that regulate immune activation [93]. In vitro studies suggest that statins alter neutro-
phil migration [94], and a human study on 16 individuals with dyslipidaemia showed
that a year of statin therapy decreased the production of reactive oxygen species by
neutrophils [95]. Simvastatin reduced T lymphocyte proliferation and natural killer cell
cytotoxicity in a healthy volunteer study [96], and inhibited pro-inflammatory cytokines
expressed by monocytes in patients with hypercholesterolaemia [97].
The anti-inflammatory effects of statins suggest that they may have benefit in non-
atherosclerotic diseases. Atorvastatin has shown a clinical benefit in a randomised clin-
ical trial for rheumatoid arthritis [98] and statins are now being trialled in patients with
multiple sclerosis [99].
Another drug with potential anti-inflammatory properties is metformin, which reduced
the neutrophil / lymphocyte ratio in patients with polycystic ovary syndrome [100] and
reduced CRP and other inflammatory markers in patients with impaired fasting glucose
[101].
Colchicine is a drug used for treating gout, and has an antitubulin effect that inhibits
neutrophil function. In an observational study, colchicine use was associated with lower
incidence of myocardial infarction among patients with gout [102], and a randomised
clinical trial of colchicine 0.5mg/day reduced the rate of acute coronary syndrome or
stroke among patients with stable coronary disease [103].
There are two clinical trials underway to determine whether reduction of inflammation
can reduce the risk of cardiovascular events. The Canakinumab Anti-Inflammatory
Thrombosis Outcomes Study (CANTOS) is evaluating whether interleukin-1β inhibition
reduces cardiovascular events among patients with stable coronary artery disease and
elevated CRP (≥ 2 mg/L). The Cardiovascular Inflammation Reduction Trial is comparing
low dose methotrexate with placebo among patients with a history of myocardial infarction
and either diabetes or metabolic syndrome [53].
1.9 Areas of clinical uncertainty
Although there has been much interest in the inflammatory hypothesis of cardiovascular
diseases (either as a component of atherosclerosis or having effects such as weakening
blood vessel walls), epidemiological studies have focussed on a few areas such as prog-
nosis of acute coronary syndromes or heart failure. There are still substantial gaps in
our knowledge; the association between leukocyte counts and non-coronary atheroscle-
rotic diseases such as stroke and abdominal aortic aneurysm have not been investigated
extensively, and the strength of associations have not been compared between different
cardiovascular phenotypes.
It is also unclear whether leukocyte counts add value in risk prediction. Total white
blood cell count did not improve the prediction of cardiovascular death among patients
with acute coronary syndrome when incorporated into the Global Registry of Acute Coro-
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nary Events (GRACE) score [104]. However, a prediction model which incorporates all
available leukocyte subtype counts has not been tested.
Although there is some evidence that drugs such as metformin [101], statins [91] and
colchicine [103] may have beneficial effects on leukocyte counts, it is unclear how far this
explains their biological effects and whether there is justification for further trials. The true
effect size is unclear, as many of the published studies have been small and there is the
potential for publication bias.
1.10 Aim and objectives
1.10.1 Aim
To develop methods to assist in using electronic health record databases for research,
and apply them to an exemplar study investigating differential white cell counts and onset
of cardiovascular diseases.
1.10.2 Objectives
1. Develop tools to assist in analysis of electronic health record data
2. Investigate the association of differential leukocyte count with incidence of cardio-
vascular diseases
1.10.3 Approach to fulfilling aim and objectives
The first part of this thesis focusses on the methods: the CALIBER database, the validity
and provenance of the information within, and the process of converting raw data into a
research-ready format. It is vital to assess the validity of the linked data in order to be
able to use it appropriately for research (section 4.2). Identification of disease pheno-
types is time-consuming and is best performed once, with re-usable algorithms. Software
is required to facilitate this process, and I have developed a suite of R packages to do
so (section 4.3). Missing data is a pervasive problem in electronic health record datasets
but these datasets contain much information that can be used to assist in the imputation
of missing data. However, conventional parametric imputation models are limited in the
number of predictor variables they can handle, and they do not automatically account for
non-linearities and interactions between the predictors. I therefore developed an imputa-
tion method using the Random Forest machine learning algorithm (section 4.4).
I describe the phenotype definitions for initial presentations of cardiovascular diseases
in chapter 5, and demonstrate their association with type 2 diabetes. In the following
chapter, chapter 6 I explore differential white blood cell counts recorded in CALIBER, and
then investigate their associations with initial presentations of cardiovascular diseases in
chapters 7 and 8.
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I replicate an analysis of total white blood cell count and all-cause mortality in CALIBER
and the New Zealand PREDICT database (chapter 9) and finally discuss the project as a
whole.
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2 Literature review
2.1 Chapter outline
This chapter describes a systematic literature search for cohort studies investigating the
association between differential leukocyte counts (neutrophils, lymphocytes, monocytes,
eosinophils, basophils) and incidence of any of the twelve cardiovascular diseases of
interest in healthy populations.
2.2 Abstract
Background: There are biological mechanisms which suggest that leukocyte counts
might be associated with onset of cardiovascular diseases in healthy populations. This
literature review aims to identify prior cohort studies which have investigated such asso-
ciations in order to inform further studies.
Methods: I searched EMBASE and MEDLINE using the OvidSP web interface for stud-
ies relating neutrophil, lymphocyte, monocyte, eosinophil, basophil, granulocyte or total
white blood cell counts with incidence or prognosis of cardiovascular diseases, with over
2000 patients and follow-up of at least 1 year.
Results: The initial search returned 3099 articles, but on review only 15 publications
reporting results of studies in 14 cohorts fulfilled the criteria for inclusion in this review.
There was some evidence of a positive association of total white cell count and neutrophil
count with coronary artery disease, but weak, conflicting or non-significant associations
with other cardiovascular diseases or leukocyte subtypes. All studies retrieved investi-
gated leukocyte counts taken from a consented cohort as part of a bespoke study.
Discussion: There were no large-scale population-based cohort studies investigating
the associations with clinically recorded white cell counts. Neutrophil counts are likely to
be associated with coronary artery disease, but associations with other cardiovascular
diseases or leukocyte subtypes are unclear and warrant further research.
2.3 Introduction
White blood cells play a major role in atherosclerosis, which is an inflammatory pro-
cess [48], and some cardiovascular diseases such as abdominal aortic aneurysms are a
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result of other inflammatory processes which weaken blood vessel walls [44]. Although
white blood cell (leukocyte) counts are included in the full blood count, one of the most
commonly performed blood tests, these numbers are not currently used in cardiovascular
decision making [30]. This is because the association of leukocyte counts and cardiovas-
cular diseases is not well known. In contrast to lipids [105] and C reactive protein [106],
there are no recent meta-analyses or individual participant consortia investigating differ-
ential leukocyte counts and cardiovascular diseases.
I therefore carried out a systematic review to test the hypothesis that leukocyte sub-
types are differentially associated with onset of different cardiovascular diseases. I aimed
to identify large cohort studies with long-term follow-up (at least 1 year) investigating the
association of baseline leukocyte counts with incidence of cardiovascular diseases in
healthy populations. This literature review would clarify gaps in current knowledge and
help to inform the design of the studies to be performed as part of this PhD.
2.4 Methods
I searched EMBASE and MEDLINE using the OvidSP web interface (https://ovidsp.
ovid.com/) for studies relating neutrophil, lymphocyte, monocyte, eosinophil, basophil,
granulocyte or total white blood cell counts with incidence or prognosis of cardiovascular
diseases (ischaemic heart disease, transient ischaemic attack, subarachnoid haemor-
rhage, ischaemic or haemorrhagic stroke, abdominal aortic aneurysm, peripheral vascu-
lar disease, heart failure, cardiac arrest or sudden cardiac death). I searched on phrases
in the text or abstract and also used Medical Subject Headings (MeSH terms) as follows:
1. (leukocytes or eosinophils or neutrophils or lymphocytes or granulocytes
or monocytes or basophils or "leukocyte count" or "lymphocyte count").mp.
[mp=ti, ab, ot, nm, hw, kf, ps, rs, ui, sh, tn, dm, mf, dv, kw]
2. (("white blood cell" or "white blood cells" or "white cells" or
"white cell" or leukocyte* or eosinophil* or neutrophil* or lymphocyte*
or granulocyte* or monocyte* or basophil*) and (count or counts or
total or differential or measur* or index or indices)).m_titl.
3. (occur* or association or incidence or onset).m_titl.
4. incidence.mp. [mp=ti, ab, ot, nm, hw, kf, ps, rs, ui, sh, tn, dm, mf,
dv, kw]
5. (prognosis or mortality or survival).m_titl.
6. (prognosis or mortality or survival).mp. [mp=ti, ab, ot, nm, hw, kf,
ps, rs, ui, sh, tn, dm, mf, dv, kw]
7. exp Myocardial Ischemia/
8. ("ischaemic heart" or "ischemic heart" or angina or
"myocardial infarction" or "myocardial infarct" or
"acute coronary syndrome" or "acute coronary syndromes" or
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"coronary disease" or "coronary artery disease" or
"coronary heart disease").m_titl.
9. exp heart arrest/
10. exp "tachycardia, ventricular"/
11. ("ventricular fibrillation" or "ventricular flutter").mp. [mp=ti, ab,
ot, nm, hw, kf, ps, rs, ui, sh, tn, dm, mf, dv, kw]
12. ("heart arrest" or "cardiac arrest" or "sudden cardiac death" or
("ventricular" and ("flutter" or "fibrillation" or "tachycardia"))).m_titl.
13. exp "heart failure"/
14. ("heart failure" or "cardiac failure" or "ventricular failure").m_titl.
15. exp stroke/
16. exp "brain ischemia"/
17. (stroke or "cerebrovascular accident" or "cerebrovascular disease" or
"brain ischemia" or "transient ischaemic attack" or
"transient ischemic attack").m_titl.
18. ("cerebral hemorrhage" or "intracranial hemorrhage, hypertensive" or
"basal ganglia hemorrhage" or "subarachnoid hemorrhage").mp. [mp=ti, ab,
ot, nm, hw, kf, ps, rs, ui, sh, tn, dm, mf, dv, kw]
19. (("intracerebral" or "intra-cerebral" or "subarachnoid") and ("bleed"
or "haemorrhage" or "hemorrhage")).m_titl.
20. "peripheral arterial disease".mp. [mp=ti, ab, ot, nm, hw, kf, ps, rs,
ui, sh, tn, dm, mf, dv, kw]
21. (("peripheral arterial disease" or "peripheral vascular disease" or
"intermittent claudication" or (leg or "lower limb")) and (ischemia
or ischaemia or "arterial disease" or "vascular disease")).m_titl.
22. "aortic aneurysm, abdominal".mp. [mp=ti, ab, ot, nm, hw, kf, ps, rs,
ui, sh, tn, dm, mf, dv, kw]
23. "abdominal aortic aneurysm".m_titl.
24. 1 or 2
25. 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or
19 or 20 or 21 or 22 or 23
26. 24 and 25
27. 3 or 4 or 5 or 6
28. 26 and 27
29. remove duplicates from 28
30. limit 29 to human
This search returned 2403 articles when initially performed on 13 November 2013.
When re-run on 23 March 2015, an additional 696 titles were retrieved.
On reviewing titles and abstracts I found 328 articles which may contain epidemiological
studies of interest. I retrieved the full text of these articles and identified other relevant
articles through searches of reference lists. As the purpose of this systematic review was
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to identify research questions for the primary analysis, I did not attempt to contact study
authors or identify unpublished work, and I did not perform a formal assessment of the
quality of the studies.
I limited the results to studies in English with more than 2000 participants and follow-
up of at least 1 year, which investigated leukocyte counts and incidence of cardiovascular
disease in the general population or a healthy cohort. I collated the most highly adjusted
measure of association (generally a hazard ratio) reported in each study. Where stud-
ies reported both a linear association and a comparison of categories (e.g. quartiles), I
reported the comparison of categories as it would be easier to interpret.
The oldest study [107] reported a main analysis with log hazard ratios (beta coeffi-
cients) adjusted for age, sex and blood pressure, as well as a secondary analysis with
further adjustment for smoking and cholesterol in a small subset of the patients. I used
the results adjusted for age, sex and blood pressure because these included all the pa-
tients, and converted the effect size into a hazard ratio for 109/L higher leukocyte count
(this involved dividing the effect size by 10, as it was expressed per 100 cells/mm3 which
is equivalent to per 108 cells/L higher leukocyte count).
As the studies were heterogenous (in the way they analysed leukocyte counts as cat-
egorical or continuous variables, in their choice and definitions of endpoints, and the
level of adjustment for risk factors), it was not considered worthwhile to attempt a meta-
analysis. I referred to the MOOSE guidelines [108] in writing this report.
2.5 Results
I found 15 publications reporting results of studies in 14 cohorts investigating total white
cell counts and incidence of cardiovascular diseases. There were fewer studies reporting
associations with the differential leukocyte count. A systematic review in 2004 found
3 studies investigating the differential leukocyte count and incidence of coronary heart
disease [90]. A subsequent meta-analysis included unpublished data from additional
cohorts [49], and along with my literature search this resulted in a total of 9 publications
reporting on 8 cohorts.
All studies investigating differential leukocyte count investigated granulocyte or neutro-
phil counts (Table 2.2 on page 47). Most of these studies also investigated lymphocyte
counts (Table 2.4 on page 49) and monocyte counts (Table 2.5 on page 50). Relatively
few studies reported on eosinophil counts (Table 2.6 on page 51) or basophil counts
(Table 2.7 on page 51).
All studies reported here were based on follow-up of consented investigator-led co-
horts. None looked at more than one or two endpoints in the same study, or used clinically
recorded leukocyte counts. One recent large study was based on routine records from a
medical insurance cohort [109], but the white blood count was measured specifically for
the purpose of the study, rather than as part of clinical care.
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2.5.1 Total leukocyte count and incidence of cardiovascular diseases
There are 14 previous large cohort studies investigating total white cell counts and in-
cidence of cardiovascular diseases (Table 2.1 on page 44). The majority of studies
(9/14) focussed on the association with coronary disease, rather than other cardiovascu-
lar diseases. Five studies reported aggregate cardiovascular disease or cardiovascular
mortality and only 6 studies reported non-coronary outcomes (4 reports for stroke, 1 for
subarachnoid haemorrhage and 2 for heart failure).
Most studies reported a positive association between higher total leukocyte count and
future risk of coronary artery disease, heart failure and cerebral infarction. One study
reported a null association with haemorrhagic stroke [110]. Two studies reported hazard
ratios by sex; in the Malmo Preventive Project there was no significant difference in the
association between the sexes for stroke or coronary disease [111], but in the largest
study (based in the Korean Medical Insurance scheme) the association with mortality
from atherosclerotic disease was stronger in men than in women, and stronger among
non-smokers than smokers [109]. Higher leukocyte count was also associated with in-
creased risk of subarachnoid haemorrhage [40].
Table 2.1: Total white cell count and incidence of cardiovascular diseases: previous co-
hort studies with over 2000 participants
Endpoints other than coronary disease are shaded: pink for non-coronary endpoints and grey for
cardiovascular disease aggregates.
Author, year,
study
Population Endpoint N
events
Adjusted measure of association
Jee, 2005,
Korean Cancer
Prevention
Study [109]
438 500
government
employees,
teachers, and their
dependants insured
with Korea Medical
Insurance
Corporation
Mortality from
atherosclerotic
disease
11 676 HR (95% CI) for WBC ≥ 9 vs
< 5× 109/L:
male non-smokers 2.33 (1.71,
3.17)
male smokers 1.44 (1.25, 1.67)
female non-smokers 1.34 (1.17,
1.53)
female smokers 1.20 (0.95, 1.52)
Li, 2010, Malmo
Preventive
Project [111]
17 131 men and
2932 women with
average follow-up
24 years
MI or coronary
death
2600 HR (95% CI) for top vs bottom
quartile:
men 1.31 (1.16, 1.48)
women 1.46 (0.87, 2.46)
Stroke 1333 HR (95% CI) for top vs bottom
quartile:
men 1.11 (0.93, 1.33)
women 1.12 (0.63, 2.02)
Söderholm,
2014, Malmo
Preventive
Project [40]
17 083 men and
2711 women
Subarachnoid
haemorrhage
95 HR 2.05 (95% CI 1.06, 3.96) for top
vs bottom quartile
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Author, year,
study
Population Endpoint N
events
Adjusted measure of association
Margolis, 2005,
Women’s
Health Initiative
Observational
Study [112]
66 261 women with
mean follow-up 6.1
years
Coronary
death, MI or
stroke
1510 HR (95% CI) for top vs bottom
quartile:
overall 1.47 (1.26, 1.72)
non-Hispanic Whites 1.47 (1.25,
1.74)
Blacks 1.52 (0.91, 2.53)
Coronary
death
187 HR 2.36 (95% CI 1.51, 3.68) for top
vs bottom quartile
Nonfatal MI 701 HR 1.41 (95% CI 1.12, 1.78) for top
vs bottom quartile
Stroke 738 HR 1.46 (95% CI 1.17, 1.81) for top
vs bottom quartile
Pfister, 2012,
EPIC-
Norfolk [113]
16 011 people
without prior MI,
cancer, stroke or
heart failure
Incident heart
failure
935 HR 1.24 (95% CI 0.96, 1.60) for top
vs bottom quartile
Wheeler, 2004,
NHEFS [49]
4625 people with
average follow-up
18 years
Hospitalised
angina, MI or
coronary
death
914 HR 1.01 (95% CI 0.85, 1.20) for top
vs bottom tertile
Tamakoshi,
2007, NIPPON
DATA90 [114]
6756 Japanese
residents followed
up from nationwide
random survey
Cardiovascular
mortality
161 RR 1.79 (95% CI 0.97, 3.71) for
WBC 9− 10× 109/L vs
4− 4.9× 109/L
Shankar, 2007,
Blue Mountains
Eye Study [115]
2904 people with no
prior cardiovascular
disease or cancer
Cardiovascular
mortality
242 HR 2.01 (95% CI 1.40, 2.90) for top
vs bottom quartile
Sweetnam,
1997,
Caerphilly and
Speedwell [116]
4615 men aged 45
to 63 living in two
neighbourhoods
MI or coronary
death
565 Relative odds 2.10 (95% CI 1.51,
2.92) for top vs bottom quintile
Lee, 2001,
Atherosclerosis
Risk in
Communities
(ARIC) [117]
13 555 men and
women recruited
from 4 US
communities
MI or coronary
death
488 RR 1.8 (95% CI 1.32, 2.43) for top
vs bottom quartile
Cardiovascular
death
258 RR 2.3 (95% CI 1.58, 3.44) for top
vs bottom quartile
Stroke 220 RR 2.0 (95% CI 1.29, 2.99) for top
vs bottom quartile
Engstrom,
2009,
Malmo [118]
16 940 middle-aged
men without prior
MI or stroke
Hospitalised
heart failure
436 HR 1.73 (95% CI 1.3, 2.3) for top
vs bottom quartile
Kavousi, 2012,
Rotterdam
Study [119]
5933 people without
prior coronary
disease
MI or coronary
death
347 HR 1.8 (95% CI 1.3, 2.5) for top vs
bottom quartile
Twig, 2012,
MELANY [45]
29 120 young men
in the Israeli Army
Coronary
artery disease
on
angiography
188 HR ratio 1.84 (95% CI 1.00, 3.37)
for top vs bottom quintile
45
Chapter 2. Literature review
Author, year,
study
Population Endpoint N
events
Adjusted measure of association
Prentice, 1982,
Hiroshima &
Nagasaki [107]
12 858 people in
Adult Health Study
cohort
Angina, MI or
coronary
death
154 HR 1.09 per 109/L higher WBC (P
= 0.02) adjusted for age, sex and
blood pressure
Prentice, 1982,
Hiroshima &
Nagasaki [110]
13 040 people in
Adult Health Study
cohort
Cerebral
infarction
336 HR 1.07 per 109/L higher WBC (P
= 0.01)
Intracerebral
haemorrhage
73 HR 0.92 per 109/L higher WBC (P
= 0.21)
Olivares, 1993,
Paris
Prospective
Study II [120]
2856 White men
with no previous
coronary disease
working for SNCF or
civil service
Angina, MI or
coronary
death
46 RR 1.09 per 109/L higher WBC
adjusted for age and smoking
2.5.2 Neutrophil counts and incidence of cardiovascular diseases
Ten publications reported associations of neutrophil counts with cardiovascular diseases
in 8 cohorts (Table 2.2 on page 47). The majority of the studies found that higher neutro-
phil count was associated with increased risk of coronary artery disease. The two studies
which investigated stroke subtypes showed that neutrophil counts were positively associ-
ated with cerebral infarction but not intracerebral haemorrhage [110,122].
Smoking is strongly associated with neutrophil counts and with cardiovascular disease,
but the association between cardiovascular disease and neutrophil count has been shown
to be present among never-smokers as well as people with a smoking history [116].
Some studies investigated associations with granulocyte counts. Granulocytes include
neutrophils, eosinophils, basophils and mast cells. The majority of granulocytes are neu-
trophils; hence the granulocyte count for any individual patient is numerically similar to
the neutrophil count. Higher granulocyte counts were associated with a moderately in-
creased risk of coronary disease and heart failure (Table 2.3 on page 48).
2.5.3 Lymphocyte counts and incidence of cardiovascular diseases
Lymphocyte counts showed no consistent association with onset of coronary disease,
heart failure or stroke in 9 cohorts (Table 2.4 on page 49). Most of the associations
reported were not significantly different from null.
2.5.4 Monocyte counts and incidence of cardiovascular diseases
Previous studies investigating monocyte counts and onset of cardiovascular diseases
suggest a weak association with higher monocyte counts in some cohorts, but the only
statistically significant result was in the Paris Prospective Study II [120] (Table 2.5 on
page 50). There were no significant associations with heart failure or stroke. In the
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Table 2.2: Neutrophil counts and incidence of cardiovascular diseases: previous cohort
studies with over 2000 participants
Author,
year
Study
population
N pa-
tients
Follow up Endpoint N
events
Adjusted measure of
association
Adamsson
Eryd,
2012 [121]
Malmo Diet
and Cancer
Study
27 085 Mean 13.6
years
Coronary
death or
MI
1965 HR 1.13 (95% CI 1.08,
1.18) per SD (1.33
×109/L) higher
Zia,
2012 [122]
Malmo Diet
and Cancer
Study
26 927 Mean 13.6
years
Cerebral
infarction
1314 HR 1.3 (95% CI 1.1, 1.5)
for top vs bottom
quartile
Intracerebral
haemor-
rhage
201 HR 0.8 (95% CI 0.5, 1.2)
for top vs bottom
quartile
Wheeler,
2004 [49]
ARIC 11 305 Mean 10
years
Coronary
death or
MI
527 RR 2.0 for top vs bottom
tertile (read off graph in
meta-analysis)
Shah,
2014 [123]
National
Health and
Nutrition
Examination
Survey-III
7250 Mean 14.1
years
Nonfatal
MI or
coronary
death
231 HR 1.57 (95% CI 0.72,
3.44) for > 7.7 vs
≤ 7.7× 109/L
Gillum,
2005 [124]
NHEFS 4625 Median
18.3 years
Coronary
artery
disease or
coronary
death
914 HR 1.09 (0.93, 1.29) for
top vs bottom tertile
Olivares,
1993 [120]
Paris
Prospective
Study II
3659 Mean 66.5
months
Coronary
heart
disease
46 RR 1.03 (95% CI 0.88,
1.19) per 109/L higher
Karino,
2015 [125]
Honolulu
Heart
Program
2879 8 years ACS or
coronary
death
279 HR 1.57 (95% 1.57,
2.34) for top vs bottom
quartile (P for trend
0.02)
Prentice,
1982 [107]
Hiroshima
and Nagasaki
12 858 Mean 11
years
Angina, MI
or
coronary
death
154 HR 1.12 per 109/L
higher (P = 0.05)
Prentice,
1982 [110]
Hiroshima
and Nagasaki
13 040 Mean 11
years
Cerebral
infarction
336 HR 1.14 per 109/L
higher (P <0.001)
Intracerebral
haemor-
rhage
73 HR 0.95 per 109/L
higher (P = 0.61)
Sweetnam,
1997 [116]
Caerphilly
(men only)
2163 5 years Coronary
death or
MI
143 HR 3.54 for top vs
bottom quintile (P for
trend 0.003)
ACS = acute coronary syndrome; CI = confidence interval; HR = hazard ratio; MI; myocardial infarction; RR
= relative risk.
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Table 2.3: Granulocyte counts and incidence of cardiovascular diseases: cohort studies
with over 2000 participants
Author,
year
Study
population
N pa-
tients
Follow up Endpoint N
events
Adjusted measure of
association
Bekwelem,
2011 [126]
ARIC 14 485 Mean 15.5
years
Heart
failure
1647 HR 2.19 (95% 1.83,
2.61) for top vs bottom
quintile
Pfister,
2012 [113]
EPIC-Norfolk 16 011 Mean 12.4
years
Heart
failure
935 HR (95% CI) per 109/L
higher:
men 1.16 (1.09, 1.24)
women 1.05 (0.97, 1.13)
Karino,
2015 [125]
Honolulu
Heart
Program
2879 8 years ACS or
coronary
death
279 HR 1.66 (95% CI 1.11,
2.48) for top vs bottom
quartile (P for trend
0.01)
ACS = acute coronary syndrome; CI = confidence interval; HR = hazard ratio; MI; myocardial infarction; RR
= relative risk.
ARIC study the associations were not reported directly but had to be read off a graph or
otherwise deduced from information in the paper, so I was unable to ascertain confidence
intervals [49,126].
2.5.5 Eosinophil counts and incidence of cardiovascular diseases
The Hiroshima and Hagasaki study [107] and Caerphilly study [116] showed that higher
eosinophil count was associated with greater incidence of coronary heart disease (Table
2.6 on page 51). There was no significant association with ischaemic or haemorrhagic
stroke in the Hiroshima and Hagasaki study [110].
2.5.6 Basophil counts and incidence of cardiovascular diseases
I found only three studies investigating the association of basophils with cardiovascular
disease in the healthy population (Table 2.7 on page 51), and there were no statistically
significant associations reported with coronary disease or stroke.
2.6 Discussion
This literature review did not find any large-scale population-based cohort studies investi-
gating the association of clinically recorded white cell counts with incidence of cardiovas-
cular diseases. There was a study in a Korean medical insurance database involving over
400 000 participants with over 10 000 events, but even in this study the leukocyte counts
were obtained specifically for the study [109]. The lack of previous studies is surprising,
as white cell counts are commonly performed and frequently recorded electronically, but
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Table 2.4: Lymphocyte counts and incidence of cardiovascular diseases: previous cohort
studies with over 2000 participants
Author,
year
Study
population
N pa-
tients
Follow up Endpoint N
events
Adjusted measure of
association
Adamsson
Eryd,
2012 [121]
Malmo Diet
and Cancer
Study
27 085 Mean 13.6
years
Coronary
death or
MI
1965 HR 1.05 (95% CI 1.00,
1.11) per SD (0.88
×109/L) higher
Zia,
2012 [122]
Malmo Diet
and Cancer
Study
26 927 Mean 13.6
years
Cerebral
infarction
1314 HR 1.2 (95% CI 0.98,
1.4) for top vs bottom
quartile
Intracerebral
haemor-
rhage
201 HR 0.7 (95% CI 0.4,
1.01) for top vs bottom
quartile
Pfister,
2012 [113]
EPIC-Norfolk 16 011 Mean 12.4
years
Heart
failure
935 HR (95% CI) per 109/L
higher:
men 0.97 (0.83, 1.13)
women 0.92 (0.77, 1.10)
Bekwelem,
2011 [126]
ARIC 14 485 Mean 15.5
years
Heart
failure
1647 HR 0.86 for top vs
bottom quintile
Wheeler,
2004 [49]
ARIC 11 337 Mean 10
years
Coronary
death or
MI
531 RR 1.2 for top vs bottom
tertile (read off graph in
meta-analysis)
Shah,
2014 [123]
National
Health and
Nutrition
Examination
Survey-III
7250 Mean 14.1
years
Nonfatal
MI, fatal
CHD
231 HR 1.33 (95% CI 0.81,
2.18) for > 1.5 vs
≤ 1.5× 109/L
Gillum,
2005 [124]
NHEFS 4625 Median
18.3 years
Coronary
artery
disease or
coronary
death
914 HR 1.05 (0.89, 1.24) for
top vs bottom tertile
Olivares,
1993 [120]
Paris
Prospective
Study II
3659 Mean 66.5
months
Coronary
heart
disease
46 RR 1.06 (95% CI 0.73,
1.55) per 109/L higher
Karino,
2015 [125]
Honolulu
Heart
Program
2879 8 years ACS or
coronary
death
279 HR 1.14 (95% 0.80,
1.62) for top vs bottom
quartile (P for trend
0.94)
Prentice,
1982 [107]
Hiroshima
and Nagasaki
12 858 Mean 11
years
Angina, MI
or
coronary
death
154 HR 1.05 per 109/L
higher (P = 0.62)
Prentice,
1982 [110]
Hiroshima
and Nagasaki
13 040 Mean 11
years
Cerebral
infarction
336 HR 1.01 per 109/L
higher (P = 0.89)
Intracerebral
haemor-
rhage
73 HR 0.73 per 109/L
higher (P = 0.07)
Sweetnam,
1997 [116]
Caerphilly
(men only)
2163 5 years Coronary
death or
MI
143 HR 1.08 for top vs
bottom quintile (P for
trend 0.21)
CI = confidence interval; HR = hazard ratio; MI; myocardial infarction; RR = relative risk.
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Table 2.5: Monocyte counts and incidence of cardiovascular diseases: previous cohort
studies with over 2000 participants
Author,
year
Study
population
N pa-
tients
Follow up Endpoint N
events
Adjusted measure of
association
Pfister,
2012 [113]
EPIC-Norfolk 16 011 Mean 12.4
years
Heart
failure
935 HR (95% CI) per 109/L
higher:
men 0.71 (0.53, 0.93)
women 1.10 (0.82, 1.48)
Bekwelem,
2011 [126]
ARIC 14 485 Mean 15.5
years
Heart
failure
1647 HR 0.89 for top vs
bottom quintile
Wheeler,
2004 [49]
ARIC 11 293 Mean 10
years
Coronary
death or
MI
527 RR 1.3 for top vs bottom
tertile (read off graph in
meta-analysis)
Prentice,
1982 [107]
Hiroshima
and Nagasaki
12 858 Mean 11
years
Coronary
heart
disease
153 RR 1.26 (P = 0.26) for
monocytes ≥ 0.6
×109/L vs <0.36 ×109/L
Prentice,
1982 [110]
Hiroshima
and Nagasaki
13 040 Mean 11
years
Cerebral
infarction
336 HR 0.87 per 109/L
higher (P = 0.58)
Intracerebral
haemor-
rhage
73 HR 0.43 per 109/L
higher (P = 0.16)
Gillum,
2005 [124]
NHEFS 4625 Median
18.3 years
Coronary
artery
disease or
coronary
death
914 HR 0.96 (0.82, 1.13) for
top vs bottom tertile
Olivares,
1993 [120]
Paris
Prospective
Study II
3659 Mean 66.5
months
Coronary
heart
disease
46 RR 1.15 (95% CI 1.07,
1.24) per 108/L higher
Karino,
2015 [125]
Honolulu
Heart
Program
2879 8 years ACS or
coronary
death
279 HR 1.22 (95% 0.86,
1.74) for top vs bottom
quartile (P for trend
0.28)
Sweetnam,
1997 [116]
Caerphilly
(men only)
2163 5 years Coronary
death or
MI
143 HR 1.34 for top vs
bottom quintile (P for
trend 0.22)
CI = confidence interval; HR = hazard ratio; MI; myocardial infarction; RR = relative risk.
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Table 2.6: Eosinophil counts and incidence of cardiovascular diseases: previous cohort
studies with over 2000 participants
Author,
year
Study
population
N pa-
tients
Follow up Endpoint N
events
Adjusted measure of
association
Prentice,
1982 [107]
Hiroshima
and Nagasaki
12 858 Mean 11
years
Coronary
heart
disease
153 RR 1.78 (P = 0.01) for
eosinophils ≥ 0.3
×109/L vs <0.12 ×109/L
Prentice,
1982 [110]
Hiroshima
and Nagasaki 13 040
Mean 11
years
Cerebral
infarction
336 HR 0.92 per 109/L
higher (P = 0.79)
Intracerebral
haemor-
rhage
73 HR 1.14 per 109/L
higher (P = 0.84)
Olivares,
1993 [120]
Paris
Prospective
Study II
3659 Mean 66.5
months
Coronary
heart
disease
46 RR 1.03 (95% CI 0.87,
1.21) per 108/L higher
Sweetnam,
1997 [116]
Caerphilly
(men only)
2163 5 years Coronary
death or
MI
143 HR 2.15 for top vs
bottom quintile (P for
trend 0.05)
CI = confidence interval; HR = hazard ratio; MI; myocardial infarction; RR = relative risk.
Table 2.7: Basophil counts and incidence of cardiovascular diseases: previous cohort
studies with over 2000 participants
Author,
year
Study
population
N pa-
tients
Follow up Endpoint N
events
Adjusted measure of
association
Prentice,
1982 [107]
Hiroshima
and Nagasaki
12 858 Mean 11
years
Angina, MI
or
coronary
death
154 HR 1.12 per 109/L
higher (P = 0.53)
Prentice,
1982 [110]
Hiroshima
and Nagasaki 13 040
Mean 11
years
Cerebral
infarction
336 HR 1.54 per 109/L
higher (P = 0.69)
Intracerebral
haemor-
rhage
73 HR 4.13 per 109/L
higher (P = 0.51)
Olivares,
1993 [120]
Paris
Prospective
Study II
3659 Mean 66.5
months
Coronary
heart
disease
46 RR 1.14 (95% CI 0.94,
1.38) per 108/L higher
Sweetnam,
1997 [116]
Caerphilly
(men only)
2163 5 years Coronary
death or
MI
143 HR 1.50 for top vs
bottom quintile (P for
trend 0.36)
CI = confidence interval; HR = hazard ratio; MI; myocardial infarction; RR = relative risk.
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perhaps attention has been diverted in recent years to measurement of acute phase pro-
teins, cytokines and other novel inflammatory markers instead. There were no published
results of recent meta-analyses or large-scale consortia.
The only cardiovascular diseases investigated for their associations with the leukocyte
differential were coronary artery disease, cerebral infarction, intracerebral haemorrhage
and heart failure. There were no studies investigating other cardiovascular diseases re-
sponsible for significant morbidity and mortality such as abdominal aortic aneurysm or
peripheral arterial disease, and only one study (with just 95 events) investigating sub-
arachnoid haemorrhage, a devastating but poorly understood condition.
Previous studies have generally not studied more than one endpoint in the same anal-
ysis, so the relative strengths of associations with different cardiovascular presentations
is not known. The findings had varying levels of adjustment and some studies were not
able to adjust for smoking (e.g. in the Hiroshima and Nagasaki study, where only a lim-
ited subset of participants had smoking status recorded [107]). Therefore the finding
of increased cardiovascular risk with higher eosinophil count may be confounded; indeed
studies in other settings such as patients undergoing percutaneous intervention [127] and
patients with acute heart failure [128], low eosinophil count was found to be associated
with worse prognosis.
2.6.1 Limitations
This literature review may have missed some relevant studies, because some relative
risks of interest may be reported only in the text of articles if they are not the main focus
of the paper (e.g. if they are in a multivariable model), and thus may not be flagged in
the title. Other limitations of this review are that I did not attempt to contact authors for
unpublished studies and I limited the review to large studies published in English. This
results in a restricted and less systematic review of the literature than would be optimal,
but the larger studies are likely to be of higher quality and and are more likely to show
a true association if one exists. In any case the purpose of the review was to highlight
important research questions and verify that they have not been answered previously; the
literature is so scarce that the new CALIBER study is fully justified.
2.6.2 Conclusion
This literature review has highlighted important gaps in our knowledge of associations of
leukocyte counts with onset of cardiovascular diseases. Knowledge of these associations
can provide insight into aetiological mechanisms and guide potential future therapies.
This justifies the development of the CALIBER resource for the investigation of the
differential leukocyte count and onset of cardiovascular diseases in a large, contemporary
population-based cohort. The next few chapters describe the data sources that comprise
CALIBER, development of research tools for CALIBER and the definition of a cohort for
answering the research question.
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3 The CALIBER database
3.1 Chapter outline
This chapter describes the CALIBER programme, which is the data source for the majority
of the work in this thesis, and the following chapter (chapter 4 on page 65) describes my
contributions to validation and enhancement of CALIBER.
3.2 Introduction
CALIBER is a database of linked routinely collected electronic health records from Eng-
land [1], comprising data from primary care (Clinical Practice Research Datalink, CPRD)
[129], hospital admissions [130], the Myocardial Ischaemia National Audit Project (MI-
NAP) [9] and the national death registry at the Office for National Statistics (ONS). The
data sources complement each other in providing different types of information about a
patient’s medical history (Figure 3.1 on page 54). CALIBER also contains small-area in-
dices of deprivation from ONS (index of multiple deprivation) [131] linked by the patient’s
postcode. The index of multiple deprivation is a score calculated for each patient’s neigh-
bourhood on the basis of social indices such as income, education, and employment. The
CALIBER dataset has pseudonymised identifiers and does not identify the location of a
patient or general practice except at a very crude level (one of 10 regions in England).
3.3 Source datasets
3.3.1 Primary care data: Clinical Practice Research Datalink
The Clinical Practice Research Datalink (CPRD) contains pseudonymised primary care
electronic patient records from UK general practices, currently covering 6.9% of the UK
population with 4.4 million currently registered patients [129]. CPRD has been used
extensively for epidemiological research with over a thousand research studies published
in a wide range of disease areas [129].
History of the CPRD
The original name for what would become the CPRD was the ‘VAMP research databank’
(Value Added Medical Products). General practitioners were given free computers in re-
turn for contributing data to the research databank. The VAMP Medical clinical system
used the OXford Medical Information System (OXMIS) dictionary to encode clinical en-
tries in order to minimise the use of hard disk space. Anonymised patient records were
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Figure 3.1: How a patient’s medical history may be recorded in the CALIBER data
sources
collected at regular intervals from the practices, initially on tape and later electronically.
The text-based VAMP Medical software was replaced by Vision, which had a graphical
user interface, and practices switched from OXMIS to the Read Clinical Terminology at
varying dates in the 1990s.
The research database was renamed the General Practice Research Database
(GPRD) in 1993 [129]. It was transferred to the Office for National Statistics and sub-
sequently to the Medicines and Healthcare products Regulatory Agency (MHRA) around
the year 2000. A subset of GPRD practices in England consented to record linkage with
other datasets, and were linked to Hospital Episode Statistics and the death registry. It
was this subset that was further linked to MINAP to constitute the CALIBER dataset.
The recent change of name to ‘Clinical Practice Research Datalink’ reflects the aspi-
ration of further linkages with other registries, clinical datasets and cohort studies in the
UK [129]. The current CPRD contains only Read terms, with OXMIS terms having been
converted to the Read equivalents. CPRD has now developed a system for collecting
data from EMIS systems, which is the most commonly used GP system supplier in the
UK [132].
Validity and representativeness of CPRD
Many studies using the CPRD performed validation of the coded diagnoses against
anonymised paper records requested from the GP or anonymised electronic free text.
A systematic review of CPRD validation studies found that diagnoses were generally reli-
able [133]. However, because the only information in the database is that recorded during
usual clinical care, clinical parameters or tests would not be recorded in individuals for
whom it is not indicated.
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Patients can opt out of data collection by informing their GP, but the majority of patients
in CPRD practices contribute data, and CPRD patients are broadly representative of the
UK population in terms of age, sex [129] and ethnicity [134]. However the practices in
CPRD may not be representative of all practices in the UK by geographic distribution or
size [135], and it is likely that the quality of data is also not representative, as CPRD
practices are given data recording guidelines and regular feedback on the completeness
and quality of data.
Structure of information recorded in CPRD
Information in the CPRD is recorded in a number of tables, which can be linked by the
pseudonymised patient identifier in order to build up a complete picture of a patient’s
healthcare experience.
Patients – one row per patient, with demographic details such as year of birth, date of
death and registration dates.
Practices – one row per practice, giving details such as region of the UK and the date
when the practice achieved a good standard of data completeness for research
purposes (‘up-to-standard date’).
Consultations – each patient episode is considered a ‘consultation’ and all data are en-
tered in consultations (face-to-face, telephone or administrative). This table allows
diagnoses and prescriptions entered in the same consultation to be identified. It
can also be useful for measuring healthcare utilisation and costs, and for linking to
the staff table.
Staff – one row per staff member, with gender and role.
Events – there are a number of event tables, and a patient can have any number of
events. Each event is linked to a single consultation and has an event date, a
medical dictionary code (Read code) or product dictionary code (Multilex) and as-
sociated information.
Clinical – Read coded diagnoses entered by the GP, additional data such as blood
pressure measurements
Referrals – referrals to secondary care, with the indication recorded as a Read
code
Immunisations – records of immunisations
Therapy – prescriptions
Test – results of laboratory tests, each with a Read code
The type of information in the Test and Clinical tables is specified by the ‘entity code’ of
each record. This defines what additional data are included with the record; for example
55
Chapter 3. The CALIBER database
a haemoglobin (blood test) result will have a value, units and a normal range reported,
whereas a blood pressure record will contain systolic and diastolic measurements and a
record of the Korotkoff sound. Entity codes usually, but not always, correspond to Read
codes; usually the Read code is more specific (as there are thousands of Read codes
but only a few hundred entity codes). The entity codes can also be thought of as referring
to different information models, or ‘archetypes’, which I discuss further in the last chapter
(section 10.1.2 on page 235).
Read terms were designed for coding by GPs and incorporate synonymous terms with
variations in the way doctors may express common diagnoses. Apart from diagnoses,
the Read terminology includes codes for other categories of information such as history,
examination findings, procedures and test results [136].
Considerations when using general practice data
UK general practice databases have the advantage that individuals are registered with a
general practitioner (GP) over a defined time period, and the majority of the population
are registered. This provides a denominator and enables the database to be used for
estimating population incidence and prevalence of diseases [137,138]. These estimates
are based on the assumption that the research database population is representative and
the condition of interest is completely recorded in general practice data.
Patients can only register permanently with a single GP in the UK, so when construct-
ing a general practice database cohort, patients with temporary registration should be
ignored.
3.3.2 Hospital Episode Statistics
Hospital Episode Statistics (HES) is the database of hospital admissions in England [130].
It contains coded information about each admission such as whether it was an emergency
or elective admission, the specialty, dates of admission and discharge, and diagnoses
(primary and secondary) coded using the International Classification of Diseases, 10th
Edition (ICD-10) [139]. HES also contains records of procedures, coded using the Office
of Population Censuses and Surveys codes (OPCS-4). Data are entered by clinical cod-
ing clerks at the end of an admission. Outpatient information is available in the main HES
database but has not been linked in CALIBER.
HES provides anonymised datasets for research, with patients linked between admis-
sions and hospitals by an algorithm involving NHS number, date of birth, sex, postcode,
hospital code and local patient identifier (hospital number) [140]. Episodes which cannot
be linked will be considered to belong to a different patient. The completeness of the
linkage is higher for recent years as a greater proportion of records have an NHS number
(97% of inpatient activity in 2007–2008, compared to just 83% in 2000–2001).
Numerous epidemiological studies have been performed using HES, and validation
studies found that for severe vascular disease, including myocardial infarction, stroke and
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pulmonary embolism, HES records appeared to be both reliable and complete [141].
However, studies must exercise caution because it is an administrative dataset. The
utility of HES for research is limited by the granularity of the data and the limitations of
the ICD-10 coding system. For example, there are no specific codes for ST elevation
(STEMI) and non-ST elevation myocardial infarctions (NSTEMI), although the probability
the the event is coded using particular codes is different between STEMI and NSTEMI
(Table 4.3 on page 74). Investigations and minor procedures may be inconsistently
recorded. Uncommon or unusual conditions such as recreational drug toxicity may not
be consistently recorded [142].
3.3.3 Acute coronary syndrome registry: MINAP
MINAP (the Myocardial Ischaemia National Audit Project) is the national registry of acute
coronary syndromes, to which all acute hospitals in England and Wales contribute data.
The primary purpose of MINAP was to improve quality of care but it has also become
invaluable for research. MINAP comprises one entry per acute coronary syndrome ad-
mission, with 123 fields containing detailed clinical information such as coded electro-
cardiogram (ECG) findings, troponin results and interventions performed. Information is
abstracted from clinical notes by audit nurses or clerks [9].
MINAP contains rich information on the clinical characteristics and treatment of pa-
tients with acute coronary syndromes; for example it includes information on smoking
status and ECG findings which are not recorded electronically in most hospital systems.
However, as it is a voluntary registry there may be some selection bias in patients that are
included, and this can vary by hospital. MINAP is thought to particularly under-report non-
ST elevation myocardial infarction, but some myocardial infarctions are included twice if
the patient was transferred between hospitals acutely [9].
The information in MINAP is not used for direct clinical care, but as a clinical audit it
has been used to drive improvements in quality of care. Availability of MINAP data to
researchers is governed by the MINAP Academic Group [9].
3.3.4 Death registry
The death registry for England and Wales curated by the Office for National Statistics
(ONS) includes the date of death and the causes entered on the death certificate. A
single underlying cause of death is allocated according to the WHO ICD-10 algorithm
based on the information recorded on the death certificate, likely causal sequence and
International Classification of Diseases selection rules [143].
Deaths in England and Wales have been coded using ICD-10 since 2001 [139] and
ICD-9 in previous years. There was a change in the rules for selecting the underlying
cause from ICD-9 to ICD-10 which means that causes of death are not directly compa-
rable between 2001 onwards and previous years. However, the effect of these changes
varied by cause of death; some causes of death such as pnemonia were particularly
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affected but there was little effect on ischaemic heart disease and cerebrovascular dis-
ease [143].
3.3.5 Deprivation index
The index of multiple deprivation is a composite measure of deprivation calculated using
indicators in the following domains:
• Income deprivation
• Employment deprivation
• Health deprivation and disability
• Education, skills and training deprivation
• Barriers to housing and services
• Crime
• Living environment deprivation
The index is calculated for super output areas (postcode areas) and is available from
the Office for National Statistics. In CALIBER it was linked to patient records via the
postcode, but postcode is not included in the final pseudonymised CALIBER dataset
[131].
3.4 Linkage
CALIBER contains data from 244 CPRD general practices in England which consented
for their data to be linked to other sources. The linkage was carried out in October 2010
by a Trusted Third Party, using a deterministic match between NHS number, date of
birth and gender. 96% of patients with a valid NHS number were successfully matched.
Unfortunately the CALIBER group does not have access to further information about the
linkage which would ideally be provided, such as the linkage criteria used for matching
each pair of records or other measures of match quality.
3.4.1 Recording of death in linked data
As a simple check for errors in the CALIBER linkage I compared the recording of death
in CPRD and ONS, as both data sources should record the date of death. Death can be
recorded in CPRD as a Read code for death, transfer out of the practice with a reason of
death or a structured death notification entry.
For this investigation I used a sample of patients with unstable angina or myocardial
infarction recorded in any of the CALIBER data sources, and limited the set of patients
to those who had a record of death in ONS or CPRD while they were actively registered
with a CPRD practice.
Of the 23 474 patients with a record of death in either CPRD or ONS, 22 975 (97.9%)
had a record in both sources, 422 (1.80%) had a record in CPRD but not ONS and 77
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Table 3.1: Days difference between dates of death in death registry and primary care for
patients with acute coronary syndromes in CALIBER
Number of days death registry date is
before primary care death date
Frequency Percentage (95% CI)
>30 days before 122 0.53 (0.44, 0.64)
8–30 days before 99 0.43 (0.35, 0.53)
1–7 days before 475 2.07 (1.89, 2.26)
Same day 18 363 80.0 (79.4, 80.4)
1–7 days after 1926 8.38 (8.03, 8.75)
8–30 days after 1728 7.52 (7.19, 7.87)
>30 days after 262 1.14 (1.01, 1.29)
(0.33%) had a record in ONS but not CPRD. I compared the difference in the date of
death between the two data sources (Table 3.1 on page 59).
This shows that the vast majority of deaths in CALIBER are recorded in both the death
registry and primary care. Deaths might not be recorded in the death registry if the patient
died abroad, or there was a linkage problem (missed match). Deaths might be recorded
in the death registry but not primary care if the GP was not informed of the death or there
was a false match on linkage.
The date of death in primary care data was usually on the same day as the death
registry date of death, rarely before, but was up to 30 days after in almost 16% of patients.
The date of death might be later in CPRD than the death registry if the general practitioner
records the death as occurring on the date he or she finds out rather than the actual date
of death. If the date of death is earlier in CPRD than in the death registry it suggests that
the CPRD date of death is incorrect – there were a few deaths which were out by exactly
1 year, suggesting a data entry error.
3.5 Access to CALIBER data
Access to CALIBER data operates by a ‘safe haven’ model, where researchers have ac-
cess to the data only under the terms of a collaborative project with the CALIBER group
at UCL. Researchers have to be physically located at University College London, the
London School of Hygiene and Tropical Medicine or another of the collaborating institu-
tions in order to access the data. The raw data are stored in a MySQL database which is
accessible only to the data manager.
The CALIBER database is stored with a pseudonymised identifier linking records from
the same patient in the different datasets. CALIBER has defined a collection of variables
and clinical phenotypes which have been converted to SQL scripts for rapid extraction
from the master database.
CALIBER data for a specific project can be extracted either in raw form or as derived
CALIBER variables depending on the researcher’s preference, and is limited to the cohort
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of patients used for that project. For the work described in this thesis I required both the
raw form (for a subset of patients) to explore the data, and derived CALIBER variables
for ease of processing datasets with millions of patients.
3.6 Ethics and approvals
Ethics and governance. CPRD was set up as a research database with ethical ap-
proval, and individual studies using CPRD data require local CPRD approval but not full
ethical review. Data collection and re-use is permitted as the data are anonymous to
researchers, with identifiers such as date of birth, name and address removed. The free
text associated with coded data is not routinely available to researchers, although it can
be requested (with a cost for manual anonymisation) and has been used for validation
studies [18], but may not be routinely collected in the future.
Use of identifiable data (e.g. for linkage) requires application for an exemption under
section 251 of the NHS Act 2006. This legislation permits the Secretary of State for
Health to make regulations to set aside the common law duty of confidentiality for defined
medical purposes [144]. Identifiable data should only be used where essential and would
be accessible only to those who need it, i.e. researchers performing the linkage.
Patients in participating practices are opted in for data collection by default but have the
opportunity to inform their GP that they wish their data not to be uploaded. The number of
patients that opt out is small, so CPRD patients are broadly representative of the general
population [129].
The CALIBER dataset comprises CPRD data linked to HES, ONS and MINAP by a
trusted third party [1] and the final dataset is held in a pseudonymised form. Although
direct identifiers such as name and date of birth are not contained within the data, the
amount of information about individual patients is quite detailed so it is treated as sensi-
tive. CALIBER researchers are provided with pseudonymised data and have to commit
to not disclosing any information that may be able to identify a patient. Datasets should
be stored and analysed on secure servers and only aggregate data should be exported
or published.
CPRD has Multi-centre Research Ethics Committee approval for all purely observa-
tional research using CPRD data. The CALIBER record linkage study has had sepa-
rate ethical approval (09/H0810/16). Individual studies using CALIBER data have been
approved by the CPRD Independent Scientific Advisory Committee (ISAC) and the MI-
NAP Academic Group (MAG). CALIBER also has a Scientific Oversight Committee
which approves researchers’ analytic protocols to ensure that the research being per-
formed using the dataset is appropriate. It is CALIBER policy that analytic protocols
have to be circulated among the group and approved, and the study registered with
www.clinicaltrials.gov before data are released to the researcher.
The validation study on myocardial infarction in CALIBER (section 4.2) was approved
by ISAC ‘Comparison of the information recorded in MINAP, GPRD and HES’, protocol
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11_088, and is registered on clinicaltrials.gov (unique identifier NCT01569139, https:
//www.clinicaltrials.gov/ct2/show/NCT01569139).
The study investigating the association of type 2 diabetes with initial presentation of car-
diovascular diseases (chapter 5) falls within the remit of the ISAC: ‘Initial presentation of
cardiovascular diseases’ protocol 12_153R, and is registered on clinicaltrials.gov (unique
identifier NCT01804439, https://www.clinicaltrials.gov/ct2/show/NCT01804439).
The studies investigating the association of white cell counts with initial presenta-
tion of cardiovascular diseases and all-cause mortality (chapters 6, 7, 8 and 9) are
registered on clinicaltrials.gov (unique identifier unique identifier NCT02014610, https:
//www.clinicaltrials.gov/ct2/show/NCT02014610), and also fall within the remit of the
ISAC: ‘Initial presentation of cardiovascular diseases’ protocol 12_153R.
The study on missing data methods (section 4.4) falls within the remit of ISAC ‘Cardio-
metabolic biomarkers in the prognosis of specific coronary disease phenotypes’, protocol
10_160. It is not registered on clinicaltrials.gov because it is a methodological study.
3.7 CALIBER data portal
The CALIBER data portal (Figure 3.2 on page 62) is a web portal for researchers to
access descriptions of contributed CALIBER variable definitions (phenotypes), the un-
derlying algorithms and lists of Read, ICD-10 or OPCS codes used to define research
variables (‘codelists’). Each phenotype page has a link to web pages describing each of
the component variables. Flow diagrams are used where necessary to help users un-
derstand the creation of complex phenotypes (example for stable angina: Figure 3.3 on
page 63). These show how different data sources are combined, and how diagnoses can
be inferred if there are records of relevant investigations or procedures without an explicit
diagnosis (for example, coronary artery bypass grafting or coronary angioplasty imply a
diagnosis of stable angina if there is no recent record of acute coronary syndrome).
Information on the CALIBER data portal is licensed under a Creative Commons non-
commercial licence. Algorithms are freely accessible on the website but users have to
register to access the codelists. There is no charge for registration because its purpose
is purely for tracking the use of the site.
Underlying the data portal is a GitHub repository, which stores the codelists and SQL
code for querying the database in order to extract the variable. GitHub (https://github.
com/) is a website which can host a set of files under control of the Git distributed version
control system. Git tracks changes to multiple files and stores a list of user-written commit
messages alongside a record of the changes. This makes it possible to view the changes
in a file over time, and revert files to any previous state. It can merge changes from
different versions of files, which enables multiple users to work on the same set of files
simultaneously.
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Figure 3.2: Screenshot of the CALIBER web portal
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Figure 3.3: Flowchart showing data sources for stable angina phenotype
Ischaemic chest pain (CPRD)
Stable angina (CPRD)
Stable angina (HES)
CABG (CPRD)
PCI (CPRD)
CABG (HES)
PCI (HES)
Myocardial infarctionor unstable angina inthe previous 30 days?
Anti-anginal prescription (CPRD) Another subsequentanti-anginal prescriptionin the record?
Abnormal stress echo (CPRD)
Abnormal coronary angiogram (CPRD)
Abnormal CT coronary angiogram (CPRD)
Abnormal MR coronary angiogram (CPRD)
Abnormal exercise ECG (CPRD)
Myocardial ischaemia on resting ECG (CPRD)
Abnormal myocardial perfusion scan (CPRD)
Stable anginadiagnosis date= earliest dateof angina recordin any source
Inferreddiagnosisof stable anginaas indication forrevascularisation
Revascularisationwas due to recentacute coronarysyndrome
One-oﬀprescription
Recordeddiagnosis ofstable angina
Test resultssuggestingstable angina
Yes, likelyto have angina
No
Yes
No
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3.8 Summary and conclusions
CALIBER is a rich and exciting resource for large-scale epidemiology spanning primary
and secondary care. It harnesses the wealth of data in clinical general practice systems
and supplements it with information on hospitalisation, acute coronary syndromes and
deaths from national registries.
However, there are many steps to be taken before CALIBER data are usable in a
research dataset. These steps could have been done in an ad hoc manner for this single
project, but I sought to develop reusable tools and resources as far as possible in order
to aid reproducibility of research findings and facilitate a range of different future studies.
The next chapter will describe these tools and processes. The first project involved
cross-referencing and validation of the source datasets for myocardial infarction; this is
essential in order to be able to obtain unbiased inferences from the data. Secondly, I
developed software to assist in generating and processing the datasets in a reproducible
way. Thirdly, I sought to address the problem of missing data in epidemiological datasets
by developing and testing a novel imputation method.
Following on from these methodological projects in chapter 4, I will specify the study
cohort and endpoint definitions in chapter 5.
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4.1 Chapter outline
CALIBER contains a wealth of data which can yield profound insights into disease pro-
cesses and healthcare, but converting clinical data into a research dataset is not straight-
forward. The process can be facilitated at a number of steps by the three projects de-
scribed in this chapter.
The first project was to validate myocardial infarction diagnoses in the linked data
sources (section 4.2). This was a joint project with Emily Herrett (London School of
Hygiene and Tropical Medicine) and has been published in BMJ [18].
The second project (section 4.3 on page 80) describes common methods for converting
raw CALIBER data into a research-ready format. This includes a suite of packages for the
R statistical system to manipulate CALIBER data and clinical terminologies [145, 146]. I
also describe the process of defining a clinical phenotype using coded diagnoses and
other information in the electronic health record database.
The third project (section 4.4 on page 90) addresses the issue of missing data, one
of the most common problems in analysing clinically-collected data. I developed a new
method for multiple imputation using the Random Forest algorithm within the framework
of Multivariate Imputation by Chained Equations (MICE) [147,148].
4.2 Validation of acute myocardial infarction diagnoses in CALIBER
This is a condensed version of a paper in BMJ [18] cross-referencing acute myocardial in-
farction records in the electronic health record data sources that comprise CALIBER. We
also produced a video abstract (http://www.bmj.com/content/346/bmj.f2350?view=
long&pmid=23692896).
4.2.1 Abstract
Background: Linked electronic health records are increasingly used in health research.
For a common acute medical condition, myocardial infarction, no previous study has com-
pared four electronic health record sources.
Aim: To determine the completeness and diagnostic validity of myocardial infarction
recording across four national health record sources: primary care, hospital care, a dis-
ease registry, and mortality register.
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Methods: We used a sample of patients with acute myocardial infarction in England
between January 2003 and March 2009, identified in four prospectively collected, linked
electronic health record sources: the primary care Clinical Practice Research Datalink
(CPRD), Hospital Episode Statistics (HES), acute coronary syndrome registry (Myocar-
dial Ischaemia National Audit Project, MINAP) and cause-specific mortality data from the
Office for National Statistics (ONS). The main outcome measures were recording of acute
myocardial infarction, all-cause mortality within one year of acute myocardial infarction,
diagnostic validity of acute myocardial infarction compared to electrocardiographic and
troponin findings in the disease registry (gold standard).
Results: We found 21 482 patients with a record of acute myocardial infarction in one
or more sources. Risk factors and non-cardiovascular co-existing conditions were similar
across patients identified in CPRD, HES and MINAP. Immediate all-cause mortality was
highest among acute myocardial infarction patients recorded in CPRD, which (unlike HES
and MINAP) includes patients who did not reach hospital, but at one year mortality rates
in cohorts from each source were similar. 5561 patients with non-fatal acute myocardial
infarction (31.0%) were recorded in all three sources and 11 482 (63.9%) in at least two
sources. Crude incidence of acute myocardial infarction was underestimated by 25–50%
using one source compared to using all three. Compared to acute myocardial infarction
defined in MINAP, the positive predictive value of acute myocardial infarction recorded in
CPRD was 92.2% (95% confidence interval (CI) 91.6, 92.8) and in HES was 91.5% (95%
CI 90.8, 92.1).
Conclusion: Failure to use linked electronic health records from primary care, hospi-
tal admission, disease registry and death certificates may lead to biased estimates of
myocardial infarction incidence and outcome.
4.2.2 Introduction
Linked electronic health records are increasingly used in research, in measuring out-
comes of health care, and in health policy. However, for acute myocardial infarction the
overlap between these four electronic health record sources, the patient risk factors and
subsequent mortality have not previously been compared. Previous cross-referencing
studies have typically compared one or two electronic sources, such as coded hospi-
tal discharge diagnoses and cause of death, to case note review [149–151], question-
naire to general practitioners [141] or active case finding in a prospective consented
study [152–154].
Linkages with the national, ongoing acute coronary syndrome registry allowed detailed
myocardial infarction diagnoses (with coded electrocardiographic findings and markers of
myocardial necrosis, not available in other sources) to be compared with primary care and
hospitalisation diagnoses. Linkages with primary care allowed evaluation of risk factors
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in patients with a record of acute myocardial infarction in any source. Linkages with
the death record allowed evaluation of cause specific mortality of myocardial infarction
recorded in any source, including among cases not admitted to hospital.
Our objective therefore was to compare incidence, recording, agreement of dates and
codes, risk factors and all-cause mortality of acute myocardial infarction recorded in pri-
mary care, hospital discharges, national acute coronary syndrome registry and the na-
tional death registry.
4.2.3 Methods
We used the CALIBER four-source linked dataset (primary care data from CPRD, hospital
admission data from HES, mortality data from ONS and detailed information about acute
coronary syndromes from MINAP) as described in chapter 3. We identified patients with
acute myocardial infarction in any of the CALIBER data sources between January 2003
and March 2009 and compared the characteristics of patients recorded in each source.
We identified myocardial infarction in CPRD by searching for any of 62 Read codes
for myocardial infarction in the patient’s record, in HES by ICD-10 codes I21, I22 or I23
recorded as the primary discharge diagnosis for the first episode of the hospital admis-
sion, and in MINAP using the recorded discharge diagnosis, markers of myocardial necro-
sis and coded electrocardiogram findings.
We studied the first myocardial infarction per patient during the study period. We cal-
culated the incidence of myocardial infarction and all cause mortality within one year for
different combinations of sources, with the denominator being a patient’s registration pe-
riod with a CPRD general practice during the time that the practice met CPRD recording
standards.
We assessed the diagnostic validity of myocardial infarction recorded in CPRD or HES
compared to the MINAP gold standard. Further details are given in the publication [18].
The study period was 1 January 2003 to 31 March 2009 (when all record sources were
concurrent) and confined to patients who had been registered with their general practice
for at least a year and the practice had been submitting data for at least one year that met
Clinical Practice Research Datalink data quality standards for continuity and plausibility of
data recording. In the main analysis we included only patients with at least one record of
admission to hospital in Hospital Episode Statistics at any time (for any cause) as these
patients were shown to be linkable, but we conducted a sensitivity analysis including all
patients. We selected the first record of myocardial infarction during the patient’s study
period as the index event and considered myocardial infarction records in the other data
sources as representing the same event if they were dated within 30 days of the index
event.
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Table 4.1: Recording of risk factors in CPRD before myocardial infarction recorded in any
of the CALIBER data sources from 1st January 2003 to 31st March 2009
CPRD HES MINAP ONS
Number of patients 15 819 13 831 10 351 4017
Age in years, median (IQR) 73 (61–81) 73 (61–82) 72 (61–81) 81 (73–87)
N women (%) 5810 (36.7) 5072 (36.7) 3649 (35.3) 1752 (43.6)
Most deprived quintile, n (%) 3211 (20.3) 2641 (19.1) 1997 (19.3) 849 (21.1)
Smoking, n (%)
Current 4147 (26.2) 3608 (26.1) 2729 (26.4) 638 (15.9)
Ex 9414 (59.5) 8176 (59.1) 6194 (59.8) 2622 (65.3)
Non 1933 (12.2) 1745 (12.6) 1341 (13.0) 521 (13.0)
Missing 325 (2.1) 302 (2.2) 87 (0.8) 236 (5.9)
Systolic blood pressure
mmHg, mean (SD) 145 (15.4) 145 (15.6) 145 (15.2) 146 (16.1)
Missing n (%) 385 (2.4) 351 (2.5) 198 (1.9) 64 (1.6)
Use of blood pressure lowering
drugs, n (%) 9149 (57.8) 7907 (57.2) 5950 (57.5) 2919 (72.7)
Total serum cholesterol
mmol/L, mean (SD) 5.4 (0.9) 5.4 (0.9) 5.4 (0.9) 5.2 (0.9)
Missing n (%) 4646 (29.3) 4291 (31.0) 2927 (28.3) 1101 (27.4)
HDL cholesterol mmol/L, mean
(SD) 1.3 (0.3) 1.3 (0.3) 1.3 (0.3) 1.4 (0.3)
Missing n (%) 6985 (44.2) 6214 (44.9) 4443 (42.9) 1703 (42.4)
Use of lipid lowering
medications, n (%) 5632 (35.6) 4686 (33.9) 3669 (35.4) 1757 (43.7)
Framingham hard coronary heart disease risk score, n (%)
<10% 1273 (8.0) 1019 (7.4) 851 (8.2) 186 (4.6)
10–20% 4718 (29.8) 4121 (29.8) 3181 (30.7) 1248 (31.1)
>20% 2799 (17.7) 2439 (17.6) 1841 (17.8) 872 (21.7)
Missing 7029 (44.4) 6252 (45.2) 4478 (43.3) 1711 (42.6)
Diabetes, n (%) 2885 (18.2) 2467 (17.8) 1858 (17.9) 927 (23.1)
Charlson index, mean (SD) 2.5 (1.7) 2.4 (1.6) 2.4 (1.6) 3.2 (1.9)
Primary care consultation rate
per year, median (IQR) 3.7 (1.6–7.9) 3.5 (1.5–7.7) 3.6 (1.6–7.8) 5.0 (2.3–9.8)
Deprivation was assessed by the index of multiple deprivation. Blood pressure and cholesterol values are
the mean of measurements before the date of myocardial infarction. The Framingham score is based on
patients with complete data for blood pressure and cholesterol.
The total number of patients was 21 482. Patients might be represented in more than one column if their
myocardial infarction was recorded in more than one source.
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Cardiovascular risk factors and non-cardiovascular coexisting conditions
For patients with acute myocardial infarction, we identified risk factors recorded in primary
care, including age, sex, social deprivation [131], smoking, use of antihypertensives or
lipid lowering drugs, diabetes mellitus, Charlson comorbidity index [155], and primary
care consultation rate before the event. We used mean measures of systolic blood pres-
sure, total cholesterol and high density lipoprotein cholesterol before myocardial infarction
along with age, sex and smoking status (where recorded) to estimate the 10 year Fram-
ingham risk for acute myocardial infarction or coronary death [156].
Follow-up for mortality
We followed all patients with a record of myocardial infarction in any source for one year
for death as recorded in the ONS death registry. We categorised patients as having fatal
or non-fatal myocardial infarction by whether they died of any cause within seven days
of the myocardial infarction. If a patient had a myocardial infarction record in CPRD,
HES, or MINAP after their date of death, we considered that they died on the day of their
myocardial infarction.
Agreement in recording
If the time difference between the earliest date of acute myocardial infarction in one
source and the date in another source was no more than 30 days we considered that
the records of acute myocardial infarction in the different sources agreed. A myocardial
infarction recorded more than 30 days after the earliest date was considered a new event
and was not included, ensuring that each patient appeared only once in the analysis.
We chose 30 days to account for any delay in recording of myocardial infarction in pri-
mary care, assuming that any record within 30 days of a hospital admission was likely
to represent the same event and anything after 30 days could feasibly be a subsequent
myocardial infarction. We carried out a sensitivity analysis using a 90 day threshold.
Statistical analysis
Incidence. We estimated population based incidence rates of fatal and non-fatal acute
myocardial infarction using the denominator of all adults in the CALIBER primary care
population aged 18 and over (2.2 million), followed up for a mean 4.1 years between
2003 and 2009. We used each of the data sources separately and together to identify
incident myocardial infarction, ending the follow-up period for a patient on the date of
their first myocardial infarction during the study period, death, or de-registration from the
general practice.
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Cardiovascular risk factors and non-cardiovascular coexisting conditions. We
compared patients with fatal and non-fatal acute myocardial infarction identified in the
four data sources for risk factors and coexisting conditions recorded in primary care.
Death after acute myocardial infarction. We produced cumulative incidence curves
for coronary and non-coronary mortality for patients recorded in each data source and
compared mortality using a Cox proportional hazards model adjusted for age and sex.
Agreement in recording. We would expect patients who survived seven days after
myocardial infarction to be recorded in the primary care, disease registry, and hospital
admissions sources, and we assessed agreement between these three sources in a Venn
diagram. For patients who died within seven days, we examined the proportion recorded
by each source but did not compare agreement across all four sources as we would
not expect the hospital discharge data and disease registry to record patients who died
before reaching hospital.
We calculated the positive predictive value of primary care or hospital discharge diag-
noses of acute myocardial infarction among patients who also had a record in the acute
coronary syndrome registry. For each Read code for myocardial infarction, we calculated
the proportion of patients with a myocardial infarction also recorded in HES or MINAP,
and used this information to refine the phenotyping algorithm for myocardial infarction for
use in the studies in this thesis (see section 5.4.4).
Data were analysed using Stata 12 and R 2.14 [157].
4.2.4 Results
We identified 21 482 patients with acute myocardial infarction in any of the four data
sources.
Incidence
Among the single source crude estimates for incidence of myocardial infarction, primary
care data (CPRD) gave the highest estimate, of 187 per 100 000 patient years (95%
confidence interval (CI) 184, 190), followed by hospital discharge data (HES) with 154 per
100 000 patient years (95% CI 152, 157), acute coronary syndrome registry (MINAP) with
115 per 100 000 patient years (95% CI 113, 118), and death registry with 45 per 100 000
patient years (95% CI 43, 46). Combining these three sources yielded an estimate of
243 per 100 000 patient years (95% CI 239, 246, Figure 4.3 on page 74). The crude
incidence of acute myocardial infarction was 25% lower using only CPRD and 50% lower
using only MINAP compared with using all three sources.
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Cardiovascular risk factors and comorbidity
Overall, the cohorts identified from CPRD, HES and MINAP had a similar prevalence of
cardiovascular risk factors and comorbidities. However, compared with those recorded
in MINAP or HES, patients with fatal or non-fatal myocardial infarction recorded only in
CPRD were on average two years younger and more likely to be current smokers and in
the most deprived fifth (P <0.001 for these comparisons). Patients recorded by the death
registry were older than patients recorded in the other sources and had a higher bur-
den of risk factors reflecting their age. However, other demographic characteristics and
cardiovascular risk factors were broadly similar across patients recorded in the different
sources (Table 4.1 on page 68).
Death after acute myocardial infarction
Immediate all cause mortality was highest among patients with acute myocardial infarc-
tion recorded in CPRD, which (unlike HES and MINAP) included patients who did not
reach hospital. Patients with myocardial infarction identified in MINAP had a lower crude
30 day mortality (10.8%, 95% CI 10.2%, 11.4%) than those identified in HES (13.9%, 95%
CI 13.3%, 14.4%) or in CPRD (14.9%, 95% CI 14.4%, 15.5%, Figure 4.1 on page 73).
At one year, however, mortality was similar amongst patients with myocardial infarction
identified in any of the three sources, at around 20%.
Non-fatal acute myocardial infarction: agreement between record sources
Among the 17 964 patients with at least one record of non-fatal acute myocardial infarc-
tion, 13 380 (74.5%) were recorded by CPRD, 12 189 (67.9%) by HES, and 9438 (52.5%)
by MINAP. Overall, 5561 (31.0%) of patients had the event recorded in all three sources
and 11 482 (63.9%) in at least two sources (Figure 4.2 on page 73). When we ex-
tended the recording window from 30 days to 90 days, the proportion recorded in all three
sources increased only slightly, to 32.0% (n=5747). When we included patients who had
never had a record of a hospital admission in HES, the proportion of non-fatal myocar-
dial infarctions recorded in all three sources decreased slightly to 30.0% (5561/18 536)
and the proportion recorded only in primary care increased from 17.7% (3188/17 964)
to 20.3% (3760/18 536). A sensitivity analysis in which the HES case definition included
secondary diagnoses of myocardial infarction, where myocardial infarction was not the
reason for admission, produced a slight increase in the proportion recorded in all three
sources (5812/18 283, 32.0%), and identified 306 additional myocardial infarctions that
were not in any other source.
Positive predictive value
For patients with myocardial infarction in CPRD or HES who also had an associated
record in MINAP, the positive predictive value of the myocardial infarction diagnosis (the
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Table 4.2: Information recorded in the disease registry (MINAP) within 30 days for non-
fatal myocardial infarction (MI) recorded in primary care (CPRD) or hospital
admission (HES)
Positive predictive value of HES or CPRD MI is calculated considering a MINAP diagnosis of MI to be the
gold standard. Numbers in parentheses are percentages unless stated otherwise.
Whether MI is recorded in CPRD, HES or both
Information in MINAP CPRD HES CPRD and HES
Number of patients 7224 7489 6006
ECG findings
ST elevation 3373 (46.7) 3455 (46.1) 3062 (51.0)
Other abnormality 2337 (32.4) 2485 (33.2) 1816 (30.2)
Normal 389 (5.4) 429 (5.7) 306 (5.1)
Not recorded 1125 (15.6) 1120 (15) 822 (13.7)
Cardiac markers
Raised 6149 (85.1) 6358 (84.9) 5121 (85.3)
Normal 368 (5.1) 411 (5.5) 299 (5.0)
Missing 707 (9.8) 720 (9.6) 586 (9.8)
Peak troponin
N (%) with peak troponin recorded 6109 (84.6) 6357 (84.9) 5029 (83.7)
Median (inter-quartile range) 2.03 (0.47-10.0) 2.04 (0.45-10.2) 2.34 (0.53-11.6)
CALIBER diagnosis
ST elevation MI 3386 (46.9) 3441 (46.0) 3064 (51.0)
Non ST elevation MI 3274 (45.3) 3410 (45.5) 2497 (41.6)
Unstable angina 384 (5.3) 425 (5.7) 312 (5.2)
Other 180 (2.5) 213 (2.8) 133 (2.2)
Positive predictive value for MI, with
MINAP MI as the gold standard (95% CI) 92.2 (91.6, 92.8) 91.5 (90.8, 92.1) 92.6 (91.9, 93.3)
probability that the diagnosis recorded in MINAP was myocardial infarction rather than un-
stable angina or a non-cardiac diagnosis) was 92.2% (6660/7224, 95% CI 91.6%, 92.8%)
for CPRD and 91.5% (6851/7489, 95% CI 90.8%, 92.1%) for HES (Table 4.2 on page
72).
Unlike MINAP, HES did not record the type of myocardial infarction (ST elevation my-
ocardial infarction, STEMI or non ST elevation myocardial infarction, NSTEMI), because
ICD-10 does not contain specific codes for the type of myocardial infarction. However, the
pattern of ICD-10 codes differed between STEMI and NSTEMI, with STEMI more likely
to be recorded using codes I210 or I211 and NSTEMI more likely to be recorded as I214
or I219 (Table 4.3 on page 74). Read codes denoting a myocardial infarction record in
CPRD varied in how likely they were to be associated with myocardial infarction in HES
or MINAP, as shown in Table 4.4 on page 75.
For patients with a record in MINAP and either CPRD or HES, the positive predictive
value of the acute myocardial infarction diagnosis (i.e. the probability that the diagno-
sis recorded in MINAP was myocardial infarction rather than unstable angina or a non-
cardiac diagnosis) was 92.2% (95% CI 91.6%, 92.8%) for myocardial infarction in CPRD
and 91.5% (95% CI 90.8%, 92.1%) for myocardial infarction in HES (Table 4.2 on page
72).
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Figure 4.1: Kaplan Meier curves showing all cause mortality, stratified by record source
CPRD N=15,819, HES N=13,831, MINAP N=10,351; total 20,819 patients
Figure 4.2: Number and percentage of records from primary care (CPRD), hospital data
(HES) and the disease registry (MINAP) for non-fatal myocardial infarction
N=17,964 patients
73
Chapter 4. Methods development of the CALIBER resource
Figure 4.3: Crude incidence of acute fatal and non-fatal myocardial infarction estimated
using different combinations of primary care data (CPRD), hospital admission
data (HES), disease registry (MINAP) and death registry (ONS)
Table 4.3: Distribution of ICD-10 codes for ST and non-ST elevation myocardial infarction
ICD-10 STEMI NSTEMI
code ICD-10 term N % N %
I210 Acute transmural myocardial infarction of anterior wall 1122 30.2 171 4.8
I211 Acute transmural myocardial infarction of inferior wall 1472 39.6 228 6.4
I212 Acute transmural myocardial infarction of other sites 119 3.2 75 2.1
I213 Acute transmural myocardial infarction of unspecified site 19 0.5 6 0.2
I214 Acute subendocardial myocardial infarction 119 3.2 836 23.5
I219 Acute myocardial infarction, unspecified 606 16.3 1803 50.7
I220 Subsequent myocardial infarction of anterior wall 63 1.7 21 0.6
I221 Subsequent myocardial infarction of inferior wall 114 3.1 24 0.7
I228 Subsequent myocardial infarction of other sites 17 0.5 84 2.4
I229 Subsequent myocardial infarction of unspecified site 61 1.6 309 8.7
I230 Haemopericardium as current complication following acutemyocardial infarction 0 0.0 1 0.0
I232 Ventricular septal defect as current complication following acutemyocardial infarction 0 0.0 1 0.0
I238 Other current complications following acute myocardial infarction 2 0.1 0 0.0
STEMI, ST elevation myocardial infarction; NSTEMI, non-ST elevation myocardial infarction
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Table 4.4: Proportion of CPRD myocardial infarctions associated with HES primary diag-
nosis of myocardial infarction and MINAP diagnosis of myocardial infarction,
by Read term
N HES MINAP MINAP New
Read term patients primary STEMI NSTEMI category
G30..00 Acute myocardial
infarction 5220 3458 (66.2%) 1425 (27.3%) 1120 (21.5%) Acute MI
G30..15 MI - acute myocardial
infarction 3312 2166 (65.4%) 920 (27.8%) 726 (21.9%) Acute MI
G307100 Acute non-ST segment
elevation myocardial infarction 2653 1908 (71.9%) 103 (3.9%) 1205 (45.4%) NSTEMI
G30z.00 Acute myocardial
infarction NOS 754 500 (66.3%) 162 (21.5%) 183 (24.3%) Acute MI
G30X000 Acute ST segment
elevation myocardial infarction 714 616 (86.3%) 463 (64.8%) 62 (8.7%) STEMI
G308.00 Inferior myocardial
infarction NOS 450 375 (83.3%) 256 (56.9%) 29 (6.4%) Acute MI
G301z00 Anterior myocardial
infarction NOS 115 93 (80.9%) 67 (58.3%) 11 (9.6%) Acute MI
G301.00 Other specified anterior
myocardial infarction 79 50 (63.3%) 28 (35.4%) 6 (7.6%) Acute MI
G30..14 Heart attack 74 32 (43.2%) 13 (17.6%) 14 (18.9%) Uncertain MI
G300.00 Acute anterolateral
infarction 58 48 (82.8%) 29 (50%) 4 (6.9%) Acute MI
G302.00 Acute inferolateral
infarction 57 45 (78.9%) 31 (54.4%) 2 (3.5%) Acute MI
G307000 Acute non-Q wave
infarction 40 25 (62.5%) 4 (10%) 11 (27.5%) Acute MI
G301100 Acute anteroseptal
infarction 34 28 (82.4%) 16 (47.1%) 6 (17.6%) Acute MI
323..00 ECG: myocardial
infarction 31 13 (41.9%) 6 (19.4%) 2 (6.5%) MI on ECG
G307.00 Acute subendocardial
infarction 30 22 (73.3%) 1 (3.3%) 11 (36.7%) Acute MI
G304.00 Posterior myocardial
infarction NOS 23 14 (60.9%) 8 (34.8%) 4 (17.4%) Acute MI
G30..17 Silent myocardial
infarction 22 2 (9.1%) 0 (0%) 1 (4.5%) Uncertain MI
G38..00 Postoperative
myocardial infarction 18 1 (5.6%) 1 (5.6%) 3 (16.7%) Acute MI
G30A.00 Mural thrombosis 17 3 (17.6%) 0 (0%) 0 (0%) Uncertain MI
G303.00 Acute inferoposterior
infarction 16 13 (81.3%) 8 (50%) 3 (18.8%) Acute MI
G305.00 Lateral myocardial
infarction NOS 14 8 (57.1%) 6 (42.9%) 1 (7.1%) Acute MI
G310.11 Dressler’s syndrome 13 0 (0%) 0 (0%) 0 (0%) MI complica-tions
G30y.00 Other acute myocardial
infarction 9 7 (77.8%) 2 (22.2%) 2 (22.2%) Acute MI
G30y200 Acute septal infarction 8 2 (25%) 3 (37.5%) 0 (0%) Acute MI
G30..11 Attack - heart 7 2 (28.6%) 2 (28.6%) 0 (0%) Uncertain MI
Results shown for 25 most common Read terms for MI. STEMI, ST elevation myocardial infarction; NSTEMI,
non-ST elevation myocardial infarction
‘New category’ is a suggested classification of myocardial infarction Read codes based on this work.
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4.2.5 Discussion
We compared electronic health records on one major disease event – acute myocardial
infarction – across four English, ongoing sources of health record data: primary care
(CPRD), hospital admissions (HES), a quality improvement disease registry (MINAP),
and the death registry (ONS). We found that each data source missed a substantial
proportion of myocardial infarction events, but that patients with a myocardial infarction
record in any source had risk factor profiles and one-year mortality consistent with true
myocardial infarction. Taken together, these findings support the wider use of linkage of
multiple record sources by clinicians, policy makers, and researchers.
Fatal myocardial infarction
Both primary care and death registry data can be used to capture fatal myocardial infarc-
tion occurring out of hospital among people without a record of myocardial infarction in
HES or MINAP. The death registry is a useful source of fatal acute myocardial infarction
for research, as most (83.0%) patients who were identified as having acute myocardial
infarction in any of the data sources and died within seven days had myocardial infarction
recorded as their underlying cause of death. These figures agree with results from the
Oxford Record Linkage Study, where among 5686 patients admitted to hospital with my-
ocardial infarction 85.2% who died within 30 days had myocardial infarction recorded as
the underlying cause of death [158].
Non-fatal myocardial infarction
We found that each record source misses cases, with only one third of non-fatal myocar-
dial infarctions being recorded in all three data sources (CPRD, HES and MINAP). Two
thirds of non-fatal myocardial infarctions were recorded in at least two sources. CPRD
was the single most complete source of non-fatal myocardial infarction records (one quar-
ter of all non-fatal myocardial infarction events not recorded), HES missed one third, and
MINAP missed nearly half (Figure 4.2 on page 73). Previous two-source comparison
studies in Scotland [159], Australia [160], Denmark [161], and the Netherlands [154] have
shown that hospital records alone underestimate the true incidence of myocardial infarc-
tion. Despite the low sensitivity of these data sources, in our study the positive predictive
value of myocardial infarction records in primary care and hospital admission sources
were over 90% compared with the disease registry gold standard (Table 4.2 on page
72). However, some of the myocardial infarctions recorded only in primary care are likely
to be historical diagnoses because the mortality rate in the first month is much lower than
among those also recorded in hospital sources.
Our results using cross referencing of electronic health records in 20 000 patients are
consistent with previous manual approaches to validation in primary care, which validated
Read coded diagnoses in a few hundred patients against anonymised free text, death
76
4.2. Validation of acute myocardial infarction diagnoses in CALIBER
certificates, paper medical records, hospital discharge summaries, or questionnaires to
general practitioners [133, 162–167]. Our much larger sample size, however, allowed us
to evaluate individual Read terms that are used to record myocardial infarction (Table
4.4 on page 75). This type of validation has not been done previously for myocardial
infarction and may be relevant to other common conditions that can be recorded using a
variety of codes, such as stroke [168].
Hospital admission data
To our knowledge, no studies have examined the positive predictive value of ICD-10
coded myocardial infarction diagnosis in hospital admission data against an ongoing dis-
ease registry. We found that 62.8% of non-fatal myocardial infarctions recorded in CPRD
and 72.6% recorded in MINAP were also recorded in HES.
Disease registry and maximising true positives
The strength of the disease registry MINAP is that it contains detailed diagnostic records:
troponin values, coded electrocardiographic findings, and cardiologist diagnosis of STEMI
or NSTEMI. These data items provide validated endpoints from all hospitals in Eng-
land and Wales, and are not available in other sources. An acute myocardial infarction
recorded in MINAP can be considered an electronic health record ‘gold standard’, as a
myocardial infarction recorded by a registry is likely to fulfil international diagnostic crite-
ria [9]. Validation of myocardial infarctions in CPRD or HES against those recorded by
MINAP showed a positive predictive value of over 90%, making them suitable for detect-
ing endpoints in cohort studies and trials, where poor endpoint resolution can dilute any
observed effect and reduce the power of a study [169]. The positive predictive value was
not 100% because some myocardial infarction records in primary care may actually have
been related to unstable angina or chest pain of an unknown cause.
Limitations of this study
One limitation is that our data were from a sample of English general practices rather
than the entire population, but patients included in CPRD have been shown to be repre-
sentative of the UK population (see section 3.3.1). A second limitation concerns the gen-
eralisability of our findings for the quality of primary care data. Practices contributing data
to the CPRD are advised of recording guidelines and their data are accepted only when
they meet standards of data completeness, so they are likely to record disease events
better than general practices that do not contribute. Our estimates of agreement from this
study may therefore be higher than for practices that do not contribute to CPRD. Thirdly,
our validation of HES and CPRD myocardial infarctions against MINAP was limited to
the subset of patients with a MINAP record, and caution must be exercised in extending
these conclusions to patients with myocardial infarctions without a MINAP record.
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Clinical and policy implications
With the current emphasis on measuring clinical outcomes in health systems, our study
has important implications for practice and policy. Firstly, we propose much wider use of
linked record sources in commissioning and in research to estimate disease occurrence
and outcome, because of the biases inherent in using only one source of records. Chang-
ing the estimates for incidence of myocardial infarction could potentially alter the modelled
effect of population based healthcare interventions. Our findings underscore the impor-
tance of international initiatives to accelerate availability of linked data [170–172].
Secondly, a national strategy for biomedical informatics is required to tackle manifest
system failings: a single health event should, ideally, have a single record that is propa-
gated in multiple record systems. Disease registries such as MINAP could be improved
if embedded in real time clinical care of all patients with myocardial infarction, rather than
the current situation in which hospitals employ audit staff to retrospectively enter records
on patients in coronary care units. This is applicable to many disease areas, not just
coronary care. In section 10.1.2 (page 235) I outline how this may be achieved in a
standardised way using openEHR archetypes.
Thirdly, primary care records could be improved by recording precise dates of events,
and avoidance of repeat recording of acute events. This can be achieved by having
user-friendly problem-based medical records and ensuring that healthcare staff can use
it correctly and easily.
Future research
Several lines of research are warranted by our findings. Firstly, research is required to
understand how electronic health record data are coded, and how this can be improved.
Secondly, more extensive cross referencing is required against additional sources of infor-
mation on myocardial infarction. These include self reported myocardial infarction (which
may be less dependent on specific setting in the health system), manual review of all the
available local case records (paper and electronic), and investigation of electronic free
text recorded by general practitioners (for diagnoses that are not recorded using a Read
code). Such efforts are underway in the UK Biobank cohort (n=500 000) [169]. There is
a need for investigator led cohorts and trials to link with the primary care record [173].
It is important to evaluate how other registries, such as cancer registries, compare with
primary care and hospital data sources [174]. This is essential for large studies where
manual review of case records is not feasible.
Conclusion
Failure to use linked electronic health records from primary care, hospital care, disease
registry, and death certificates may lead to biased estimates of the incidence and out-
come of myocardial infarction. The use of linked data helps to overcome limitations of the
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individual sources, but it is important to cross-reference and understand the data sources
in order to be able to use them effectively in research [18].
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4.3 Converting raw data to research-ready variables in CALIBER
4.3.1 Abstract
Introduction. Researchers using electronic health record databases have had to de-
velop complex algorithms and compile lists of diagnosis terms in order to define cohorts
and extract clinical characteristics or phenotypes of the patients in the study. Typically
these methods have not been shared among research communities, which has led to
duplication of effort and difficulties in reproducing research findings.
Methods. I wrote a set of packages for the R statistical system was developed to assist
in generation of codelists (lists of diagnosis, procedure or other terms that are used to
define a research variable), data management and handling missing data. A process was
developed for developing phenotype algorithms, documenting them and publishing them
on the CALIBER web portal.
Results. Three R packages have been published and are currently being used by other
CALIBER researchers, and are accessible to any researcher to download and use. The
CALIBER team has developed 25 disease phenotypes and over 400 other variables,
which are curated on the CALIBER portal.
Discussion. The existence of the CALIBER portal and other tools has greatly facilitated
research using the CALIBER database. However, looking beyond CALIBER there is a
need for a broader repository of open access methods for using electronic health records.
4.3.2 Introduction
Researchers using electronic health record databases such as the CPRD have had to
develop algorithms, some of which may be quite complex, to identify patients with partic-
ular phenotypes. These involve identifying diagnoses and other coded information. Lists
of diagnoses codes are typically shared informally within a research group, and some-
times published along with papers, but the lack of systematic sharing of algorithms can
result in duplicated effort, lack of transparency and non-comparability of studies that used
different definitions.
It is now being recognised that this is an inefficient way to do research, and there are
new initiatives to encourage sharing of code and algorithms. One notable example is
the Electronic Medical Records and Genomics (eMERGE) network [6], which aims to
bring together electronic health record datasets from a number of US hospitals to explore
phenotype-genotype associations in larger number of patients. Members of the eMERGE
consortium publish their phenotyping algorithms (methods for deducing a patient’s clinical
characteristics based on information in the electronic health record) on the eMERGE
Phenotype Knowledgebase (PheKB) website https://phekb.org/phenotypes?.
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The slow steps taken towards sharing methods in electronic health record research
contrast with the early adoption of standardisation and sharing of methods in bioinformat-
ics. The CALIBER programme aims to take further steps in this direction, by providing a
portal for sharing and distributing data preparation algorithms and phenotype definitions
(https://caliberresearch.org/portal).
Creating a research variable from CALIBER raw data typically requires the researcher
to first define the diagnoses or procedures of interest by looking for terms in a relevant ter-
minology (e.g. Read, ICD-10 or OPCS), then to extract records with the terms of interest,
and finally to process the data to arrive at a workable definition for a study. For exam-
ple, creation of a variable for body mass index requires extraction of height and weight
records, data cleaning to convert all the measurements into the same units and remove
erroneous results, a method for handling measurements recorded at different times, and
calculation of the final body mass index from the cleaned data [175].
4.3.3 R packages
R is an increasingly popular open source statistical system and programming language
[157]. A key strength of R is the large number of user-contributed extension packages
which can extend its functionality and interface with other programs. R has a well-
documented, structured system for creating packages which mandates the creation of
comprehensive help documentation. Creating re-usable code in a package is initially
more work than writing an ad hoc function, but the code can be published and used more
easily by other researchers so it is beneficial in the long run – both in terms of saving time
and improving the transparency of research.
I created a set of R packages which are available from the ‘caliberanalysis’ project page
on R-Forge (www.caliberanalysis.r-forge.r-project.org):
CALIBERcodelists – functions to create, modify, compare, merge, export and convert
codelists. A codelist is a list of Read, OPCS and ICD-10 codes for identifying a
particular condition in raw CALIBER data.
CALIBERdatamanage – data management and display tools, including functions for
loading databases with automatic date conversion, for creating a variable per pa-
tient from data at multiple time points, and producing summary tables and forest
plots.
CALIBERrfimpute – Random Forest multiple imputation for MICE (see section 4.4 on
page 90). This package is published on the peer-reviewed Comprehensive R
Archive Network repository, which is an online resource of quality-assured pack-
ages that can be installed directly by anyone running R.
In addition I created a package ‘CALIBERlookups’ containing dictionaries and lookup
tables for CALIBER, for use within our research group or other NHS / UK academic col-
laborations. CALIBERlookups is a compilation of CPRD lookups, ICD-10 and OPCS
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dictionaries from the UK Terminology Centre, and ICD-9-CM codes from the US National
Centre for Health Statistics. By providing all these resources within a single convenient
package it spares researchers from having to download and prepare each individual dic-
tionary.
CALIBERlookups is not published on R-Forge. It cannot be released generally because
the WHO has granted a restricted licence to the Department of Health for use of the ICD-
10 dictionary solely for healthcare and health research in the UK, which means that I
am not permitted to publish it. (In contrast, Read and OPCS are available on the Open
Government Licence, which does permit redistribution and reuse.)
The R packaging system enables R code, help files, test cases, examples and docu-
mentation to be distributed in an organised way, so that other researchers can understand
and use the code. The source code and history of modifications to the code are curated
on R-Forge.
4.3.4 CALIBER data management
The CALIBER data management R package provides convenient interfaces for certain
data management tasks. In particular it streamlines the handling of large datasets, which
can either be handled in memory as ‘data.table’ objects (very fast and flexible, but limited
by the amount of computer memory), or on disk as ‘ffdf’ objects (which can be much
larger, and leave more memory free for analysis, but have a less flexible programming
interface). My CALIBERdatamanage package provides convenient functions for convert-
ing between the ‘data.table’ and ‘ffdf’ dataset formats, and defines data management
functions with a common interface to data in either format.
These are some of the functions included in the package:
importDT Imports file to data.table, automatically detecting date format and extracting
files from a zip file.
importFFDF Imports a single file or multiple files to ffdf, automatically detecting date
format and extracting files from a zip file.
cohort Designates a dataset as a ‘cohort’ object, with one row per patient, a defined
patient identifier and the facility to include a data dictionary.
extractCodes Subsets a data.table or ffdf object according to ICD-10, Read or OPCS
codes in a codelist.
transferVariables Transfers variables from one dataset to another based on a key col-
umn. This makes it easier to work with multiple datasets each containing a few
variables, saving computer memory.
addCodelistToCohort Creates a one-row-per-patient extract of a file based on a codelist
(e.g. earliest diagnosis within a particular time window, based on an index date) and
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merges it onto a cohort. This single function can replace several lines of code and
make scripts more intuitive.
addToCohort Creates a one-row-per-patient extract of a file based on a value (e.g. lab
result within a particular time window, based on an index date) and merges it onto
a cohort.
multiforest A flexible function to create multiple forest plots with annotations, based on
a specification in a spreadsheet format (which can include formatting information
as well as values and text).
4.3.5 Codelists
Before describing the CALIBER system for deploying codelists, I will briefly define some
relevant words and phrases:
Controlled vocabulary – an authoritative list of terms (words or phrases) to be used in
indexing [176].
Terminology – a type of controlled vocabulary which covers the set of terms in a pro-
fessional domain. For example, OPCS and the Read Clinical Terms Version 3 are
terminologies [177]. Terminologies may be classifications or ontologies.
Classification / taxonomy – arranges all the concepts in the domain into groups or a hi-
erarchical structure; the International Classification of Disease is an example [139].
Ontology – a set of concepts with definitions of the relationship between different con-
cepts, such as ‘is a part of’ or ‘is a type of’ [176]. SNOMED-CT is a large terminol-
ogy which contains the Read and ICD-10 terms and will eventually replace Read
in the NHS. It is supposed to be an ontology, with each term defined in terms of
relationships with other terms, although currently many of the terms do not have
such relationships defined.
Algorithms for extracting research variables from electronic health record (EHR) data
sources frequently need to identify records according to a terminology (e.g. selecting all
ICD-10 terms for myocardial infarction). There are thousands of potential terms included
in the terminologies, and for aggregation purposes one may require a handful of terms or
hundreds of terms.
Codelists are developed by an iterative process which involves searching for terms in
the dictionaries, combining selections of terms to derive a final set of chosen terms, and
assigning a category to these terms (Figure 4.4 on page 84). In CALIBER, codelists are
stored in a custom human-readable text file format which includes a column for metadata
such as the author’s name, version number and date. This file format can be opened
in a simple text editor, a spreadsheet program, a statistical package or custom software
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Figure 4.4: Process for generating a codelist using the R CALIBERcodelists package
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1. Decide which source dictionaries to use, e.g. Read, ICD-10 and/or OPCS.
2. Create a selection of terms from the source dictionaries. e.g. all terms containing the word ‘angina’,
or all ICD-10 codes beginning with ‘I20’. Combine selections using Boolean operators such as AND,
OR or NOT to identify exactly which terms are of interest.
3. Allocate a category to terms in a particular selection, e.g. ‘history of angina’.
4. Set the metadata for the codelists under construction (version number, category descriptions, author
name, date). Extract the Read, ICD-10 and OPCS codelists and save them in a standard file format.
5. Ask clinicians and epidemiologists to review the codelists and suggest any changes. Also it may
be useful to validate the codelist by exploring CALIBER data, e.g. comparing myocardial infarction
records extracted using a Read codelist versus records in MINAP. The algorithm can be changed and
the results compared with the previous version if necessary.
6. Approved codelists with documentation can be shared on the CALIBER data portal (section 3.7 on
page 61) for use in subsequent studies.
developed by the CALIBER data manager to automatically extract records of interest
from the CALIBER master database. All codelists stored on the data portal have a version
number in order to track which versions of each codelist were used for a particular project.
4.3.6 Phenotyping algorithms
The phenotype of an individual is the set of observable characteristics about that person,
which may include clinical measurements such as height and blood pressure, or disease
states such as diabetes or coronary artery disease. In electronic health record research,
one is interested in studying the phenotype but the information about the phenotype is
what is recorded in the electronic health record. It is crucial to understand the process by
which information about a subject enters the record in order to be able to interpret it and
infer the phenotype correctly [178].
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For example, suppose one is interested in the phenotype of type 2 diabetes. If the only
data source is hospitalisation data (HES) and the patient is never hospitalised, one cannot
determine their diabetes status. If the patient is hospitalised and there is no diagnosis
code for diabetes, it could mean any of the following:
• The patient is not diabetic
• The patient is diabetic, but was not tested for diabetes, and neither the patient nor
the healthcare team know the patient is diabetic
• The patient is diabetic and the healthcare team know about it, but it is not entered
in the patient record or not coded
• The patient knows their diabetes status, but the doctor does not
Ideally evidence should be gathered to inform the probabilities of each of these sce-
narios. Cross-referencing with other data sources, or looking at other information which
might give clues (e.g. test results or medication in linked data) [179] may help. Frequently
it is necessary to make some assumptions based on clinical knowledge, and develop a
strategy for allocating a diagnostic label to the patient (e.g. diabetes confirmed, probable
diabetes). This type of strategy is called a phenotyping algorithm.
There are few diseases or conditions for which it is possible to create a ‘perfect’ phe-
notype (identifying all cases of the disease with perfect accuracy), because it relies on
having accurate information in the clinic and for that information to be entered consis-
tently and accurately in the electronic health record. Instead a phenotyping algorithm
may choose to maximise either diagnostic specificity or sensitivity, or aim to obtain an
unbiased estimate of incidence. Studies using electronic health record data can include
sensitivity analyses using different phenotyping algorithms (e.g. using different sets of
data sources, or using restricted or expanded sets of diagnoses codes). This can be
used to show that the limitations of the phenotyping process have not introduced bias
into the results.
Cross-referencing between linked data sources can help inform the best use of each
data source, as demonstrated in section 4.2.
Example: phenotyping algorithm for type 2 diabetes
This is an example of a CALIBER phenotyping algorithm for type 2 diabetes. It uses
CPRD and HES data sources to classify whether a patient is diabetic at a particular point
in time, and attempts to identify the type of diabetes. The algorithm was developed for
a cohort study comparing the prognosis of people with type 2 diabetes or no diabetes,
which is reported in chapter 5. It was assumed that the majority of diabetic patients of
the age group included in the study (i.e. adults of all ages) would have type 2 diabetes,
which becomes more prevalent with older age [180].
The aim of the algorithm was to identify patients with type 2 diabetes. It was not es-
sential to exclude people with diabetes from the ‘normal’ comparison population with
absolute certainty, because the normal population is so large that a small amount of mis-
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classification would not substantially change the nature of the population. The algorithm
was not designed to identify patients with type 1 diabetes, nor to accurately calculate
the incidence of type 2 diabetes, because of the limitations on classifying the type of
diabetes.
In developing the algorithm I reviewed previous algorithms for identifying diabetes in
UK primary care datasets [181] and undertook exploratory work cross-referencing dia-
betes diagnoses with medication, glucose tests, HbA1c, date of diagnosis and patient
registration date at the practice.
Type of diabetes can be classified using a combination of the following types of infor-
mation in the electronic health record, each of which has potential limitations:
Diagnoses codes Assuming the patient and healthcare professional know what type of
diabetes the patient has, it can theoretically be coded using the specific Read codes
for type 1, type 2, or other specific types of diabetes. However, the recommended
diagnosis codes can change over time, as they have done for myocardial infarction
(as discussed in section 4.2), and I found that patients diagnosed in earlier years
were less likely to have a specific code for diabetes. An additional problem is that
some Read terms are ambiguous, for example ‘insulin-dependent diabetes’ is sup-
posed to mean ‘type 1 diabetes’ but may be inappropriately applied to patients with
type 2 diabetes on insulin. Some patients had conflicting diagnostic codes.
Medication Patients with type 1 diabetes are almost always treated with insulin, whereas
patients with type 2 diabetes may have no medication (diet control), oral medication
or insulin. Patients on oral glucose lowering medication are most likely to have
type 2 diabetes (except for women on metformin, who may have polycystic ovary
syndrome).
History Age at diagnosis, body mass index (BMI) at diagnosis, initial medication and
other features of a patient’s diabetes history can give important clues as to the type
of diabetes, but this relies on patients having been registered at their GP throughout
that time. CPRD only contains data from a patient’s current period of registration,
and only important summary diagnoses are entered for their previous history.
Clinical measurements Glucose and HbA1c are recorded inconsistently for patients
without diabetes. High glucose in the absence of a formal diagnosis of diabetes
may mean that the patient has diabetes but it is not coded; however interpreta-
tion should be cautious in the absence of the full clinical information that would be
available to a clinician seeing the patient (e.g. whether the patient has symptoms).
Although others have developed detailed algorithms for classifying type of diabetes
based on medication, history of medication (e.g. whether the patient was given insulin
from the outset), age at diagnosis, body mass index etc. [181], the limitations in the
recording of these additional pieces of information would limit any benefit to be gained
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by a more complex algorithm. It would also risk introducing more selection bias, if only
patients with detailed records can be classified accurately. Instead I reviewed the char-
acteristics of patients identified by a simple algorithm based solely on diagnosis codes
(Figure 4.5 on page 89) and found that they were reasonable for a population with type
2 diabetes (Table 5.2 on page 114). I also performed a sensitivity analysis by different
levels of certainty of the type 2 diabetes diagnosis. The majority of diabetic patients in
this cohort had type 2 diabetes, so the population with ‘any diabetes’ should be quite sim-
ilar to the population with type 2 diabetes, and if similar associations with cardiovascular
disease are observed in both populations, the lack of precision of diagnosis coding is not
of concern.
This algorithm identifies patients with type 2 diabetes on a specified index date (e.g.
study entry date) based solely on diagnostic information recorded in CPRD and HES.
It does not use any information after study entry to classify people, in order to reduce
immortal time bias (i.e. patients who survived would be more likely to be classified in a
particular category), but such information could be included appropriately as auxiliary in-
formation if the multiple imputation approach is used. However this bias is not eliminated
completely because some codes specifying the type of diabetes may have been entered
retrospectively only for patients who survived.
The algorithm was designed to identify patients with type 2 diabetes or any diabetes,
and was not designed to identify all patients with type 1 diabetes (because many were
left with an unclassified type of diabetes). Ideally the type of diabetes for the unclassified
patients could be inferred from other clinical information, and the uncertainty propagated
in the analysis (e.g. using multiple imputation).
I calculated the age-specific prevalence of diabetes in CALIBER to help to validate this
algorithm. These estimates (shown in Table 4.5 on page 88) are broadly similar to the
prevalence in the Health Survey for England 2003, in which the percentage of people
reporting doctor-diagnosed diabetes was 3.5% in men and 2.5% in women aged 45–54,
increasing to 8.1% and 4.6% respectively in those aged 55–64 [182]. The prevalence of
diabetes has increased considerably over the past decade; in 2010 it was estimated that
11.1% of men and 8.0% of women aged 55–64 in England were diabetic [180].
4.3.7 Discussion
In this section I have described tools to assist reproducible research using CALIBER
including the definition of phenotypes, and management of datasets and codelists.
The R packages have been successfully used by a number of researchers within CAL-
IBER, which has been extremely useful for suggesting improvements and finding errors.
However there is a need for more researchers to be aware of the utility of such packages,
and the practice of making a package from ad-hoc functions enforces discipline such as
good documentation and testing, which improves the quality of code and can be a good
exercise even if the aim is not to share the code with the wider community.
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Table 4.5: Age and sex-specific prevalence of diabetes recorded in CALIBER
Percentage of patients with diabetes mellitus at baseline (95% CI)
Age N Any Type 1 Type 2 Diabetes of
Sex group patients diabetes diabetes diabetes unspecified type
Men 30–40 420 975 0.87 (0.85, 0.90) 0.47 (0.45, 0.49) 0.28 (0.26, 0.30) 0.13 (0.12, 0.14)
40–50 215 607 2.25 (2.19, 2.32) 0.50 (0.47, 0.53) 1.37 (1.32, 1.42) 0.38 (0.36, 0.41)
50–60 170 679 4.41 (4.32, 4.51) 0.45 (0.42, 0.48) 3.24 (3.16, 3.33) 0.73 (0.69, 0.77)
60–70 119 507 8.31 (8.15, 8.46) 0.52 (0.48, 0.56) 6.32 (6.18, 6.46) 1.47 (1.40, 1.54)
70–80 80 614 10.5 (10.3, 10.8) 0.53 (0.48, 0.58) 7.89 (7.71, 8.08) 2.12 (2.03, 2.23)
≥ 80 38 991 9.96 (9.66, 10.3) 0.39 (0.33, 0.46) 7.32 (7.06, 7.58) 2.25 (2.10, 2.40)
Women 30–40 411 996 0.77 (0.74, 0.80) 0.35 (0.33, 0.37) 0.25 (0.23, 0.26) 0.17 (0.16, 0.19)
40–50 198 619 1.52 (1.47, 1.57) 0.34 (0.31, 0.37) 0.90 (0.86, 0.95) 0.28 (0.25, 0.30)
50–60 166 467 2.90 (2.82, 2.98) 0.34 (0.31, 0.37) 2.03 (1.96, 2.10) 0.53 (0.49, 0.56)
60–70 123 553 5.79 (5.66, 5.93) 0.36 (0.33, 0.40) 4.37 (4.26, 4.49) 1.06 (1.00, 1.11)
70–80 103 284 7.82 (7.66, 7.98) 0.42 (0.38, 0.46) 5.70 (5.56, 5.84) 1.70 (1.62, 1.78)
≥ 80 85 325 7.69 (7.51, 7.87) 0.31 (0.27, 0.35) 5.59 (5.43, 5.74) 1.79 (1.71, 1.88)
The CALIBER data portal is an unusual resource because it exposes and shares re-
search methods that have previously been kept within research groups. This has led to
duplication of effort and has hampered the reproducibility of research using EHR. How-
ever, the portal is limited to methods for using CALIBER data; it would be useful to have
a repository which was more widely applicable for research using EHR data. Some algo-
rithms can be quite generic and some may require specialisation to handle the idiosyn-
crasies of particular data sources.
Comparison with other resources
There have been a number of recent initiatives to encourage and facilitate the sharing
of algorithms within the EHR research community. A notable example is the Phenotype
Knowledgebase of the eMERGE consortium [6]. It has a similar number of public pheno-
types to CALIBER, about 30 as of June 2015 (https://phekb.org/phenotypes?). Phe-
notyping algorithms are proposed by one centre in the consortium and can be adapted
and validated in other centres. The technicalities of the algorithms are different (e.g. the
terminology used is ICD-9 rather than Read or ICD-10) and documents are stored as
PDF files to be read by humans rather than in a computable standardised format. The
advantage of having CALIBER codelists in a standardised format is that it is easy and
automatic to extract relevant records from the master CALIBER database.
The phenotyping algorithms used in eMERGE are in some ways more advanced than
those in CALIBER because they use more detailed hospital data. For example, they may
incorporate algorithms based on echocardiogram or other imaging, or natural language
processing using the free text in the medical record, which is not routinely available in
CPRD or CALIBER.
The clinical codes website run by the University of Manchester (https://
clinicalcodes.rss.mhs.man.ac.uk/) has some similarities with the CALIBER portal in
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Figure 4.5: CALIBER phenotype algorithm for diabetes
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that it stores codelists in a standardised format, but there are also some differences. The
clinical codes website is open and anyone is free to download a codelist, unlike CAL-
IBER which requires registration. The clincal codes website curates codelists in isolation
without algorithms, and the codelists are not organised in a structured way. In contrast,
the CALIBER portal is organised in a hierarchical way similar to ICD-10; this requires
ongoing manual curation by the data management team.
These early steps should be built upon to create a wider open repository of EHR meth-
ods and codelists, which would greatly facilitate reproducible research using EHR.
Conclusions
The existence of the CALIBER portal and other tools has greatly facilitated data prepa-
ration using the CALIBER database, particularly for the research reported in this thesis.
The next section describes a new method I have developed to assist in imputing missing
data.
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4.4 Methods for handling missing data
This section is a condensed version of a manuscript published in American Journal of Epi-
demiology [148], and describes the development and testing of a new method for multiple
imputation which is particularly suited to epidemiological datasets. This Random Forest
imputation method was used in the studies investigating differential leukocyte counts and
incidence of cardiovascular diseases and mortality in this thesis (chapters 7, 8 and 9).
The program is published in the CALIBERrfimpute package [147] on the Comprehen-
sive R Archive Network http://cran.r-project.org/web/packages/CALIBERrfimpute/
index.html, and is starting to be used by other researchers. Random Forest imputation
methods are starting to be used in diverse research areas such as imagery enhance-
ments in cognitive behavioural group therapy [183], and exploring factors associated with
pressure ulcers [184].
4.4.1 Abstract
Introduction: Multivariate Imputation by Chained Equations (MICE) is commonly used
for imputing missing data in epidemiological research. The ‘true’ imputation model may
contain non-linearities which are not included in default imputation models. Random For-
est imputation is a machine learning technique which can accommodate non-linearities
and interactions and does not require a particular regression model to be specified.
Aims: To develop a new Random Forest based MICE algorithm and compare it to para-
metric MICE.
Methods: A simulation study was performed by taking 1000 random samples of 2000
patients drawn from the 10 128 patients with stable angina in the CALIBER database and
completely recorded covariates, artificially making some variables missing at random and
comparing parameter estimates obtained using different imputation methods.
Results: Both MICE methods produced unbiased estimates of (log) hazard ratios but
Random Forest was more efficient and produced narrower confidence intervals.
Conclusions: Random Forest imputation may be useful for imputing complex epidemi-
ological datasets in which some patients have missing data.
4.4.2 Introduction
Missing data are a pervasive problem in epidemiological studies, particularly for research
using clinically collected health records [185] such as CALIBER. Incomplete datasets are
frequently analysed using multiple imputation, which involves creating multiple complete
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versions of the dataset with missing values imputed by random draws from distributions
inferred from observed data [186].
Multivariate Imputation by Chained Equations (MICE), also called Full Conditional
Specification (FCS), is a common method of generating imputed values by drawing from
estimated conditional distributions of each variable given all the others [187]. Imputation
models must be appropriately specified for analyses based on imputed datasets to yield
unbiased parameter estimates and associated standard errors. The default setting in im-
plementations of MICE is for imputation models to include continuous variables as linear
terms only with no interactions, but omission of important non-linear terms may lead to
biased results [188]. Other potential problems with parametric regression models are that
they cannot include more predictor variables than the number of observations without re-
course to prior information [189], and inclusion of highly correlated variables may cause
problems due to collinearity.
Random Forest is an extension of Classification And Regression Trees (CART) [190],
which are predictive models that recursively subdivide the dataset based on values of the
predictor variables. They do not rely on distributional assumptions and can accommodate
non-linear relations and interactions [191]. Stekhoven et al. have developed a Random
Forest-based algorithm for missing data imputation called missForest [192], but it aims
to predict individual missing values accurately rather than taking random draws from a
distribution, so it would not be appropriate for imputing values for use in further analysis.
The aim of this study was to develop a MICE imputation method using Random Forest,
and test it in a realistically complex survival analysis based on patients with stable angina
in the CALIBER database [1].
4.4.3 Methods
Missing data imputed using MICE where each variable is imputed using Random
Forest
Within the MICE framework, missing values of continuous variables are conventionally
imputed by fitting a linear regression model for the observed values, predicting the con-
ditional mean for each missing value and randomly imputing a value from a normal dis-
tribution centred on this conditional mean. My new method uses Random Forest re-
gression on a bootstrap sample of records with observed values of the variable to be
imputed. Records with missing values in the dependent variable are imputed by random
draws from independent normal distributions centred on conditional means predicted us-
ing Random Forest. I used the ‘out-of-bag’ mean square error [191] as the estimator of
residual variance (which I assumed to be normally distributed).
For binary or unordered categorical variables, I used Random Forest to fit individual
regression trees to a bootstrap sample of the data, and imputed each missing value as
the prediction of a randomly chosen tree.
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The Random Forest imputation functions are available on the Comprehensive R
Archive Network [147].
Study population
The cohort for the current study was derived from an existing CALIBER study on stable
angina. Patients were eligible to enter the cohort after 2001 when they had been regis-
tered for at least a year with a participating general practice. An ‘index date’ was defined
for each patient as the date of the first record of stable angina during the period that they
were eligible to enter the cohort. Stable angina was defined as two or more prescriptions
of anti-anginal medication in CPRD, a record of percutaneous coronary intervention or
coronary artery bypass grafting, or a diagnostic code for stable angina in CPRD or HES.
Patients were followed up until the earliest of: non-fatal myocardial infarction (as recorded
in HES or MINAP), death (as recorded in ONS) or transfer out of the general practice. Pa-
tients who died or experienced unstable angina or myocardial infarction within 7 days of
cohort entry were excluded.
Measurement of variables
For continuous measures such as blood pressure and blood biomarkers, the mean mea-
surement over the 2 years prior to the index date was used as the variable in modelling,
and an auxiliary variable was generated containing the nearest value after the index date
to use in imputation models. Serum creatinine, neutrophil counts and lymphocyte counts
were log transformed using base 2 logarithms. Comorbidities were considered to be
present if there was an appropriate diagnostic Read code in CPRD on or before the index
date (or a record in MINAP or HES for previous myocardial infarction). Smoking status
was identified in CPRD using the most recent smoking record prior to the index date
if available, otherwise the earliest record after the index date. The year in which gen-
eral practices started to receive blood results electronically was estimated by the annual
number of lymphocyte count blood tests recorded.
Endpoints
The composite endpoint consisted of non-fatal myocardial infarction identified in HES or
MINAP, or death from any cause identified in ONS. The type of event at the endpoint was
not used in the survival model, but was used as an auxiliary variable in missingness and
imputation models.
Survival analysis
The substantive analysis aimed to investigate the association between blood biomark-
ers and prognosis among patients with stable angina in CALIBER. The fully observed
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predictor variables were: age, age squared, gender, previous myocardial infarction, dia-
betes, previous stroke, peripheral arterial disease, and heart failure. Smoking status was
a partially observed 3-category variable (never, ex, current), and I included the following
partially observed continuous variables: systolic blood pressure, log neutrophil count, log
lymphocyte count, high density lipoprotein (HDL) cholesterol, haemoglobin concentration
and log serum creatinine. For each of these variables I took the mean of any observed
values in the 2 years prior to the start of follow-up. I used the Efron approximation for ties.
I did not investigate alternative models and ignored clustering by general practice.
Generation of sample datasets for simulation study
I created datasets with missing data for which I knew the ‘true’ values, with a missingness
pattern similar to that observed in the actual dataset but which was Missing At Random
(MAR), such that the MAR assumption underlying most multiple imputation approaches
was satisfied. I denoted the entire cohort of 52 576 stable angina patients as dataset ‘A’.
Patients with no missing values in any of the variables in the survival model were denoted
dataset ‘B’ (13 308 patients) (Figure 4.6 on page 94).
I used logistic regression based on completely observed variables to investigate factors
associated with a patient having a complete record (i.e. whether a patient was in dataset
B). The subset of patients with complete recording of all analysis and auxiliary variables
were denoted dataset ‘C’ (10 128 patients), and they formed the basis for the resampling
study. I drew 1000 random samples from dataset C, each with 2000 patients. I carried
out sampling with replacement. I carried out simulations with one of two missingness
mechanisms: (1) missing at random (MAR) in a similar pattern to dataset A, or (2) an
artificial pattern of missingness completely at random (MCAR) in which only categorical
variables were missing.
Multiple imputation of test datasets
Imputation models included all the variables in the substantive Cox model, event status,
marginal Nelson-Aalen cumulative hazard [193] and the following auxiliary variables: type
of endpoint, whether the practice was receiving electronic lab results, and the earliest
recorded value after the index date of blood pressure and the five blood biomarkers. I
imputed continuous variables using MICE with normal-based linear regression, predictive
mean matching with 3 nearest neighbours (‘PMM’), and my new Random Forest method
with 10 or 100 trees (‘MICE RF 10’, ‘MICE RF 100’). I imputed categorical variables using
MICE with logistic or polytomous regression, or MICE with Random Forest (choice of 10
or 100 trees).
I generated 10 MICE imputations, each drawn from a separate chain with a different
random seed, with 10 cycles of imputation before drawing the imputed dataset. In addition
to MICE, I also evaluated missForest [192], generating multiple imputations by running
missForest using different random seeds.
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Figure 4.6: Schematic diagram showing generation of datasets with artificial missingness
from a population of patients with stable angina in the CALIBER database.
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Regardless of the imputation method, all datasets were analysed using the same mul-
tivariable semi-parametric Cox model described above. The log hazard ratios from the
Cox model were combined using Rubin’s rules [194], which assumes that imputed val-
ues were drawn from the appropriate Bayesian posterior. I carried out analyses using R
2.12.1 [157].
Comparison of results obtained by different methods
I considered the Cox proportional hazards model fitted to the entire dataset C as the
‘true’ result for the assessment of bias and confidence interval coverage of hazard ratios.
I compared the length of 95% confidence intervals between two methods using paired
sample t tests. I compared coverage of 95% confidence intervals for each coefficient
separately using McNemar’s test, defining discordant pairs as datasets in which the 95%
confidence interval included the ’true’ value for one method but not the other. I compared
the efficiency of the estimators by calculating their empirical standard deviations.
4.4.4 Results
The prevalence of missingness among partially observed variables ranged from 1.5% for
smoking to 56.7% for lymphocyte counts and 56.8% for neutrophil counts (Table 4.6 on
page 96). The logistic regression model showed that patients with diabetes, peripheral
arterial disease and previous stroke were more likely to have complete records (Table 4.7
on page 97). Coefficients from Cox models for patients with complete data (dataset C)
were similar to the average results from full data analysis of the subsamples (as expected
in the absence of small sample bias), so I compared imputation estimates to those from
dataset C (Table 4.8 on page 97).
Estimates from complete record analysis were biased for some parameters under MAR
(missingness mechanism 1); this may be expected because I had introduced missingness
dependent on the outcome. The Random Forest MICE estimate for smoking (categorical)
was biased towards the null (Table 4.10 on page 99, Figure 4.8 on page 101), but there
was no material bias in other parameters estimated by Random Forest or parametric
MICE. However, imputation using missForest produced materially biased estimates for
all continuous variables missing at random (Table 4.9 on page 98, Figure 4.7 on page
100).
All the imputation methods tested produced more efficient parameter estimates than
complete record analysis. MICE with Random Forest produced slightly more efficient es-
timates than parametric MICE, and the average between-imputation variance was also
lower. Parametric MICE yielded confidence intervals with approximately 93–95% cover-
age. The mean lengths of confidence intervals were shorter using Random Forest MICE
than parametric MICE (P <0.001 for each comparison) but coverage was either equal or
greater using Random Forest MICE (Table 4.9 on page 98, Table 4.10 on page 99).
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Table 4.6: Characteristics of patients with complete records (dataset B) and patients with
missing data in a CALIBER study of patients with stable angina (N = 52 576)
Patients with complete records Patients with missing data
(in dataset B, N=13 308) (in dataset A but not B, N=39 268)
Variable Mean (SD) % % missing Mean (SD) % % missing
Predictors
Age (years) 68 (11) 0 69 (12) 0
Female gender 43.4 0 44.1 0
Smoking status 0 2.0
Never smoker 15.0 12.8
Ex smoker 57.1 46.7
Current smoker 27.9 38.5
Medical history *
Diabetes 22.3 0 13.9 0
Previous myocardial
infarction
19.2 0 23.8 0
Previous stroke 10.0 0 9.0 0
Previous peripheral arterial
disease
8.3 0 7.5 0
Previous heart failure 9.0 0 11.2 0
Mean of continuous variables over 2 years before index date:
Mean creatinine (µmol/L) 98 (34) 0 101 (40) 48.4
Mean haemoglobin (g/dL) 14 (1.5) 0 14 (1.6) 63.3
Mean HDL cholesterol
(mmol/L)
1.4 (0.43) 0 1.3 (0.45) 76.0
Mean lymphocytes (×109/L) 2.1 (1.1) 0 2.1 (1.6) 75.9
Mean neutrophils (×109/L) 4.4 (1.6) 0 4.7 (1.9) 76.0
Mean systolic blood
pressure (mmHg)
142 (16) 0 144 (18) 13.3
Endpoints
Follow-up in years 3.6 (2.5) 5.2 (2.9)
Composite endpoint 13.4 26.7
Non-fatal myocardial
infarction
2.2 5.8
Fatal coronary heart disease 3.4 6.2
Death due to other cause 7.9 14.8
Auxiliary
Whether general practice
receiving lab data
86.1 0 48.0 0
Earliest measurement of continuous variables after index date:
Creatinine (µmol/L) 99 (40) 7.8 102 (44) 9.1
Haemoglobin (g/dL) 13 (1.7) 14.4 14 (1.7) 15.4
HDL cholesterol (mmol/L) 1.3 (0.41) 15.9 1.4 (0.51) 25.7
Lymphocyte count (×109/L) 2.1 (1.2) 15.3 2.1 (1.3) 20.2
Neutrophil count (×109/L) 4.5 (1.9) 15.3 4.6 (2.0) 20.1
Systolic blood pressure
(mmHg)
138 (20) 4.6 140 (21) 5.3
* Medical history variables were completely observed because the absence of a recorded diagnosis was
considered to represent absence of the condition
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Table 4.7: Logistic regression model for factors associated with the outcome of having a
complete record
Variable Odds ratio 95% confidence interval
Age, per 10 years older 4.81 *** 4.02, 5.75
Age squared (10 years)2 0.89 *** 0.87, 0.90
Female gender 1.08 ** 1.03, 1.12
Diabetes 1.74 *** 1.64, 1.84
Peripheral arterial disease 1.24 *** 1.15, 1.35
Previous stroke 1.26 *** 1.17, 1.36
Heart failure 0.96 0.89, 1.04
Previous myocardial infarction 1.03 0.98, 1.09
Whether practice receives electronic lab results 4.74 *** 4.48, 5.01
Endpoint: fatal coronary heart disease 0.40 *** 0.36, 0.45
Endpoint: non-fatal myocardial infarction 0.29 *** 0.26, 0.34
Endpoint: non-coronary death 0.42 *** 0.39, 0.45
Cumulative hazard 0.03 *** 0.02, 0.03
Significance level: * P <0.05, ** P <0.01, *** P <0.001
Table 4.8: Cox proportional hazards model for death or non-fatal myocardial infarction
among patients with stable angina in the CALIBER database: results from
complete data (dataset C) and empirical average from 1000 samples of 2000
patients
Complete dataset C Average from samples
Variable HR 95% CI HR 95% CI Bias of log HR
Age, per 10 years older 1.07 0.53, 2.16 1.14 0.22, 5.89 0.0589
Age squared (10 years)2 1.05 1.00, 1.10 1.05 0.93, 1.17 -0.0028
Female gender 0.80 0.69, 0.92 0.79 0.57, 1.09 -0.0143
Diabetes 1.60 1.40, 1.81 1.61 1.20, 2.17 0.0103
Peripheral arterial disease 1.51 1.29, 1.77 1.53 1.07, 2.21 0.0164
Previous stroke 1.34 1.15, 1.56 1.35 0.95, 1.92 0.0046
Heart failure 2.13 1.85, 2.45 2.16 1.56, 3.00 0.0143
Previous myocardial
infarction 1.33 1.17, 1.51 1.34 1.00, 1.79 0.0059
Neutrophils per doubling 1.47 1.30, 1.66 1.47 1.11, 1.95 0.0029
Lymphocytes per doubling 0.81 0.72, 0.90 0.80 0.61, 1.04 -0.0068
Haemoglobin per g/dL 0.90 0.87, 0.94 0.90 0.81, 1.00 -0.0034
HDL cholesterol per mmol/L 1.07 0.91, 1.25 1.05 0.74, 1.51 -0.0158
Creatinine per doubling 1.80 1.54, 2.09 1.80 1.27, 2.57 0.0043
Systolic blood pressure per
10mmHg 1.00 0.97, 1.04 1.01 0.93, 1.09 0.0023
Smoking status:
Never smoker 1 Reference 1 Reference
Ex smoker 1.21 0.99, 1.47 1.22 0.77, 1.92 0.0105
Current smoker 1.39 1.13, 1.71 1.41 0.87, 2.29 0.0185
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Figure 4.7: Boxplots showing bias of estimates of log hazard ratios for partially observed
continuous variables with data missing at random (missingness mechanism
1) in 1000 samples of patients with stable angina in the CALIBER database.
The solid horizontal line is the ‘true’ log hazard ratio from the full dataset C; the dashed lines are±1 empirical
standard error.
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4.4. Methods for handling missing data
Figure 4.8: Boxplots showing bias of estimates of log hazard ratios for partially observed
categorical variables missing completely at random (missingness mechanism
2) in 1000 samples of patients with stable angina in the CALIBER database.
The solid horizontal line is the ‘true’ log hazard ratio from dataset C; the dashed lines are ±1 empirical
standard error.
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For categorical variables, missForest produced imputed values which were more likely
to be equal to the ‘true’ (observed) value than the MICE methods, but confidence intervals
were too small with below nominal coverage, and between-imputation variance was very
small (Table 4.10 on page 99, Figure 4.8 on page 101). There was no difference in bias,
precision or coverage between normal-based MICE and predictive mean matching (Table
4.9 on page 98). Random Forest MICE with 100 trees for continuous variables produced
estimates with slightly narrower confidence intervals than with 10 trees, but with greater
bias, worse coverage of 95% confidence intervals and 10 times the computational cost
(Table 4.9 on page 98). For categorical variables, Random Forest MICE with 10 or 100
trees produced almost identical results (Table 4.10 on page 99).
4.4.5 Discussion
Summary of main findings
In this resampling study of methods for handling missing data, parametric and Random
Forest MICE produced estimates with no material bias for a Cox model on data with artifi-
cially introduced MAR missingness. Random Forest-based MICE produced more efficient
estimates and narrower confidence intervals than parametric MICE, yet in some cases
coverage probability was greater than 95%, suggesting that some confidence intervals
may be conservative. A possible explanation for the efficiency gain with Random Forest
MICE is that it was able to make better use of the available information by accommodat-
ing non-linearities among the predictors. Random Forest imputation may be useful for
imputing complex epidemiological datasets in which some patients have missing data.
Imputation methods for MICE
It is important that imputation models are correctly specified for analyses to yield unbi-
ased estimates, and Random Forest may help avoid the bias that can occur with paramet-
ric MICE if the latter’s imputation models are mis-specified. Standard parametric MICE
performed well, suggesting that the true imputation models did not contain significant
non-linearities or interactions, and hence Random Forest did not confer an advantage
from the perspective of bias. The default settings for MICE do not include interactions
between the variables and it is routine practice to include only those interactions that
are in the substantive model, rather than actively searching for all possible interactions
and non-linearities. Imputation models should also be compatible with the substantive
model [195], and Random Forest avoids the need to specify how the outcome should be
conditioned on in the imputation models for covariates.
A disadvantage of Random Forest is that the ‘models’ are complex and not easily
interpretable, although arguably this is not a shortcoming for the purpose of imputation.
My method assumes that the residuals from the Random Forest regression are normally
distributed with constant variance.
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On these 2000-patient datasets, computation time was 3 times as long for Random
Forest MICE with 10 trees compared to parametric MICE, but Random Forest may yield
a saving in analyst time because there is theoretically less need for transformation of fully
observed variables or investigation of non-linearities and interactions. It is also possible
to include a large number of related predictor variables in Random Forest models without
encountering problems due to collinearity.
MissForest was included as an example of algorithms for completing single datasets
[192], but it replaces missing values with predicted values rather than drawing from a
distribution, leading to biased parameter estimates.
Limitations
Although this study has strengths (it was based on a real dataset, and the analysis was
realistically complex) it also has important limitations. The most important limitation in
producing general recommendations is that it was based on a single analysis of a single
study, so results should be generalised to other datasets with caution.
A limitation of the resampling methodology was that in order to avoid excessive com-
puting time I used only ten imputations for most of the comparisons, leading to noisy
estimates of between-imputation variability. To save time I also restricted the number of
cycles of MICE to ten, and although I looked at plots of chain means and standard devia-
tions between cycles for a few runs, this is a crude way of assessing chain convergence
and it is possible that the chains may not have converged by the end of every run.
I ignored practice-level clustering at the imputation and analysis stage, for simplicity,
but could have properly accounted for this by hierarchical models [196].
Recommendations for further development
Random Forest multiple imputation should be tested on a larger range of datasets and
in simulations to explore whether it gives unbiased estimates where there are non-trivial
non-linearities or interactions in imputation models, such that a standard parametric MICE
which ignores them gives biased results. Random Forest tuning parameters (such as the
number of trees and number of nodes) should be further investigated.
4.4.6 Conclusions
Standard parametric MICE and my new Random Forest MICE method work reasonably
well under artificially introduced missingness at random in a realistically complex dataset.
Random Forest imputation should be further investigated in situations where MICE with
default parametric imputation models produces biased results.
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4.5 Overall summary of chapter
In this chapter I have presented work on validation and novel tools for data management
and statistical analysis. Although all these projects were based on the CALIBER dataset,
the methods and principles have much wider application.
Specifically for this project, the work on cross-referencing myocardial infarction records
was used to refine the CALIBER phenotyping algorithm for myocardial infarction, such
as the selection of Read codes to use. The data management and codelist packages
were used for defining variables and manipulating data. The Random Forest missing
data method was applied to the dataset used in the main analysis alongside conventional
parametric imputation in chapters 7, 8 and 9; the similarity of the results obtained using
Random Forest and parametric MICE helps to validate the method, and suggests that it
should be further developed and deployed in the future.
The next chapter describes the cohort specification for investigating the onset of car-
diovascular disease in CALIBER, and applies this to a study investigating type 2 diabetes
and the twelve initial presentations of cardiovascular disease.
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5 Investigating the initial presentation of cardiovascular
diseases in linked electronic health records: an example of
type 2 diabetes
5.1 Chapter outline
This chapter describes the approach to studying the initial presentation of cardiovascular
disease in CALIBER, including the cohort definition and ascertainment of endpoints in
linked record sources. This is applied to the example of type 2 diabetes. The work de-
scribed in this chapter has been published in Lancet Diabetes and Endocrinology [197].
5.2 Abstract
Background: The contemporary associations of type 2 diabetes with a wide range of
incident cardiovascular diseases have not been compared. I aimed to study associations
between type 2 diabetes and 12 initial manifestations of cardiovascular disease.
Methods: I used linked primary care, hospitalisation, disease registry and death certifi-
cate records from 1997 to 2010 in the CALIBER programme. The cohort included 1.92
million people in England aged 30 and older who were free from cardiovascular disease
at baseline. I compared cumulative incidence curves for the initial presentation of car-
diovascular disease and used Cox models to estimate cause-specific hazard ratios. This
study is registered at clinicaltrials.gov (NCT01804439).
Results: 113 638 first presentations of cardiovascular disease occurred during a me-
dian follow-up of 5.5 years. Among the 34 198 people with type 2 diabetes, 6137 expe-
rienced a first cardiovascular presentation, of which the most common were peripheral
arterial disease (16.2%) and heart failure (14.1%). Type 2 diabetes was positively asso-
ciated with peripheral arterial disease (adjusted hazard ratio (HR) 2.98; 95% confidence
interval (CI) 2.76, 3.22), ischaemic stroke (HR 1.72, 95% CI 1.52, 1.95), stable angina
(HR 1.62, 95% CI 1.49, 1.77), heart failure (HR 1.56, 95% CI 1.45, 1.69), and non-fatal
myocardial infarction (HR 1.54, 95% CI 1.42, 1.67), but was inversely associated with ab-
dominal aortic aneurysm (HR 0.46, 95% CI 0.35, 0.59) and subarachnoid haemorrhage
(HR 0.48, 95% CI 0.26, 0.89), and not associated with arrhythmia or sudden cardiac
death (HR 0.95, 95% CI 0.76, 1.19). With the exception of non-fatal myocardial infarction
in younger patients, where the association with T2D was stronger in women, there were
no other significant sex differences in these associations.
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Conclusions: Heart failure and peripheral arterial disease are the most common initial
manifestations of cardiovascular disease in type 2 diabetes. The differences between
relative risks of different cardiovascular diseases in patients with type 2 diabetes have
implications for clinical risk assessment and trial design.
5.3 Introduction
Type 2 diabetes has become an increasingly common disease estimated to affect 380 mil-
lion people worldwide by 2025 [198]. People with type 2 diabetes (T2D) are at increased
risk of cardiovascular diseases and their clinical complications [199].
Previous studies have not compared the relationship between T2D and a wide range
of cardiovascular outcomes such as heart failure, peripheral arterial disease, abdominal
aortic aneurysm, and ventricular arrhythmias in the same study, but focussed instead on
a narrower range of disease outcomes, usually just one or two [200]. Such comparisons
require large studies to reliably estimate associations for rare outcomes. Several small
studies have shown an impact of T2D on cardiovascular manifestation by outcome [44]
and sex [201], but these studies were not designed to reliably assess associations with
multiple cardiovascular diseases or across population subgroups.
In this project I investigated twelve cardiovascular diseases that are important causes
of morbidity and mortality: coronary artery disease (stable angina, unstable angina, fatal
and non-fatal myocardial infarction), cerebrovascular disease (transient ischaemic attack,
ischaemic stroke, haemorrhagic stroke, subarachnoid haemorrhage), arrhythmias, heart
failure, peripheral arterial disease and abdominal aortic aneurysm. The rationale for
choosing these conditions is described earlier (section 1.5 on page 28), but briefly they
are a set of serious, symptomatic cardiovascular conditions that share some aspects of
pathogenesis (atherosclerosis, thrombosis and inflammation).
The aim of this study was to investigate and compare associations between T2D and
future risk of twelve of the most common initial cardiovascular presentations in men and
women in the CALIBER dataset.
5.4 Methods
5.4.1 Study population
The study population was drawn from the CALIBER programme [1], as described in chap-
ter 3. The study period was January 1997 to March 2010, and individuals were eligible
for inclusion when they were aged 30 or over and had been registered for at least one
year in a practice which met research data recording standards.
Follow-up was censored at the occurrence of an endpoint, death, de-registration from
the practice or the last data collection for the practice, whichever occurred first. Individuals
with a prior history of cardiovascular disease (defined as any of the endpoints, or a non-
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specific entry of ‘cardiovascular disease’ or ‘atherosclerotic disease’ in any of the data
sources) were excluded.
5.4.2 Diabetes status
I developed a phenotyping algorithm to identify patients with type 2 diabetes at base-
line based on coded diagnoses recorded in CPRD or HES on or before study en-
try; for more details see section 4.3.6 on page 85. Lists of Read and ICD-10 di-
agnosis codes which convey diabetic status are curated on the CALIBER data portal
(https://www.caliberresearch.org/portal/chapter/6).
Patients who developed new onset diabetes during follow-up were analysed according
to their baseline status of no diabetes. This study compared people with T2D to those
without diabetes, excluding people with type 1 diabetes or diabetes of uncertain type.
5.4.3 Covariates
For continuous variables (body mass index (BMI), high density lipoprotein (HDL) chole-
sterol, total cholesterol, and systolic blood pressure) I used the most recent measurement
in CPRD in the year prior to study entry as the baseline value, but included measurements
outside this time window in imputation models. Social deprivation was included in mod-
els as quintiles of the index of multiple deprivation [131], described in subsection 3.3.5 on
page 58. Data recorded prior to study entry was used to classify participants as never,
ex or current smokers at baseline.
5.4.4 Endpoints
The primary endpoint was the first record of one of twelve cardiovascular presentations in
any of the data sources. Any events occurring after the first cardiovascular presentation
were ignored. If more than one endpoint occurred on the same day, the top endpoint
in Table 5.1 on page 108 was chosen. Secondary outcomes included cardiovascular
mortality and all-cause mortality.
The definition of each endpoint was formalised as a CALIBER phenotype, similar to
the diabetes example (section 4.3.6 on page 85)
Endpoint definitions
Cardiovascular phenotype definitions based on the CALIBER data sources are curated
on the CALIBER data portal (www.caliberresearch.org/portal).
1. Arrhythmia or sudden cardiac death. https://caliberresearch.org/portal/
show/phenotype_scd
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Table 5.1: Data sources for initial presentation of cardiovascular diseases (study
endpoints)
Priority Endpoint Type Source
1
Arrhythmia, cardiac arrest or
sudden cardiac death
Fatal or non-fatal CPRD, HES, ONS
2 Heart failure Fatal or non-fatal CPRD, HES, ONS
3 Unheralded coronary death Fatal ONS
4 Myocardial infarction Non-fatal CPRD, MINAP, HES
5 Unstable angina Non-fatal CPRD, MINAP, HES
6 Stable angina Non-fatal CPRD
7
Coronary disease not otherwise
specified
Non-fatal CPRD, HES
8 Abdominal aortic aneurysm Fatal or non-fatal CPRD, HES, ONS
9 Peripheral arterial disease Fatal or non-fatal CPRD, HES, ONS
10 Subarachnoid haemorrhage Fatal or non-fatal CPRD, HES, ONS
11 Intracerebral haemorrhage Fatal or non-fatal CPRD, HES, ONS
12 Ischaemic stroke Fatal or non-fatal CPRD, HES, ONS
13 Stroke not otherwise specified Fatal or non-fatal CPRD, HES, ONS
14 Transient ischaemic attack Non-fatal CPRD, HES
15 Death due to other cause Fatal ONS
A composite of ventricular arrhythmias, implantable cardioverter defibrillator, and sud-
den cardiac death. It was defined using diagnoses and procedure codes in primary care,
secondary care and death certificates.
The definition used in this type 2 diabetes study also included procedure codes for car-
dioversion. The codes for cardioversion were subsequently removed as the majority of
patients undergoing cardioversion had atrial fibrillation rather than a ventricular arrhyth-
mia. The updated definition, as used in the leukocyte study (chapters 7 and 8), does not
include cardioversion as a component of the endpoint, and has been renamed ‘Ventricu-
lar arrhythmia or sudden cardiac death’.
2. Heart failure. https://caliberresearch.org/portal/show/phenotype_hf
Defined by coded diagnoses in primary care, secondary care and death certificates.
3. Unheralded coronary death. https://caliberresearch.org/portal/show/
phenotype_ucd
Death with the primary cause certified as coronary heart disease, and no prior history
of cardiovascular disease. Patients with myocardial infarction who died on the day of their
infarct were considered to have unheralded coronary death.
4. Non-fatal myocardial infarction. https://caliberresearch.org/portal/show/
phenotype_mi
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Defined as a disease registry diagnosis of an acute coronary syndrome with elevated
troponin, or a primary or secondary care diagnosis of myocardial infarction.
The definition used in this type 2 diabetes study was an older definition, which was
updated based on the results of the validation study (section 4.2). The leukocyte study
(chapters 7 and 8) used the updated definition.
5. Unstable angina. https://caliberresearch.org/portal/show/phenotype_ua
Defined as a primary or secondary care diagnosis of unstable angina, or an acute
coronary syndrome without myocardial infarction recorded in the disease registry.
6. Stable angina. https://caliberresearch.org/portal/show/phenotype_sa
Defined by a coded diagnosis in primary or secondary care of ischaemic chest pain or
stable angina, a positive myocardial ischaemia test, two or more prescriptions of antiang-
inal medication, or coronary revascularisation. Information from primary and secondary
care data sources were combined as shown in the flowchart Figure 3.3 on page 63.
7. Coronary disease not further specified. https://caliberresearch.org/portal/
show/phenotype_chd_nos
A non-specific diagnosis of ischaemic or coronary heart disease in primary or sec-
ondary care that does not fall into one of the more specific categories. It was not included
among the twelve diseases in the main displays of hazard ratios, but for cumulative inci-
dence calculations it was combined with unstable angina.
8. Abdominal aortic aneurysm. https://caliberresearch.org/portal/show/
phenotype_aaa
Defined by coded diagnoses and procedures in primary care, secondary care and
death certificates.
9. Peripheral arterial disease. https://caliberresearch.org/portal/show/
phenotype_pad
This includes intermittent claudication, limb ischemia or gangrene due to atheroscle-
rotic disease in the arteries of the legs. It was defined by coded diagnoses and proce-
dures in primary care, secondary care and death certificates.
10. Subarachnoid haemorrhage. https://caliberresearch.org/portal/show/
phenotype_stroke_subarachnoid
Defined by coded diagnoses in primary care, secondary care and death certificates.
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11. Intracerebral haemorrhage. https://caliberresearch.org/portal/show/
phenotype_stroke_intracerebral_haem
Defined by coded diagnoses in primary care, secondary care and death certificates.
12. Ischaemic stroke. https://caliberresearch.org/portal/show/phenotype_
stroke_ischaemic
Defined using coded diagnoses in primary care, secondary care and death certificates.
Patients with a procedure code for carotid endarterectomy within 90 days of a stroke of
unspecified type were considered to have ischaemic stroke.
13. Stroke not further specified. https://caliberresearch.org/portal/show/
phenotype_stroke_nos
Diagnosis of stroke which does not state it is ischaemic or haemorrhagic. This clinical
event was not included among the twelve diseases in the main displays of hazard ratios,
but for cumulative incidence calculations it was combined with ischaemic stroke.
14. Transient ischaemic attack. https://caliberresearch.org/portal/show/
phenotype_tia
Defined by coded diagnoses in primary or secondary care.
5.4.5 Statistical analysis
To describe the incidence of each initial presentation over time I constructed cumulative
incidence curves, taking into account the other possible initial presentations as competing
events. Normal-based confidence intervals were constructed based on Greenwood’s
variance formula, as implemented in the R prodlim package [202].
I carried out survival analysis to describe and model the first occurrence of any car-
diovascular disease. A patient’s follow-up ended when they experienced one of the car-
diovascular endpoints or when they were censored. Subsequent events (e.g. myocardial
infarction occurring after stable angina) were not analysed.
I considered using either Cox models (for modelling cause-specific hazards) or the
Fine and Gray model (to compare cumulative incidence curves by modelling subdistri-
bution hazards). As the aim of this study was observational epidemiology – to explore
associations rather than predict risk – I decided to use the Cox model, as cause specific
hazard ratios were appropriate quantities to estimate. The Fine and Gray model com-
pares cumulative incidence curves but the subdistribution hazard ratios that it estimates
do not have a straightforward interpretation, unlike cause-specific hazards. However,
cause specific hazards cannot be used to predict cumulative incidence.
I used follow-up time as the timescale for the Cox models in order to investigate interac-
tions with age, and I verified the proportional hazards assumption by plotting Schoenfeld
residuals against transformed time.
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In the primary analysis, I compared individuals with T2D to those without diabetes,
adjusting for age, sex, body mass index, deprivation, HDL cholesterol, total cholesterol,
systolic blood pressure, smoking status, and prescription of statins or antihypertensive
medication in the year before study entry. The baseline hazard function of each model
was stratified by general practice and sex, and missing covariate data were handled
using multiple imputation. I also carried out analyses adjusted for age and sex only,
and adjusted for age, sex and cardiovascular risk factors. I evaluated interactions with
age and sex.
Among patients with type 2 diabetes, I carried out a secondary analysis of the associa-
tion of glycaemic control with cardiovascular endpoints. Glycaemic control was measured
by the mean HbA1c from 3 years before to 3 years after study entry, ignoring values oc-
curring after an endpoint. I categorised HbA1c with cutpoints at 48 mmol/mol (= 6.5%, the
threshold for diagnosis of diabetes) [203], and 58 mmol/mol (= 7.5%, the recommended
threshold for initiation of thiazolidinedione or insulin in T2D in UK guidelines) [204].
5.4.6 Multiple imputation
Missing data were handled by Multiple Imputation by Chained Equations implemented in
the mice package in R [187]. Imputation models were estimated separately for men and
women and included:
• All the baseline covariates used in the main analysis (age, quadratic age, sex, body
mass index, deprivation, high density lipoprotein cholesterol, total cholesterol, sys-
tolic blood pressure, smoking status, statins and antihypertensive prescriptions).
• Prior (between 14 and 4 years before study entry) and post (between 0 and 1 year
after study entry) averages of continuous covariates in the main analysis.
• Baseline measurements of covariates not considered in the main analysis (dias-
tolic blood pressure, alcohol intake, white cell count, haemoglobin, creatinine and
alanine aminotransferase).
• Baseline medications (low-dose aspirin, loop diuretics, oral contraceptives and hor-
mone replacement therapy).
• Coexisting medical conditions (history of depression, cancer, renal disease, liver
disease and chronic obstructive pulmonary disease).
• The Nelson-Aalen hazard and the event status for each endpoint analysed in the
data [193].
Non-normally distributed variables were log-transformed for imputation and exponen-
tiated back to their original scale for analysis. Five multiply imputed datasets were gen-
erated, and Cox models were fitted to each dataset. Coefficients were combined using
Rubin’s rules.
The Random Forest imputation method described in section 4.4 was being developed
in parallel and was not ready for use at the time of this study. However, it was used in the
remaining studies in this thesis (chapters 7, 8 and 9).
111
Chapter 5. Type 2 diabetes and initial presentation of cardiovascular disease
5.4.7 Sensitivity analyses
Fifteen percent of people with diabetes did not have a code for their type of diabetes
(Figure 5.1 on page 113) and were excluded from the primary analyses. To assess the
impact of this potential misclassification bias, I performed a sensitivity analysis comparing
individuals with any diabetes diagnosis to those without diabetes (the majority of diabetic
patients in a cohort of this age would have T2D). I performed sensitivity analyses ignor-
ing endpoints recorded only in primary care (from CPRD), restricted to fatal endpoints,
or restricted to individuals who entered the study after 2004 (when recording of covari-
ates would be expected to be more complete following introduction of the Quality and
Outcomes Framework) [205]. Data were analysed using R 2.15 [157].
5.5 Results
5.5.1 Baseline characteristics of study participants
The study cohort included 1 887 062 participants without diabetes and 34 198 with type
2 diabetes (Figure 5.1 on page 113). People with T2D had lower mean HDL cholesterol
and higher mean BMI than people without diabetes. The use of statins and antihyper-
tensive medication was higher in people with T2D and increased over time. People with
T2D were approximately twice as likely to have Black or South Asian ethnicity as those
without diabetes (Table 5.2 on page 114). During follow-up, 51 690 participants were
newly diagnosed with diabetes, with a median time to diagnosis of 4.9 years.
5.5.2 Comparison of associations between type 2 diabetes and twelve initial
cardiovascular presentations
I analysed 113 638 cardiovascular events over 11.6 million person-years of follow-up
(median follow-up 5.5 years). Of these, 8056 events were in people with type 2 diabetes,
who accrued 162 756 person-years of follow-up. Peripheral arterial disease and heart
failure were the most common endpoints among people with T2D (16.2% and 14.1%)
(Figure 5.2 on page 115); the proportions of these endpoints in people without diabetes
were 9.4% and 12.2% (Table 5.3 on page 115). Cumulative incidence curves showed
substantial differences in the direction and strength of the associations between each
of the cardiovascular manifestations and T2D (Figure 5.3 on page 116 and Table 5.4
on page 117). Peripheral arterial disease showed the largest difference of all the dis-
eases in cumulative incidence; a woman with T2D at age 40 had 9.7% risk (95% CI 8.4,
11.1) of developing peripheral arterial disease as her first presentation of cardiovascular
disease by age 80; a woman without diabetes had a 3.2% risk (95% CI 3.1, 3.3). The
corresponding figures for men were 11.7% (95% CI 10.5, 13.0) and 4.5% (95% CI 4.4,
4.7).
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Figure 5.1: Flow of patients through the study
4 703 682 patients registered with
primary care practices in CALIBER
during study period
1 937 360 patients included in study
Reasons for exclusion (number of patients):
- Missing sex (135)
- Age < 30 years (1 858 924)
- Less than 1 year registration prior to study entry (709 006)
- History of cardiovascular disease before study entry (159 239)
- Pregnant within 6 months of study entry (39 018)
Diagnosis of diabetes on or prior to study entry?
According to diagnosis codes recorded in hospital admission data (ICD-10 code
E10, E11, E13, E14, G590, G632, H280, H360, M142, N083, O240, O241, O243)
or Read codes in primary care data.
1 887 062 patients
with no diabetes
48 666 patients with diabetes
34 198 patients
with Type 2 diabetes
7206 patients
with Type 1 diabetes
7262 patients with
diabetes type not recorded
or conflicting records
Groups compared in main analysis
Diabetes type classified according
to ICD-10 and Read codes on or
prior to study entry
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Table 5.2: Baseline patient characteristics among 1 921 260 people without cardiovascu-
lar diseases at baseline, according to type 2 diabetes status
Women Men
No diabetes Type 2 diabetes No diabetes Type 2 diabetes
Number of patients 955 655 15 805 931 407 18 393
Age in years, mean (SD) 48.2 (16.2) 64.7 (14.4) 45.4 (14) 60.8 (13)
Most deprived quintile, n (%) 184 942 (19.4%) 4313 (27.3%) 189 247 (20.3%) 4285 (23.3%)
Ethnicity, n (%): White 503 274 (90.8%) 9641 (81.8%) 388 763 (90.5%) 10 716 (82.4%)
South Asian 14 673 (2.6%) 912 (7.7%) 12 865 (3.0%) 1041 (8.0%)
Black 16 722 (3.0%) 748 (6.3%) 13 148 (3.1%) 670 (5.2%)
Other 19 328 (3.5%) 491 (4.2%) 14 640 (3.4%) 579 (4.5%)
Smoking, n (%): Current 130 946 (17.6%) 2028 (14.4%) 148 020 (23.7%) 3327 (20.6%)
Ex 108 593 (11.4%) 2927 (18.5%) 109 538 (11.8%) 5507 (29.9%)
Never 506 383 (67.9%) 9158 (64.9%) 366 729 (58.7%) 7327 (45.3%)
Values of continuous measurements, most recent within 1 year prior to study entry, mean (SD)
Systolic blood pressure*,
mmHg 127 (19.6) 141 (19.7) 133 (17.2) 139 (17.6)
Diastolic blood pressure*,
mmHg 77.1 (10.3) 79.5 (10.1) 80.3 (10.0) 80.5 (10.0)
Total cholesterol*, mmol/l 5.54 (1.14) 5.08 (1.22) 5.39 (1.11) 4.77 (1.16)
HDL cholesterol*, mmol/l 1.57 (0.45) 1.34 (0.39) 1.28 (0.37) 1.14 (0.33)
Body mass index*, kg/m2 26.0 (5.59) 30.5 (6.76) 26.5 (4.43) 29.3 (5.43)
Random glucose*, mmol/l 5.35 (1.16) 10.4 (4.93) 5.56 (1.29) 10.7 (4.78)
Fasting glucose*, mmol/l 5.14 (0.75) 8.72 (3.53) 5.31 (0.79) 9.1 (3.51)
Glycaemic control**
HbA1c recorded, n (%) 12 835 (1.3%) 12 187 (77.1%) 12 031 (1.3%) 14 435 (78.5%)
HbA1c, mean (SD)
mmol/mol 44.3 (14.7) 59.3 (18) 46.9 (16.3) 60.5 (18.1)
HbA1c < 48 mmol/mol, n
(%) 9468 (73.8%) 3445 (28.3%) 8030 (66.7%) 3671 (25.4%)
HbA1c 48-58 mmol/mol, n
(%) 1854 (14.4%) 3458 (28.4%) 2004 (16.7%) 4075 (28.2%)
HbA1c ≥ 58 mmol/mol, n
(%) 1513 (11.8%) 5284 (43.4%) 1997 (16.6%) 6689 (46.3%)
Diabetes treatment in year before study entry, %
Diet alone 4591 (29.0%) 5467 (29.7%)
Metformin 884 (0.1%) 7714 (48.8%) 106 (0.0%) 8764 (47.6%)
Sulphonylurea 133 (0.0%) 6241 (39.5%) 124 (0.0%) 7526 (40.9%)
Insulin 189 (0.0%) 1939 (12.3%) 77 (0.0%) 1882 (10.2%)
Thiazolidinedione 5 (0.0%) 962 (6.1%) 6 (0.0%) 1225 (6.7%)
DPP4 inhibitor, meglitinide
derivative or GLP-1 agonist 1 (0.0%) 153 (1.0%) 1 (0.0%) 182 (1.0%)
Cardiovascular preventive treatment in year prior to study entry, %
Statin 18 233 (1.9%) 5636 (35.7%) 19 537 (2.1%) 6680 (36.3%)
Any antihypertensive 156 098 (16.3%) 9404 (59.5%) 99 179 (10.6%) 9898 (53.8%)
ACE inhibitor 59 412 (6.2%) 5278 (33.4%) 44 176 (4.7%) 6333 (34.4%)
Angiotensin receptor blocker 7324 (0.8%) 1357 (8.6%) 5276 (0.6%) 1263 (6.9%)
Beta blocker 54 861 (5.7%) 2755 (17.4%) 34 455 (3.7%) 2730 (14.8%)
* Most recent measurement within 1 year of study entry
** Mean HbA1c over 3 years before or after study entry
Percentage of patients with non-missing values of covariates: ethnicity 52.5%, smoking 72.9%, systolic blood
pressure 42.2%, diastolic blood pressure 42.2%, total cholesterol 8.3%, HDL cholesterol 5.4%, body mass
index 30.3%.
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Figure 5.2: Distribution of initial presentations of cardiovascular disease among patients
with type 2 diabetes and no prior history of cardiovascular disease
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Table 5.3: Distribution of events, time to event and age at event for initial presentation of
cardiovascular disease among patients with no diabetes or type 2 diabetes
No diabetes (107 501 events) Type 2 diabetes (6137 events)
Median Median Median Median
Initial presentation of % of time to event age at event % of time to event age at event
cardiovascular disease events (years) (years) events (years) (years)
Stable angina 11.4 3.2 67.0 11.9 2.5 68.6
Unstable angina 4.9 4.5 63.1 4.0 2.8 64.7
Coronary disease not further
specified
9.3 4.4 67.3 10.2 3.3 67.4
Non-fatal myocardial
infarction
14.1 4.7 66.7 11.5 3.4 71.1
Unheralded coronary death 4.7 5.1 76.2 4.2 4.1 77.0
Heart failure 12.2 3.6 79.8 14.1 3.1 76.9
Arrhythmia or sudden
cardiac death
3.0 5.0 67.1 1.6 4.0 68.3
Transient ischaemic attack 10.2 4.0 74.3 8.4 3.4 75.2
Ischaemic stroke 5.2 5.5 76.4 5.1 4.0 76.0
Stroke not further specified 9.4 3.4 79.7 10.3 2.5 78.3
Subarachnoid haemorrhage 1.2 4.4 57.3 0.2 2.8 74.4
Intracerebral haemorrhage 2.1 4.8 74.0 1.4 4.2 74.7
Peripheral arterial disease 9.4 4.4 70.1 16.2 3.5 71.7
Abdominal aortic aneurysm 2.8 5.0 76.2 1.0 4.5 77.8
Overall 100.0 4.2 72.0 100.0 3.2 72.6
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Figure 5.3: Cumulative incidence of twelve cardiovascular diseases by diabetes status
Crude cumulative incidence curves taking into account competing risks, for patients with type 2 diabetes or
without diabetes at age 40.
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Table 5.4: Cumulative incidence of initial presentation of cardiovascular diseases at age
80 for patients with type 2 diabetes or no diabetes at age 40
Cumulative incidences expressed as percentages (95% CI), taking into account risk of competing events
Women Men
Initial presentation No diabetes Type 2 diabetes No diabetes Type 2 diabetes
Stable angina 4.5 (4.4, 4.6) 10.1 (8.7, 11.5) 5.7 (5.5, 5.8) 9.5 (8.4, 10.7)
Unstable angina or
coronary disease not
further specified
5.2 (5.1, 5.3) 11.6 (10.0, 13.2) 7.1 (6.9, 7.3) 13.1 (11.7, 14.5)
Non-fatal myocardial
infarction
3.4 (3.3, 3.5) 6.0 (4.9, 7.2) 8.0 (7.8, 8.1) 11.4 (9.9, 12.8)
Unheralded coronary death 0.9 (0.9, 1.0) 1.5 (0.9, 2.0) 2.2 (2.1, 2.3) 2.4 (1.9, 2.9)
Heart failure 3.3 (3.1, 3.4) 6.4 (5.4, 7.3) 3.7 (3.6, 3.9) 6.1 (5.2, 6.9)
Arrhythmia or sudden
cardiac death
0.9 (0.8, 1.0) 0.7 (0.4, 1.0) 1.7 (1.6, 1.8) 1.8 (1.2, 2.4)
Transient ischaemic attack 3.6 (3.5, 3.7) 4.1 (3.3, 4.9) 3.8 (3.7, 3.9) 3.9 (3.3, 4.6)
Ischaemic or unspecified
stroke
3.9 (3.8, 4.1) 7.3 (6.2, 8.5) 4.7 (4.6, 4.9) 6.1 (5.3, 6.9)
Subarachnoid
haemorrhage
0.6 (0.5, 0.6) 0.2 (0.0, 0.4) 0.3 (0.3, 0.4) 0.0 (0.0, 0.1)
Intracerebral haemorrhage 0.7 (0.6, 0.7) 0.4 (0.2, 0.6) 0.8 (0.7, 0.8) 0.8 (0.5, 1.1)
Peripheral arterial disease 3.2 (3.1, 3.3) 9.7 (8.4, 11.1) 4.5 (4.4, 4.7) 11.7 (10.5, 13.0)
Abdominal aortic aneurysm 0.5 (0.5, 0.6) 0.1 (0.0, 0.2) 1.7 (1.6, 1.8) 0.6 (0.4, 0.8)
All cardiovascular
presentations
30.7 (30.3, 31.0) 58.2 (54.9, 61.4) 44.3 (43.8, 44.7) 67.4 (64.4, 70.4)
Death from other causes
without any cardiovascular
disease prior to death
14.7 (14.5, 15.0) 12.4 (11.0, 13.8) 16.4 (16.2, 16.6) 11.9 (10.7, 13.1)
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Figure 5.4: Hazard ratios for association of type 2 diabetes with twelve cardiovascular
diseases
Hazard ratios for different initial presentations of cardiovascular diseases associated with type 2 diabetes,
adjusted for age, sex, smoking, body mass index, deprivation, high density lipoprotein cholesterol, total
cholesterol, systolic blood pressure, smoking status, statins and antihypertensive prescriptions. P values ***
<0.001, ** <0.01, * <0.05.
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In multiply adjusted Cox models, there were strong positive associations between T2D
and peripheral arterial disease (HR 2.98, 95% CI 2.76, 3.22), ischaemic stroke (HR 1.72,
95% CI 1.52, 1.95), stable angina (HR 1.62, 95% CI 1.49, 1.77), heart failure (HR 1.56,
95% CI 1.45, 1.69), and non-fatal myocardial infarction (HR 1.54, 95% CI 1.42, 1.67)
(Figure 5.4 on page 118 and Table 5.5 on page 121).
In contrast, T2D was inversely associated with abdominal aortic aneurysm (HR 0.46,
95% CI 0.35, 0.59) and subarachnoid haemorrhage (HR 0.48, 95% CI 0.26, 0.89). There
was no statistically significant association with arrhythmia / sudden cardiac death (HR
0.95, 95% CI 0.76, 1.19). The strengths of associations were slightly attenuated by ad-
justment for risk factors and medication compared to the model adjusted for age and sex
only (Table 5.6 on page 123, Figure 5.5 on page 119).
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Figure 5.5: Association of type 2 diabetes with initial presentation of cardiovascular dis-
eases using different adjustments
‘Risk factors’ adjustment includes age, sex, body mass index, deprivation, high density lipoprotein chole-
sterol, total cholesterol, systolic blood pressure, and smoking status. ‘Treatment’ includes statins and antihy-
pertensive prescription in the year before study entry. P values *** <0.001, ** <0.01, * <0.05
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Figure 5.6: Hazard ratios for association of type 2 diabetes with twelve cardiovascular
diseases by sex and age
Hazard ratios by sex and age group for the association of different initial presentations of cardiovascular dis-
ease with type 2 diabetes, adjusted for age, smoking, body mass index, deprivation, high density lipoprotein
cholesterol, total cholesterol, systolic blood pressure, smoking status, statins and antihypertensive prescrip-
tions. P values *** <0.001, ** <0.01, * <0.05
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Table 5.5: Hazard ratios for association of type 2 diabetes with cardiovascular disease
incidence using different levels of adjustment
Both analyses used the complete dataset with multiple imputation of missing covariate values. ‘Risk factors’
comprised body mass index, deprivation, high density lipoprotein cholesterol, total cholesterol, systolic blood
pressure and smoking status.
Primary analysis (adjusted for Adjusted for age, sex and
age, sex, risk factors, statins risk factors
and antihypertensives)
Hazard ratio Hazard ratio
Initial presentation (95% CI) P value (95% CI) P value
Stable angina 1.62 (1.49, 1.77) < 0.0001 1.79 (1.64, 1.95) < 0.0001
Unstable angina 1.53 (1.32, 1.76) < 0.0001 1.71 (1.49, 1.97) < 0.0001
Coronary disease not further
specified
1.58 (1.45, 1.73) < 0.0001 1.93 (1.76, 2.11) < 0.0001
Non-fatal myocardial infarction 1.54 (1.42, 1.67) < 0.0001 1.50 (1.38, 1.62) < 0.0001
Unheralded coronary death 1.43 (1.23, 1.65) < 0.0001 1.39 (1.20, 1.60) < 0.0001
Heart failure 1.56 (1.45, 1.69) < 0.0001 1.58 (1.47, 1.70) < 0.0001
Arrhythmia or sudden cardiac
death
0.95 (0.76, 1.19) 0.65 0.99 (0.80, 1.24) 0.94
Transient ischaemic attack 1.45 (1.31, 1.60) < 0.0001 1.40 (1.27, 1.55) < 0.0001
Ischaemic stroke 1.72 (1.52, 1.95) < 0.0001 1.68 (1.49, 1.91) < 0.0001
Stroke not further specified 1.64 (1.48, 1.81) < 0.0001 1.64 (1.48, 1.82) < 0.0001
Subarachnoid haemorrhage 0.48 (0.26, 0.89) 0.020 0.48 (0.26, 0.89) 0.020
Intracerebral haemorrhage 1.28 (1.02, 1.62) 0.035 1.18 (0.94, 1.49) 0.15
Peripheral arterial disease 2.98 (2.76, 3.22) < 0.0001 3.07 (2.84, 3.32) < 0.0001
Abdominal aortic aneurysm 0.46 (0.35, 0.59) < 0.0001 0.49 (0.38, 0.63) < 0.0001
Other death 1.10 (1.05, 1.17) 0.0004 1.01 (0.96, 1.07) 0.70
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5.5.3 Associations in women and men, by age group and ethnicity
For individuals aged 40 years without cardiovascular disease, the overall estimated risk
of developing any cardiovascular disease by age 80 was 30.7% for women and 44.3% for
men without diabetes, compared to 58.2% for women and 67.4% for men with T2D (Table
5.4 on page 117). I observed slightly greater risk of non-fatal myocardial infarction asso-
ciated with T2D in women under 60 years of age (HR 2.68, 95% CI 2.03, 3.54) compared
to men under 60 years of age (HR 1.71, 95% CI 1.45, 2.00; p = 0.0048 for interaction)
but no other statistically significant sex differences (Figure 5.6 on page 120). Associa-
tions between T2D and coronary endpoints, transient ischaemic attack, ischaemic stroke
and peripheral arterial disease were significantly stronger among younger compared to
older age groups (Figure 5.7 on page 125). Hazard ratios for T2D and cardiovascular
endpoints were consistent across ethnic groups for the common endpoints such as heart
failure, stable angina and peripheral arterial disease, but the results for less common
endpoints were imprecise because of the small number of events (Figure 5.8 on page
126).
5.5.4 Glycaemic control in patients with type 2 diabetes
The risk of cardiovascular diseases associated with the presence of T2D was highest for
those with an HbA1c ≥ 58 mmol/mol or those in whom the HbA1c had not been recorded
(Figure 5.9 on page 127). Individuals with T2D and an HbA1c <48 mmol/mol had an
increased risk of peripheral arterial disease (HR 1.82, 95% CI 1.52, 2.18) and ischaemic
stroke (HR 1.53, 95% CI 1.18, 1.98), but no greater risk of any of the other cardiovascular
diseases.
5.5.5 Sensitivity analyses and secondary outcomes
Overall results were similar among the subset of individuals with completely recorded
covariates (Table 5.7 on page 123), but effect estimates were imprecise because the
number of patients was much smaller. Hazard ratios for any diabetes versus no diabetes
were similar to the main results (T2D versus no diabetes), and restricting the patient
population to those entering the study after 2004 also made little difference to the results
(Table 5.8 on page 124). Apart from a slightly stronger association with heart failure
(HR 2.15; 95% CI 1.96, 2.36 versus 1.56; 95% CI 1.45, 1.69), results did not differ when
primary care data was omitted as a source of endpoint information (Figure 5.10 on page
128). T2D was strongly associated with composite cardiovascular mortality and all cause
mortality (Table 5.9 on page 124). Plots of Schoenfeld residuals showed that hazard
ratios were constant over time, i.e. the proportional hazards assumption of the Cox model
was not violated (Figure 5.11 on page 129).
122
5.5. Results
Table 5.6: Age and sex adjusted hazard ratios for association of type 2 diabetes with initial
presentation of cardiovascular diseases
All patients Patients with completely
recorded covariates
Hazard ratio Hazard ratio
Initial presentation (95% CI) P value (95% CI) P value
Stable angina 1.93 (1.79, 2.08) < 0.0001 2.10 (1.67, 2.64) < 0.0001
Unstable angina 1.84 (1.62, 2.10) < 0.0001 1.19 (0.83, 1.72) 0.34
Coronary disease not further
specified
2.11 (1.95, 2.29) < 0.0001 1.75 (1.41, 2.16) < 0.0001
Non-fatal myocardial infarction 1.57 (1.46, 1.70) < 0.0001 1.48 (1.17, 1.88) 0.0011
Unheralded coronary death 1.48 (1.31, 1.68) < 0.0001 1.73 (1.16, 2.59) 0.0070
Heart failure 1.80 (1.68, 1.93) < 0.0001 3.29 (2.48, 4.35) < 0.0001
Arrhythmia or sudden cardiac
death
1.12 (0.92, 1.37) 0.26 0.83 (0.46, 1.51) 0.55
Transient ischaemic attack 1.42 (1.30, 1.55) < 0.0001 1.20 (0.89, 1.61) 0.23
Ischaemic stroke 1.72 (1.53, 1.93) < 0.0001 1.47 (0.98, 2.19) 0.060
Stroke not further specified 1.77 (1.63, 1.92) < 0.0001 1.22 (0.88, 1.69) 0.23
Subarachnoid haemorrhage 0.45 (0.25, 0.81) 0.0077 − −
Intracerebral haemorrhage 1.20 (0.97, 1.50) 0.099 0.93 (0.45, 1.93) 0.85
Peripheral arterial disease 3.14 (2.94, 3.35) < 0.0001 2.80 (2.24, 3.49) < 0.0001
Abdominal aortic aneurysm 0.52 (0.40, 0.67) < 0.0001 0.31 (0.14, 0.66) 0.0026
Other death 1.04 (0.99, 1.09) 0.11 1.45 (1.24, 1.69) < 0.0001
Table 5.7: Hazard ratios from complete case analyses for association of type 2 diabetes
with initial presentation of cardiovascular diseases
These analyses were limited to the subset of individuals with completely recorded covariate information:
59 116 with no diabetes and 12 411 with type 2 diabetes. ‘Risk factors’ comprised body mass index, depri-
vation, high density lipoprotein cholesterol, total cholesterol, systolic blood pressure and smoking status.
Adjusted for age, sex, risk factors, Adjusted for age, sex and
statins and antihypertensives risk factors
Hazard ratio Hazard ratio
Initial presentation (95% CI) P value (95% CI) P value
Stable angina 2.03 (1.59, 2.60) < 0.0001 2.10 (1.65, 2.67) < 0.0001
Unstable angina 1.16 (0.78, 1.73) 0.45 1.28 (0.87, 1.88) 0.22
Coronary disease not further
specified
1.64 (1.30, 2.07) < 0.0001 1.69 (1.35, 2.13) < 0.0001
Non-fatal myocardial infarction 1.50 (1.17, 1.93) 0.0016 1.49 (1.16, 1.90) 0.0018
Unheralded coronary death 2.22 (1.43, 3.46) 0.0004 1.93 (1.24, 3.02) 0.0038
Heart failure 3.01 (2.22, 4.07) < 0.0001 2.96 (2.19, 3.99) < 0.0001
Arrhythmia or sudden cardiac
death
0.92 (0.49, 1.73) 0.79 0.88 (0.47, 1.63) 0.68
Transient ischaemic attack 1.33 (0.97, 1.81) 0.076 1.27 (0.93, 1.73) 0.13
Ischaemic stroke 1.61 (1.05, 2.46) 0.028 1.57 (1.03, 2.40) 0.034
Stroke not further specified 1.16 (0.83, 1.64) 0.39 1.14 (0.81, 1.60) 0.46
Subarachnoid haemorrhage − − − −
Intracerebral haemorrhage 1.20 (0.55, 2.63) 0.66 1.15 (0.53, 2.50) 0.73
Peripheral arterial disease 3.05 (2.40, 3.88) < 0.0001 3.16 (2.50, 4.01) < 0.0001
Abdominal aortic aneurysm 0.30 (0.14, 0.67) 0.0034 0.30 (0.14, 0.65) 0.0026
Other death 1.63 (1.38, 1.93) < 0.0001 1.53 (1.29, 1.80) < 0.0001
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Table 5.8: Hazard ratios from secondary analyses for association of type 2 diabetes with
initial presentation of cardiovascular diseases
Hazard ratios were adjusted for age, sex, risk factors (body mass index, deprivation, high density lipopro-
tein cholesterol, total cholesterol, systolic blood pressure, smoking status), and statin and antihypertensive
prescription in the year before study entry.
Patients with any Type 2 diabetes versus no
diabetes versus no diabetes diabetes, restricted to patients
entering the study after 2004
Hazard ratio Hazard ratio
Initial presentation (95% CI) P value (95% CI) P value
Stable angina 1.70 (1.57, 1.83) < 0.0001 1.62 (1.17, 2.23) 0.0030
Unstable angina 1.66 (1.47, 1.87) < 0.0001 1.30 (0.86, 1.95) 0.21
Coronary disease not further
specified
1.73 (1.60, 1.87) < 0.0001 1.33 (1.03, 1.73) 0.031
Non-fatal myocardial infarction 1.74 (1.62, 1.86) < 0.0001 1.48 (1.14, 1.91) 0.0031
Unheralded coronary death 1.81 (1.60, 2.04) < 0.0001 1.93 (1.31, 2.84) 0.00098
Heart failure 1.76 (1.65, 1.87) < 0.0001 2.02 (1.55, 2.63) < 0.0001
Arrhythmia or sudden cardiac
death
1.16 (0.97, 1.39) 0.11 1.10 (0.58, 2.06) 0.78
Transient ischaemic attack 1.54 (1.42, 1.68) < 0.0001 1.24 (0.91, 1.69) 0.18
Ischaemic stroke 1.72 (1.54, 1.92) < 0.0001 1.42 (1.00, 2.01) 0.051
Stroke not further specified 1.80 (1.65, 1.95) < 0.0001 1.24 (0.99, 1.56) 0.059
Subarachnoid haemorrhage 0.54 (0.33, 0.89) 0.016 − −
Intracerebral haemorrhage 1.40 (1.15, 1.70) 0.0007 1.10 (0.53, 2.27) 0.80
Peripheral arterial disease 3.33 (3.12, 3.55) < 0.0001 2.70 (2.12, 3.44) < 0.0001
Abdominal aortic aneurysm 0.49 (0.39, 0.62) < 0.0001 0.33 (0.15, 0.72) 0.0056
Other death 1.39 (1.33, 1.45) < 0.0001 1.46 (1.29, 1.64) < 0.0001
Table 5.9: Hazard ratios for composite endpoints
All analyses used the complete dataset with multiple imputation of missing covariate values. ‘Risk factors’
comprised body mass index, deprivation, high density lipoprotein cholesterol, total cholesterol, systolic blood
pressure and smoking status.
Adjusted for age, sex, risk factors, Adjusted for age, sex and
statins and antihypertensives risk factors
Hazard ratio Hazard ratio
Initial presentation (95% CI) P value (95% CI) P value
Cardiovascular death 1.53 (1.45, 1.62) < 0.0001 1.62 (1.53, 1.71) < 0.0001
Non-cardiovascular
death
1.29 (1.24, 1.34) < 0.0001 1.22 (1.17, 1.26) < 0.0001
Death due to any
cause
1.35 (1.31, 1.39) < 0.0001 1.31 (1.27, 1.36) < 0.0001
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Figure 5.7: Adjusted hazard ratios for type 2 diabetes and initial presentations of cardio-
vascular diseases by age group
Hazard ratios by age group for the association of different initial presentations of cardiovascular disease with
type 2 diabetes, adjusted for sex, body mass index, deprivation, high density lipoprotein cholesterol, total
cholesterol, systolic blood pressure, smoking status, statins and antihypertensive prescriptions. P values ***
<0.001, ** <0.01, * <0.05
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Figure 5.8: Adjusted hazard ratios for type 2 diabetes and initial presentations of cardio-
vascular diseases by ethnicity
Hazard ratios by ethnicity for the association of different initial presentations of cardiovascular disease with
type 2 diabetes, adjusted for age, sex, body mass index, deprivation, high density lipoprotein cholesterol, to-
tal cholesterol, systolic blood pressure, smoking status, statins and antihypertensive prescriptions. P values
*** <0.001, ** <0.01, * <0.05
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Figure 5.9: Association of type 2 diabetes with initial presentation of cardiovascular dis-
eases by level of glycaemic control
Hazard ratios for initial presentations of cardiovascular diseases associated with type 2 diabetes with different
levels of HbA1c (mean in mmol/mol within 3 years of baseline), compared with no diabetes, adjusted for
age, sex, body mass index, deprivation, high density lipoprotein cholesterol, total cholesterol, systolic blood
pressure, smoking status, statins and antihypertensive prescriptions. P values *** <0.001, ** <0.01, * <0.05
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Figure 5.10: Association of type 2 diabetes with initial presentation of cardiovascular dis-
eases using different subsets of the data sources
Hazard ratios adjusted for age, sex, body mass index, deprivation, high density lipoprotein cholesterol, total
cholesterol, systolic blood pressure, smoking status, statins and antihypertensive prescriptions. P values ***
<0.001, ** <0.01, * <0.05
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Figure 5.11: Schoenfeld residuals and tests for proportional hazards
Scaled Shoenfeld residuals for type 2 diabetes versus no diabetes, adjusted for age, sex, body mass index,
deprivation, high density lipoprotein cholesterol, total cholesterol, systolic blood pressure, smoking status,
statins and antihypertensive prescriptions. The lines show the estimate and 95% confidence interval for the
beta coefficient for type 2 diabetes over time. The top left corner of each graph contains ρ, χ2 and p value for
the correlation between transformed survival time and scaled Schoenfeld residuals. For clarity, points plotted
on the graph are for a random sample of 20 000 patients rather than all 1.9 million.
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5.6 Discussion
5.6.1 Summary of main findings
This study demonstrates the value of the CALIBER dataset in investigating the initial
presentation of cardiovascular disease. Findings of increased risk of many cardiovascular
diseases in patients with T2D provides a reassuring check on the validity of the dataset for
this type of study. However, this study also provides new information that the associations
with different cardiovascular presentations differ in terms of direction and magnitude of
effects.
5.6.2 Outcomes with increased risk in type 2 diabetes
A group of atherosclerotic diseases including coronary heart disease and peripheral arte-
rial disease have a similar association of increased risk in individuals with type 2 diabetes.
Peripheral arterial disease is among the most common first presentations of cardiovascu-
lar disease, consistent with the increase in prevalence between 2000 and 2010 found in
a recent systematic review [206]. Furthermore, of all the twelve diseases studied, periph-
eral arterial disease showed the strongest association with T2D, with an adjusted hazard
ratio of 3, consistent with previous studies [206]. Heart failure was also among the most
common first presentations (accounting for 14.4% of events among people with T2D).
The definition used in this study excludes heart failure occurring after acute myocardial
infarction, but this result must be interpreted with caution because it is known that all data
sources miss some cases of myocardial infarction (section 4.2). Possible mechanisms
may involve prolonged hypertension, chronic hyperglycemia, microvascular disease, gly-
cosylation of myocardial proteins, diabetic nephropathy and autonomic neuropathy [198].
Similar to the meta-analysis of cohort studies in the Emerging Risk Factors Collabora-
tion [200], I found a weaker association of cardiovascular disease with T2D among older
people.
5.6.3 Outcomes with reduced risk in type 2 diabetes
A novel finding was the association of T2D with reduced incidence of two major aneurys-
mal diseases: abdominal aortic aneurysm and subarachnoid haemorrrhage. An inverse
association between diabetes AAA has been suggested by cross-sectional studies of ab-
dominal aortic aneurysm screening and case-control studies [44,207,208], but evidence
from large prospective cohort studies has been mixed [209,210].
No previous cohort study has been large enough to investigate the association of type
2 diabetes with subarachnoid haemorrhage, but there have been a number of case con-
trol studies which are consistent with my results [211]. These findings support the need
to identify potential mechanisms which might have therapeutic implications. Such mecha-
nisms may include diabetes-mediated changes in the vascular extracellular matrix, such
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as glycation of the extracellular matrix and covalent cross-linking between elastin and
collagen in the aortic wall [212].
5.6.4 Outcomes not significantly associated with type 2 diabetes
Several studies have shown that T2D is associated with out of hospital cardiac arrest
and sudden cardiac death [213], and an important unanswered question has been the
extent to which this effect is mediated by incident diseases known to increase arrhythmic
risk such as myocardial infarction and heart failure. In this study I looked at the initial
presentation of cardiovascular disease, i.e. arrhythmia with no prior myocardial infarction
or heart failure, and my finding of no association suggests that the higher risk of cardiac
arrest with T2D is mediated by atherosclerotic coronary disease.
5.6.5 Sex differences
The absolute risk for coronary heart disease morbidity and mortality is lower in women
compared to men, but the relative risk associated with diabetes has generally been re-
ported to be higher in women than men [201,214,215]. The most recent meta-analysis of
prospective studies reported relative risks for incident coronary heart disease of 2.63 for
women and 1.85 for men with diabetes [201]. Sex differences in the association of T2D
with outcomes other than coronary heart disease have less often been reported, with
conflicting results for stroke [216, 217]. I observed weak evidence of a slightly stronger
association of T2D with myocardial infarction in women compared to men among those
aged under 60, which is consistent with previous reports, but no other sex differences in
associations between T2D and cardiovascular outcomes [218].
5.6.6 HbA1c and glycaemic control
The finding that levels of HbA1c were associated with the risk of many cardiovascular
diseases strengthens the case for the causal relevance of blood glucose. These associ-
ations were particularly strong for peripheral arterial disease, and persisted even among
those with HbA1c <48 mmol/mol, suggesting that risk is not controlled in this group. In-
dividuals in whom HbA1c had not been measured were at higher risk, consistent with
measurement being a marker of overall quality of care.
5.6.7 Clinical and research implications
These results will help inform drug development and the design of trials in T2D. To date,
trials often include acute myocardial infarction and acute stroke as their primary event
endpoints, because of a previous perception that these were the main disease burdens or
that they are easier to ascertain and validate than chronic disease endpoints. The results
of this study suggest that it is also important to consider chronic disease endpoints such
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as heart failure, peripheral arterial disease and stable angina because they are common,
have a high morbidity burden and may have different treatment effects from myocardial
infarction or stroke.
5.6.8 Limitations
Although a strength of this study is the ability to resolve a wide range of cardiovascular
diseases in a validated electronic health record (EHR) linkage, EHRs are limited in the
accuracy and detail they include. Residual confounding, due to diet, physical activity,
stress and environmental factors, may be a potential source of bias. Although T2D cod-
ing has error in clinical practice [181], this is unlikely to be an important source of bias in
this study because analyses based on the diagnostic marker of HbA1c were consistent.
Error may occur in recording the cardiovascular outcomes; one might expect those which
are more reliably coded (such as non-fatal myocardial infarction) to show stronger associ-
ations than diseases which are less reliably coded (such as stable angina). The fact that
this was not observed suggests that the heterogeneity is real. It was also reassuring that
similar associations with T2D were seen when endpoint ascertainment was restricted to
hospital admissions and deaths. The lifetime risks were somewhat artificial, as they were
based on extrapolation of event rates observed in people entering the cohort at different
ages, but this meant they were more contemporaneous than estimates from long term
follow-up of cohorts diagnosed decades ago.
5.6.9 Conclusion
This CALIBER study showed that type 2 diabetes was associated with increased risk
of many cardiovascular diseases. Heart failure and peripheral arterial disease are the
most common initial manifestations of cardiovascular disease in type 2 diabetes. The
differences between relative risks of different cardiovascular diseases in patients with
type 2 diabetes may have implications for clinical risk assessment and trial design.
5.7 Summary
In this chapter I described the definition of a cohort for studying initial presentation of
cardiovascular diseases in CALIBER, and the identification of twelve initial presentations
of cardiovascular disease. These definitions will be used in the remainder of the thesis
for investigating leukocyte counts and cardiovascular diseases.
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6.1 Chapter outline
Full blood counts are commonly performed in general practice, and are available within
the CPRD data in CALIBER. This chapter contains preparatory work for a cohort study
in CALIBER investigating differential leukocyte counts and risk of incident cardiovascular
diseases. The results of this study are reported in the subsequent two chapters.
6.2 Abstract
Objective: To develop an analysis plan for investigating the association of the leukocyte
differential with initial presentation of cardiovascular diseases in CALIBER.
Methods: I performed a sample size and power calculation to find out the minimum
difference in effect sizes that a CALIBER study would be able to detect. I developed algo-
rithms to extract leukocyte counts from the CALIBER master database. I defined a study
cohort of patients with leukocyte counts and explored the association of the differential
leukocyte count with cardiovascular risk factors, in order to inform an analysis plan.
Results: For an endpoint with frequency 8 per 100 000 patient-years, a sample size of
700 000 patients with mean follow-up 3 years has approximately 80% power to detect that
hazard ratios of 1.2 and 1.8 are significantly different. I identified a cohort of 1 811 724
individuals in CALIBER with no prior cardiovascular disease, of whom 776 861 had a
full blood count measurement. Current smokers had higher neutrophil, lymphocyte and
monocyte counts than non or ex smokers.
Discussion: These findings inform the analysis protocol for the main study investigating
leukocyte counts and cardiovascular diseases, reported in chapters 7 and 8. Smoking
was found to have strong associations with leukocyte counts and will be an important
confounder to adjust for in analyses.
6.3 Sample size and power calculation
I performed a sample size calculation by simulation to estimate the power to detect a dif-
ference in the hazard ratio per standard deviation higher white blood cell count between
two event types. This calculation was based on a baseline incidence of 8 per 100 000
133
Chapter 6. Full blood count data in CALIBER
Table 6.1: Sample size estimation for detection of difference in hazard ratio for two
endpoints
Hazard ratio per
1 SD higher
biomarker level
Baseline incidence
of event per 100 000
patient years
Power (%) to detect difference
between two hazard ratios (mean 3
year follow-up) by sample size
Event 1 Event 2 Event 1 Event 2 100 000 300 000 500 000 700 000
1.2 1.6 8 8 5.4 10.7 10.0 23.7
1.2 1.8 8 8 18.4 41.0 41.4 80.1
1.2 1.6 16 16 31.6 68.4 68.3 96.6
1.2 1.8 16 16 49.1 84.2 85.6 100.0
patient-years (as for subarachnoid haemorrhage, the endpoint expected to have the low-
est incidence [219]).
I created 1000 simulated datasets, each containing 100 000 to 700 000 patients. I as-
sumed white cell counts were distributed according to a standard normal distribution, and
event times were distributed exponentially. The cause-specific hazard was dependent on
white cell count with specified hazard ratios. Follow-up times were uniformly distributed
between 0 and 6 years (i.e. mean 3 year follow-up).
I analysed the simulated data using cause-specific Cox models, considering event 1
as censoring when analysing event 2 and vice versa. The two cause-specific hazard
ratios were considered to be significantly different if their 95% confidence intervals did
not overlap.
The sample size calculation estimates that for an endpoint with frequency 8 per 100 000
patient-years, a sample size of 700 000 patients with mean follow-up 3 years has approx-
imately 80% power to detect that hazard ratios of 1.2 and 1.8 are significantly different
(Table 6.1 on page 134). This sample size is significantly larger than the UK Biobank
cohort (n=500 000) and is generally only achievable in EHR cohorts or large consortia.
6.4 Definition of CALIBER study population
The patient flow diagram for this study is shown in Figure 6.1 on page 135.
The start and end dates for the study were decided based on the quality and complete-
ness of data available in the CALIBER data sources. Although CPRD practices have
been collecting data since the late 1980s, linkage to Hospital Episode Statistics com-
menced in January 1997. Each CPRD practice has an ‘up-to-standard’ date, defined as
the earliest date that set of data completeness indicators are fulfilled. The eligibility start
date was therefore chosen as January 1998, and individuals were eligible for inclusion
when they were at least 30 years of age and had been registered for at least one year
in an ‘up-to-standard’ practice. The lower age limit of 30 was chosen because below this
age the incidence of cardiovascular endpoints was very low.
I extracted all full blood count measurements (including haemoglobin concentration,
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Figure 6.1: Patient flow diagram
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1 161 449 patients
with no FBC record 973 166 patients with FBC record
1630 patients with FBC
excluded
Calculate duration of registration
during study period.
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comparison with people who had
a full blood count measurement.
Exclude if dialysis, splenectomy or HIV 
before index date, as these affect the
interpretation of the FBC
196305 patients excluded
Generate index date = date of
first FBC measurement
Exclude if any record of cardiovascular
disease prior to index date, or pregnant
within 6 months of indexdate, or
fewer than 100 patients in the practice126586 patients excluded
154 179 patients with
'acute' FBC measurement 621 052 patients with 'stable'FBC measurement
1 034 863 patients with
no FBC measurement
Did patient have an acute condition (e.g. infection)
or medication that can affect FBC (e.g. steroids)
at time of blood count measurement
(according to EMERGE criteria)?
No Yes
Yes No
platelet count, total leukocyte count and differential leukocyte count) for all patients in the
cohort. Details of the algorithm for extracting full blood counts are given in section 6.7 on
page 139. The ‘index date’ (study start date) for each participant was the date of the first
full blood count recorded in CPRD while the participant was eligible. Patients with a prior
history of cardiovascular disease and women with a pregnancy record within 6 months of
the start of the study were excluded, as in other CALIBER studies investigating the initial
presentation of cardiovascular diseases [35,36,197,220].
The study end date was March 2010, the last collection date of CPRD data. Patients
were censored if they transferred out of the practice before the end of the study.
6.5 Classification of patient status at time of blood tests
White cell counts can be affected by many factors such as acute and chronic infections,
autoimmune diseases, medication and haematological conditions. The electronic Medical
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Records and Genomics (eMERGE) consortium has proposed an algorithm to identify the
stable underlying white cell count in electronic health records using information about
intercurrent illnesses and prescriptions [55]. This algorithm was developed for genetic
studies investigating determinants of a patient’s genetically determined stable white cell
count. Studies using these methods do not aim to predict prognosis based on the white
cell count; hence they can use all the information in the medical record regardless of
time [56,221].
My aim was slightly different; I wished to investigate the prognostic significance of white
blood cell counts according to whether the patient had an acute medical condition that
may affect white cell counts. Using information after the blood test (such as a diagnosis
of infection) to classify patient status could create immortal time bias, as patients who
survived would be more likely to have such information recorded. Therefore I limited the
time window for information pertaining to patient status to be on or before the date of the
blood test.
I converted the ICD-9, CPT4 and HCPC codes as used in the eMERGE algorithm to
ICD-10, OPCS and Read codes for use with CALIBER data, and identified the relevant
drug preparations (e.g. chemotherapy agents, methotrexate and steroids) in the CPRD
drug dictionary.
The criteria for an ‘acute’ patient state were: in hospital on the date of blood test, vacci-
nation in the previous 7 days, anaemia diagnosis within the previous 30 days, symptoms
or diagnosis of infection within the previous 30 days, prior diagnosis of myelodysplastic
syndrome, prior diagnosis of haemoglobinopathy, cancer chemotherapy or G-CSF within
6 months before index date, or the use of drugs affecting the immune system such as
methotrexate or steroids within the previous 3 months.
In secondary analyses, I explored associations between onset of cardiovascular dis-
eases and the mean of the first two ‘stable’ leukocyte count measurements taken since
the start of eligibility.
6.6 Extracting covariate data
I extracted demographic variables, cardiovascular risk factors, comorbidities and acute
conditions and prescriptions around the time of the blood test from CPRD. I extracted
hospitalisation records and comorbidities additionally from HES.
For continuous covariates I used the most recent value in the year prior or up to 1 day
after the full blood count measurement. I also extracted the first measurement after this
time window and the most recent measurement before the time window, along with the
timing of these measurements relative to the index date, to use as auxiliary variables
for multiple imputation. The CALIBER variable definitions for continuous variables spec-
ified a valid range for each continuous variable; values outside this range (which were
biologically implausible and almost certainly errors) were ignored.
I calculated body mass index from height and weight records in CPRD, handling outliers
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and errors according to the algorithm of Bhaskaran et al. [175]. For smoking, I used all
information prior to the index date in order to determine smoking status. Patients whose
most recent record stated they were a smoker were considered to be current smokers. Of
the remainder, those who had any previous record of being a current or ex smoker were
considered to be ex smokers, and those with at least one non smoking record and no ex
or current smoking records were considered to be never smokers.
Characteristics of patients included and excluded from the study are shown in Table 6.2
on page 138. For patients with a full blood count recorded, covariate information is based
on the date of the blood count. For other patients, I generated a ‘pseudo’ index date for
this comparison. I generated this pseudo index date as follows. First, I set a duration of
registration prior to the index date for each patient without a full blood count recorded.
I randomly selected this duration from the distribution of durations between registration
and index date among patients with a full blood count recorded and a similar total duration
of registration. The pseudo index date was generated by adding this duration to the date
the patient registered with the practice.
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Table 6.2: Characteristics of individuals in CALIBER with no prior history of cardiovascu-
lar disease
FBC recorded while eligible for study
No FBC Patients excluded ‘Acute’ FBC ‘Stable’ FBC
N patients 1 034 863 1630 154 179 621 052
Women, n (%) 455 290 (44.0%) 780 (47.9%) 94 383 (61.2%) 367 573 (59.2%)
Age, median (IQR) 41.5 (33.9-53.8) 53.1 (42.7-65.0) 56.2 (43.1-68.9) 51.6 (41.1-63.4)
Most deprived quintile, n
(%) 220 256 (21.4%) 328 (20.2%) 27 196 (17.7%) 105 775 (17.1%)
Duration of registration
before index date
(years), median (IQR)
5.63 (1.98-13.6) 11.3 (4.09-19.1) 11.1 (4.21-20.3) 10.9 (4.22-19.6)
Total duration of
registration during study
period (years), median
(IQR)
8.18 (3.47-17.3) 15.8 (8-23.7) 15.9 (8.34-24.8) 15.7 (8.39-24.1)
Ethnicity, n (%):
White 389 590 (87.1%) 1086 (91.3%) 96 591 (92.7%) 348 443 (92.8%)
South Asian 14 697 (3.3%) 12 (1.0%) 3015 (2.9%) 10 435 (2.8%)
Black 20 471 (4.6%) 68 (5.7%) 2301 (2.2%) 7673 (2.0%)
Other 22 511 (5.0%) 24 (2.0%) 2282 (2.2%) 9038 (2.4%)
Missing 587 594 (56.8%) 440 (27.0%) 49 990 (32.4%) 245 463 (39.5%)
Smoking status, n(%):
Never 456228 (53.2%) 754 (49.1%) 75432 (51.6%) 311270 (52.9%)
Ex 146577 (17.1%) 386 (25.1%) 37055 (25.4%) 140144 (23.8%)
Current 254115 (29.7%) 395 (25.7%) 33600 (23.0%) 137421 (23.3%)
Missing 177943 (17.2%) 95 (5.8%) 8092 (5.2%) 32217 (5.2%)
Recording within 1 year before index date:
HDL and total cholesterol 43 157 (4.2%) 448 (27.5%) 40 520 (26.3%) 204 507 (32.9%)
Blood pressure 267 706 (25.9%) 1062 (65.2%) 97 069 (63.0%) 409 775 (66.0%)
eGFR 48 033 (4.6%) 892 (54.7%) 79 971 (51.9%) 284 628 (45.8%)
Body mass index 137 518 (13.3%) 540 (33.1%) 47 194 (30.6%) 195 144 (31.4%)
Most recent value within one year prior to index date:
Systolic blood pressure,
mmHg 129 (118-140) 134 (122-146) 136 (122-150) 136 (121-150)
Body mass index, kg/m2 26.1 (23.1-30.1) 26.4 (23.4-30.3) 26.9 (23.5-31.1) 27.1 (23.8-31.1)
Total cholesterol, mmol/L 5.3 (4.54-6) 5.32 (4.6-6.2) 5.4 (4.7-6.2) 5.5 (4.8-6.21)
HDL cholesterol, mmol/L 1.32 (1.1-1.6) 1.35 (1.1-1.7) 1.4 (1.11-1.7) 1.4 (1.13-1.7)
eGFR, mL/min/1.73m2 86.8 (72.4-100) 80.1 (63.5-94.6) 79.8 (66.2-93.5) 82.5 (69.6-95.5)
Diagnoses on or before index date:
Atrial fibrillation 3777 (0.4%) 35 (2.1%) 2221 (1.4%) 5501 (0.9%)
Cancer 30 216 (2.9%) 355 (21.8%) 37 565 (24.4%) 9956 (1.6%)
Diabetes 18 733 (1.8%) 140 (8.6%) 8361 (5.4%) 28 766 (4.6%)
Atopy (hayfever, asthma
or atopic dermatitis) 130 120 (12.6%) 334 (20.5%) 31 951 (20.7%) 114 716 (18.5%)
Chronic obstructive
pulmonary disease 9294 (0.9%) 50 (3.1%) 6396 (4.1%) 8625 (1.4%)
Connective tissue disease 9295 (0.9%) 81 (5.0%) 11 208 (7.3%) 10 651 (1.7%)
Inflammatory bowel
disease 4723 (0.5%) 26 (1.6%) 3489 (2.3%) 5157 (0.8%)
Medication use in the year before index date:
Antihypertensives 96 323 (9.3%) 825 (50.6%) 43 779 (28.4%) 153 502 (24.7%)
Statins 19 388 (1.9%) 185 (11.3%) 9442 (6.1%) 37 364 (6.0%)
FBC, full blood count
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6.7 Extraction of leukocyte counts from CPRD data
Laboratory values are generally transferred automatically to the general practice system
and are recorded in CPRD as numerical values, with additional data fields for the operator
(equal, greater than or less than), units and reference range. Each record is associated
with an ‘entity type’ defining the type of result contained in the record (e.g. ‘Neutrophil
count’) and defining the meaning of the other data fields, and a Read code (e.g. ‘Percent-
age neutrophils’, specifying the test in more detail. There are a few hundred entity types
in the CPRD information model but thousands of potential Read terms.
A common format for the majority of blood test results was as follows:
Column Description
patid Patient identifier
eventdate Date of the blood test
sysdate System date (date the information was entered on the GP system)
enttype Entity type
medcode CPRD medical code corresponding to Read code / Read term
data1 Operator (coded entry: =, <, >)
data2 Value (numeric)
data3 Unit of measure (coded entry: 10*9/L, %, etc.)
data4 Qualifier (coded entry: High, Low, Normal, Abnormal, etc.)
data5 Normal range from (numeric)
data6 Normal range to (numeric)
data7 Normal range basis (coded entry: age based, age and sex etc.)
The meaning of the data fields could vary between entity types. I used a sample CAL-
IBER dataset (100,000 patients with stable coronary disease) to investigate how white
cell counts were recorded and what steps would be required to convert the raw values
into a variable suitable for use in modelling.
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6.7.1 Example: extraction of total white cell count
First I generated a codelist for total white cell count:
Read code Read term
42H..00 Total white cell count
42H..11 White blood count
42H..12 White cell count
42H1.00 White cell count normal
42H2.00 Leucopenia - low white count
42H2.11 Leucopenia
42H3.00 Leucocytosis -high white count
42H3.11 Leucocytosis
42H5.00 White cell count abnormal
42H7.00 Total white blood count
42H8.00 Total WBC (IMM)
42HZ.00 Total white cell count NOS
D400A00 Leucopenia
D40y.11 Leucocytosis
D40y.12 Leukocytosis
D40yz11 Leucocytosis
Next I tabulated the entity types associated with codes in this codelist.
Entity code Entity description Number of records
207 Total White Blood cell count 708810
288 Other laboratory tests 24
346 Other autoantibodies 1
363 Lipoprotein electrophoresis 1
I decided to extract only entity type 207; there may be a few white cell counts recorded
with entity type 288, but including this entity type in the extraction algorithm would make
it more complicated and increase the risk of error without much benefit.
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This is a tabulation of the 8 most frequent units associated with entity type 207:
Unit of measure Percentage of records
10*9/L 94.2
(Missing) 2.4
10*9 1.3
/L 0.7
10*12/L 0.3
10*9/mL 0.3
10*6/L 0.2
(ph) 0.2
I plotted the distribution of values associated with each of these units to verify that they
seemed sensible, and identify if any units had the wrong scale (Figure 6.2 on page 142).
Some values had missing units, and in order to decide whether to use these values I
reviewed their distribution to see if it was possible to assume what the unit should be.
I decided how to handle zero values based on whether it is biologically plausible for a
value to be zero; this was the case for white cell counts (severely immunocompromised
patients might have a white cell count of zero) but not for measures such as haemoglobin
or HbA1c.
In the case of total white cell count I found that values with missing units were much
more likely to be zero, suggesting that many of the zero values are actually missing.
However, as it is impossible to differentiate between a missing and true zero value, I
excluded all values without units.
Based on this exploratory work and a consensus on the range of biologically plausible
values (based on the literature and clinical experience), I derived an algorithm for ex-
traction of each white cell count and other clinically recorded biomarkers. The algorithm
pseudocode was converted into SQL by the data manager in order to extract the values
from the master CALIBER database. This is the algorithm pseudocode for total white cell
count:
If Read code is in the total_wbc_gprd codelist
AND enttype = 207
AND data2 [value] < 50
AND data3 [units] IN (37 [10*9/L], 153 [10*9], 17 [/L])
THEN total_wbc_gprd = data2
The algorithms are published on the CALIBER data portal (https://www.
caliberresearch.org/portal/). The algorithm for total white cell count is here: https:
//www.caliberresearch.org/portal/show/total_wbc_gprd
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Figure 6.2: Distribution of values associated with different units for raw CPRD white cell
count data
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Figure 6.3: Number of full blood count tests per patient in CALIBER
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The data extraction algorithm was implemented on the main CALIBER server to extract
the components of the full blood count as recorded in CPRD: haemoglobin concentration,
platelet count, total white cell count, neutrophil count, eosinophil count, basophil count,
monocyte count and lymphocyte count. If a patient had more than one measurement on
a given day, the values were aggregated by taking the mean.
6.7.2 Results
The median number of full blood counts available per patient was 2 (mean 3.7, standard
deviation 5.2, maximum 240). Two-thirds of patients (731 900 / 1 092 068, 67.0%) had
more than one full blood count measurement, 513 009 (47.0%) had more than two and
52 137 (4.8%) had more than ten (Figure 6.3 on page 143).
The median interval between two full blood count blood tests was 0.50 years. There
was no general trend for leukocyte counts over time (Figure 6.4 on page 144), but there
was only moderate correlation between blood tests performed at different times in the
same patient. For example, the within-person correlation of neutrophil counts taken under
‘stable’ conditions was 0.568. This compares to 0.68 for total cholesterol and 0.73 for HDL
cholesterol [105].
143
Chapter 6. Full blood count data in CALIBER
Figure 6.4: Binned scatterplots of difference between any two consecutive leukocyte
counts in the same patient, by time between measurements.
The central solid line is lowess smoothed mean; the dotted lines are lowess smoothed percentile lines at
2.5%, 25%, 75% and 97.5%. ρ is the correlation coefficient between two consecutive measurements.
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6.8 Associations between differential leukocyte counts and cardiovascular
risk factors
I plotted frequency polygons for the distribution of leukocyte counts by age, sex and levels
of cardiovascular risk factors which are known or suspected to be associated with leuko-
cyte counts. These included smoking [62], ethnicity [222], diabetes [63] and the patient’s
clinical condition at the time of blood testing. I using Mann-Whitney-Wilcoxon tests (for
two groups) or Kruskal-Wallis tests (for multiple groups) to compare the distributions of
leukocyte counts by values of cardiovascular risk factors.
Current smokers had higher neutrophil, lymphocyte and monocyte counts than non or
ex smokers (P <0.001 by Kruskal-Wallis tests; Figure 6.5 on page 146).
Leukocyte counts were fairly similar across age groups (Figure 6.6 on page 147) and
between genders (Figure 6.7 on page 148), apart from slightly higher neutrophil counts
in women and higher monocyte counts in men in this population (both P <0.001).
Black people had lower neutrophil counts than other ethnicities (Figure 6.8 on page
149) (P <0.001). Individuals with diabetes and those with blood tests taken under ‘acute’
conditions tended to have higher neutrophil counts and lower lymphocyte counts than
those taken under ‘stable’ conditions (Figure 6.9 on page 150, Figure 6.10 on page
151) (all P <0.001).
These associations of leukocyte counts with other cardiovascular risk factors show that
they may be confounders and it is essential to adjust for them in multivariable models in-
vestigating leukocyte counts and incidence of cardiovascular diseases. Given the strong
associations with smoking, it may also be necessary to examine interactions with smok-
ing status. This is because imprecise recording of smoking severity in this dataset can
cause residual confounding. Testing for interactions by smoking status can overcome this
limitation; if the same associations are seen in never-smokers as in smokers, it cannot be
due to confounding by smoking status.
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Figure 6.5: Distribution of leukocyte counts by smoking status
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Figure 6.6: Distribution of leukocyte counts by age
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Figure 6.7: Distribution of leukocyte counts by sex
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Figure 6.8: Distribution of leukocyte counts by ethnic group
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Figure 6.9: Distribution of leukocyte counts by patient condition at time of blood testing
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Figure 6.10: Distribution of leukocyte counts by diabetes status
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6.9 Summary
For an endpoint with frequency 8 per 100 000 patient-years, a sample size of 700 000
patients with mean follow-up 3 years has approximately 80% power to detect that hazard
ratios of 1.2 and 1.8 are significantly different.
I identified a cohort of 1 811 724 individuals in CALIBER patients with no prior cardio-
vascular disease, of whom 776 861 had a full blood count measurement while eligible.
After excluding 1630 individuals with a history of dialysis, splenectomy or HIV, the cohort
contained 621 052 individuals with a full blood count measured while clinically ‘stable’
and 154 179 with an ‘acute’ measurement.
Current smokers had higher neutrophil, lymphocyte and monocyte counts than non or
ex smokers. Black people had lower neutrophil counts than other ethnicities. Individuals
with diabetes and those with blood tests taken under ‘acute’ conditions tended to have
higher neutrophil counts and lower lymphocyte counts than those taken under ‘stable’
conditions. Smoking has a strong association with both cardiovascular diseases and
leukocyte counts, and is an important confounder to be adjusted for in the analysis.
This cohort will be used to investigate the association of differential leukocyte counts
with the onset of cardiovascular diseases (reported in chapters 7 and 8). The following
chapter, chapter 9 compares the association of total leukocyte count and mortality in
CALIBER and the New Zealand PREDICT cohort.
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7 Associations of neutrophils and other leukocyte counts with
specific initial presentations of cardiovascular diseases
7.1 Chapter outline
This chapter investigates the association of neutrophil counts with incidence of cardio-
vascular diseases. The cohort definition is described in chapter 6.
7.2 Abstract
Background: The white blood cell (leukocyte) differential is one of the most common
blood tests and some components, particularly neutrophils, reflect a patient’s inflam-
matory state. Inflammation is a key process in atherosclerosis, which underlies many
cardiovascular diseases, but little is known about the association of neutrophil counts
with a wide range of cardiovascular diseases.
Methods: The data source was a linked primary care, hospital admission, disease reg-
istry, and mortality dataset for England (the CALIBER programme). The study population
comprised people aged 30 or older who had a leukocyte differential recorded and were
free from cardiovascular disease at baseline. Individuals were followed up for the first
occurrence one of twelve cardiovascular presentations in any of the data sources: stable
angina, unstable angina, myocardial infarction, unheralded coronary death, heart fail-
ure, ventricular arrhythmia / sudden cardiac death, transient ischaemic attack, ischaemic
stroke, haemorrhagic stroke, subarachnoid haemorrhage, abdominal aortic aneurysm or
peripheral arterial disease. Cox models were used to estimate cause-specific hazard ra-
tios (HR) adjusted for smoking, other cardiovascular risk factors and acute conditions that
could affect leukocyte counts (such as infections and immunosuppressant medication).
Results: Among 775 231 individuals in the cohort, there were 54 980 initial presenta-
tions of cardiovascular disease over median follow up of 3.8 years. Adjusted hazard ratios
comparing neutrophil counts 6−7 vs 2−3×109/L (within the normal range) showed strong
associations with heart failure (HR 2.04; 95% confidence interval (CI) 1.82, 2.29), non-
fatal myocardial infarction (HR 1.58; 95% CI 1.42, 1.76) and unheralded coronary death
(HR 1.78; 95% CI 1.51, 2.10), but not stable angina (HR 0.97; 95% CI 0.88, 1.07) or
unstable angina (HR 1.00; 95% CI 0.84, 1.19). The association with ischaemic stroke
was weaker (HR 1.36; 95% CI 1.17, 1.57) and there was no association with haemor-
rhagic stroke, but there were strong associations with peripheral arterial disease (HR
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1.95; 95% CI 1.72, 2.21) and abdominal aortic aneurysm (HR 1.72; 95% CI 1.34, 2.21).
The associations of cardiovascular diseases with monocyte counts were similar to those
with neutrophils but less strong. Low lymphocyte counts and high basophil counts were
associated with increased incidence of heart failure.
Conclusions: Neutrophil counts are strongly associated with myocardial infarction,
heart failure and peripheral arterial disease. Given the known causal relevance of neu-
trophils in cardiovascular diseases, the clinical relevance of this inflammatory marker
should be further investigated in risk prediction.
7.3 Introduction
The differential white blood cell (leukocyte) count is one of the most common blood tests
in medical practice. It comprises counts of different cell types associated with immu-
nity and inflammation, such as neutrophils, lymphocytes, monocytes, eosinophils and
basophils. These circulating blood cells play a major role in atherosclerosis, the patho-
logical condition underlying coronary disease [48]. However, clinicians rarely use these
cell counts in cardiovascular decision making, due to insufficient understanding how they
relate to onset of cardiovascular diseases.
Previous studies found that neutrophil counts are associated with higher incidence of
coronary disease [49,116,120,121,124,125], heart failure [113] and stroke [122] (Table
2.2 on page 47). However, these studies failed to disaggregate the spectrum of coro-
nary diseases, and tended to be small, with limited power to study interactions with age
or sex. The association of neutrophil counts with acute as compared to chronic coro-
nary initial presentations are not known, and no studies have investigated associations
with vascular disease outside the heart and brain, such as abdominal aortic aneurysm
or peripheral arterial disease. These associations cannot be extrapolated from other car-
diovascular diseases; previous studies on other cardiovascular risk factors have found
that the strength and direction of associations can vary considerably by cardiovascular
presentation [35,36,197,220].
The aim of this study was to investigate the association of counts of neutrophils and
other leukocytes with the initial presentation of cardiovascular diseases in the CALIBER
cohort [1].
7.4 Methods
7.4.1 Study population
The study population was drawn from the CALIBER linked electronic health record
dataset [1] and is described in section 6.4. Briefly, individuals were eligible for inclu-
sion when they were aged 30 or older and had been registered for at least one year in a
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practice which met research data recording standards.
The study start date, (‘index date’) for each participant was the date of the first full
blood count measurement recorded in CPRD while the participant was eligible. Patients
with a prior history of cardiovascular disease and women with a pregnancy record within
6 months of the start of the study were excluded.
7.4.2 Exposure
The main exposure was the differential white cell count as recorded in CPRD, which
was extracted as described in subsection 6.7.2. White cell counts can be affected by
many factors such as acute and chronic infections, autoimmune diseases, medication
and haematological conditions. Information recorded in CALIBER around the time of
blood count measurement was used to allocate the patient state as ‘stable’ or ‘acute’
(section 6.5). Patients with HIV, splenectomy or on dialysis were excluded from this study,
as their leukocyte counts may be difficult to interpret.
In secondary analyses, I explored associations between onset of cardiovascular dis-
eases and the mean of the first two ‘stable’ measurements of neutrophil count taken
since the start of eligibility.
7.4.3 Follow-up and endpoints
Patients were followed up while registered at the practice until the occurrence of an initial
presentation of cardiovascular disease, death or transfer out of the practice. The primary
endpoint was the first record of one of 12 initial presentations of cardiovascular disease
in any of the data sources, as described earlier (section 5.4.4).
7.4.4 Covariates
I extracted demographic variables, cardiovascular risk factors, comorbidities and acute
conditions and prescriptions around the time of the blood test from CPRD, as described
in section 6.6.
7.4.5 Statistical analysis
I examined associations of cardiovascular diseases and quintiles of leukocyte subtypes in
order to explore the shape of any associations. If the association was found to be linear,
I also investigated models including the leukocyte subtype count as a linear variable.
The precision with which leukocyte subtype counts were recorded varied from one to two
decimal places (units: cells ×109/L). In order to avoid biasing the category allocation by
precision, I adjusted the category boundaries so that the second decimal place was 5.
Basophil counts were very low relative to the precision of recording so I generated three
categories instead of five. All category intervals were closed at the lower end and open
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at the higher end; for example the category 3.45–4.25 includes 3.45 and all intermediate
values up to but not including 4.25, and can be formally represented as “[3.45, 4.25)”.
For neutrophil counts I sought to present results for clinically meaningful neutrophil
counts, and separate values within and outside the reference range. Therefore although
the initial exploratory analyses used quintiles of neutrophil count, I categorised neu-
trophils in units of 1 × 109 cells/L for the main results, to make them easier to interpret.
For this study I defined ‘normal’ neutrophil counts as 2− 7× 109/L, which is a commonly
quoted reference range [223] (although all laboratories quote slightly different ranges).
This lent itself to convenient 5-level categorisation of neutrophil counts within the ‘normal’
range, with 2 additional categories for values lower or higher than the limits of the ‘normal’
range.
I generated cumulative incidence curves by category of neutrophil counts under a com-
peting risks framework. I used the Cox proportional hazards model to generate cause-
specific hazards for the different cardiovascular endpoints. Hazard ratios were adjusted
for age (linear and quadratic), sex, age / sex interaction, index of multiple deprivation,
ethnicity, smoking status, diabetes, body mass index, systolic blood pressure, estimated
glomerular filtration rate (eGFR), high density lipoprotein cholesterol (HDL), total chole-
sterol, atrial fibrillation, inflammatory conditions (autoimmune conditions, inflammatory
bowel disease or chronic obstructive pulmonary disease (COPD)), cancer, statin use,
blood pressure medication and acute conditions at the time of blood testing. The base-
line hazard was stratified by practice and sex. I plotted Schoenfeld residuals to assess
the proportional hazards assumption, and split the follow-up time if hazard ratios changed
over time. I handled missing baseline covariate data by multiple imputation as described
in subsection 7.4.7.
7.4.6 Survival analysis and competing risks
I carried out survival analysis to describe and model the first occurrence of any cardio-
vascular disease. A patient’s follow-up ended when they experienced one of the cardio-
vascular endpoints or when they were censored. Subsequent events (e.g. myocardial
infarction occurring after stable angina) were not analysed.
To describe the incidence of each initial presentation over time we constructed cu-
mulative incidence curves, taking into account the other possible initial presentations as
competing events. Normal-based confidence intervals were constructed based on Green-
wood’s variance formula, as implemented in the R prodlim package [202].
For multivariable modelling I considered using Cox models (for modelling cause-
specific hazards) or the Fine and Gray model (to compare cumulative incidence curves by
modelling subdistribution hazards). As the aim of this study was observational epidemi-
ology – to explore associations rather than predict risk – I decided that cause specific
hazard ratios were the most appropriate quantity to estimate. Cause specific hazards
should be interpreted together with cumulative incidence curves but cannot be used to
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predict cumulative incidence. I experimented with the Fine and Gray model in R but found
that it was computationally intensive, and would require significant software engineering
or computing time to apply it to the large dataset used in these analyses.
I used follow-up time as the timescale for the Cox models in order to investigate how
the strength of association between a leukocyte count measurement and outcome varies
depending on time since measurement, and determine whether it is more useful for short
/ medium or long term prediction.
7.4.7 Multiple imputation
I used two methods of multiple imputation for imputing missing data: Random Forest and
normal-based MICE. For the primary analysis I used Random Forest multiple imputation,
as described in section 4.4, and implemented in the CALIBERrfimpute package [147].
Categorical variables were imputed using the ‘rfcat’ function, in which each imputed value
is the prediction from a randomly chosen tree. Continuous variables were imputed using
the ‘rfcont’ function, in which imputed values are randomly drawn from normal distribu-
tions centred on imputed means estimated using Random Forest.
As Random Forest imputation is a novel method, I also applied the established method
of normal-based MICE imputation. I included the following variables in imputation models:
• Full blood count parameters: total leukcocyte count, neutrophil count, lymphocyte
count, eosinophil count, basophil count, monocyte count, haemoglobin concentra-
tion, platelet count. For normal-based imputation, I included leukocyte subtype
counts as categorical variables (quintiles) as they would be used in the analysis, in
order to avoid imposing linearity in the imputation models.
• Cardiovascular risk factors including those in the substantive models: age, age
squared, sex, body mass index, blood pressure, diabetes, smoking, total chole-
sterol, HDL cholesterol, triglycerides, eGFR, index of multiple deprivation
• Event indicator
• Type of event
• Time as the marginal Nelson-Aalen cumulative hazard [193]
• Use of statins or blood pressure lowering medication in the year before study entry
• Conditions potentially affecting blood counts, based on eMERGE criteria [55]:
haemoglobinopathy, prior diagnosis of myelodysplasia, anaemia diagnosis within 30
days prior, anaemia diagnosis in folowing 30 days, prior diagnosis of cancer, cancer
diagnosis in following 2 years, chemotherapy within 6 months prior, chemotherapy
in following 3 months, renal dialysis prior, HIV diagnosis prior, steroid prescription
within 3 months prior, methotrexate prescription within 3 months prior, prescription
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for another drug affecting the immune system within 30 days prior, infection diagno-
sis within 30 days prior, infection diagnosis within 30 days after, infective symptoms
within 30 days prior, infective symptoms within 30 days after, splenectomy prior,
immunisation within 1-7 days prior
• Prior record of other comorbidities: atrial fibrillation, chronic obstructive pulmonary
disease, inflammatory bowel disease, atopy, asthma, cancer, systemic autoimmune
conditions
For imputing continuous measurements using Random Forest, I additionally used the
last measurement before the 1-year time window before study entry, and the first mea-
surement after study entry, along with the timing of these measurements relative to the
study start date, as auxiliary variables for the imputation of that variable.
I log transformed skewed variables (HDL cholesterol, eGFR, total cholesterol and
triglycerides) before imputation because both rfcont and normal-based multiple impu-
tation functions assume a normal distribution of residuals. I exponentiated the imputed
values and truncated the upper end of the distribution to the maximum value in the origi-
nal data in order to remove extreme values (this affected only a small number of observa-
tions, but the values were very large and would affect any normal-based linear modelling).
I split the dataset by gender and geographical region for multiple imputation, with gen-
eral practice included as a categorical variable. I generated imputations in parallel on the
CALIBER high performance computing cluster. I generated 20 imputations, each drawn
from 20 iterations of MICE.
I reviewed plots of chain means and variances of imputed variables to check that chains
were mixed adequately. I combined the results of Cox models using Rubin’s rules [224]. I
verified that the ratio of between-imputation variance to total variance (‘fraction of missing
information’) for each parameter of interest was less than 20% in order to verify that 20
imputations were sufficient [187].
7.5 Results
The cohort included 621 052 patients with differential leukocyte counts recorded while
clinically ‘stable’ and 154 179 patients with differential leukocyte counts performed during
acute illness or treatment (Figure 6.1 on page 135). There were 54 980 initial presenta-
tions of cardiovascular disease over a median follow up of 3.8 years (interquartile range
(IQR) 1.7 years to 6.0 years).
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Figure 7.1: Selected characteristics of patients that vary significantly by neutrophil count
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The overall standard deviation of neutrophil counts was 1.87 × 109 cells/L. Non-
smokers, women and individuals with Black ethnicity tended to have lower neutrophil
counts (Figure 7.1 on page 159). Patients with higher neutrophil count were more likely
to smoke, live in a deprived area, and experience comorbidities such as asthma, COPD,
diabetes, connective tissue diseases and inflammatory bowel disease (Table 7.1 on page
160). Higher neutrophil count was associated with higher counts of other leukocytes
(Figure 7.2 on page 164) and higher platelet counts (Table 7.1 on page 160).
Individuals with higher total white cell counts tended to have higher counts of neu-
trophils, lymphocytes and platelets. Total white cell counts had a similar association with
smoking and ethnicity as neutrophil counts (Table 7.2 on page 161).
Neutrophil counts outside the normal range were more likely to be associated with an
acute condition at the time of blood testing (22 678 / 82 376, 27.5%) than those within
the normal range (131 501 / 692 855, 19.0%) (P <0.0001). Symptoms or diagnosis of
infection were the most frequent reason for the patient’s condition to be classified as
‘acute’ (Table 7.3 on page 162).
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Table 7.1: Characteristics of patients by quintiles of neutrophil count
Quintile 1 (lowest) 2 3 4 5 (highest)
Neutrophils, ×109/L < 2.85 [2.85, 3.45) [3.45, 4.25) [4.25, 5.35) ≥ 5.35
N patients 155 194 137 526 172 488 154 522 155 501
Women, n (%) 91 693 (59.1%) 78 026 (56.7%) 99 744 (57.8%) 93 470 (60.5%) 99 023 (63.7%)
Age, median (IQR) 52.7 (41.9-62.8) 53.2 (42.5-64.1) 53.4 (42.5-65.3) 52.5 (41.6-65.9) 49.8 (38.6-65.2)
Most deprived
quintile, n (%) 25 060 (16.2%) 23 266 (17.0%) 31 830 (18.5%) 32 523 (21.1%) 36 004 (23.2%)
Ethnicity, n (%):
White 81 153 (88.7%) 76 193 (92.6%) 98 708 (93.3%) 91 638 (94.0%) 97 342 (94.9%)
South Asian 2380 (2.6%) 2478 (3.0%) 3223 (3.0%) 2924 (3.0%) 2445 (2.4%)
Black 5137 (5.6%) 1575 (1.9%) 1398 (1.3%) 974 (1.0%) 890 (0.9%)
Other 2862 (3.1%) 2042 (2.5%) 2493 (2.4%) 1987 (2.0%) 1936 (1.9%)
Missing 63 662 (41.0%) 55 238 (40.2%) 66 666 (38.6%) 56 999 (36.9%) 52 888 (34.0%)
Full blood count parameters on index date, median (IQR):
Eosinophils, ×109/L 0.12 (0.1-0.2) 0.17 (0.1-0.22) 0.19 (0.1-0.26) 0.2 (0.1-0.30) 0.2 (0.1-0.3)
Lymphocytes, ×109/L 1.8 (1.48-2.19) 1.9 (1.6-2.3) 2 (1.6-2.4) 2.1 (1.7-2.58) 2.1 (1.62-2.66)
Monocytes, ×109/L 0.4 (0.3-0.5) 0.41 (0.35-0.5) 0.5 (0.4-0.6) 0.5 (0.4-0.63) 0.6 (0.5-0.8)
Basophils, ×109/L 0.01 (0-0.04) 0.02 (0-0.06) 0.03 (0-0.07) 0.03 (0-0.09) 0.03 (0-0.1)
Haemoglobin, g/dL 13.8 (12.9-14.7) 14 (13.1-14.9) 14 (13.1-15) 14 (13-15) 13.8 (12.7-14.9)
Platelets, ×109/L 237 (203-276) 250 (214-290) 259 (222-301) 271 (231-316) 288 (243-342)
Smoking status, n (%):
Never 93 085 (63.1%) 76 531 (58.6%) 88 060 (53.8%) 69 871 (47.7%) 59 155 (40.4%)
Ex 36 445 (24.7%) 33 182 (25.4%) 41 251 (25.2%) 35 168 (24.0%) 31 153 (21.3%)
Current 17 970 (12.2%) 20 959 (16.0%) 34 483 (21.1%) 41 350 (28.2%) 56 259 (38.4%)
Missing 7694 (5.0%) 6854 (5.0%) 8694 (5.0%) 8133 (5.3%) 8934 (5.7%)
Most recent value within one year prior to index date, median (IQR):
Systolic blood
pressure, mmHg 134 (120-148) 137 (123-150) 138 (124-150) 138 (124-150) 134 (120-149)
Body mass index,
kg/m2 26.1 (23.2-29.6) 27 (23.9-30.7) 27.4 (24.2-31.3) 27.6 (24.1-32) 27 (23.4-31.9)
Total cholesterol,
mmol/L 5.5 (4.8-6.3) 5.5 (4.8-6.3) 5.5 (4.8-6.3) 5.4 (4.7-6.2) 5.3 (4.6-6.1)
HDL cholesterol,
mmol/L 1.5 (1.2-1.8) 1.4 (1.18-1.7) 1.36 (1.11-1.62) 1.3 (1.1-1.6) 1.3 (1.1-1.6)
eGFR,
mL/min/1.73m2 83.2 (71-95.7) 81.9 (69.5-94.4) 81.2 (68.3-94.1) 81.2 (67.8-94.7) 82.4 (67.4-96.6)
Diagnoses on or before index date, n (%):
Atrial fibrillation 1038 (0.7%) 1157 (0.8%) 1746 (1.0%) 1798 (1.2%) 1983 (1.3%)
Cancer 9881 (6.4%) 7998 (5.8%) 10598 (6.1%) 9379 (6.1%) 9665 (6.2%)
Diabetes 5167 (3.3%) 5669 (4.1%) 8541 (5.0%) 8816 (5.7%) 8934 (5.7%)
Asthma 16 894 (10.9%) 15 902 (11.6%) 21 039 (12.2%) 20 319 (13.1%) 22 643 (14.6%)
COPD 1224 (0.8%) 1632 (1.2%) 2943 (1.7%) 3663 (2.4%) 5559 (3.6%)
Connective tissue
disease 3081 (2.0%) 3044 (2.2%) 4501 (2.6%) 4762 (3.1%) 6471 (4.2%)
IBD 1274 (0.8%) 1350 (1.0%) 1798 (1.0%) 1819 (1.2%) 2405 (1.5%)
Medication use in the year before index date, n (%):
Antihypertensives 33 405 (21.5%) 33 244 (24.2%) 46 025 (26.7%) 43 297 (28.0%) 41 310 (26.6%)
Statins 7801 (5.0%) 8264 (6.0%) 11 242 (6.5%) 10 358 (6.7%) 9141 (5.9%)
COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; HDL, high density
lipoprotein cholesterol, IBD, inflammatory bowel disease; IQR, interquartile range.
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Table 7.2: Characteristics of patients by quintiles of total white cell count
Total white cell
count, ×109/L
1 (lowest) 2 3 4 5 (highest)
<5.35 [5.35, 6.25) [6.25, 7.25) [7.25, 8.65) ≥8.65
N patients 163 779 151 462 160 754 153 454 145 782
Women, n (%) 100 067 (61.1%) 87 602 (57.8%) 93 879 (58.4%) 91 450 (59.6%) 88 958 (61.0%)
Age, median (IQR) 52.8 (42.2-63.4) 53.3 (42.4-64.5) 53.2 (42.1-65.4) 52.4 (41.2-65.5) 50.1 (39-64.1)
Most deprived
quintile, n (%) 23 135 (14.2%) 22 287 (14.8%) 26 385 (16.5%) 28 937 (18.9%) 32 227 (22.2%)
Acute condition at
time of blood test,
n (%)
30 772 (18.8%) 26 529 (17.5%) 29 495 (18.3%) 30 605 (19.9%) 36 778 (25.2%)
Ethnicity, n (%):
White 88 603 (91.0%) 84 086 (92.6%) 92 034 (92.9%) 90 374 (93.2%) 89 937 (94.1%)
South Asian 1891 (1.9%) 2416 (2.7%) 3014 (3.0%) 3241 (3.3%) 2888 (3.0%)
Black 4228 (4.3%) 2045 (2.3%) 1621 (1.6%) 1151 (1.2%) 929 (1.0%)
Other 2635 (2.7%) 2284 (2.5%) 2361 (2.4%) 2174 (2.2%) 1866 (2.0%)
Missing 66 422 (40.6%) 60 631 (40.0%) 61 724 (38.4%) 56 514 (36.8%) 50 162 (34.4%)
Full blood count parameters on index date, median (IQR):
Neutrophils, ×109/L 2.5 (2.17-2.9) 3.3 (2.94-3.6) 3.9 (3.5-4.3) 4.76 (4.28-5.27) 6.5 (5.62-7.64)
Lymphocytes, ×109/L 1.58 (1.3-1.81) 1.85 (1.58-2.14) 2.04 (1.7-2.4) 2.25 (1.83-2.7) 2.5 (1.91-3.1)
Eosinophils, ×109/L 0.1 (0.1-0.2) 0.15 (0.1-0.2) 0.19 (0.1-0.26) 0.2 (0.1-0.3) 0.2 (0.1-0.3)
Monocytes, ×109/L 0.38 (0.3-0.44) 0.4 (0.35-0.5) 0.5 (0.4-0.6) 0.53 (0.42-0.67) 0.65 (0.5-0.8)
Basophils, ×109/L 0.01 (0-0.04) 0.02 (0-0.06) 0.03 (0-0.07) 0.03 (0-0.1) 0.04 (0-0.1)
Haemoglobin, g/dL 13.7 (12.8-14.7) 13.9 (13-14.9) 14 (13.1-15) 14 (13.1-15) 14 (12.9-15)
Platelets, ×109/L 235 (201-274) 250 (215-289) 261 (224-303) 272 (233-317) 291 (247-345)
Smoking status, n (%):
Never 100 561 (64.7%) 85 335 (59.4%) 82 201 (53.9%) 68 264 (46.9%) 50 341 (36.5%)
Ex 37 796 (24.3%) 36 733 (25.6%) 38 659 (25.4%) 35 083 (24.1%) 28 928 (21.0%)
Current 16 985 (10.9%) 21 647 (15.1%) 31 633 (20.7%) 42 121 (29.0%) 58 635 (42.5%)
Missing 8437 (5.2%) 7747 (5.1%) 8261 (5.1%) 7986 (5.2%) 7878 (5.4%)
IQR, interquartile range.
Cumulative incidence curves showed that there was a particularly high incidence of
non-fatal myocardial infarction, unheralded coronary death, heart failure, peripheral arte-
rial disease and abdominal aortic aneurysm among individuals in the top quintile of white
cell count compared to those in the bottom quintile (Figure 7.3 on page 165). Plotting
these curves for high and low neutrophil counts within the normal range revealed a similar
pattern of associations with different cardiovascular presentations (Figure 7.4 on page
166). The risk appeared to be greatest for the first few months, but differences persisted
for at least 8 years (Figure 7.4 on page 166).
The distribution of initial cardiovascular presentations varied by neutrophil count; indi-
viduals with higher neutrophil counts were more likely to present with unheralded coro-
nary death, heart failure or peripheral arterial disease, and were relatively less likely to
present with stable angina (Table 7.4 on page 163).
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Table 7.3: Prevalence of acute conditions by category of neutrophil count within and out-
side the normal range
Below normal
range Within normal range
Above normal
range
Neutrophils, ×109/L < 2 [2, 3) [3, 5) [5, 7) ≥ 7
N patients 26 588 154 863 395 466 142 526 55 788
Women, n (%) 16 592 (62.4%) 89 956 (58.1%) 229 869 (58.1%) 89 817 (63.0%) 35 722 (64.0%)
Age, median (IQR) 51.3 (40.6–61.8) 53 (42.2–63.1) 53.2 (42.3–65.1) 51 (40.1–65.6) 48.2 (36.9–64.7)
Any acute condition
at time of blood
test, n (%)
5670 (21.3%) 26 932 (17.4%) 72 676 (18.4%) 31 893 (22.4%) 17 008 (30.5%)
In hospital on date
of blood test 149 (0.6%) 263 (0.2%) 893 (0.2%) 732 (0.5%) 1043 (1.9%)
Vaccination within
previous 7 days 285 (1.1%) 1575 (1.0%) 4383 (1.1%) 1463 (1.0%) 465 (0.8%)
Anaemia diagnosis
within 30 days
before
243 (0.9%) 752 (0.5%) 1659 (0.4%) 710 (0.5%) 393 (0.7%)
Infection diagnosis
within 30 days
before
1846 (6.9%) 9446 (6.1%) 25 280 (6.4%) 11 266 (7.9%) 6413 (11.5%)
Infective symptoms
within 30 days
before
1470 (5.5%) 7242 (4.7%) 20237 (5.1%) 9242 (6.5%) 4987 (8.9%)
Prior diagnosis of
myelodysplastic
syndrome
74 (0.3%) 80 (0.1%) 98 (0.0%) 38 (0.0%) 16 (0.0%)
Prior diagnosis of
haemoglobino-
pathy
268 (1.0%) 668 (0.4%) 1161 (0.3%) 389 (0.3%) 163 (0.3%)
Chemotherapy or
G-CSF within 6
months prior
364 (1.4%) 391 (0.3%) 692 (0.2%) 292 (0.2%) 317 (0.6%)
Methotrexate within
3 months prior 39 (0.1%) 346 (0.2%) 1423 (0.4%) 856 (0.6%) 413 (0.7%)
Steroid within 3
months prior 383 (1.4%) 2108 (1.4%) 8204 (2.1%) 5741 (4.0%) 4740 (8.5%)
Other immune drug
within 3 months
prior
376 (1.4%) 1611 (1.0%) 3829 (1.0%) 1725 (1.2%) 852 (1.5%)
Prior diagnosis of
cancer 2089 (7.9%) 9343 (6.0%) 23 910 (6.0%) 8421 (5.9%) 3758 (6.7%)
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Table 7.4: Endpoints by category of neutrophil count within and outside the normal range
Below normal
range Within normal range
Above normal
range
Neutrophils, ×109/L < 2 [2, 3) [3, 5) [5, 7) ≥ 7
Initial presentation of cardiovascular disease
Stable angina 229 (20.7%) 1763 (22.0%) 5174 (18.2%) 1840 (14.5%) 542 (11.3%)
Unstable angina 70 (6.3%) 526 (6.6%) 1523 (5.4%) 574 (4.5%) 187 (3.9%)
Coronary disease not
further specified 135 (12.2%) 943 (11.8%) 2648 (9.3%) 904 (7.1%) 293 (6.1%)
Non-fatal myocardial
infarction 100 (9.0%) 874 (10.9%) 3465 (12.2%) 1514 (11.9%) 613 (12.8%)
Unheralded coronary
death 38 (3.4%) 338 (4.2%) 1499 (5.3%) 823 (6.5%) 392 (8.2%)
Heart failure 105 (9.5%) 646 (8.1%) 3042 (10.7%) 1733 (13.7%) 698 (14.6%)
Ventricular arrhythmia or
sudden cardiac death 20 (1.8%) 109 (1.4%) 373 (1.3%) 168 (1.3%) 77 (1.6%)
Transient ischaemic
attack 109 (9.9%) 794 (9.9%) 2702 (9.5%) 1094 (8.6%) 377 (7.9%)
Ischaemic stroke 80 (7.2%) 532 (6.7%) 1907 (6.7%) 873 (6.9%) 298 (6.2%)
Stroke not further
specified 87 (7.9%) 519 (6.5%) 2143 (7.5%) 1035 (8.2%) 407 (8.5%)
Subarachnoid
haemorrhage 22 (2.0%) 107 (1.3%) 269 (0.9%) 117 (0.9%) 62 (1.3%)
Intracerebral
haemorrhage 29 (2.6%) 176 (2.2%) 548 (1.9%) 224 (1.8%) 83 (1.7%)
Peripheral arterial
disease 66 (6.0%) 528 (6.6%) 2468 (8.7%) 1384 (10.9%) 620 (13.0%)
Abdominal aortic
aneurysm 16 (1.4%) 143 (1.8%) 683 (2.4%) 388 (3.1%) 136 (2.8%)
Total 1106 7998 28444 12671 4785
Other deaths
Cancers 675 (63.4%) 2107 (55.2%) 7443 (52.4%) 4308 (52.8%) 3060 (57.4%)
Dementia 22 (2.1%) 157 (4.1%) 825 (5.8%) 414 (5.1%) 187 (3.5%)
Pneumonia 41 (3.8%) 201 (5.3%) 931 (6.6%) 560 (6.9%) 331 (6.2%)
Chronic obstructive
pulmonary disease 11 (1.0%) 78 (2.0%) 470 (3.3%) 444 (5.4%) 323 (6.1%)
Liver disease 65 (6.1%) 192 (5.0%) 354 (2.5%) 144 (1.8%) 114 (2.1%)
Other causes of death 251 (23.6%) 1084 (28.4%) 4184 (29.5%) 2295 (28.1%) 1320 (24.7%)
Total 1065 3819 14 207 8165 5335
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Figure 7.2: Binned scatterplots showing correlations between counts of neutrophils and
other leukocyte subtypes
The lines are based on linear regression models for neutrophil count on the count of another leukocyte
subtype.
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Figure 7.3: Cumulative incidence curves for different initial presentations of cardiovascu-
lar disease by total white cell count
Curves are shown for the highest and lowest quintiles of total white cell count (WBC).
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Figure 7.4: Cumulative incidence curves for different initial presentations of cardiovascu-
lar disease by level of neutrophil count within the normal range
Curves are shown for the highest and lowest categories of neutrophil count within the normal range.
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Figure 7.5: Hazard ratios for association of neutrophil quintiles with different initial pre-
sentations of cardiac disease, by level of adjustment
‘Multiple adjustment’ includes adjustment for age, sex, deprivation, ethnicity, smoking, diabetes, body mass
index, systolic blood pressure, eGFR, HDL, total cholesterol, atrial fibrillation, inflammatory conditions, can-
cer, statin use, blood pressure medication and acute conditions at the time of blood testing. P values * <
0.05, ** < 0.01, *** < 0.001
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Ventricular arrhythmia or sudden cardiac death
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[3.45, 4.25)
[4.25, 5.35)
≥ 5.35
Adjusted for age and sex
0.5 1 2 4
Hazard ratio relative to middle category
Hazard ratio (95% CI)
0.88 (0.83, 0.94) ***
0.93 (0.87, 0.99) *
1 (reference)
1.07 (1.01, 1.14) *
1.09 (1.02, 1.16) **
0.85 (0.76, 0.96) **
0.93 (0.83, 1.04)
1 (reference)
0.97 (0.87, 1.08)
1.16 (1.04, 1.30) **
0.93 (0.85, 1.01)
0.95 (0.88, 1.04)
1 (reference)
1.05 (0.97, 1.14)
1.03 (0.95, 1.13)
0.68 (0.62, 0.74) ***
0.82 (0.76, 0.89) ***
1 (reference)
1.18 (1.10, 1.26) ***
1.46 (1.37, 1.57) ***
0.69 (0.60, 0.79) ***
0.71 (0.62, 0.81) ***
1 (reference)
1.32 (1.19, 1.46) ***
1.85 (1.67, 2.04) ***
0.68 (0.62, 0.75) ***
0.84 (0.77, 0.91) ***
1 (reference)
1.23 (1.14, 1.32) ***
1.76 (1.64, 1.89) ***
0.85 (0.67, 1.09)
0.93 (0.73, 1.18)
1 (reference)
1.14 (0.92, 1.42)
1.54 (1.25, 1.90) ***
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Hazard ratio relative to middle category
Hazard ratio (95% CI)
1.01 (0.95, 1.08)
0.98 (0.92, 1.04)
1 (reference)
1.02 (0.96, 1.08)
1.00 (0.94, 1.07)
0.97 (0.86, 1.09)
0.98 (0.88, 1.10)
1 (reference)
0.92 (0.83, 1.03)
1.05 (0.94, 1.18)
1.06 (0.97, 1.15)
1.02 (0.93, 1.11)
1 (reference)
1.01 (0.93, 1.10)
1.01 (0.92, 1.10)
0.81 (0.74, 0.88) ***
0.89 (0.82, 0.97) **
1 (reference)
1.08 (1.01, 1.16) *
1.22 (1.13, 1.31) ***
0.78 (0.68, 0.89) ***
0.76 (0.66, 0.86) ***
1 (reference)
1.21 (1.09, 1.34) ***
1.54 (1.39, 1.71) ***
0.76 (0.69, 0.84) ***
0.89 (0.81, 0.97) **
1 (reference)
1.15 (1.07, 1.24) ***
1.49 (1.39, 1.61) ***
0.91 (0.71, 1.16)
0.97 (0.76, 1.23)
1 (reference)
1.09 (0.88, 1.36)
1.36 (1.10, 1.69) **
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Figure 7.6: Adjusted hazard ratios for association of neutrophil quintiles with differ-
ent initial presentations of non-cardiac cardiovascular endpoints, by level of
adjustment
‘Multiple adjustment’ includes adjustment for age, sex, deprivation, ethnicity, smoking, diabetes, body mass
index, systolic blood pressure, eGFR, HDL, total cholesterol, atrial fibrillation, inflammatory conditions, can-
cer, statin use, blood pressure medication and acute conditions at the time of blood testing. P values * <
0.05, ** < 0.01, *** < 0.001
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1.33 (1.21, 1.46) ***
0.79 (0.71, 0.88) ***
0.90 (0.81, 0.99) *
1 (reference)
1.22 (1.12, 1.33) ***
1.45 (1.33, 1.58) ***
0.98 (0.76, 1.26)
0.84 (0.64, 1.11)
1 (reference)
0.99 (0.77, 1.28)
1.44 (1.14, 1.83) **
1.01 (0.83, 1.22)
0.89 (0.73, 1.09)
1 (reference)
1.06 (0.89, 1.27)
1.26 (1.05, 1.51) *
0.58 (0.52, 0.65) ***
0.71 (0.64, 0.78) ***
1 (reference)
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Hazard ratio (95% CI)
0.90 (0.82, 0.98) *
0.98 (0.89, 1.07)
1 (reference)
1.01 (0.93, 1.09)
1.11 (1.02, 1.21) *
0.89 (0.80, 1.00)
0.94 (0.85, 1.05)
1 (reference)
1.05 (0.96, 1.16)
1.18 (1.07, 1.30) ***
0.83 (0.74, 0.92) ***
0.92 (0.83, 1.02)
1 (reference)
1.17 (1.07, 1.27) ***
1.31 (1.20, 1.44) ***
1.09 (0.84, 1.41)
0.89 (0.67, 1.17)
1 (reference)
0.91 (0.70, 1.18)
1.16 (0.91, 1.48)
1.00 (0.82, 1.22)
0.90 (0.74, 1.10)
1 (reference)
1.03 (0.86, 1.23)
1.14 (0.95, 1.37)
0.73 (0.65, 0.81) ***
0.80 (0.72, 0.88) ***
1 (reference)
1.23 (1.13, 1.33) ***
1.47 (1.36, 1.59) ***
0.76 (0.61, 0.94) *
0.94 (0.78, 1.13)
1 (reference)
1.21 (1.03, 1.41) *
1.51 (1.29, 1.76) ***
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Figure 7.7: Association of neutrophil categories with different initial presentations of car-
diovascular diseases
Hazard ratios are adjusted for age, sex, deprivation, ethnicity, smoking, diabetes, systolic blood pressure,
blood pressure medication, body mass index, total cholesterol, HDL cholesterol, statin use, eGFR, atrial
fibrillation, autoimmune conditions, inflammatory bowel disease, COPD, cancer, and acute conditions at the
time of blood testing. P values * < 0.05, ** < 0.01, *** < 0.001
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Age-adjusted hazard ratios from cause-specific Cox models showed heterogeneous
associations between neutrophil counts and different cardiac (Figure 7.5 on page 167)
and non-cardiac (Figure 7.6 on page 168) initial presentations of cardiovascular disease.
The directions of associations were the same between age-sex adjusted and multiply ad-
justed models, but the associations were generally stronger in age-sex adjusted models.
Using separate categories for neutrophil counts outside the reference range demon-
strated that the linear association was strongest among neutrophil counts within the nor-
mal range (Figure 7.7 on page 169). Adjusted hazard ratios (HR) comparing neutrophil
counts 6− 7 vs 2− 3× 109/L (within the normal range) showed strong associations with
heart failure (HR 2.04, 95% confidence interval (CI) 1.82–2.29), non-fatal myocardial in-
farction (HR 1.58, 95% CI 1.42–1.76) and unheralded coronary death (HR 1.78, 95% CI
1.51–2.10), but not stable angina (HR 0.97, 95% CI 0.88–1.07) or unstable angina (HR
1.00, 95% CI 0.84–1.19). The association with ischaemic stroke was weaker (HR 1.36,
95% CI 1.17–1.57) and there was no association with haemorrhagic stroke, but there
were strong associations with peripheral arterial disease (HR 1.95, 95% CI 1.72–2.21)
and abdominal aortic aneurysm (HR 1.72, 95% CI 1.34–2.21) (Figure 7.7 on page 169).
There was a J-shaped association between neutrophil counts and non-cardiovascular
death (Figure 7.7 on page 169).
As the associations with cardiovascular endpoints were monotonic and approximately
linear, I treated neutrophil count as a linear variable in subsequent modelling. Associ-
ations were stronger among the subgroup of patients with neutrophil counts within the
normal range (Figure 7.8 on page 172).
The strength of some associations were stronger for neutrophil counts taken when the
patient was clinically stable, particularly for peripheral arterial disease and heart failure
(Figure 7.9 on page 173). Some associations were further enhanced by using the mean
of two consecutive stable neutrophil counts, which were available in 393 543 patients
and were taken median 1.4 years apart (IQR 0.6, 2.7 years) (Figure 7.9 on page 173).
The within-patient correlation between these two values was only moderate (ρ = 0.568),
and the standard deviation of the differences was 1.67×109/L, with no variation over time
(Figure 7.10 on page 174).
Plots of scaled Schoenfeld residuals showed evidence of non-proportional hazards,
with stronger associations in the first 6 months for many endpoints (Figure 7.11 on page
175). I therefore split the follow-up time by 6 months, and found an inverse association
of neutrophil count and stable angina as the initial presentation of cardiovascular disease
in the first 6 months but a stronger positive association with heart failure, unheralded
coronary death and ischaemic stroke thereafter (Figure 7.12 on page 176).
Associations with coronary endpoints, heart failure and peripheral arterial disease were
stronger among younger patients (Figure 7.13 on page 177). The association between
neutrophil count and initial presentation with heart failure was stronger in men (HR per
109 higher neutrophil count 1.10 vs 1.07, p = 0.001). There was an association between
neutrophil count and initial presentation with transient ischaemic attack in women but not
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men (HR 1.05 vs 1.00, p = 0.007) (Figure 7.14 on page 178), but no other significant
interactions with sex, and no interaction by smoking status (Figure 7.15 on page 179).
Other leukocyte subtypes exhibited different associations with incidence of cardiovas-
cular diseases. The associations with monocyte count were similar to those with neu-
trophils but less strong Figure 7.16 on page 180. Low lymphocyte counts and high
basophil counts were associated with increased incidence of heart failure, unheralded
coronary death and other death (Figure 7.17 on page 181, Figure 7.18 on page 182).
Detailed results for eosinophil counts are reported in chapter 8.
The two methods of multiple imputation, Random Forest and normal-based MICE,
yielded almost identical estimates (Figure 7.19 on page 183).
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Figure 7.8: Linear association of neutrophil count with different initial presentations of
cardiovascular disease
Hazard ratios are adjusted for age, sex, deprivation, ethnicity, smoking, diabetes, systolic blood pressure,
blood pressure medication, body mass index, total cholesterol, HDL cholesterol, statin use, eGFR, atrial
fibrillation, autoimmune conditions, inflammatory bowel disease, COPD, cancer, and acute conditions at the
time of blood testing. P values * < 0.05, ** < 0.01, *** < 0.001
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All patients
Neutrophils confined to normal range
All patients
Neutrophils confined to normal range
All patients
Neutrophils confined to normal range
All patients
Neutrophils confined to normal range
All patients
Neutrophils confined to normal range
All patients
Neutrophils confined to normal range
All patients
Neutrophils confined to normal range
All patients
Neutrophils confined to normal range
All patients
Neutrophils confined to normal range
All patients
Neutrophils confined to normal range
All patients
Neutrophils confined to normal range
All patients
Neutrophils confined to normal range
All patients
Neutrophils confined to normal range
0.9 1 1.1 1.2 1.3
Hazard ratio per 109 higher neutrophil count
Hazard ratio (95% CI)
0.99 (0.98, 1.00)
1.01 (0.99, 1.03)
1.01 (0.98, 1.03)
1.01 (0.98, 1.05)
1.00 (0.98, 1.02)
0.99 (0.97, 1.02)
1.07 (1.05, 1.08) ***
1.11 (1.08, 1.13) ***
1.11 (1.09, 1.12) ***
1.20 (1.16, 1.24) ***
1.08 (1.07, 1.09) ***
1.20 (1.17, 1.23) ***
1.06 (1.02, 1.10) **
1.09 (1.02, 1.17) *
1.03 (1.01, 1.05) ***
1.05 (1.02, 1.08) ***
1.04 (1.02, 1.06) ***
1.09 (1.05, 1.12) ***
1.07 (1.05, 1.08) ***
1.14 (1.11, 1.18) ***
1.04 (0.99, 1.09)
1.02 (0.94, 1.10)
1.02 (0.99, 1.06)
1.04 (0.98, 1.10)
1.10 (1.09, 1.12) ***
1.20 (1.17, 1.23) ***
1.07 (1.04, 1.10) ***
1.19 (1.13, 1.25) ***
P value for
interaction
0.026
0.57
0.28
0.0018
0.014
<0.0001
0.71
0.08
0.031
0.00082
0.038
0.89
<0.0001
0.00021
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Figure 7.9: Linear association of neutrophil count with different initial presentations of
cardiovascular disease, by patient’s clinical state at the time of testing
‘Mean of 2 stable’ refers to the
mean of two consecutive
neutrophil counts performed in
a stable clinical state. Hazard
ratios are adjusted for age, sex,
deprivation, ethnicity, smoking,
diabetes, systolic blood
pressure, blood pressure
medication, body mass index,
total cholesterol, HDL
cholesterol, statin use, eGFR,
atrial fibrillation, autoimmune
conditions, inflammatory bowel
disease, COPD and cancer. P
values * < 0.05, ** < 0.01, *** <
0.001
Initial presentation
Stable angina
Unstable angina
Coronary disease not further specified
Non−fatal myocardial infarction
Unheralded coronary death
Heart failure
Ventricular arrhythmia or sudden cardiac death
Transient ischaemic attack
Ischaemic stroke
Stroke not further specified
Subarachnoid haemorrhage
Intracerebral haemorrhage
Peripheral arterial disease
Abdominal aortic aneurysm
Acute
Stable
Mean of 2 stable
Acute
Stable
Mean of 2 stable
Acute
Stable
Mean of 2 stable
Acute
Stable
Mean of 2 stable
Acute
Stable
Mean of 2 stable
Acute
Stable
Mean of 2 stable
Acute
Stable
Mean of 2 stable
Acute
Stable
Mean of 2 stable
Acute
Stable
Mean of 2 stable
Acute
Stable
Mean of 2 stable
Acute
Stable
Mean of 2 stable
Acute
Stable
Mean of 2 stable
Acute
Stable
Mean of 2 stable
Acute
Stable
Mean of 2 stable
0.9 1 1.1 1.2 1.3
Hazard ratio per 109 higher neutrophil count
Hazard ratio (95% CI)
0.98 (0.96, 1.00)
1.00 (0.98, 1.01)
1.01 (0.99, 1.03)
0.97 (0.93, 1.01)
1.02 (0.99, 1.05)
1.02 (0.98, 1.06)
1.00 (0.97, 1.03)
1.00 (0.98, 1.02)
1.00 (0.97, 1.04)
1.04 (1.02, 1.07) ***
1.08 (1.06, 1.09) ***
1.11 (1.08, 1.13) ***
1.09 (1.06, 1.12) ***
1.12 (1.10, 1.14) ***
1.16 (1.13, 1.20) ***
1.05 (1.03, 1.07) ***
1.10 (1.09, 1.12) ***
1.16 (1.13, 1.18) ***
1.03 (0.97, 1.10)
1.08 (1.03, 1.12) ***
1.09 (1.02, 1.17) *
1.01 (0.99, 1.04)
1.04 (1.02, 1.06) ***
1.04 (1.02, 1.07) **
1.03 (1.00, 1.06)
1.05 (1.03, 1.07) ***
1.06 (1.03, 1.10) ***
1.04 (1.01, 1.06) **
1.09 (1.07, 1.11) ***
1.11 (1.07, 1.14) ***
1.08 (1.01, 1.16) *
1.02 (0.96, 1.07)
1.00 (0.92, 1.09)
1.00 (0.94, 1.06)
1.04 (0.99, 1.08)
1.03 (0.96, 1.10)
1.07 (1.05, 1.09) ***
1.12 (1.10, 1.14) ***
1.15 (1.13, 1.18) ***
1.03 (0.99, 1.08)
1.09 (1.06, 1.13) ***
1.11 (1.05, 1.17) ***
P value for
interaction
0.19
0.4
0.042
0.87
0.95
0.88
0.016
0.039
0.08
0.024
<0.0001
0.0001
0.24
0.71
0.12
0.76
0.23
0.49
0.0012
0.3
0.15
0.82
0.3
0.87
0.00064
0.029
0.042
0.69
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Chapter 7. Neutrophils and initial presentation of cardiovascular disease
Figure 7.10: Binned scatterplot showing difference between two consecutive neutrophil
counts taken when a patient was clinically ‘stable’
N = 374 460. Correlation coefficient = 0.568. The solid line is lowess smoothed mean and the dotted lines
are lowess smoothed 2.5% and 97.5% centiles.
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7.5. Results
Figure 7.11: Scaled Schoenfeld residuals for adjusted hazard ratios comparing highest
versus middle quintile of neutrophil count, for different initial presentations of
cardiovascular disease
Hazard ratios adjusted for age, sex, deprivation, ethnicity, smoking, diabetes, body mass index, systolic
blood pressure, eGFR, HDL, total cholesterol, atrial fibrillation, inflammatory conditions, cancer, statin use,
blood pressure medication and acute conditions at the time of blood testing. The lines show the estimate
and 95% confidence interval for the beta coefficient. The top left corner of each graph contains ρ, χ2 and p
value for the correlation between log survival time and scaled Schoenfeld residuals. For clarity, points plotted
on the graph are for a random sample of 20 000 patients.
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Figure 7.12: Linear association of neutrophil count with different initial presentations of
cardiovascular disease, by time since measurement
Hazard ratios are adjusted for
age, sex, deprivation, ethnicity,
smoking, diabetes, systolic
blood pressure, blood pressure
medication, body mass index,
total cholesterol, HDL
cholesterol, statin use, eGFR,
atrial fibrillation, autoimmune
conditions, inflammatory bowel
disease, COPD, cancer, and
acute conditions at the time of
blood testing. P values * < 0.05,
** < 0.01, *** < 0.001
Initial presentation
Stable angina
Unstable angina
Coronary disease not further specified
Non−fatal myocardial infarction
Unheralded coronary death
Heart failure
Ventricular arrhythmia or sudden cardiac death
Transient ischaemic attack
Ischaemic stroke
Stroke not further specified
Subarachnoid haemorrhage
Intracerebral haemorrhage
Peripheral arterial disease
Abdominal aortic aneurysm
First 6 months
6 months onwards
Time updated analysis
First 6 months
6 months onwards
Time updated analysis
First 6 months
6 months onwards
Time updated analysis
First 6 months
6 months onwards
Time updated analysis
First 6 months
6 months onwards
Time updated analysis
First 6 months
6 months onwards
Time updated analysis
First 6 months
6 months onwards
Time updated analysis
First 6 months
6 months onwards
Time updated analysis
First 6 months
6 months onwards
Time updated analysis
First 6 months
6 months onwards
Time updated analysis
First 6 months
6 months onwards
Time updated analysis
First 6 months
6 months onwards
Time updated analysis
First 6 months
6 months onwards
Time updated analysis
First 6 months
6 months onwards
Time updated analysis
0.9 1 1.1 1.2 1.3
Hazard ratio per 109 higher neutrophil count
Hazard ratio (95% CI)
0.96 (0.94, 0.99) **
1.00 (0.98, 1.01)
0.99 (0.98, 1.01)
1.01 (0.96, 1.07)
1.00 (0.98, 1.03)
1.03 (1.00, 1.05) *
1.00 (0.97, 1.04)
0.99 (0.97, 1.01)
1.01 (1.00, 1.03)
1.08 (1.05, 1.10) ***
1.06 (1.05, 1.07) ***
1.09 (1.07, 1.10) ***
1.13 (1.11, 1.16) ***
1.09 (1.08, 1.11) ***
1.13 (1.12, 1.15) ***
1.09 (1.08, 1.11) ***
1.07 (1.05, 1.08) ***
1.12 (1.11, 1.13) ***
1.06 (0.97, 1.14)
1.06 (1.02, 1.10) **
1.08 (1.04, 1.11) ***
1.04 (1.01, 1.07) *
1.02 (1.01, 1.04) **
1.05 (1.03, 1.06) ***
1.09 (1.06, 1.12) ***
1.03 (1.01, 1.05) *
1.08 (1.07, 1.10) ***
1.07 (1.04, 1.10) ***
1.06 (1.04, 1.08) ***
1.09 (1.08, 1.11) ***
1.09 (1.00, 1.19)
1.03 (0.98, 1.08)
1.03 (0.99, 1.08)
1.06 (0.98, 1.14)
1.01 (0.98, 1.05)
1.04 (1.01, 1.08) *
1.10 (1.07, 1.13) ***
1.10 (1.08, 1.11) ***
1.11 (1.10, 1.12) ***
1.10 (1.06, 1.14) ***
1.05 (1.02, 1.09) ***
1.10 (1.08, 1.13) ***
P for interaction
(first 6 months
vs 6 months onwards)
0.0069
0.74
0.7
0.32
0.016
0.019
0.92
0.44
0.00038
0.73
0.24
0.34
0.96
0.063
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Figure 7.13: Linear association of neutrophil count with different initial presentations of
cardiovascular disease, by age group
Hazard ratios are adjusted for age, sex, deprivation, ethnicity, smoking, diabetes, systolic blood pressure,
blood pressure medication, body mass index, total cholesterol, HDL cholesterol, statin use, eGFR, atrial
fibrillation, autoimmune conditions, inflammatory bowel disease, COPD, cancer, and acute conditions at the
time of blood testing. P values * < 0.05, ** < 0.01, *** < 0.001
Initial presentation
Stable angina
Unstable angina
Coronary disease not further specified
Non−fatal myocardial infarction
Unheralded coronary death
Heart failure
Ventricular arrhythmia or sudden cardiac death
Transient ischaemic attack
Ischaemic stroke
Stroke not further specified
Subarachnoid haemorrhage
Intracerebral haemorrhage
Peripheral arterial disease
Abdominal aortic aneurysm
Age < 60
Age ≥ 60
Age < 60
Age ≥ 60
Age < 60
Age ≥ 60
Age < 60
Age ≥ 60
Age < 60
Age ≥ 60
Age < 60
Age ≥ 60
Age < 60
Age ≥ 60
Age < 60
Age ≥ 60
Age < 60
Age ≥ 60
Age < 60
Age ≥ 60
Age < 60
Age ≥ 60
Age < 60
Age ≥ 60
Age < 60
Age ≥ 60
Age < 60
Age ≥ 60
0.9 1 1.1 1.2 1.3
Hazard ratio per 109 higher neutrophil count
Hazard ratio (95% CI)
1.05 (1.03, 1.07) ***
0.95 (0.94, 0.97) ***
1.02 (0.99, 1.05)
0.99 (0.96, 1.02)
1.04 (1.01, 1.06) **
0.97 (0.95, 0.99) *
1.10 (1.09, 1.12) ***
1.04 (1.02, 1.06) ***
1.15 (1.12, 1.18) ***
1.10 (1.08, 1.12) ***
1.14 (1.11, 1.16) ***
1.07 (1.06, 1.08) ***
1.07 (1.02, 1.13) **
1.05 (1.00, 1.10) *
1.05 (1.02, 1.08) **
1.02 (1.01, 1.04) **
1.07 (1.03, 1.11) ***
1.04 (1.02, 1.06) ***
1.10 (1.07, 1.14) ***
1.06 (1.05, 1.08) ***
1.06 (1.01, 1.12) *
0.99 (0.92, 1.07)
1.06 (0.99, 1.13)
1.01 (0.97, 1.05)
1.13 (1.11, 1.15) ***
1.09 (1.07, 1.11) ***
1.08 (1.00, 1.16)
1.07 (1.04, 1.10) ***
P value for
interaction
<0.0001
0.17
0.00015
<0.0001
0.0049
<0.0001
0.51
0.19
0.19
0.04
0.13
0.25
0.0062
0.93
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Figure 7.14: Linear association of neutrophil count with different initial presentations of
cardiovascular disease, by sex
Hazard ratios are adjusted for age, sex, deprivation, ethnicity, smoking, diabetes, systolic blood pressure,
blood pressure medication, body mass index, total cholesterol, HDL cholesterol, statin use, eGFR, atrial
fibrillation, autoimmune conditions, inflammatory bowel disease, COPD, cancer, and acute conditions at the
time of blood testing. P values * < 0.05, ** < 0.01, *** < 0.001
Initial presentation
Stable angina
Unstable angina
Coronary disease not further specified
Non−fatal myocardial infarction
Unheralded coronary death
Heart failure
Ventricular arrhythmia or sudden cardiac death
Transient ischaemic attack
Ischaemic stroke
Stroke not further specified
Subarachnoid haemorrhage
Intracerebral haemorrhage
Peripheral arterial disease
Abdominal aortic aneurysm
Women
Men
Women
Men
Women
Men
Women
Men
Women
Men
Women
Men
Women
Men
Women
Men
Women
Men
Women
Men
Women
Men
Women
Men
Women
Men
Women
Men
0.9 1 1.1 1.2 1.3
Hazard ratio per 109 higher neutrophil count
Hazard ratio (95% CI)
0.98 (0.96, 0.99) *
1.01 (0.99, 1.02)
0.98 (0.95, 1.01)
1.03 (1.00, 1.06)
0.99 (0.97, 1.02)
1.00 (0.98, 1.02)
1.06 (1.04, 1.08) ***
1.07 (1.05, 1.09) ***
1.11 (1.09, 1.13) ***
1.11 (1.08, 1.13) ***
1.07 (1.05, 1.08) ***
1.10 (1.09, 1.12) ***
1.04 (0.99, 1.10)
1.08 (1.03, 1.13) **
1.05 (1.03, 1.07) ***
1.00 (0.98, 1.03)
1.04 (1.01, 1.06) **
1.05 (1.02, 1.08) ***
1.06 (1.04, 1.08) ***
1.09 (1.06, 1.11) ***
1.03 (0.97, 1.09)
1.06 (0.98, 1.13)
1.03 (0.98, 1.07)
1.02 (0.97, 1.07)
1.09 (1.07, 1.11) ***
1.11 (1.09, 1.13) ***
1.08 (1.04, 1.13) ***
1.07 (1.04, 1.10) ***
P value for
interaction
0.018
0.029
0.7
0.49
0.9
0.00099
0.3
0.007
0.52
0.071
0.56
0.82
0.14
0.63
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Figure 7.15: Linear association of neutrophil count with different initial presentations of
cardiovascular disease, by smoking status
Hazard ratios are adjusted for age, sex, deprivation, ethnicity, smoking, diabetes, systolic blood pressure,
blood pressure medication, body mass index, total cholesterol, HDL cholesterol, statin use, eGFR, atrial
fibrillation, autoimmune conditions, inflammatory bowel disease, COPD, cancer, and acute conditions at the
time of blood testing. P values * < 0.05, ** < 0.01, *** < 0.001
Initial presentation
Stable angina
Unstable angina
Coronary disease not further specified
Non−fatal myocardial infarction
Unheralded coronary death
Heart failure
Ventricular arrhythmia or sudden cardiac death
Transient ischaemic attack
Ischaemic stroke
Stroke not further specified
Subarachnoid haemorrhage
Intracerebral haemorrhage
Peripheral arterial disease
Abdominal aortic aneurysm
Non or ex smokers
Current smokers
Non or ex smokers
Current smokers
Non or ex smokers
Current smokers
Non or ex smokers
Current smokers
Non or ex smokers
Current smokers
Non or ex smokers
Current smokers
Non or ex smokers
Current smokers
Non or ex smokers
Current smokers
Non or ex smokers
Current smokers
Non or ex smokers
Current smokers
Non or ex smokers
Current smokers
Non or ex smokers
Current smokers
Non or ex smokers
Current smokers
Non or ex smokers
Current smokers
0.9 1 1.1 1.2 1.3
Hazard ratio per 109 higher neutrophil count
Hazard ratio (95% CI)
0.98 (0.97, 1.00) *
1.02 (0.99, 1.04)
1.00 (0.97, 1.02)
1.02 (0.99, 1.06)
0.99 (0.97, 1.02)
1.00 (0.97, 1.04)
1.06 (1.05, 1.08) ***
1.07 (1.05, 1.09) ***
1.11 (1.09, 1.13) ***
1.10 (1.08, 1.13) ***
1.08 (1.07, 1.10) ***
1.08 (1.05, 1.10) ***
1.07 (1.02, 1.11) **
1.04 (0.97, 1.12)
1.02 (1.01, 1.04) **
1.04 (1.01, 1.07) **
1.04 (1.02, 1.06) ***
1.05 (1.02, 1.09) **
1.07 (1.05, 1.09) ***
1.06 (1.03, 1.09) ***
1.01 (0.94, 1.08)
1.06 (1.00, 1.12) *
1.01 (0.97, 1.05)
1.05 (0.99, 1.11)
1.10 (1.08, 1.12) ***
1.11 (1.09, 1.13) ***
1.07 (1.04, 1.11) ***
1.08 (1.03, 1.12) ***
P value for
interaction
0.012
0.23
0.64
0.6
0.85
0.74
0.54
0.33
0.49
0.75
0.28
0.33
0.34
0.88
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Figure 7.16: Association of quintiles of monocyte counts with different initial presentations
of cardiovascular disease
Hazard ratios are adjusted for age, sex, deprivation, ethnicity, smoking, diabetes, systolic blood pressure,
blood pressure medication, body mass index, total cholesterol, HDL cholesterol, statin use, eGFR, atrial
fibrillation, autoimmune conditions, inflammatory bowel disease, COPD, cancer, and acute conditions at the
time of blood testing. P values * < 0.05, ** < 0.01, *** < 0.001
Initial
presentation
Stable angina
Unstable angina
Coronary disease not further specified
Non−fatal myocardial infarction
Unheralded coronary death
Heart failure
Ventricular arrhythmia or sudden cardiac death
<0.35
[0.35, 0.45)
[0.45, 0.55)
[0.55, 0.65)
≥ 0.65
<0.35
[0.35, 0.45)
[0.45, 0.55)
[0.55, 0.65)
≥ 0.65
<0.35
[0.35, 0.45)
[0.45, 0.55)
[0.55, 0.65)
≥ 0.65
<0.35
[0.35, 0.45)
[0.45, 0.55)
[0.55, 0.65)
≥ 0.65
<0.35
[0.35, 0.45)
[0.45, 0.55)
[0.55, 0.65)
≥ 0.65
<0.35
[0.35, 0.45)
[0.45, 0.55)
[0.55, 0.65)
≥ 0.65
<0.35
[0.35, 0.45)
[0.45, 0.55)
[0.55, 0.65)
≥ 0.65
Adjusted hazard ratio
0.5 1 2 4
Hazard ratio relative to middle category
Hazard ratio (95% CI)
0.92 (0.86, 0.98) *
0.95 (0.89, 1.01)
1 (reference)
0.98 (0.92, 1.04)
0.93 (0.87, 0.99) *
0.98 (0.87, 1.11)
0.89 (0.80, 1.00) *
1 (reference)
0.98 (0.87, 1.11)
1.00 (0.90, 1.12)
0.94 (0.86, 1.04)
0.96 (0.88, 1.04)
1 (reference)
0.95 (0.87, 1.04)
0.98 (0.90, 1.07)
0.86 (0.79, 0.94) **
0.93 (0.86, 1.00)
1 (reference)
1.02 (0.94, 1.10)
1.15 (1.07, 1.23) ***
0.86 (0.75, 0.98) *
0.85 (0.76, 0.96) **
1 (reference)
1.00 (0.89, 1.12)
1.27 (1.15, 1.41) ***
0.86 (0.78, 0.94) ***
0.88 (0.81, 0.96) **
1 (reference)
1.08 (1.00, 1.17)
1.29 (1.20, 1.38) ***
0.84 (0.66, 1.07)
0.70 (0.56, 0.88) **
1 (reference)
0.89 (0.70, 1.12)
1.10 (0.89, 1.35)
Initial
presentation
Transient ischaemic attack
Ischaemic stroke
Stroke not further specified
Subarachnoid haemorrhage
Intracerebral haemorrhage
Peripheral arterial disease
Abdominal aortic aneurysm
Other death
<0.35
[0.35, 0.45)
[0.45, 0.55)
[0.55, 0.65)
≥ 0.65
<0.35
[0.35, 0.45)
[0.45, 0.55)
[0.55, 0.65)
≥ 0.65
<0.35
[0.35, 0.45)
[0.45, 0.55)
[0.55, 0.65)
≥ 0.65
<0.35
[0.35, 0.45)
[0.45, 0.55)
[0.55, 0.65)
≥ 0.65
<0.35
[0.35, 0.45)
[0.45, 0.55)
[0.55, 0.65)
≥ 0.65
<0.35
[0.35, 0.45)
[0.45, 0.55)
[0.55, 0.65)
≥ 0.65
<0.35
[0.35, 0.45)
[0.45, 0.55)
[0.55, 0.65)
≥ 0.65
<0.35
[0.35, 0.45)
[0.45, 0.55)
[0.55, 0.65)
≥ 0.65
Adjusted hazard ratio
0.5 1 2 4
Hazard ratio relative to middle category
Hazard ratio (95% CI)
0.92 (0.83, 1.01)
0.98 (0.90, 1.07)
1 (reference)
1.07 (0.98, 1.17)
1.10 (1.01, 1.19) *
0.91 (0.81, 1.02)
1.01 (0.91, 1.12)
1 (reference)
1.09 (0.98, 1.21)
1.15 (1.05, 1.27) **
0.90 (0.81, 1.00)
0.93 (0.85, 1.03)
1 (reference)
1.03 (0.94, 1.14)
1.06 (0.97, 1.16)
0.77 (0.58, 1.03)
1.13 (0.88, 1.44)
1 (reference)
1.11 (0.84, 1.45)
1.23 (0.96, 1.58)
0.90 (0.74, 1.11)
0.95 (0.79, 1.15)
1 (reference)
0.91 (0.75, 1.11)
0.98 (0.82, 1.17)
0.83 (0.75, 0.92) ***
0.89 (0.81, 0.98) *
1 (reference)
1.20 (1.10, 1.31) ***
1.35 (1.25, 1.47) ***
0.86 (0.70, 1.06)
0.96 (0.80, 1.15)
1 (reference)
1.16 (0.97, 1.38)
1.31 (1.12, 1.52) ***
1.01 (0.97, 1.05)
0.94 (0.90, 0.97) ***
1 (reference)
1.09 (1.05, 1.14) ***
1.47 (1.43, 1.52) ***
180
7.5. Results
Figure 7.17: Association of quintiles of lymphocyte counts with different initial presenta-
tions of cardiovascular disease
Hazard ratios are adjusted for age, sex, deprivation, ethnicity, smoking, diabetes, systolic blood pressure,
blood pressure medication, body mass index, total cholesterol, HDL cholesterol, statin use, eGFR, atrial
fibrillation, autoimmune conditions, inflammatory bowel disease, COPD, cancer, and acute conditions at the
time of blood testing. P values * < 0.05, ** < 0.01, *** < 0.001
Initial
presentation
Stable angina
Unstable angina
Coronary disease not further specified
Non−fatal myocardial infarction
Unheralded coronary death
Heart failure
Ventricular arrhythmia or sudden cardiac death
<1.45
[1.45, 1.85)
[1.85, 2.15)
[2.15, 2.55)
≥ 2.55
<1.45
[1.45, 1.85)
[1.85, 2.15)
[2.15, 2.55)
≥ 2.55
<1.45
[1.45, 1.85)
[1.85, 2.15)
[2.15, 2.55)
≥ 2.55
<1.45
[1.45, 1.85)
[1.85, 2.15)
[2.15, 2.55)
≥ 2.55
<1.45
[1.45, 1.85)
[1.85, 2.15)
[2.15, 2.55)
≥ 2.55
<1.45
[1.45, 1.85)
[1.85, 2.15)
[2.15, 2.55)
≥ 2.55
<1.45
[1.45, 1.85)
[1.85, 2.15)
[2.15, 2.55)
≥ 2.55
Adjusted hazard ratio
0.5 1 2 4
Hazard ratio relative to middle category
Hazard ratio (95% CI)
1.01 (0.95, 1.09)
1.03 (0.96, 1.09)
1 (reference)
1.04 (0.98, 1.12)
1.08 (1.01, 1.15) *
0.99 (0.87, 1.13)
1.03 (0.92, 1.16)
1 (reference)
1.16 (1.03, 1.30) *
1.15 (1.02, 1.30) *
0.92 (0.83, 1.01)
0.96 (0.88, 1.04)
1 (reference)
1.01 (0.92, 1.10)
1.02 (0.93, 1.11)
1.02 (0.94, 1.11)
1.02 (0.94, 1.10)
1 (reference)
1.02 (0.94, 1.10)
1.12 (1.03, 1.21) **
1.27 (1.13, 1.42) ***
1.03 (0.92, 1.15)
1 (reference)
0.95 (0.83, 1.07)
0.92 (0.81, 1.04)
1.61 (1.48, 1.74) ***
1.19 (1.09, 1.29) ***
1 (reference)
1.02 (0.93, 1.12)
0.97 (0.88, 1.06)
1.22 (0.97, 1.52)
0.85 (0.68, 1.07)
1 (reference)
0.75 (0.58, 0.96) *
1.01 (0.80, 1.28)
Initial
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Transient ischaemic attack
Ischaemic stroke
Stroke not further specified
Subarachnoid haemorrhage
Intracerebral haemorrhage
Peripheral arterial disease
Abdominal aortic aneurysm
Other death
<1.45
[1.45, 1.85)
[1.85, 2.15)
[2.15, 2.55)
≥ 2.55
<1.45
[1.45, 1.85)
[1.85, 2.15)
[2.15, 2.55)
≥ 2.55
<1.45
[1.45, 1.85)
[1.85, 2.15)
[2.15, 2.55)
≥ 2.55
<1.45
[1.45, 1.85)
[1.85, 2.15)
[2.15, 2.55)
≥ 2.55
<1.45
[1.45, 1.85)
[1.85, 2.15)
[2.15, 2.55)
≥ 2.55
<1.45
[1.45, 1.85)
[1.85, 2.15)
[2.15, 2.55)
≥ 2.55
<1.45
[1.45, 1.85)
[1.85, 2.15)
[2.15, 2.55)
≥ 2.55
<1.45
[1.45, 1.85)
[1.85, 2.15)
[2.15, 2.55)
≥ 2.55
Adjusted hazard ratio
0.5 1 2 4
Hazard ratio relative to middle category
Hazard ratio (95% CI)
1.11 (1.02, 1.22) *
1.01 (0.93, 1.10)
1 (reference)
1.03 (0.94, 1.13)
1.05 (0.96, 1.15)
1.08 (0.97, 1.20)
1.00 (0.91, 1.11)
1 (reference)
0.94 (0.84, 1.05)
1.00 (0.89, 1.11)
1.33 (1.20, 1.47) ***
1.04 (0.94, 1.14)
1 (reference)
1.06 (0.95, 1.18)
1.06 (0.95, 1.18)
1.30 (0.99, 1.70)
0.97 (0.74, 1.25)
1 (reference)
0.82 (0.62, 1.09)
1.09 (0.84, 1.41)
1.46 (1.20, 1.77) ***
1.11 (0.91, 1.36)
1 (reference)
1.04 (0.84, 1.30)
1.02 (0.82, 1.27)
1.10 (1.00, 1.22) *
0.99 (0.90, 1.09)
1 (reference)
1.06 (0.97, 1.17)
1.26 (1.15, 1.38) ***
0.82 (0.69, 0.97) *
0.83 (0.70, 0.98) *
1 (reference)
0.88 (0.74, 1.05)
0.89 (0.75, 1.05)
1.65 (1.59, 1.71) ***
1.10 (1.06, 1.14) ***
1 (reference)
0.94 (0.90, 0.98) **
0.96 (0.92, 1.00) *
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Figure 7.18: Association of basophil counts with different initial presentations of cardio-
vascular disease
Hazard ratios are adjusted for age, sex, deprivation, ethnicity, smoking, diabetes, systolic blood pressure,
blood pressure medication, body mass index, total cholesterol, HDL cholesterol, statin use, eGFR, atrial
fibrillation, autoimmune conditions, inflammatory bowel disease, COPD, cancer, and acute conditions at the
time of blood testing. P values * < 0.05, ** < 0.01, *** < 0.001
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Coronary disease not further specified
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Ventricular arrhythmia or sudden cardiac death
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≥ 0.15
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≥ 0.15
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[0.05, 0.15)
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Adjusted hazard ratio
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Hazard ratio
Hazard ratio (95% CI)
1 (reference)
1.07 (1.03, 1.12) **
1.15 (0.96, 1.37)
1 (reference)
1.05 (0.96, 1.14)
1.16 (0.84, 1.60)
1 (reference)
1.04 (0.97, 1.11)
1.04 (0.80, 1.36)
1 (reference)
1.09 (1.03, 1.16) **
1.29 (1.06, 1.57) *
1 (reference)
1.07 (0.98, 1.16)
1.70 (1.32, 2.19) ***
1 (reference)
1.04 (0.98, 1.10)
1.24 (1.00, 1.52) *
1 (reference)
0.91 (0.77, 1.08)
0.83 (0.41, 1.68)
Initial
presentation
Transient ischaemic attack
Ischaemic stroke
Stroke not further specified
Subarachnoid haemorrhage
Intracerebral haemorrhage
Peripheral arterial disease
Abdominal aortic aneurysm
Other death
<0.05
[0.05, 0.15)
≥ 0.15
<0.05
[0.05, 0.15)
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<0.05
[0.05, 0.15)
≥ 0.15
<0.05
[0.05, 0.15)
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<0.05
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[0.05, 0.15)
≥ 0.15
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[0.05, 0.15)
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<0.05
[0.05, 0.15)
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Adjusted hazard ratio
0.5 1 2 4
Hazard ratio
Hazard ratio (95% CI)
1 (reference)
1.09 (1.03, 1.16) **
1.03 (0.79, 1.33)
1 (reference)
1.10 (1.03, 1.19) **
1.01 (0.75, 1.38)
1 (reference)
1.06 (0.99, 1.14)
1.21 (0.94, 1.56)
1 (reference)
1.07 (0.89, 1.29)
1.26 (0.64, 2.48)
1 (reference)
1.04 (0.91, 1.20)
0.83 (0.44, 1.56)
1 (reference)
1.16 (1.09, 1.24) ***
1.35 (1.08, 1.69) **
1 (reference)
1.04 (0.92, 1.17)
1.43 (0.97, 2.12)
1 (reference)
1.00 (0.97, 1.02)
1.42 (1.30, 1.54) ***
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Figure 7.19: Association of neutrophil quintiles with different initial presentations of car-
diovascular disease, using different methods of multiple imputation
Hazard ratios are adjusted for age, sex, deprivation, ethnicity, smoking, diabetes, systolic blood pressure,
body mass index, total cholesterol, HDL cholesterol, eGFR, atrial fibrillation, autoimmune conditions, inflam-
matory bowel disease, COPD, cancer, statin use, blood pressure medication and acute conditions at the time
of blood testing. P values * < 0.05, ** < 0.01, *** < 0.001
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1 (reference)
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1.05 (0.95, 1.15)
1.18 (1.07, 1.30) ***
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1 (reference)
0.91 (0.70, 1.17)
1.15 (0.90, 1.47)
1.00 (0.82, 1.22)
0.90 (0.74, 1.11)
1 (reference)
1.02 (0.85, 1.22)
1.12 (0.93, 1.34)
0.74 (0.66, 0.82) ***
0.80 (0.72, 0.89) ***
1 (reference)
1.23 (1.13, 1.33) ***
1.46 (1.35, 1.59) ***
0.78 (0.63, 0.97) *
0.95 (0.79, 1.14)
1 (reference)
1.20 (1.03, 1.41) *
1.49 (1.28, 1.74) ***
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
Random Forest MICE
0.5 1 2 4
Hazard ratio relative to middle category
Hazard ratio (95% CI)
1.01 (0.95, 1.08)
0.98 (0.92, 1.04)
1 (reference)
1.02 (0.96, 1.08)
1.00 (0.94, 1.07)
0.97 (0.86, 1.09)
0.98 (0.88, 1.10)
1 (reference)
0.92 (0.83, 1.03)
1.05 (0.94, 1.18)
0.81 (0.74, 0.88) ***
0.89 (0.82, 0.97) **
1 (reference)
1.08 (1.01, 1.16) *
1.22 (1.13, 1.31) ***
0.78 (0.68, 0.89) ***
0.76 (0.66, 0.86) ***
1 (reference)
1.21 (1.09, 1.34) ***
1.54 (1.39, 1.71) ***
0.76 (0.69, 0.84) ***
0.89 (0.81, 0.97) **
1 (reference)
1.15 (1.07, 1.24) ***
1.49 (1.39, 1.61) ***
0.91 (0.71, 1.16)
0.97 (0.76, 1.23)
1 (reference)
1.09 (0.88, 1.36)
1.36 (1.10, 1.69) **
0.90 (0.82, 0.98) *
0.98 (0.89, 1.07)
1 (reference)
1.01 (0.93, 1.09)
1.11 (1.02, 1.21) *
0.89 (0.80, 1.00)
0.94 (0.85, 1.05)
1 (reference)
1.05 (0.96, 1.16)
1.18 (1.07, 1.30) ***
1.09 (0.84, 1.41)
0.89 (0.67, 1.17)
1 (reference)
0.91 (0.70, 1.18)
1.16 (0.91, 1.48)
1.00 (0.82, 1.22)
0.90 (0.74, 1.10)
1 (reference)
1.03 (0.86, 1.23)
1.14 (0.95, 1.37)
0.73 (0.65, 0.81) ***
0.80 (0.72, 0.88) ***
1 (reference)
1.23 (1.13, 1.33) ***
1.47 (1.36, 1.59) ***
0.76 (0.61, 0.94) *
0.94 (0.78, 1.13)
1 (reference)
1.21 (1.03, 1.41) *
1.51 (1.29, 1.76) ***
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7.6 Discussion
Neutrophil counts within the normal range had strong linear associations with specific
initial presentations of cardiovascular diseases in a large population-based cohort. Unlike
previous studies which did not disaggregate coronary endpoints, I found that neutrophil
counts had strong monotonic positive associations with myocardial infarction, unheralded
coronary death and ventricular arrhythmia / sudden cardiac death, but no association
with stable or unstable angina. Consistent with previous studies (Table 2.2 on page
47), I also found a strong association of neutrophil count with heart failure [113, 126], a
moderate association with cerebral infarction [122] and no association with intracerebral
haemorrhage [122]. Low neutrophil count (below the lower limit of the reference range)
was not associated with increased risk of cardiovascular diseases, but was associated
with significantly increased risk of non-cardiovascular death.
7.6.1 Role of neutrophils in thrombosis, inflammation and atherosclerosis
Neutrophils are the most numerous type of white blood cell in peripheral blood, and
neutrophil counts are known to be raised in acute infections and other inflammatory
states. Inflammation is a key process in the development of atherosclerotic plaques [48],
which is why inflammatory biomarkers are of much interest in cardiovascular risk pre-
diction. Many modifiable factors can increase the level of chronic low-grade inflam-
mation, such as obesity [225, 226], periodontal disease [227], smoking [89], lack of ex-
ercise [228] and air pollution [229]. Air pollution is associated with increased incidence
of heart failure [230], ischaemic heart disease and stroke [231]. Regular exercise sup-
presses pro-inflammatory cytokine production [228], whereas central obesity is thought
to cause chronic inflammation via pro-inflammatory cytokines produced by adipose tis-
sue [225,226].
The pattern of associations seen in this study suggests that as well as their role in
inflammation and atherosclerosis, neutrophils may also increase the risk of arterial throm-
bosis. Possible mechanisms include interactions with the endothelium and platelets [57]
and overactivity of neutrophil extracellular traps [58]. This would explain why neutrophil
counts are more strongly associated with myocardial infarction than stable or unstable
angina.
This study cannot ascertain whether it is circulating neutrophils per se that confer the
additional risk, or merely the underlying inflammatory state (with circulating cytokines) of
which the neutrophil count is a surrogate marker [47]. Evidence for the causal relevance
of neutrophils comes from a clinical trial of colchicine among patients with stable coronary
disease [103]. Colchicine acts by inhibiting microtubule formation in neutrophils [232] and
reduced the incidence of acute coronary syndrome and stroke in the trial [103].
Reducing chronic inflammation is thus a potentially important novel therapeutic av-
enue in atherosclerotic disease. Trials are currently underway to examine whether anti-
inflammatory agents such as methotrexate [233] or canakinumab, a human monoclonal
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antibody that selectively neutralizes interleukin-1β [234], can prevent cardiovascular dis-
ease in high risk individuals.
7.6.2 Neutrophils and cardiovascular risk
Neutrophil counts in relation to cardiovascular risk have been relatively under-studied in
the general population (Table 2.2 on page 47), in contrast to circulating cytokines (e.g.
interleukin-6 [51]) and acute phase proteins (e.g. C reactive protein, fibrinogen [50]).
These biomarkers of inflammation are strongly associated with increased risk of coronary
disease [50, 51] and US guidelines recommend that measurement of high-sensitivity C
reactive protein can be considered to inform a cardiovascular risk treatment decision in
uncertain cases [30]. The advantage of using neutrophil count over other biomarkers
of inflammation in clinical risk prediction is that it is already performed, and would not
incur any additional costs for testing. In contrast, C reactive protein is rarely measured
in general practice and only in a highly selected subset of patients with suspected acute
inflammation or infection, and the other biomarkers are not measured in clinical practice.
The strength of the association between neutrophil count and cardiovascular diseases
suggest that it should be considered a cardiovascular risk factor in a similar league to
systolic blood pressure (SBP). Comparing the strength of associations for heart failure
with neutrophil count or SBP across the normal range (i.e. 90–140 mmHg for SBP), the
hazard ratio of 2.04 for neutrophil count is significantly greater than 1.51 (95% CI 1.36,
1.64) for SBP (scaled to a 50mmHg difference from Supplementary Figure S5 in Rapso-
maniki et al. [36]). Neutrophil count and SBP have similar strengths of association with
unheralded coronary death (HR 1.78 and 1.71 respectively). The finding that neutrophil
count is associated with myocardial infarction but not stable angina implies that neutrophil
count may be related to thrombosis as well as atherosclerosis.
Neutrophils are short-lived cells and are affected by acute illnesses; I found there was
significant variation between repeat tests on the same individual, giving a within-person
correlation of neutrophil counts taken under ‘stable’ conditions of 0.568. This compares
to 0.68 for total cholesterol and 0.73 for HDL cholesterol [105]. Hence inter-test variabil-
ity could affect the usefulness of the neutrophil count as a cardiovascular risk marker. I
did not adjust for this regression dilution bias in these analyses, because although the
adjusted results would convey more accurately the strength of the biological association
with average neutrophil count (or the underlying inflammatory process that it represents),
they would give a misleading impression of the predictive value of the single or small
number of differential leukocyte measurements that would be performed in practice. In
an analysis adjusted for regression dilution bias the exposure would effectively be the
unobservable mean neutrophil count. I found that associations were stronger among
patients with neutrophil counts taken under ‘stable’ conditions, and were further strength-
ened when the mean of two such measurements were used, which would provide a more
precise estimate of the level of chronic inflammation.
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Smoking causes elevation of neutrophil counts [89,235]. The finding of similar strength
of associations in non-smokers and smokers shows that residual confounding due to
imprecise recording of smoking severity cannot explain away these results. I adjusted
for smoking in the main analysis in order to demonstrate the independent association
of neutrophil counts with cardiovascular diseases unconfounded by other risk factors.
However, if a raised neutrophil count (or the underlying chronic inflammation of which it
is a proxy) is on one of the causal pathways linking smoking to cardiovascular disease
[89], adjustment for smoking may result in ‘over-adjustment’, with under-estimation of the
component of cardiovascular risk conveyed by chronic inflammation or neutrophils.
7.6.3 Limitations
Although this study has strengths – large size, population base, extensive adjustment for
potential confounders – it also has important limitations. As with any observational study,
the results cannot be taken to imply causation because there is the possibility of residual
confounding. Another limitation is selection bias, as participants were only included if
they had a full blood count performed in routine clinical care, and the indications for
this test could vary widely. However I investigated conditions and medication that may
acutely affect the leukocyte count and obtained consistent results in a range of sensitivity
analyses.
The measurement of leukocyte counts was undertaken in routine clinical care, by a
large number of different laboratories without study-wide protocols. However, this would
be expected to lead to random error rather than systematic bias. My results are consistent
with previous studies which recruited healthy individuals and measured leukocyte counts
under standardised conditions.
As the study was based on electronic health records, some values of baseline variables
were missing for some patients. However, I obtained similar results by imputing missing
data using two different methods of multiple imputation, and I used rich datasets for im-
putation with many clinical variables as auxiliary variables in imputation models, which
would help to ensure that data were Missing at Random.
The ascertainment of endpoints was in routinely coded clinical data, without endpoint
adjudication. It is known that all of the data sources used in this study miss some events;
however the validation study of myocardial infarction showed that events recorded in each
source had the expected prognosis and patient characteristics of myocardial infarction,
suggesting that the sources have good specificity (see section 4.2). Validation studies
of the CPRD have also shown that diagnoses recorded in primary care are likely to be
correct [133]. Any failures in endpoint recording are likely to be non-differential in relation
to the leukocyte count.
186
7.6. Discussion
7.6.4 Research implications
There are two broad avenues for further research: investigating potential causal mecha-
nisms and using neutrophil counts in risk prediction. Investigation of causal mechanisms
could involve epidemiological studies of associations involving upstream determinants
of neutrophil counts, such as granulocyte colony stimulating factor, interleukin-17 and
interleukin-23 [236]. Mendelian randomisation studies using SNPs for genes associated
with neutrophil count, such as those identified in the 17q21 region [56, 237], may also
help to determine whether the neutrophil count itself is causal in atherosclerotic disease.
This would strengthen the case for immune modulation to be considered as a therapy to
prevent or treat cardiovascular diseases, and may suggest novel therapeutic targets.
Neutrophil counts are almost always measured as part of a full leukocyte differential,
meaning that they are usually associated with measures of other cell types (lymphocytes,
monocytes, eosinophils and basophils). Monocytes are part of the immune response
and migrate into atherosclerotic plaques to form foam cells [48]; they showed similar
associations with cardiovascular diseases to neutrophils (Figure 7.16 on page 180). Low
counts of lymphocytes were associated with increased heart failure, unheralded coronary
death and other death (Figure 7.17 on page 181). Previous studies [113, 126] have
not been large enough to demonstrate a statistically significant association. There was
no clear pattern to the remaining results, consistent with previous studies (Table 2.4
on page 49), probably because the overall lymphocyte count comprises a number of
subtypes with different roles (e.g. B cells, killer T cells, T regulatory cells). This is in
contrast to neutrophils, which comprise a single class of cell all with the same function.
Low lymphocyte count is associated with malnutrition [238] and may also be due to bone
marrow insufficiency and general frailty.
A recommendation arising from this research is that the components of the leukocyte
differential should be tested in predictive models for cardiovascular diseases [30, 47].
Given the variability in neutrophil counts, more accurate predictions may be obtained
using repeat measurements.
7.6.5 Clinical implications
Leukocyte counts are commonly performed in clinical practice, but they tend to inform
clinical management only if the results are outside the reference range. Much prognostic
information is conveyed by neutrophil counts within the reference range, and it should
be considered as a continuous measure like cholesterol or blood pressure. Neutrophil
count is affected by behavioural cardiovascular risk factors such as smoking and lack of
exercise, so it may be useful for monitoring a patient’s progress with a cardiovascular
risk reduction programme; for example smoking cessation reduced the mean neutrophil
count by 1.0× 109/L [239], and a clinical trial of moderate regular exercise (8 kcal per kg
body weight per week) reduced the mean neutrophil count by 0.1 × 109/L in overweight
postmenopausal women [240].
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7.6.6 Conclusion
Neutrophil counts are differentially associated with the short and long term risk of initial
presentations of cardiovascular diseases. Clinicians should be aware of the prognostic
information conveyed by neutrophil counts even within the reference range. The leukocyte
differential should be investigated for use in cardiovascular risk prediction models.
7.7 Summary
This study uses the large sample size and rich clinical information in the CALIBER dataset
to show that neutrophil counts are differentially associated specific initial presentations of
cardiovascular diseases. There were also interesting findings in relation to eosinophil
counts, which are described in the next chapter, chapter 8. These novel findings should
be replicated in other settings, so I present a replication study in chapter 9.
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8 Associations of eosinophil counts with specific initial
presentations of cardiovascular diseases
8.1 Chapter outline
This chapter investigates the association of eosinophil counts with incidence of cardio-
vascular diseases. The cohort definition is described in chapter 6 and is the same that
which yielded the results for neutrophils (chapter 7).
8.2 Abstract
Background: The eosinophil count is a component of the white blood cell (leukocyte)
differential, a common blood test. Eosinophils may be implicated in coronary disease, but
the association of eosinophil counts with the onset of cardiovascular diseases has not
previously been investigated in large population-based studies.
Methods: The data source was a linked primary care, hospital admission, disease reg-
istry, and mortality dataset for England (the CALIBER programme). The study included
people aged 30 or older with a leukocyte differential recorded, who were free from cardio-
vascular disease as baseline. Participants were followed for the first occurrence of stable
angina, unstable angina, myocardial infarction, unheralded coronary death, heart fail-
ure, ventricular arrhythmia / sudden cardiac death, transient ischaemic attack, ischaemic
stroke, haemorrhagic stroke, subarachnoid haemorrhage, abdominal aortic aneurysm or
peripheral arterial disease. Cox models were used to estimate cause-specific hazard
ratios (HR). This study is registered at ClinicalTrials.gov (NCT02014610).
Results: The cohort comprised 775 231 individuals, of whom 54 980 experienced an
initial presentation of cardiovascular disease over a median follow up of 3.8 years. Low
eosinophil count was associated with low levels of cardiovascular risk factors such as
smoking and diabetes. There was a strong association of low eosinophil counts (<0.05
compared to 0.15–0.25 ×109/L) over the first 6 months with heart failure (adjusted HR
2.05; 95% confidence interval (CI) 1.72, 2.43), and unheralded coronary death (adjusted
HR 1.94, 95% CI 1.40, 2.69), but not stable angina or non-fatal myocardial infarction.
Associations beyond the first 6 months were weaker.
Conclusions: Low eosinophil counts are strongly associated with increased short-term
incidence of heart failure and coronary death.
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8.3 Introduction
Eosinophils are multifunctional leukocytes (white blood cells) which have various roles in
inflammatory processes [74], and are thought to be particularly important for maintenance
of tissue homeostasis through ‘Local Immune And Remodelling / Repair’ activities [75].
Eosinophil counts are routinely measured in peripheral blood as part of the full blood
count (complete blood count), one of the most widely performed blood tests in medical
practice. The exact nature of their roles in relation to cardiovascular diseases are unclear.
Eosinophil counts increase acutely after myocardial infarction [76] and histological studies
found large numbers of eosinophils in coronary thrombi [77] and post-mortem hearts with
cardiac rupture [78], suggesting that eosinophils may be implicated in the pathogenesis
of myocardial infarction. This hypothesis is supported by the finding of a non-synonymous
SNP associated both with eosinophil count and myocardial infarction [79].
Prospective cohort studies investigating the association of baseline eosinophil counts
with development of cardiovascular disease in healthy people have been few in number
and small in size (Table 2.6 on page 51). In the Hiroshima and Nagasaki study [107] and
Caerphilly study [116], higher eosinophil counts were associated with greater incidence
of coronary heart disease. Conversely, in populations with cardiovascular disease (e.g.
patients undergoing percutaneous intervention [127] or with acute heart failure [128]),
lower eosinophil counts were associated with worse prognosis. Low eosinophil count was
also found to be associated with worse short-term mortality in critical care patients [241].
The existing evidence relating eosinophil counts to cardiovascular diseases is thus
scarce and contradictory. Previous studies were small, had limited adjustment for cardio-
vascular risk factors, and investigated a narrow range of cardiac endpoints. It is unknown
whether eosinophil counts are associated with other cardiovascular diseases such as
stroke, heart failure or peripheral arterial disease, and whether associations differ by
short or long term risk. The aim of this study was to address these gaps in knowledge by
means of a large population-based cohort study in the CALIBER linked electronic health
record database [1].
8.4 Methods
The cohort definition, covariates and multiple imputation methods were as described
in section 7.4. Briefly, patients aged 30 or over who had at least one full blood count
recorded while registered at a CPRD practice were eligible for the study. The patient
state at the time of the blood test was classified as ‘acute’ or ‘stable’, and patients were
followed up for the initial presentation of one of twelve cardiovascular diseases. Baseline
covariate data were extracted as described in Section 6.6.
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Figure 8.1: Histogram showing distribution of eosinophil counts and category cutpoints
Histogram of eosinophil counts
× 109 cells/L
D
en
si
ty
0.0 0.1 0.2 0.3 0.4 0.5
0
2
4
6
8
10
12
14
8.4.1 Exposure
The main exposure was the eosinophil count as recorded in CPRD. If a patient had more
than one measurement on a given day, the values were aggregated by taking the mean.
I examined quintiles of eosinophil count in order to avoid presuming a particular shape
for the association with cardiovascular diseases. The precision with which eosinophil
counts were recorded (in cells ×109/L) varied from one to two decimal places (Figure 8.1
on page 191). In order to avoid biasing the category allocation by precision, I manually
adjusted the category boundaries so that the second decimal place was 5, thus ensuring
that any value recorded to two decimal places would end up in the same category as if it
were recorded to only one decimal place. All category intervals were closed at the lower
end and open at the higher end.
In secondary analyses, I explored associations between onset of cardiovascular dis-
eases and the mean of the first two ‘stable’ measurements of eosinophil count taken
since the start of eligibility. I also carried out a sensitivity analysis excluding patients with
a history of prior loop diuretic use, who might have symptoms of heart failure without a
formal diagnosis.
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8.4.2 Statistical analysis
I generated cumulative incidence curves by category of eosinophil counts under a com-
peting risks framework. I used the Cox proportional hazards model to generate cause-
specific hazards for the different cardiovascular endpoints. Hazard ratios were adjusted
for age (linear and quadratic), sex, age / sex interaction, index of multiple deprivation,
ethnicity, smoking status, diabetes, body mass index, systolic blood pressure, eGFR,
HDL, total cholesterol, atrial fibrillation, inflammatory conditions (autoimmune conditions,
inflammatory bowel disease or COPD), cancer, statin use, blood pressure medication
and acute conditions at the time of blood testing. The baseline hazard was stratified
by practice and sex. I plotted Schoenfeld residuals to assess the proportional hazards
assumption, and split the follow-up time if hazard ratios changed over time. I handled
missing baseline covariate data by multiple imputation using chained equations [187],
using Random Forest multiple imputation models [148], as described previously (subsec-
tion 7.4.7).
8.5 Results
The cohort included 621 052 patients with differential leukocyte counts while clinically
‘stable’ and 154 179 patients with differential leukocyte counts performed during acute
illness or treatment (Figure 6.1 on page 135). 54 980 initial presentations of cardiovas-
cular disease were observed over a median of 3.8 (IQR 1.7, 6.0) years follow-up.
Eosinophil counts were low and measured imprecisely, so the categories contain un-
equal numbers of patients (Table 8.1 on page 193). Amongst patients in the lowest
category, 28 791 had 0 eosinophils. Of these, only 104 (0.4%) also had zero neutrophils.
Patients in the lowest eosinophil category were most likely to have an acute state at the
time of the blood test (Table 8.2 on page 194).
Lower eosinophil count was associated with cancer, being female, and Black ethnicity,
whereas higher eosinophil count was associated with male sex, deprivation, South Asian
ethnicity, higher body mass index, and atopy (Figure 8.2 on page 195).
Crude cumulative incidence curves showed that individuals with eosinophil counts less
than 0.05 ×109/L had a greater incidence of heart failure as the initial presentation of
cardiovascular disease, at least in the first few months (Figure 8.3 on page 196).
In multiply adjusted analyses there was a strong association of low eosinophil counts
(<0.05 compared to 0.15–0.25 ×109/L) with incident heart failure (adjusted hazard ratio
(HR) 1.39; 95% confidence interval (CI) 1.26, 1.54), unheralded coronary death (HR 1.29,
95% CI 1.12, 1.50) and ventricular arrhythmia or sudden cardiac death (HR 1.49, 95%
CI 1.12, 2.00), but not stable angina (HR 0.93, 95% CI 0.84, 1.03), non-fatal myocardial
infarction (HR 1.00, 95% CI 0.89, 1.12) or ischaemic stroke (HR 1.02, 95% CI 0.88, 1.19)
(Figure 8.4 on page 197).
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Table 8.1: Characteristics of patients by category of eosinophil count
Category 1 (lowest) 2 3 4 5 (highest)
Eosinophils, ×109/L < 0.05 [0.05, 0.15) [0.15, 0.25) [0.25, 0.35) ≥ 0.35
N patients 44 112 307 668 228 639 106 092 88 720
Women, n (%) 29 990 (68.0%) 199 375 (64.8%) 132 275 (57.9%) 55 902 (52.7%) 44 414 (50.1%)
Age, median (IQR) 52 (39.8-66.8) 52.1 (41-64.3) 53 (42.1-64.6) 52.8 (42-64.5) 51.9 (41.1-64.4)
Most deprived
quintile, n (%) 7805 (17.7%) 54 017 (17.6%) 44 765 (19.6%) 22 237 (21.0%) 19 859 (22.5%)
Ethnicity, n (%):
White 25 511 (91.7%) 175 418 (93.0%) 131 908 (93.5%) 61 286 (92.8%) 50 911 (90.7%)
South Asian 552 (2.0%) 4187 (2.2%) 3774 (2.7%) 2238 (3.4%) 2699 (4.8%)
Black 1051 (3.8%) 4496 (2.4%) 2356 (1.7%) 1017 (1.5%) 1054 (1.9%)
Other 714 (2.6%) 4564 (2.4%) 3056 (2.2%) 1501 (2.3%) 1485 (2.6%)
Missing 16 284 (36.9%) 119 003 (38.7%) 87 545 (38.3%) 40 050 (37.8%) 32 571 (36.7%)
Full blood count parameters on index date, median (IQR):
Neutrophils, ×109/L 3.98 (2.8-5.7) 3.7 (2.9-4.8) 3.9 (3.1-4.97) 4 (3.2-5.12) 4.2 (3.3-5.36)
Lymphocytes, ×109/L 1.6 (1.2-2) 1.87 (1.5-2.3) 2 (1.66-2.5) 2.1 (1.71-2.6) 2.2 (1.8-2.73)
Monocytes, ×109/L 0.42 (0.3-0.6) 0.44 (0.35-0.6) 0.5 (0.4-0.6) 0.5 (0.4-0.64) 0.53 (0.4-0.7)
Basophils, ×109/L 0 (0-0.02) 0.02 (0-0.05) 0.03 (0-0.08) 0.04 (0-0.1) 0.05 (0-0.1)
Haemoglobin, g/dL 13.5 (12.5-14.5) 13.8 (12.9-14.8) 14 (13.1-15) 14.1 (13.1-15.1) 14.1 (13.1-15.1)
Platelets, ×109/L 249 (206-297) 255 (217-299) 261 (223-306) 266 (227-312) 273 (233-321)
Smoking status, n (%):
Never 25 034 (61.0%) 167 598 (57.6%) 109 365 (50.3%) 46 699 (46.2%) 38 006 (45.1%)
Ex 8840 (21.5%) 68 595 (23.6%) 53 712 (24.7%) 25 193 (24.9%) 20 859 (24.7%)
Current 7158 (17.4%) 54 997 (18.9%) 54 292 (25.0%) 29 089 (28.8%) 25 485 (30.2%)
Missing 3080 (7.0%) 16 478 (5.4%) 11 270 (4.9%) 5111 (4.8%) 4370 (4.9%)
Most recent value within one year prior to index date, median (IQR):
Systolic blood
pressure, mmHg 133 (120-148) 135 (120-150) 138 (123-150) 138 (124-150) 136 (122-150)
Body mass index,
kg/m2 25 (22-28.5) 26.5 (23.3-30.4) 27.6 (24.3-31.7) 27.8 (24.4-32) 27.5 (24.2-31.7)
Total cholesterol,
mmol/L 5.36 (4.6-6.1) 5.5 (4.8-6.27) 5.5 (4.8-6.3) 5.5 (4.8-6.2) 5.4 (4.7-6.2)
HDL cholesterol,
mmol/L 1.5 (1.2-1.8) 1.4 (1.2-1.71) 1.36 (1.1-1.63) 1.3 (1.1-1.6) 1.3 (1.1-1.6)
eGFR,
mL/min/1.73m2 81.4 (67.6-95.4) 82.1 (69.1-95.2) 81.7 (68.8-94.6) 81.9 (68.7-95.1) 82.4 (68.7-95.7)
Diagnoses on or before index date, n (%):
Atrial fibrillation 555 (1.3%) 3137 (1.0%) 2163 (0.9%) 1027 (1.0%) 840 (0.9%)
Cancer 3895 (8.8%) 19 459 (6.3%) 13 523 (5.9%) 5950 (5.6%) 4694 (5.3%)
Diabetes 1502 (3.4%) 12 125 (3.9%) 11 941 (5.2%) 6022 (5.7%) 5537 (6.2%)
Asthma or atopy 9783 (22.2%) 73 708 (24.0%) 63 179 (27.6%) 33 355 (31.4%) 32 875 (37.1%)
COPD 863 (2.0%) 4417 (1.4%) 4445 (1.9%) 2484 (2.3%) 2812 (3.2%)
Connective tissue
disease 1680 (3.8%) 8526 (2.8%) 6236 (2.7%) 2916 (2.7%) 2501 (2.8%)
IBD 704 (1.6%) 3077 (1.0%) 2400 (1.0%) 1249 (1.2%) 1216 (1.4%)
Medication use in the year before index date, n (%):
Antihypertensives 9988 (22.6%) 73 943 (24.0%) 60 755 (26.6%) 28 752 (27.1%) 23 843 (26.9%)
Statins 1654 (3.7%) 15 864 (5.2%) 15 207 (6.7%) 7503 (7.1%) 6578 (7.4%)
COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; HDL, high density
lipoprotein cholesterol, IBD, inflammatory bowel disease; IQR, interquartile range.
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Table 8.2: Prevalence of acute conditions on date of blood testing by category of eosino-
phil count
Category 1 (lowest) 2 3 4 5 (highest)
Eosinophils, ×109/L < 0.05 [0.05, 0.15) [0.15, 0.25) [0.25, 0.35) ≥ 0.35
In hospital on date of blood
test 662 (1.5%) 1177 (0.4%) 670 (0.3%) 291 (0.3%) 280 (0.3%)
Vaccination within previous
7 days 399 (0.9%) 2998 (1.0%) 2446 (1.1%) 1276 (1.2%) 1052 (1.2%)
Anaemia diagnosis within
30 days before 393 (0.9%) 1617 (0.5%) 940 (0.4%) 407 (0.4%) 400 (0.5%)
Infection diagnosis within 30
days before 3859 (8.7%) 20 129 (6.5%) 15 622 (6.8%) 7543 (7.1%) 7098 (8.0%)
Infective symptoms within
30 days before 3439 (7.8%) 16 166 (5.3%) 11 902 (5.2%) 5719 (5.4%) 5952 (6.7%)
Prior diagnosis of
myelodysplastic syndrome 79 (0.2%) 117 (0.0%) 55 (0.0%) 31 (0.0%) 24 (0.0%)
Prior diagnosis of
haemoglobinopathy 200 (0.5%) 1082 (0.4%) 688 (0.3%) 352 (0.3%) 327 (0.4%)
Chemotherapy or G-CSF
within 6 months prior 561 (1.3%) 780 (0.3%) 390 (0.2%) 153 (0.1%) 172 (0.2%)
Methotrexate within 3
months prior 203 (0.5%) 1175 (0.4%) 966 (0.4%) 391 (0.4%) 342 (0.4%)
Steroid within 3 months
prior 2304 (5.2%) 7244 (2.4%) 5473 (2.4%) 2849 (2.7%) 3306 (3.7%)
Other immune drug within 3
months prior 993 (2.3%) 3308 (1.1%) 2182 (1.0%) 992 (0.9%) 918 (1.0%)
Prior diagnosis of cancer 3895 (8.8%) 19 459 (6.3%) 13 523 (5.9%) 5950 (5.6%) 4694 (5.3%)
Any acute condition 12 068(27.4%)
58 821
(19.1%)
43 324
(18.9%)
20 619
(19.4%)
19 347
(21.8%)
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Figure 8.2: Selected characteristics of patients that varied significantly by eosinophil
count
Bars represent 95% confidence intervals for the summary statistics
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Figure 8.3: Cumulative incidence curves for different initial presentations of cardiovascu-
lar disease by category of eosinophil count
196
8.5. Results
Figure 8.4: Association of eosinophil categories with different initial presentations of car-
diovascular disease
Hazard ratios are adjusted for age, sex, deprivation, ethnicity, smoking, diabetes, systolic blood pressure,
body mass index, total cholesterol, HDL cholesterol, eGFR, atrial fibrillation, autoimmune conditions, inflam-
matory bowel disease, COPD, cancer, statin use, blood pressure medication and acute conditions at the time
of blood testing. P values * < 0.05, ** < 0.01, *** < 0.001
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Table 8.3: Endpoints by category of eosinophil count
Category 1 (lowest) 2 3 4 5 (highest)
Eosinophils, ×109/L < 0.05 [0.05, 0.15) [0.15, 0.25) [0.25, 0.35) ≥ 0.35
Initial presentation of cardiovascular disease
Stable angina 440 (13.6%) 3494 (17.3%) 2975 (18.0%) 1475 (18.2%) 1164 (16.8%)
Unstable angina 151 (4.7%) 1061 (5.3%) 876 (5.3%) 441 (5.4%) 351 (5.1%)
Coronary disease not
further specified 193 (6.0%) 1805 (8.9%) 1546 (9.3%) 772 (9.5%) 607 (8.8%)
Non-fatal myocardial
infarction 335 (10.4%) 2219 (11.0%) 2039 (12.3%) 1062 (13.1%) 911 (13.2%)
Unheralded coronary death 240 (7.4%) 1119 (5.5%) 895 (5.4%) 436 (5.4%) 400 (5.8%)
Heart failure 545 (16.9%) 2391 (11.8%) 1761 (10.6%) 794 (9.8%) 733 (10.6%)
Ventricular arrhythmia or
sudden cardiac death 60 (1.9%) 288 (1.4%) 215 (1.3%) 91 (1.1%) 93 (1.3%)
Transient ischaemic attack 311 (9.6%) 1931 (9.6%) 1538 (9.3%) 704 (8.7%) 592 (8.6%)
Ischaemic stroke 223 (6.9%) 1418 (7.0%) 1082 (6.5%) 542 (6.7%) 425 (6.1%)
Stroke not further specified 307 (9.5%) 1638 (8.1%) 1181 (7.1%) 558 (6.9%) 507 (7.3%)
Subarachnoid haemorrhage 38 (1.2%) 246 (1.2%) 155 (0.9%) 74 (0.9%) 64 (0.9%)
Intracerebral haemorrhage 91 (2.8%) 432 (2.1%) 303 (1.8%) 114 (1.4%) 120 (1.7%)
Peripheral arterial disease 240 (7.4%) 1708 (8.5%) 1576 (9.5%) 799 (9.9%) 743 (10.7%)
Abdominal aortic aneurysm 58 (1.8%) 448 (2.2%) 420 (2.5%) 231 (2.9%) 209 (3.0%)
Total 3232 20198 16562 8093 6919
Other deaths
Cancers 2132 (54.9%) 6858 (53.7%) 4578 (55.3%) 2105 (53.9%) 1920 (51.1%)
Dementia 167 (4.3%) 682 (5.3%) 370 (4.5%) 204 (5.2%) 182 (4.8%)
Pneumonia 277 (7.1%) 790 (6.2%) 498 (6.0%) 240 (6.2%) 259 (6.9%)
Chronic obstructive
pulmonary disease 129 (3.3%) 479 (3.8%) 352 (4.3%) 171 (4.4%) 195 (5.2%)
Liver disease 127 (3.3%) 367 (2.9%) 212 (2.6%) 86 (2.2%) 77 (2.1%)
Other causes of death 1052 (27.1%) 3597 (28.2%) 2267 (27.4%) 1096 (28.1%) 1122 (29.9%)
Total 3884 12773 8277 3902 3755
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Figure 8.5: Association of categories of eosinophil count with different initial presentations
of cardiovascular disease, by patient’s clinical state at time of blood test
Hazard ratios are adjusted for age, sex, deprivation, ethnicity, smoking, diabetes, systolic blood pressure,
body mass index, total cholesterol, HDL cholesterol, eGFR, atrial fibrillation, autoimmune conditions, inflam-
matory bowel disease, COPD, cancer, statin use and blood pressure medication. P values * < 0.05, ** <
0.01, *** < 0.001
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1.11 (0.59, 2.09)
1.26 (0.82, 1.92)
0.90 (0.66, 1.21)
1 (reference)
1.07 (0.72, 1.57)
1.15 (0.78, 1.71)
0.80 (0.62, 1.02)
0.96 (0.83, 1.11)
1 (reference)
1.00 (0.84, 1.20)
1.17 (0.98, 1.39)
0.71 (0.43, 1.17)
1.01 (0.78, 1.32)
1 (reference)
1.01 (0.73, 1.41)
0.86 (0.61, 1.23)
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
Stable eosinophil count
0.5 1 2 4
Hazard ratio relative to middle category
Hazard ratio (95% CI)
0.96 (0.85, 1.08)
0.97 (0.92, 1.02)
1 (reference)
1.06 (0.99, 1.14)
1.00 (0.93, 1.08)
1.14 (0.93, 1.39)
1.01 (0.92, 1.12)
1 (reference)
1.05 (0.92, 1.20)
1.01 (0.88, 1.17)
1.01 (0.88, 1.17)
0.95 (0.88, 1.02)
1 (reference)
1.09 (1.00, 1.19) *
1.07 (0.98, 1.17)
1.39 (1.17, 1.65) ***
0.96 (0.86, 1.06)
1 (reference)
0.98 (0.86, 1.12)
1.04 (0.90, 1.19)
1.41 (1.24, 1.60) ***
1.05 (0.97, 1.13)
1 (reference)
0.96 (0.87, 1.06)
1.02 (0.92, 1.13)
1.64 (1.16, 2.32) **
1.10 (0.89, 1.35)
1 (reference)
0.95 (0.72, 1.26)
1.20 (0.91, 1.58)
0.98 (0.85, 1.14)
0.95 (0.88, 1.03)
1 (reference)
0.99 (0.89, 1.09)
0.99 (0.88, 1.11)
1.03 (0.86, 1.22)
1.01 (0.92, 1.10)
1 (reference)
1.01 (0.90, 1.14)
1.01 (0.89, 1.15)
1.27 (0.83, 1.93)
1.22 (0.97, 1.53)
1 (reference)
1.06 (0.78, 1.45)
1.10 (0.79, 1.53)
1.37 (1.02, 1.83) *
1.09 (0.92, 1.30)
1 (reference)
0.72 (0.56, 0.94) *
0.97 (0.75, 1.25)
0.91 (0.77, 1.07)
0.90 (0.83, 0.98) **
1 (reference)
1.03 (0.94, 1.14)
1.07 (0.97, 1.19)
0.84 (0.60, 1.18)
0.92 (0.79, 1.08)
1 (reference)
1.07 (0.89, 1.29)
1.12 (0.92, 1.36)
P value for
interaction
0.26
0.48
0.39
0.89
0.29
0.48
1
0.73
0.63
0.16
0.058
0.21
0.23
0.095
0.95
0.89
0.8
0.64
0.44
0.88
0.29
0.48
0.16
0.076
0.8
1
0.98
0.68
0.99
0.93
0.093
0.52
0.89
0.69
0.69
0.99
0.75
0.26
0.1
0.46
0.38
0.43
0.79
0.41
0.59
0.56
0.76
0.2
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Low eosinophil counts were also associated with significantly increased risk of non-
cardiovascular death (HR 1.79, 95% CI 1.72, 1.86), without any clear preponderance for
a particular cause of death (Table 8.3 on page 198). There was no significant difference
in these associations between eosinophil counts measured when a patient was ‘acute’ or
‘stable’ (Figure 8.5 on page 199).
In models adjusted only for age and sex, low eosinophil count was associated with
reduced hazard of stable angina (HR 0.83, 95% CI 0.75, 0.92) and peripheral arterial
disease (HR 0.81, 95% CI 0.70, 0.92) (Figure 8.6 on page 201), but these associations
were no longer present with multiple adjustment (Figure 8.4 on page 197).
Plots of scaled Schoenfeld residuals showed evidence of non-proportional hazards
over time, particularly for the heart failure endpoint (Figure 8.7 on page 202). I there-
fore split the follow-up time at 6 months and found that all associations were stronger in
the first 6 months and weak or null thereafter (Figure 8.8 on page 203). In the first 6
months the hazard ratio associating low eosinophil counts (<0.05 compared to 0.15–0.25
×109/L) with incident heart failure was 2.05 (95% CI 1.72, 2.43). The corresponding haz-
ard ratio for unheralded coronary death was 1.94 (95% CI 1.40, 2.69), and for ventricular
arrhythmia or sudden cardiac death was 3.05 (95% CI 1.48, 6.28) (Figure 8.8 on page
203).
Considering linear associations with eosinophil count, there was some evidence that
higher stable eosinophil counts were weakly associated with increased risk of non-fatal
myocardial infarction (HR per 0.1× 109 higher eosinophil count 1.02, 95% CI 1.01, 1.04,
p = 0.0088) and peripheral arterial disease (HR 1.03, 95% CI 1.01, 1.04, p = 0.003);
see Figure 8.9 on page 204. These associations were weak relative to the distribution
of eosinophil counts in the study population (standard deviation 0.16 × 109/L). Splitting
follow-up time revealed a similar picture: higher eosinophil counts were associated with
slightly increased risk of non-fatal myocardial infarction or peripheral arterial disease from
6 months onwards (Figure 8.9 on page 204).
There were no significant interactions with age (Figure 8.10 on page 205) or sex
(Figure 8.11 on page 206). Results from sensitivity analysis in which patients with a
history of loop diuretic use were excluded were consistent with the main results (data not
shown). Results obtained using the two different methods of multiple imputation, Random
Forest MICE and normal-based MICE, were also very similar (Figure 8.12 on page 207).
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Figure 8.6: Association of eosinophil categories with different initial presentations of car-
diovascular diseases, adjusted for age and sex
P values * < 0.05, ** < 0.01, *** < 0.001
Initial
presentation
Stable angina
Unstable angina
Coronary disease not further specified
Non−fatal myocardial infarction
Unheralded coronary death
Heart failure
Ventricular arrhythmia or sudden cardiac death
<0.05
[0.05, 0.15)
[0.15, 0.25)
[0.25, 0.35)
≥ 0.35
<0.05
[0.05, 0.15)
[0.15, 0.25)
[0.25, 0.35)
≥ 0.35
<0.05
[0.05, 0.15)
[0.15, 0.25)
[0.25, 0.35)
≥ 0.35
<0.05
[0.05, 0.15)
[0.15, 0.25)
[0.25, 0.35)
≥ 0.35
<0.05
[0.05, 0.15)
[0.15, 0.25)
[0.25, 0.35)
≥ 0.35
<0.05
[0.05, 0.15)
[0.15, 0.25)
[0.25, 0.35)
≥ 0.35
<0.05
[0.05, 0.15)
[0.15, 0.25)
[0.25, 0.35)
≥ 0.35
0.5 1 2 4
Hazard ratio relative to middle category
Hazard ratio (95% CI)
0.83 (0.75, 0.92) ***
0.91 (0.86, 0.95) ***
1 (reference)
1.07 (1.01, 1.14) *
1.04 (0.97, 1.11)
0.96 (0.80, 1.14)
0.93 (0.85, 1.02)
1 (reference)
1.08 (0.97, 1.21)
1.05 (0.93, 1.19)
0.73 (0.63, 0.85) ***
0.93 (0.86, 0.99) *
1 (reference)
1.06 (0.97, 1.15)
1.01 (0.92, 1.11)
0.90 (0.80, 1.01)
0.85 (0.80, 0.90) ***
1 (reference)
1.10 (1.02, 1.18) *
1.13 (1.05, 1.23) **
1.26 (1.09, 1.45) **
0.94 (0.86, 1.03)
1 (reference)
1.03 (0.92, 1.16)
1.13 (1.00, 1.27) *
1.37 (1.24, 1.51) ***
1.00 (0.94, 1.06)
1 (reference)
0.97 (0.90, 1.06)
1.08 (0.99, 1.18)
1.44 (1.08, 1.92) *
1.01 (0.85, 1.21)
1 (reference)
0.90 (0.71, 1.16)
1.11 (0.87, 1.41)
Initial
presentation
Transient ischaemic attack
Ischaemic stroke
Stroke not further specified
Subarachnoid haemorrhage
Intracerebral haemorrhage
Peripheral arterial disease
Abdominal aortic aneurysm
<0.05
[0.05, 0.15)
[0.15, 0.25)
[0.25, 0.35)
≥ 0.35
<0.05
[0.05, 0.15)
[0.15, 0.25)
[0.25, 0.35)
≥ 0.35
<0.05
[0.05, 0.15)
[0.15, 0.25)
[0.25, 0.35)
≥ 0.35
<0.05
[0.05, 0.15)
[0.15, 0.25)
[0.25, 0.35)
≥ 0.35
<0.05
[0.05, 0.15)
[0.15, 0.25)
[0.25, 0.35)
≥ 0.35
<0.05
[0.05, 0.15)
[0.15, 0.25)
[0.25, 0.35)
≥ 0.35
<0.05
[0.05, 0.15)
[0.15, 0.25)
[0.25, 0.35)
≥ 0.35
0.5 1 2 4
Hazard ratio relative to middle category
Hazard ratio (95% CI)
0.99 (0.88, 1.12)
0.94 (0.88, 1.00)
1 (reference)
1.00 (0.91, 1.09)
1.02 (0.93, 1.12)
0.97 (0.84, 1.12)
0.97 (0.89, 1.05)
1 (reference)
1.09 (0.98, 1.21)
1.03 (0.92, 1.16)
1.13 (1.00, 1.29) *
1.00 (0.93, 1.08)
1 (reference)
1.03 (0.93, 1.14)
1.13 (1.01, 1.25) *
1.27 (0.89, 1.81)
1.16 (0.95, 1.41)
1 (reference)
1.06 (0.80, 1.40)
1.13 (0.84, 1.51)
1.44 (1.13, 1.82) **
1.05 (0.91, 1.22)
1 (reference)
0.82 (0.66, 1.02)
1.05 (0.85, 1.30)
0.81 (0.70, 0.92) **
0.83 (0.78, 0.89) ***
1 (reference)
1.09 (1.00, 1.19) *
1.23 (1.13, 1.35) ***
0.73 (0.56, 0.97) *
0.86 (0.75, 0.98) *
1 (reference)
1.12 (0.96, 1.32)
1.19 (1.01, 1.40) *
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Figure 8.7: Scaled Schoenfeld residuals for adjusted hazard ratios comparing lowest ver-
sus middle category of eosinophil count, for different initial presentations of
cardiovascular disease
Hazard ratios adjusted for age, sex, deprivation, ethnicity, smoking, diabetes, body mass index, systolic
blood pressure, eGFR, HDL, total cholesterol, atrial fibrillation, inflammatory conditions, cancer, statin use,
blood pressure medication and acute conditions at the time of blood testing. The lines show the estimate
and 95% confidence interval for the beta coefficient. The top left corner of each graph contains ρ, χ2 and p
value for the correlation between log survival time and scaled Schoenfeld residuals. For clarity, points plotted
on the graph are for a random sample of 20 000 patients.
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Figure 8.8: Association of eosinophil categories with different initial presentations of car-
diovascular disease, by time after measurement
Hazard ratios are adjusted for age, sex, deprivation, ethnicity, smoking, diabetes, systolic blood pressure,
body mass index, total cholesterol, HDL cholesterol, eGFR, atrial fibrillation, autoimmune conditions, inflam-
matory bowel disease, COPD, cancer, statin use, blood pressure medication and acute conditions at the time
of blood testing. P values * < 0.05, ** < 0.01, *** < 0.001
Initial
presentation
Stable angina
Unstable angina
Non−fatal myocardial infarction
Unheralded coronary death
Heart failure
Ventricular arrhythmia or sudden cardiac death
Transient ischaemic attack
Ischaemic stroke
Subarachnoid haemorrhage
Intracerebral haemorrhage
Peripheral arterial disease
Abdominal aortic aneurysm
<0.05
[0.05, 0.15)
[0.15, 0.25)
[0.25, 0.35)
≥ 0.35
<0.05
[0.05, 0.15)
[0.15, 0.25)
[0.25, 0.35)
≥ 0.35
<0.05
[0.05, 0.15)
[0.15, 0.25)
[0.25, 0.35)
≥ 0.35
<0.05
[0.05, 0.15)
[0.15, 0.25)
[0.25, 0.35)
≥ 0.35
<0.05
[0.05, 0.15)
[0.15, 0.25)
[0.25, 0.35)
≥ 0.35
<0.05
[0.05, 0.15)
[0.15, 0.25)
[0.25, 0.35)
≥ 0.35
<0.05
[0.05, 0.15)
[0.15, 0.25)
[0.25, 0.35)
≥ 0.35
<0.05
[0.05, 0.15)
[0.15, 0.25)
[0.25, 0.35)
≥ 0.35
<0.05
[0.05, 0.15)
[0.15, 0.25)
[0.25, 0.35)
≥ 0.35
<0.05
[0.05, 0.15)
[0.15, 0.25)
[0.25, 0.35)
≥ 0.35
<0.05
[0.05, 0.15)
[0.15, 0.25)
[0.25, 0.35)
≥ 0.35
<0.05
[0.05, 0.15)
[0.15, 0.25)
[0.25, 0.35)
≥ 0.35
First 6 months
0.5 1 2 4
Hazard ratio relative to middle category
Hazard ratio (95% CI)
0.81 (0.65, 1.00)
0.92 (0.83, 1.02)
1 (reference)
0.97 (0.85, 1.10)
1.02 (0.89, 1.17)
0.76 (0.44, 1.33)
1.13 (0.89, 1.44)
1 (reference)
1.13 (0.83, 1.53)
0.77 (0.53, 1.12)
1.28 (0.95, 1.71)
1.03 (0.87, 1.22)
1 (reference)
0.99 (0.80, 1.23)
0.95 (0.76, 1.20)
1.94 (1.40, 2.69) ***
1.06 (0.83, 1.35)
1 (reference)
1.05 (0.77, 1.43)
1.09 (0.80, 1.51)
2.05 (1.72, 2.43) ***
1.22 (1.08, 1.39) **
1 (reference)
0.77 (0.64, 0.93) **
0.88 (0.72, 1.06)
3.0 (1.5, 6.3) **
1.90 (1.12, 3.21) *
1 (reference)
1.42 (0.72, 2.81)
1.10 (0.51, 2.36)
0.88 (0.65, 1.19)
0.92 (0.78, 1.09)
1 (reference)
0.86 (0.68, 1.07)
0.97 (0.77, 1.22)
0.78 (0.51, 1.20)
1.06 (0.85, 1.32)
1 (reference)
0.98 (0.72, 1.31)
0.98 (0.72, 1.35)
3.4 (1.4, 7.8) **
1.64 (0.86, 3.11)
1 (reference)
0.58 (0.19, 1.76)
1.56 (0.67, 3.61)
1.86 (0.94, 3.66)
1.27 (0.77, 2.07)
1 (reference)
1.19 (0.62, 2.29)
1.30 (0.67, 2.55)
0.63 (0.44, 0.89) **
0.69 (0.59, 0.82) ***
1 (reference)
0.83 (0.68, 1.03)
0.93 (0.75, 1.14)
1.10 (0.62, 1.94)
1.10 (0.79, 1.53)
1 (reference)
1.11 (0.75, 1.66)
1.18 (0.79, 1.76)
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
6 months onwards
0.5 1 2 4
Hazard ratio relative to middle category
Hazard ratio (95% CI)
0.96 (0.86, 1.08)
0.97 (0.92, 1.03)
1 (reference)
1.07 (1.00, 1.15)
1.00 (0.92, 1.08)
1.11 (0.93, 1.34)
0.97 (0.88, 1.07)
1 (reference)
1.04 (0.92, 1.18)
1.04 (0.91, 1.18)
0.95 (0.84, 1.08)
0.91 (0.85, 0.97) **
1 (reference)
1.06 (0.98, 1.15)
1.06 (0.97, 1.15)
1.17 (0.99, 1.38)
0.99 (0.90, 1.09)
1 (reference)
0.98 (0.86, 1.11)
1.02 (0.90, 1.16)
1.15 (1.02, 1.30) *
1.01 (0.94, 1.09)
1 (reference)
1.00 (0.91, 1.09)
1.06 (0.96, 1.17)
1.32 (0.96, 1.82)
0.97 (0.80, 1.17)
1 (reference)
0.80 (0.61, 1.05)
1.05 (0.81, 1.36)
1.01 (0.88, 1.16)
0.96 (0.89, 1.03)
1 (reference)
1.01 (0.92, 1.12)
1.01 (0.91, 1.12)
1.06 (0.91, 1.24)
0.99 (0.91, 1.08)
1 (reference)
1.08 (0.96, 1.20)
0.99 (0.88, 1.12)
1.08 (0.72, 1.62)
1.15 (0.93, 1.43)
1 (reference)
1.09 (0.81, 1.45)
1.05 (0.77, 1.44)
1.27 (0.98, 1.64)
1.02 (0.87, 1.20)
1 (reference)
0.78 (0.62, 0.98) *
1.00 (0.80, 1.25)
0.92 (0.79, 1.07)
0.97 (0.89, 1.04)
1 (reference)
1.07 (0.97, 1.18)
1.14 (1.03, 1.25) **
0.72 (0.52, 0.99) *
0.91 (0.79, 1.06)
1 (reference)
1.05 (0.88, 1.25)
1.02 (0.85, 1.24)
P value for
interaction
0.17
0.36
0.17
0.77
0.21
0.26
0.65
0.14
0.07
0.19
0.56
0.4
0.0064
0.62
0.68
0.69
<0.0001
0.011
0.02
0.08
0.038
0.019
0.13
0.91
0.42
0.68
0.18
0.79
0.19
0.61
0.54
0.96
0.018
0.31
0.29
0.39
0.3
0.42
0.23
0.46
0.047
0.0005
0.031
0.085
0.2
0.3
0.8
0.54
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Figure 8.9: Linear association of eosinophil count with different initial presentations of
cardiovascular disease, by acuity and time since measurement
Hazard ratios are adjusted for age, sex, deprivation, ethnicity, smoking, diabetes, systolic blood pressure,
body mass index, total cholesterol, HDL cholesterol, eGFR, atrial fibrillation, autoimmune conditions, inflam-
matory bowel disease, COPD, cancer, statin use, blood pressure medication and acute conditions at the time
of blood testing. P values * < 0.05, ** < 0.01, *** < 0.001
Initial presentation
Stable angina
Unstable angina
Coronary disease not further specified
Non−fatal myocardial infarction
Unheralded coronary death
Heart failure
Ventricular arrhythmia or sudden cardiac death
Transient ischaemic attack
Ischaemic stroke
Stroke not further specified
Subarachnoid haemorrhage
Intracerebral haemorrhage
Peripheral arterial disease
Abdominal aortic aneurysm
First 6 months
6 months onwards
First 6 months
6 months onwards
First 6 months
6 months onwards
First 6 months
6 months onwards
First 6 months
6 months onwards
First 6 months
6 months onwards
First 6 months
6 months onwards
First 6 months
6 months onwards
First 6 months
6 months onwards
First 6 months
6 months onwards
First 6 months
6 months onwards
First 6 months
6 months onwards
First 6 months
6 months onwards
First 6 months
6 months onwards
0.9 0.95 1 1.05 1.1
Hazard ratio per 0.1 × 109 higher eosinophil count
Hazard ratio (95% CI)
1.01 (0.98, 1.03)
1.00 (0.99, 1.02)
0.94 (0.87, 1.01)
1.00 (0.98, 1.02)
0.98 (0.94, 1.02)
1.01 (1.00, 1.03)
0.97 (0.93, 1.02)
1.02 (1.01, 1.03) **
0.97 (0.92, 1.03)
1.00 (0.97, 1.02)
0.89 (0.86, 0.93) ***
1.00 (0.98, 1.02)
0.90 (0.78, 1.04)
0.99 (0.94, 1.04)
1.01 (0.97, 1.05)
1.00 (0.98, 1.02)
1.00 (0.95, 1.06)
0.99 (0.97, 1.02)
1.02 (0.99, 1.05)
1.01 (0.99, 1.03)
0.89 (0.73, 1.08)
0.97 (0.91, 1.03)
0.97 (0.85, 1.10)
0.99 (0.95, 1.03)
1.03 (1.00, 1.06) *
1.02 (1.01, 1.04) **
0.98 (0.91, 1.05)
1.01 (0.98, 1.04)
P value for
interaction
0.74
0.12
0.17
0.057
0.5
<0.0001
0.24
0.85
0.79
0.59
0.43
0.73
0.58
0.41
Initial presentation
Stable angina
Unstable angina
Coronary disease not further specified
Non−fatal myocardial infarction
Unheralded coronary death
Heart failure
Ventricular arrhythmia or sudden cardiac death
Transient ischaemic attack
Ischaemic stroke
Stroke not further specified
Subarachnoid haemorrhage
Intracerebral haemorrhage
Peripheral arterial disease
Abdominal aortic aneurysm
Acute
Stable
Acute
Stable
Acute
Stable
Acute
Stable
Acute
Stable
Acute
Stable
Acute
Stable
Acute
Stable
Acute
Stable
Acute
Stable
Acute
Stable
Acute
Stable
Acute
Stable
Acute
Stable
0.9 0.95 1 1.05 1.1
Hazard ratio per 0.1 × 109 higher eosinophil count
Hazard ratio (95% CI)
1.00 (0.98, 1.02)
1.01 (0.99, 1.02)
0.99 (0.95, 1.03)
0.99 (0.97, 1.02)
0.99 (0.96, 1.03)
1.01 (0.99, 1.03)
1.00 (0.98, 1.03)
1.02 (1.01, 1.04) **
0.98 (0.94, 1.02)
1.00 (0.97, 1.02)
0.96 (0.94, 0.99) *
0.98 (0.96, 1.00)
0.95 (0.86, 1.04)
0.99 (0.93, 1.04)
1.00 (0.97, 1.03)
1.00 (0.98, 1.02)
0.99 (0.96, 1.03)
1.00 (0.97, 1.02)
1.01 (0.98, 1.04)
1.01 (0.99, 1.03)
0.96 (0.86, 1.09)
0.96 (0.89, 1.02)
1.01 (0.95, 1.06)
0.97 (0.93, 1.03)
1.02 (1.00, 1.04) *
1.03 (1.01, 1.04) **
0.99 (0.93, 1.04)
1.01 (0.98, 1.04)
P value for
interaction
0.7
0.91
0.27
0.19
0.4
0.35
0.5
0.8
0.91
1
0.9
0.41
0.84
0.44
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Figure 8.10: Association of categories of eosinophil count with different initial presenta-
tions of cardiovascular disease, by age group
Hazard ratios are adjusted for age, sex, deprivation, ethnicity, smoking, diabetes, systolic blood pressure,
body mass index, total cholesterol, HDL cholesterol, eGFR, atrial fibrillation, autoimmune conditions, inflam-
matory bowel disease, COPD, cancer, statin use, blood pressure medication and acute conditions at the time
of blood testing. P values * < 0.05, ** < 0.01, *** < 0.001
Initial
presentation
Stable angina
Unstable angina
Non−fatal myocardial infarction
Unheralded coronary death
Heart failure
Ventricular arrhythmia or sudden cardiac death
Transient ischaemic attack
Ischaemic stroke
Subarachnoid haemorrhage
Intracerebral haemorrhage
Peripheral arterial disease
Abdominal aortic aneurysm
<0.05
[0.05, 0.15)
[0.15, 0.25)
[0.25, 0.35)
≥ 0.35
<0.05
[0.05, 0.15)
[0.15, 0.25)
[0.25, 0.35)
≥ 0.35
<0.05
[0.05, 0.15)
[0.15, 0.25)
[0.25, 0.35)
≥ 0.35
<0.05
[0.05, 0.15)
[0.15, 0.25)
[0.25, 0.35)
≥ 0.35
<0.05
[0.05, 0.15)
[0.15, 0.25)
[0.25, 0.35)
≥ 0.35
<0.05
[0.05, 0.15)
[0.15, 0.25)
[0.25, 0.35)
≥ 0.35
<0.05
[0.05, 0.15)
[0.15, 0.25)
[0.25, 0.35)
≥ 0.35
<0.05
[0.05, 0.15)
[0.15, 0.25)
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≥ 0.35
<0.05
[0.05, 0.15)
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≥ 0.35
<0.05
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≥ 0.35
<0.05
[0.05, 0.15)
[0.15, 0.25)
[0.25, 0.35)
≥ 0.35
<0.05
[0.05, 0.15)
[0.15, 0.25)
[0.25, 0.35)
≥ 0.35
Patients aged under 60
0.5 1 2 4
Hazard ratio relative to middle category
Hazard ratio (95% CI)
0.83 (0.69, 1.00) *
0.93 (0.86, 1.01)
1 (reference)
1.05 (0.95, 1.16)
1.07 (0.96, 1.20)
0.96 (0.73, 1.26)
0.92 (0.81, 1.05)
1 (reference)
1.14 (0.97, 1.33)
1.01 (0.85, 1.20)
0.88 (0.70, 1.11)
0.85 (0.77, 0.94) **
1 (reference)
1.12 (0.99, 1.26)
1.15 (1.02, 1.31) *
1.34 (0.89, 2.02)
0.99 (0.79, 1.24)
1 (reference)
1.45 (1.13, 1.85) **
1.29 (0.99, 1.69)
1.39 (1.01, 1.93) *
1.03 (0.86, 1.23)
1 (reference)
1.03 (0.81, 1.29)
1.10 (0.87, 1.40)
1.63 (1.05, 2.53) *
0.96 (0.73, 1.26)
1 (reference)
0.73 (0.49, 1.09)
0.99 (0.68, 1.44)
0.94 (0.70, 1.26)
0.84 (0.73, 0.97) *
1 (reference)
1.06 (0.89, 1.28)
1.19 (0.98, 1.43)
1.14 (0.78, 1.64)
0.98 (0.81, 1.19)
1 (reference)
1.08 (0.85, 1.37)
1.01 (0.78, 1.31)
0.84 (0.47, 1.47)
1.16 (0.89, 1.51)
1 (reference)
1.15 (0.81, 1.62)
1.11 (0.77, 1.61)
1.35 (0.78, 2.33)
0.99 (0.72, 1.37)
1 (reference)
1.02 (0.67, 1.55)
1.09 (0.70, 1.69)
0.75 (0.56, 1.02)
0.93 (0.82, 1.06)
1 (reference)
0.95 (0.81, 1.12)
1.19 (1.02, 1.40) *
0.41 (0.10, 1.68)
0.72 (0.45, 1.16)
1 (reference)
1.11 (0.67, 1.84)
1.21 (0.72, 2.03)
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
Patients aged 60 and over
0.5 1 2 4
Hazard ratio relative to middle category
Hazard ratio (95% CI)
0.98 (0.86, 1.10)
0.98 (0.92, 1.04)
1 (reference)
1.05 (0.97, 1.13)
0.96 (0.88, 1.05)
1.16 (0.92, 1.46)
1.07 (0.94, 1.21)
1 (reference)
0.97 (0.82, 1.15)
0.99 (0.83, 1.18)
1.05 (0.91, 1.20)
0.96 (0.89, 1.04)
1 (reference)
1.01 (0.92, 1.11)
0.98 (0.89, 1.08)
1.28 (1.09, 1.50) **
1.00 (0.91, 1.10)
1 (reference)
0.89 (0.78, 1.01)
0.98 (0.85, 1.12)
1.39 (1.25, 1.55) ***
1.06 (1.00, 1.14)
1 (reference)
0.93 (0.85, 1.02)
1.00 (0.91, 1.10)
1.41 (0.96, 2.08)
1.13 (0.89, 1.43)
1 (reference)
0.96 (0.70, 1.32)
1.10 (0.80, 1.52)
1.01 (0.88, 1.15)
0.98 (0.91, 1.06)
1 (reference)
0.96 (0.87, 1.07)
0.95 (0.85, 1.06)
1.01 (0.86, 1.18)
1.01 (0.92, 1.10)
1 (reference)
1.06 (0.94, 1.19)
0.98 (0.87, 1.12)
1.91 (1.18, 3.08) **
1.26 (0.92, 1.73)
1 (reference)
0.86 (0.54, 1.38)
1.09 (0.68, 1.76)
1.33 (1.02, 1.73) *
1.06 (0.89, 1.25)
1 (reference)
0.76 (0.59, 0.97) *
1.00 (0.78, 1.28)
0.90 (0.77, 1.05)
0.91 (0.84, 0.99) *
1 (reference)
1.05 (0.95, 1.17)
1.05 (0.95, 1.17)
0.83 (0.62, 1.10)
0.97 (0.84, 1.11)
1 (reference)
1.05 (0.89, 1.25)
1.04 (0.87, 1.24)
P value for
interaction
0.15
0.32
0.98
0.11
0.29
0.1
0.18
0.9
0.2
0.055
0.21
0.049
0.84
0.95
0.00058
0.063
0.99
0.74
0.44
0.47
0.63
0.37
0.29
0.67
0.68
0.067
0.35
0.044
0.56
0.78
0.9
0.87
0.028
0.69
0.34
0.96
0.97
0.74
0.24
0.74
0.29
0.79
0.29
0.2
0.33
0.24
0.85
0.59
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Figure 8.11: Association of categories of eosinophil count with different initial presenta-
tions of cardiovascular disease, by sex
Hazard ratios are adjusted for age, sex, deprivation, ethnicity, smoking, diabetes, systolic blood pressure,
body mass index, total cholesterol, HDL cholesterol, eGFR, atrial fibrillation, autoimmune conditions, inflam-
matory bowel disease, COPD, cancer, statin use, blood pressure medication and acute conditions at the time
of blood testing. P values * < 0.05, ** < 0.01, *** < 0.001
Initial
presentation
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Unstable angina
Non−fatal myocardial infarction
Unheralded coronary death
Heart failure
Ventricular arrhythmia or sudden cardiac death
Transient ischaemic attack
Ischaemic stroke
Subarachnoid haemorrhage
Intracerebral haemorrhage
Peripheral arterial disease
Abdominal aortic aneurysm
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≥ 0.35
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[0.05, 0.15)
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≥ 0.35
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[0.15, 0.25)
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≥ 0.35
<0.05
[0.05, 0.15)
[0.15, 0.25)
[0.25, 0.35)
≥ 0.35
<0.05
[0.05, 0.15)
[0.15, 0.25)
[0.25, 0.35)
≥ 0.35
Women
0.5 1 2 4
Hazard ratio relative to middle category
Hazard ratio (95% CI)
0.93 (0.82, 1.07)
0.98 (0.92, 1.05)
1 (reference)
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1 (reference)
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1 (reference)
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1.39 (1.14, 1.68) ***
1.00 (0.88, 1.13)
1 (reference)
0.93 (0.78, 1.12)
1.04 (0.86, 1.26)
1.38 (1.22, 1.56) ***
1.04 (0.95, 1.12)
1 (reference)
0.91 (0.81, 1.03)
1.04 (0.92, 1.17)
1.71 (1.18, 2.49) **
1.03 (0.80, 1.32)
1 (reference)
0.93 (0.65, 1.33)
1.12 (0.77, 1.61)
1.10 (0.95, 1.27)
0.96 (0.88, 1.05)
1 (reference)
1.01 (0.89, 1.14)
0.97 (0.84, 1.11)
1.07 (0.90, 1.28)
0.98 (0.89, 1.09)
1 (reference)
1.04 (0.90, 1.20)
1.06 (0.91, 1.25)
1.42 (0.95, 2.14)
1.16 (0.91, 1.48)
1 (reference)
1.03 (0.72, 1.46)
1.18 (0.82, 1.71)
1.44 (1.07, 1.94) *
1.10 (0.91, 1.34)
1 (reference)
0.84 (0.62, 1.14)
1.17 (0.87, 1.57)
0.88 (0.73, 1.06)
1.01 (0.92, 1.11)
1 (reference)
1.09 (0.96, 1.24)
1.06 (0.93, 1.22)
0.74 (0.46, 1.18)
0.91 (0.72, 1.15)
1 (reference)
1.00 (0.72, 1.38)
1.09 (0.78, 1.53)
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
Men
0.5 1 2 4
Hazard ratio relative to middle category
Hazard ratio (95% CI)
0.92 (0.79, 1.08)
0.94 (0.87, 1.01)
1 (reference)
1.06 (0.97, 1.16)
0.99 (0.90, 1.08)
0.82 (0.61, 1.10)
1.00 (0.88, 1.14)
1 (reference)
1.04 (0.89, 1.21)
0.93 (0.79, 1.10)
1.01 (0.85, 1.18)
0.92 (0.85, 1.00) *
1 (reference)
1.05 (0.96, 1.16)
0.99 (0.90, 1.09)
1.17 (0.93, 1.47)
1.00 (0.89, 1.14)
1 (reference)
1.02 (0.88, 1.19)
1.02 (0.88, 1.19)
1.42 (1.20, 1.67) ***
1.10 (1.00, 1.21)
1 (reference)
0.97 (0.86, 1.10)
0.99 (0.88, 1.13)
1.21 (0.76, 1.94)
1.10 (0.85, 1.41)
1 (reference)
0.80 (0.57, 1.13)
1.01 (0.72, 1.40)
0.80 (0.64, 1.01)
0.94 (0.85, 1.05)
1 (reference)
0.96 (0.85, 1.10)
1.03 (0.90, 1.17)
0.93 (0.72, 1.20)
1.03 (0.91, 1.17)
1 (reference)
1.09 (0.94, 1.26)
0.92 (0.79, 1.09)
0.93 (0.42, 2.05)
1.30 (0.91, 1.87)
1 (reference)
1.05 (0.66, 1.65)
0.99 (0.61, 1.61)
1.18 (0.79, 1.77)
0.97 (0.77, 1.23)
1 (reference)
0.78 (0.57, 1.06)
0.89 (0.65, 1.20)
0.87 (0.71, 1.07)
0.81 (0.74, 0.90) ***
1 (reference)
0.97 (0.86, 1.09)
1.10 (0.98, 1.23)
0.83 (0.59, 1.17)
0.96 (0.82, 1.13)
1 (reference)
1.08 (0.90, 1.30)
1.04 (0.86, 1.27)
P value for
interaction
0.91
0.37
0.66
0.69
0.019
0.95
0.79
0.2
0.96
0.75
0.89
0.058
0.25
0.93
0.46
0.88
0.79
0.37
0.46
0.62
0.26
0.71
0.56
0.68
0.024
0.8
0.63
0.55
0.38
0.55
0.65
0.23
0.35
0.6
0.95
0.56
0.44
0.42
0.72
0.2
0.95
0.0026
0.19
0.72
0.7
0.68
0.68
0.83
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Figure 8.12: Association of eosinophil categories with different initial presentations of car-
diovascular disease, using different methods of multiple imputation
Hazard ratios are adjusted for age, sex, deprivation, ethnicity, smoking, diabetes, systolic blood pressure,
body mass index, total cholesterol, HDL cholesterol, eGFR, atrial fibrillation, autoimmune conditions, inflam-
matory bowel disease, COPD, cancer, statin use, blood pressure medication and acute conditions at the time
of blood testing. P values * < 0.05, ** < 0.01, *** < 0.001
Initial
presentation
Stable angina
Unstable angina
Non−fatal myocardial infarction
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[0.05, 0.15)
[0.15, 0.25)
[0.25, 0.35)
≥ 0.35
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Hazard ratio (95% CI)
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1 (reference)
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1 (reference)
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1.05 (0.93, 1.18)
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1 (reference)
1.05 (0.97, 1.13)
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1.31 (1.13, 1.52) ***
1.01 (0.92, 1.10)
1 (reference)
0.98 (0.87, 1.10)
1.03 (0.91, 1.16)
1.40 (1.27, 1.55) ***
1.06 (1.00, 1.13) *
1 (reference)
0.94 (0.86, 1.02)
1.02 (0.93, 1.11)
1.51 (1.13, 2.03) **
1.06 (0.89, 1.27)
1 (reference)
0.86 (0.67, 1.10)
1.05 (0.83, 1.35)
1.02 (0.90, 1.16)
0.96 (0.90, 1.03)
1 (reference)
0.98 (0.90, 1.08)
1.00 (0.91, 1.10)
1.03 (0.89, 1.19)
1.00 (0.93, 1.09)
1 (reference)
1.06 (0.96, 1.18)
0.99 (0.88, 1.10)
1.30 (0.91, 1.87)
1.20 (0.98, 1.47)
1 (reference)
1.03 (0.78, 1.36)
1.09 (0.82, 1.47)
1.30 (1.02, 1.66) *
1.04 (0.90, 1.21)
1 (reference)
0.81 (0.66, 1.01)
1.01 (0.82, 1.25)
0.89 (0.78, 1.03)
0.93 (0.86, 0.99) *
1 (reference)
1.02 (0.94, 1.11)
1.09 (1.00, 1.19)
0.85 (0.64, 1.12)
0.97 (0.84, 1.11)
1 (reference)
1.05 (0.89, 1.23)
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Random Forest MICE
0.5 1 2 4
Hazard ratio relative to middle category
Hazard ratio (95% CI)
0.93 (0.84, 1.03)
0.96 (0.91, 1.01)
1 (reference)
1.05 (0.98, 1.12)
1.00 (0.94, 1.07)
1.07 (0.90, 1.28)
1.00 (0.91, 1.09)
1 (reference)
1.05 (0.94, 1.18)
1.00 (0.88, 1.13)
1.00 (0.89, 1.12)
0.93 (0.87, 0.98) *
1 (reference)
1.05 (0.97, 1.13)
1.04 (0.96, 1.13)
1.29 (1.12, 1.50) ***
1.00 (0.91, 1.09)
1 (reference)
0.99 (0.88, 1.11)
1.03 (0.91, 1.16)
1.39 (1.26, 1.54) ***
1.06 (1.00, 1.13)
1 (reference)
0.94 (0.87, 1.03)
1.01 (0.93, 1.11)
1.49 (1.12, 2.00) **
1.06 (0.88, 1.26)
1 (reference)
0.86 (0.67, 1.10)
1.05 (0.82, 1.34)
0.99 (0.88, 1.13)
0.95 (0.89, 1.02)
1 (reference)
0.99 (0.90, 1.08)
1.00 (0.91, 1.10)
1.02 (0.88, 1.19)
1.00 (0.93, 1.09)
1 (reference)
1.06 (0.96, 1.18)
0.99 (0.88, 1.11)
1.30 (0.90, 1.86)
1.20 (0.98, 1.47)
1 (reference)
1.03 (0.78, 1.37)
1.10 (0.82, 1.48)
1.33 (1.05, 1.69) *
1.04 (0.90, 1.21)
1 (reference)
0.81 (0.66, 1.01)
1.02 (0.83, 1.26)
0.87 (0.76, 1.00) *
0.92 (0.85, 0.98) *
1 (reference)
1.02 (0.94, 1.12)
1.10 (1.00, 1.20) *
0.80 (0.60, 1.05)
0.94 (0.83, 1.08)
1 (reference)
1.06 (0.90, 1.24)
1.05 (0.89, 1.25)
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8.6 Discussion
Low eosinophil counts were associated with increased short-term incidence of heart fail-
ure, unheralded coronary death and ventricular arrhythmia or sudden cardiac death as
the initial presentation of cardiovascular disease.
As far as I am aware, this is the first time an adverse association of low eosino-
phil counts on cardiovascular disease has been demonstrated in a healthy population.
I also found that low eosinophil counts were associated with increased risk of non-
cardiovascular mortality; this is consistent with studies in other settings, such as critical
care [241], which showed that low eosinophil counts were predictive of short-term mor-
tality. It may be eosinophils per se, or metabolic or immune features associated with low
eosinophil counts, that are causally related to these outcomes. For example, endogenous
mineralocorticoids suppress eosinophil count (eosinophilia is associated with adrenal in-
sufficiency [242]), and may cause increased incidence of heart failure via sodium reten-
tion.
Eosinophil counts are raised in asthma [82], tropical pulmonary eosinophilia [243],
helminth infestations [74] and hypereosinophilic syndrome [244], but their main physi-
ological role is thought to be in restoring tissue homeostasis after inflammation [75,244].
8.6.1 Interleukin-5 and cardiovascular disease
Interleukin-5 (IL-5) is the principal cytokine mediating the release of eosinophils into the
bloodstream [80]. It is strongly associated with eosinophil counts in cross-sectional stud-
ies [81] and anti-IL5 therapy is being investigated as a therapy for asthma, which is char-
acterised by an overactive immune response and high eosinophil counts [83]. However,
IL-5 also has other roles in the immune system, such as the differentiation of B lympho-
cytes to immunoglobulin-secreting plasma cells [245]. These mechanisms may explain
why higher IL-5 is associated with better outcomes in critical care patients [246], and IL-5
administration after the onset of sepsis improves survival in mice [246].
IL-5 may also be relevant to atherosclerosis; a cross-sectional study found that IL-5 was
correlated with decreased subclinical atherosclerosis [84] and variants in the IL-5 gene
are associated with coronary artery disease [85]. In mouse studies macrophage-specific
overexpression of IL-5 led to increased secretion of IgM antibodies that inhibit uptake of
oxidized low-density lipoprotein, with consequent inhibition of atherosclerosis [86].
8.6.2 Relation to previous studies
Previous studies have reported a long-term positive association of eosinophil count with
coronary disease which was stronger than observed in this study [107, 116] (Table 2.6
on page 51); this may be because I adjusted more completely for other cardiovascu-
lar risk factors (higher eosinophil count was associated with higher body mass index,
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smoking, diabetes and deprivation). Genome wide association studies found that a non-
synonymous SNP rs3184504[T] in SH2B3 is associated both with higher eosinophil count
and myocardial infarction [79], and is thought to contribute to atherosclerosis through re-
duced anti-inflammatory activity of SH2B3. However, given that my results did not show
a strong association of eosinophil count with myocardial infarction, it seems likely that the
causal pathway from rs3184504[T] is not mediated by eosinophils.
8.6.3 Limitations
The limitations of the neutrophil study described in Section 7.6.3 also apply to this study.
An additional limitation regarding the eosinophil count was that it was imprecise, with
many results recorded to only one decimal place; this may attenuate associations be-
cause of random error (regression dilution bias).
8.6.4 Clinical and research implications
Eosinophil counts are commonly performed in clinical practice, but they tend to inform
clinical management only if the results are outside the reference range. Low lymphocyte
count, which is known to be associated with worse prognosis of heart failure [247], had
a similar pattern of associations to eosinophils (Figure 7.17 on page 181). Clinicians
should be aware that low eosinophil and lymphocyte counts are associated with increased
risk of heart failure and coronary death, and studies should investigate the utility of these
biomarkers in predicting adverse outcomes.
I recommend that these findings are replicated in bespoke cohort studies such as UK
Biobank [169], with eosinophil counts measured under standardised conditions with con-
current measurement of IL-5. This would provide more precise results (many of the val-
ues in this study were measured to only one decimal place), and would also help to
elucidate the mechanistic pathway. If the atheroprotective effect of IL-5 is found to be
clinically significant, there is the theoretical potential that asthma patients treated with
anti-IL-5 may be at increased cardiovascular risk, and this should be monitored in clinical
trials and post-marketing surveillance.
8.6.5 Conclusion
Low eosinophil counts were strongly associated with increased short-term incidence of
heart failure and coronary death in a healthy population. This may have implications for
monitoring the cardiovascular safety of anti-IL-5 therapy for asthma.
8.7 Summary
This study harnesses the large CALIBER dataset to help to clarify the role of eosinophils
in cardiovascular diseases, and found an association with low eosinophil counts. Repli-
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cation of novel findings such as these in other cohorts is important; the next chapter,
chapter 9, is an example of a replication study using CALIBER and the New Zealand
PREDICT cohort.
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9 Association of total leukocyte count with all-cause
mortality: a study of cohorts in England (CALIBER) and
New Zealand (PREDICT)
Cardiovascular diseases do not respect national boundaries, and it is important to val-
idate study findings in other populations, preferably in different countries with different
population compositions. This study compares the association of total leukocyte count
with all-cause mortality in CALIBER and the New Zealand PREDICT cohort. It was a
collaborative project with Simon Thornley in New Zealand. We performed analyses inde-
pendently in the two countries following a similar protocol.
9.1 Abstract
Background: The total white blood cell count (WBC) is a commonly performed blood
test in medical practice. Associations with all cause mortality have been suggested, but
previous studies have been small or limited to selected populations.
Methods: We performed a cohort study in England and New Zealand using linked elec-
tronic health record databases. The English data source was CALIBER (linked primary
care records, hospitalisations, mortality and acute coronary syndrome registry). The New
Zealand data source was PREDICT (cardiovascular risk assessments in primary care
linked to hospitalisations, mortality, dispensed medication and laboratory results). We
included people aged 30–75 with no prior cardiovascular disease, and assessed WBC
and cardiovascular risk factors at baseline. We followed patients until death, transfer out
of the practice (in CALIBER) or study end.
Results: The study included 686 475 individuals in CALIBER and 194 513 individuals
in PREDICT. The two highest quintiles of WBC were associated with increased mortality;
the adjusted hazard ratio for highest compared to the middle quintile was 1.90 (95% con-
fidence interval (CI) 1.82, 1.99) in CALIBER and 1.53 (95% CI 1.31, 1.79) in PREDICT.
The strength of this association was strongest close to the time of WBC measurement (in
CALIBER: adjusted hazard ratio 4.1 (95% CI 3.7, 4.6) for the first 6 months, 1.60 (95%
CI 1.53, 1.68) thereafter, P for interaction < 0.0001).
Conclusions: Elevated WBC is associated with increased mortality even within the
‘normal’ range. Replication of this finding in two independent populations increases con-
fidence in our results.
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9.2 Introduction
Incomplete recording of clinical characteristics or outcomes may create potential biases.
This makes it important to replicate epidemiological findings in other settings. The re-
stricted ethnic diversity of single country studies may limit their generalisability, particu-
larly when investigating traits that vary significantly between ethnic groups.
Reasons for performing international replication or comparison include:
• Replication in cohort with different selection criteria and confounding structure
• Increasing the overall sample size
• Allowing for greater diversity of genotype and ethnicity
• Allowing for differences in geography, development, lifestyle, healthcare system,
education
The analyses in chapters 7 and 8 present novel findings about the associations of
leukocyte counts with the initial presentation of cardiovascular diseases. It is vital that
these findings are replicated in other cohorts in order to verify that they are generalis-
able and can be potentially used to inform changes to clinical practice. This study is a
replication study in a New Zealand cohort which also offers the opportunity to extend
the investigation to different ethnic groups, and increase the overall size of the combined
study.
The English cohort was CALIBER, as used for the previous studies in this thesis and
described in chapter 3. CALIBER patients are predominantly Caucasian, with small pro-
portions of South Asian or Black ethnicities [197] whereas the New Zealand population
contains a sizeable proportion of Ma¯ori, Pacific, and Chinese people [248]. The PREDICT
programme in New Zealand links cardiovascular risk assessments from primary care with
hospital admissions, mortality, dispensed medication and laboratory results [249]. The
data sources and characteristics of the study populations are shown in Table 9.1 on
page 213.
Differential leukocyte counts were not available at the time of this project so we com-
pared associations with total leukocyte count, which is similar to neutrophil count (as
neutrophils are the most numerous leukocytes in peripheral blood) and has similar as-
sociations with other patient characteristics (see Table 7.1 on page 160 and Table 7.2
on page 161). As this was the first collaborative study using PREDICT and CALIBER
we chose all-cause mortality as the endpoint. Investigation of individual cardiovascular
diseases will require harmonisation of disease definitions in the two countries, and will be
the subject of future work.
Previous studies have suggested that higher total white cell count is associated with
higher all-cause mortality [250], but there have been few large-scale population-based
studies (Table 9.2 on page 214). Some studies were limited to government employees
and their dependants [109] or survey respondents [114].
This study aimed to replicate associations between total white cell count and all-cause
mortality in two ethnically different populations from England and New Zealand.
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Table 9.1: Comparison of study populations
CALIBER (England) PREDICT (New Zealand)
Data sources
General practice data All coded data and some
anonymised free text available
Cardiovascular risk assessments
Cardiovascular risk factors Opportunistic and incomplete
recording
Complete data at time of
cardiovascular risk assessment
Medication recording Prescribed medication Dispensed medication
Hospital admission data Yes Yes
Death certificate data Coded cause of death Coded and free text cause of death
Acute coronary syndrome
registry
Yes, MINAP Not currently; due to be linked to
ANZACS
Coverage
Coverage of country’s
population
5% of England Cardiovascular risk assessment for
large proportion of North Island,
lab results for Auckland and
Christchurch regions
Number of patients 4.7 million 2 million with lab results, 400,000
with cardiovascular risk
assessment
Follow-up period While registered with GP Until end of recording (PREDICT
cannot trace residency)
Time period GP data from 1990s, hospital data
from 2000, cause of death from
2001, MINAP from 2003
2002 onwards, but poor coverage
of dispensing data before 2005, so
researchers use data from 2005
onwards.
Coding
Primary care diagnoses Read version 2 N/A
Hospital diagnoses WHO ICD-10 ICD-10 Australian modification
Cause of death WHO ICD-10 ICD-10 Australian modification (6th
edition) using WHO rules and
guidelines for mortality coding
Procedures OPCS-4 ICD-10 Australian modification
9.3 Methods
9.3.1 PREDICT study population (New Zealand)
In New Zealand, general practitioners use a standardised web-based tool to assess car-
diovascular risk for primary prevention, and the PREDICT study captures this information
centrally. PREDICT includes commonly measured risk factors for cardiovascular dis-
ease such as smoking status, diabetes, gender, age and systolic blood pressure [255].
Ethnicity was classified into Ma¯ori, Asian (e.g. Indian, Pakistani, Bangladeshi, Chinese,
Vietnamese, Thai), Pacific (e.g. Fijian, Tongan, Samoan), European or ‘Other’, accord-
ing to a standard protocol which prioritises Ma¯ori and minority ethnic groups if more
than one ethnicity is recorded for a person [256]. These records are linked to national
databases of hospital admission data and mortality using an encrypted New Zealand
national health index (NHI). Records were also linked with the NZ Pharmaceutical In-
formation database [8], a register of community dispensing, and Testsafe, a repository
of laboratory test results for the Auckland and Northland region of the North Island of
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Table 9.2: Association of total white cell count and all cause mortality in previous cohort
studies with over 2000 participants
Author, year,
study Population N deaths Adjusted measure of association
Jee, 2005, Korean
Cancer Prevention
Study [109]
438 500 government
employees, teachers,
and their dependants
insured with Korea
Medical Insurance
Corporation
48 757
HR (95% CI) for WBC ≥ 9 vs
< 5× 109/L:
male non-smokers 1.38 (1.22, 1.56)
male smokers 1.14 (1.07, 1.21)
female non-smokers 1.20 (0.94, 1.06)
female smokers 1.26 (1.12, 1.41)
Margolis, 2005,
Women’s Health
Initiative [112]
66 261 women in
observational study 1919
HR 1.52 (95% 1.33, 1.74) for top vs
bottom quartile (P for trend <0.001)
Kabagambe, 2011,
REGARDS [251]
17 845 men and women
in the Reasons for
Geographic and Racial
Differences in Stroke
Study cohort
1062
HR 1.33 (95% CI 1.03, 1.72) for top vs
bottom quartile in Whites (P for trend
= 0.03)
HR 1.13 (95% CI 0.86, 1.50) for top vs
bottom quartile in Blacks (P for trend =
0.55)
Ruggiero, 2007,
Baltimore
Longitudinal Study
of Aging [252]
2803 people recruited
from Baltimore-
Washington, DC
944 HR 1.62 (95% CI 0.92, 2.85) for WBC
> 10 vs 3.5− 6.0× 109/L
Tamakoshi, 2007,
NIPPON
DATA90 [114]
6756 Japanese
residents followed up
from nationwide random
survey
576 RR 1.61 (95% CI 1.07, 2.40) for WBC9− 10× 109/L vs 4− 4.9× 109/L
Shankar, 2007,
Blue Mountains
Eye Study [115]
2904 people with no
prior cardiovascular
disease or cancer
575 RR 1.68 (95% CI 1.35, 2.09) for top vsbottom quartile
De Labry, 1990,
Normative Aging
Study [253]
2011 healthy men in
Boston 183
HR 1.16 (95% CI 1.08, 1.25) per 109/L
higher WBC
Kim, 2013, Korean
elderly cohort [254]
9996 men and women
aged 65 or over 118
HR 1.57 (95% 0.88, 2.80) for top vs
bottom quartile (P for trend <0.073)
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New Zealand [7]. White cell count results were linked to PREDICT information using the
encrypted NHI.
This study includes patients assessed between 1 July 2005 and 24 July 2012, as full
dispensing, laboratory and outcome data were available for this period. Testsafe contains
community and hospital laboratory results from July 2006 onwards; prior to this date only
hospital test results were available from this source, or community tests which were also
copied to hospital services. The PREDICT project was approved by the national Multi
Region Ethics Committee in 2007 (MEC/07/19/EXP).
9.3.2 Inclusion and exclusion criteria
The CALIBER study population was similar to that used for the studies of differential
leukocyte count (section 6.4) but with slightly different inclusion criteria to align with the
PREDICT study population.
This study included patients aged 30 to 75 years with no prior history of cardiovascular
disease and no use of loop diuretics in the previous six months were eligible to enter the
study. In PREDICT, prior cardiovascular disease was ascertained by the cardiovascular
risk assessment questionnaire and hospitalisation records; in CALIBER prior cardiovas-
cular disease was defined as a recorded diagnosis in primary care or hospitalisation data,
or an entry in the acute coronary syndrome registry.
In CALIBER, patients entered the study on the date of the first white cell count mea-
surement after study eligibility. In PREDICT, patients entered the study on the date of the
cardiovascular risk assessment. The most recent measure of total white cell count up to
five years before or two weeks after cardiovascular risk assessment was chosen. If no
white cell count was available during this period, it was considered missing.
9.3.3 Outcomes
The primary outcome of the study was all-cause mortality. Patients who had died were
identified by linkage to the relevant national death registry, with follow-up in New Zealand
until 26 July 2012 and in CALIBER until 25 March 2010.
9.3.4 Other covariates
Cardiovascular risk factor information such as smoking status, blood pressure and total:
high density lipoprotein (HDL) cholesterol ratio were collected in PREDICT as part of the
cardiovascular risk assessment and were largely complete, as general practitioners are
required to enter all the data to receive a cardiovascular risk prediction. In CALIBER
smoking status (current smoker or non-smoker, to match the PREDICT categories) was
derived using primary care records prior to study entry, and for continuous risk factors
(blood pressure, total cholesterol and HDL cholesterol) the most recent value up to 1
year prior to study entry was used.
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Diabetes status was assessed in CALIBER by a diagnosis of diabetes recorded prior to
study entry in primary care or in a hospital admission (subsection 5.4.2). In PREDICT, pa-
tients were considered to have diabetes at baseline if their general practitioner recorded
that they were diabetic in their cardiovascular risk assessment, or if they had been dis-
pensed an oral hypoglycaemic agent or insulin in the six months before assessment, or
if they had been hospitalised with a primary diagnosis of diabetes within the previous five
years.
9.3.5 Statistical analysis
Analyses were performed on CALIBER and PREDICT data separately using a similar
protocol, as we did not have permissions to combine data from the two countries in a
single location and analyse them together. We shared R code to ensure that the anal-
yses were as similar as possible in the two countries, although some differences were
necessary because of differences in the available data.
The primary analysis used a Cox regression model with time-to-death from baseline
enrolment as the outcome. Individuals were considered censored if they reached the end
of the study period alive (PREDICT) or transferred out of the practice (CALIBER). The
total white cell counts were grouped into quintiles, based on the observed distribution of
total white cell count in the CALIBER data. As in the previous two chapters, all category
intervals were closed at the lower end and open at the higher end.
The proportional hazards assumption was assessed by plotting the scaled Schoenfeld
residuals against log time [257]. If the hazard ratio varied over time, the follow-up time
was split into two intervals. Survival models included the following cardiovascular risk
factors, chosen a priori : age, sex, total: HDL cholesterol ratio, systolic blood pressure,
diabetes status, and current smoking status. All analyses were done using R software
(version 3.0.2) [157], using the survival [258] and rms [259] packages for Cox regression.
Missing covariate data was handled using multiple imputation, with 10 multiply imputed
datasets as described below. Secondary analyses included assessment for interactions
with age group, sex and ethnicity, which were carried out in CALIBER only as it was the
larger of the two datasets.
The main analysis used a Cox proportional hazards approach to model the association
between white cell count quintiles and time to death, adjusting for the following cardio-
vascular risk factors, chosen a priori: age, sex, total:HDL cholesterol ratio, systolic blood
pressure, ethnicity, diabetes status, and current smoking status. Quintiles were based on
the CALIBER dataset as it was larger than PREDICT. For CALIBER analyses I stratified
the baseline hazard of the Cox model by general practice.
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9.3.6 Multiple imputation
PREDICT
The baseline population in PREDICT consisted of all individuals undergoing cardiovascu-
lar risk assessment in primary care. Cardiovascular risk factors were almost completely
observed but about 30% of people did not have a record of total white cell count. As indi-
viduals with a record of white cell count measured would be a (possibly biased) sample,
we carried out analyses both limited to those with a white cell count measurement and
among the entire baseline population, using multiple imputation to handle missing values.
Predictive mean matching for multiple imputation was implemented by aRegImpute
in the Hmisc package [260]. This function uses predictive mean matching with flexible
additive models, and transforms continuous predictors using restricted cubic splines with
3 knots. Imputation models included all the variables in the substantive model, event
indicator and time in the form of the marginal Nelson-Aalen cumulative hazard [193].
Analyses of 10 imputed datasets were combined using Rubin’s rules [261]. White cell
count quintiles were imputed directly (instead of imputing actual white cell count) in order
to avoid imposing linearity on the association between white cell count and any of the
predictors.
CALIBER
In CALIBER, the cohort consisted of individuals with a white cell count record and no prior
history of cardiovascular disease, whether or not they had had a formal cardiovascular
disease assessment. Total white cell count data was therefore completely observed but
some people did not have records of other baseline covariates: total cholesterol, HDL
cholesterol, blood pressure or smoking status. I wished to examine for interactions be-
tween total white cell count and predictor variables in their association with mortality, so
I chose a method of multiple imputation which would account for these interactions. For
the primary analysis I used multiple imputation using chained equations (MICE) [187]
with Random Forest multiple imputation [147], as described in section 4.4.
As Random Forest multiple imputation can be slow on very large datasets, I carried
out the imputation within general practice, thus also accounting for between-practice vari-
ability. I also performed a secondary analysis using normal-based multiple imputation
in MICE. With normal-based MICE I included the general practice as a fixed effect (i.e.
a categorical variable) and carried out the imputation separately by age group and sex,
which accounted for interactions between these variables without requiring too many ad-
ditional parameters in the imputation models.
Imputation models included all the variables in the substantive model, event indica-
tor and time in the form of the marginal Nelson-Aalen cumulative hazard, as well as
the following auxiliary variables: counts of white cell subtypes (neutrophils, basophils,
eosinophils, monocytes and lymphocytes), renal function (estimated glomerular filtration
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Figure 9.1: Patient flow diagrams for CALIBER and PREDICT studies
CALIBER (England) PREDICT (New Zealand)
2 134 615 individuals aged >30
registered with a participating
general practice for at least 1 year
194 513 individuals aged 30-75 with
cardiovascular risk assessment in
primary care and no prior
cardiovascular disease (CVD)
Included in main analysis
1 161 449 individuals
with no white cell
count excluded
760 658 individuals with no
prior CVD and not pregnant
973 166 individuals
with a white cell
count record
Included in complete
case analysis
139 030 individuals with
white cell count record
55 483 individuals with
no white cell count
Multiple imputation of
white cell count
Included in main analysis
686 475 patients aged 30-75
in main study
Multiple imputation of
baseline covariates
212 508 individuals
with pregnancy or
prior CVD excluded
74 183 individuals
outside age range
excluded
rate), and diastolic blood pressure. I used 10 iterations and generated 10 imputations.
I verified that the number of iterations was sufficient by inspecting plots of chain means
and variances. I combined the results of analysis using Rubin’s rules.
9.4 Results
The number of individuals analysed was 686 475 in CALIBER and 194 513 in PREDICT
(Table 9.3 on page 219). The median age was 50 years in CALIBER and 55 in PREDICT,
and 58% were men. The majority of patients in CALIBER were white (92% of those with
ethnicity recorded, 383 428 out of 416 828) but in PREDICT just over half were European
(104 000 / 194 513, 53%), and significant proportions of individuals belonged to Asian,
Indian, Pacific or Ma¯ori ethnic groups. In PREDICT 139 030 individuals (71%) had at
least one white cell count recorded, and 77% (107 063 / 109 874) of these records were
taken within one year before or two weeks after risk assessment. All patients in CALIBER
had record of a white cell count (as it was one of the inclusion criteria) (Table 9.3 on page
219).
Lower white cell count was associated with Asian or European ethnicity in PREDICT
and Black ethnicity in CALIBER, whereas higher white cell count was associated with
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9.4. Results
Figure 9.2: Unadjusted Kaplan Meier curves for all cause mortality by total white cell
count, in CALIBER and PREDICT
Curves shown for top, middle and bottom quintiles.
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South Asian ethnicity in CALIBER, and Ma¯ori or Pacific ethnicity in PREDICT. Higher
white cell count was associated with current smoking, diabetes and higher total: HDL
cholesterol ratio (Table 9.4 on page 220).
Median follow-up was 2.2 years in PREDICT and 4.0 years in CALIBER. The total
number of deaths was 2230 in PREDICT and 19 597 in CALIBER. Crude Kaplan Meier
curves showed a greater cumulative incidence of mortality in the highest white cell count
quintile (≥ 8.65 ×109/L) in both populations (Figure 9.2 on page 221). In CALIBER,
the gradient of this curve was steepest immediately after study entry, suggesting that the
association between white cell count and mortality was particularly strong in the first few
months.
Hazard ratios estimated from Cox models showed a J-shaped association between
white cell count and mortality, with the second quintile (5.35 to 6.25 ×109/L) associated
with the lowest risk. The strength of the association was slightly attenuated by adjust-
ment for cardiovascular risk factors (Figure 9.3 on page 222). High white cell count was
associated with particularly increased risk of mortality: the multiply adjusted hazard ratio
comparing the highest and middle quintiles (≥ 8.65 ×109/L vs. 6.25 to 7.25 ×109/L) was
1.90 (95% CI 1.82, 1.99) in CALIBER and 1.53 (95% CI 1.31, 1.79) in PREDICT (Figure
9.4 on page 222). However, the hazard ratio decreased with time as shown by the plot
of scaled Schoenfeld residuals (Figure 9.5 on page 223, p < 0.0001 for correlation with
log time). Splitting the follow-up time by 6 months after the full blood count measurement
in CALIBER produced an adjusted hazard ratio of 4.12 (95% CI 3.69, 4.60) for the first
6 months and 1.60 (95% CI 1.53, 1.68) for the subsequent time period (Figure 9.4 on
page 222), with no evidence of statistically significant non-proportionality of hazards after
6 months. A similar pattern was observed in PREDICT, but with a less extreme difference
in hazard ratios between the time periods.
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Figure 9.3: Hazard ratios for all cause mortality by quintile of total white cell count in
CALIBER and PREDICT
‘Multiple adjustment’ comprises adjustment for age, sex, total:HDL cholesterol ratio, systolic blood pressure,
ethnicity, diabetes and smoking. P values *** <0.001, ** <0.01, * <0.05
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0.97 (0.93, 1.02)
1.06 (0.88, 1.27)
0.84 (0.80, 0.89) ***
0.92 (0.76, 1.13)
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1 (reference)
1.27 (1.22, 1.33) ***
1.26 (1.05, 1.52) *
2.21 (2.12, 2.30) ***
1.77 (1.51, 2.07) ***
Multiple adjustment
0.5 1 2 4
Hazard ratio
Hazard ratio
(95% CI)
1.02 (0.97, 1.07)
1.15 (0.96, 1.39)
0.87 (0.83, 0.92) ***
0.97 (0.79, 1.18)
1 (reference)
1 (reference)
1.20 (1.14, 1.25) ***
1.20 (1.00, 1.43)
1.90 (1.82, 1.99) ***
1.53 (1.31, 1.79) ***
Figure 9.4: Hazard ratios for all cause mortality by quintile of total white cell count, by
time period in CALIBER and PREDICT
Hazard ratios were adjusted for age, sex, total:HDL cholesterol ratio, systolic blood pressure, ethnicity, dia-
betes and smoking. P values *** <0.001, ** <0.01, * <0.05
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0.84 (0.52, 1.37)
1 (reference)
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1.40 (1.23, 1.60) ***
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4.12 (3.69, 4.60) ***
2.67 (1.82, 3.92) ***
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1.01 (0.96, 1.06)
1.11 (0.92, 1.35)
0.88 (0.84, 0.93) ***
0.93 (0.76, 1.12)
1 (reference)
1 (reference)
1.17 (1.11, 1.23) ***
1.21 (1.02, 1.44) *
1.60 (1.53, 1.68) ***
1.49 (1.27, 1.76) ***
P value for
interaction
0.3
0.69
0.17
0.73
0.0084
0.95
<0.0001
0.0059
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Figure 9.5: Scaled Schoenfeld residuals for multiply adjusted hazard ratio for mortality
comparing quintiles of total white cell count in CALIBER
Hazard ratios were adjusted for age, sex, total:HDL cholesterol ratio, systolic blood pressure, ethnicity, dia-
betes and smoking, and use the middle quintile as the reference category. The lines show the estimate and
95% confidence interval for the beta coefficient. The top left corner of each graph contains ρ, χ2 and p value
for the correlation between log survival time and scaled Schoenfeld residuals. For clarity, points plotted on
the graph are for a random sample of 20 000 patients. The middle quintile was the reference category.
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Figure 9.6: Hazard ratios for all cause mortality by quintile of total white cell count, by
ethnicity in CALIBER
Hazard ratios were adjusted for age, sex, total:HDL cholesterol ratio, systolic blood pressure, ethnicity, dia-
betes and smoking. P values *** <0.001, ** <0.01, * <0.05
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(95% CI)
1.02 (0.97, 1.07)
0.71 (0.45, 1.13)
1.05 (0.63, 1.74)
1.22 (0.76, 1.97)
0.87 (0.83, 0.92) ***
0.90 (0.54, 1.47)
0.99 (0.61, 1.60)
0.96 (0.57, 1.62)
1 (reference)
1.20 (1.14, 1.25) ***
1.11 (0.59, 2.09)
0.93 (0.58, 1.49)
1.47 (0.88, 2.45)
1.90 (1.82, 1.98) ***
1.91 (1.17, 3.12) **
1.70 (1.13, 2.57) *
2.36 (1.58, 3.53) ***
P value for interaction
(White as reference)
0.13
0.92
0.46
0.91
0.6
0.7
0.82
0.29
0.43
0.98
0.6
0.29
There were no statistically significant interactions with ethnicity (Figure 9.6 on page
224) or sex (Figure 9.7 on page 225), although the proportion of ethnic minorities was
low, which limits the power of the interaction test with ethnicity. There were statistically
significant interactions with age; in the youngest age group (individuals aged 30–45), the
lowest quintile of white cell count was associated with increased risk of mortality (adjusted
hazard ratio 1.33 for comparison with middle quintile, 95% CI 1.14, 1.54) but there was
no significant association for older age groups. Conversely, the association between the
highest quintile of white cell count and mortality was weaker in the youngest age group
(p = 0.0015 for comparison with 45–60) (Figure 9.8 on page 225).
Complete case analysis of PREDICT data yielded similar estimates to the main im-
puted analysis (Figure 9.9 on page 226). The two methods of multiple imputation used
in CALIBER data (normal-based and Random Forest MICE) yielded almost identical es-
timates (Figure 9.10 on page 226).
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Figure 9.7: Hazard ratios for all cause mortality by quintile of total white cell count, by sex
in CALIBER
Hazard ratios were adjusted for age, sex, total:HDL cholesterol ratio, systolic blood pressure, ethnicity, dia-
betes and smoking. P values *** <0.001, ** <0.01, * <0.05
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1.00 (0.94, 1.07)
0.87 (0.81, 0.94) ***
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0.46
1.00
0.56
0.11
Figure 9.8: Hazard ratios for all cause mortality by quintile of total white cell count, by age
group in CALIBER
Hazard ratios were adjusted for age, sex, total:HDL cholesterol ratio, systolic blood pressure, ethnicity, dia-
betes and smoking. P values *** <0.001, ** <0.01, * <0.05
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1.33 (1.14, 1.54) ***
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0.97 (0.91, 1.03)
0.97 (0.82, 1.15)
0.84 (0.77, 0.92) ***
0.88 (0.82, 0.93) ***
1 (reference)
1.14 (0.98, 1.33)
1.20 (1.10, 1.30) ***
1.20 (1.14, 1.27) ***
1.40 (1.21, 1.62) ***
1.83 (1.69, 1.98) ***
2.03 (1.93, 2.15) ***
P value for interaction
(45−60 as reference)
0.0036
0.37
0.14
0.46
0.6
0.94
0.0015
0.028
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Figure 9.9: Hazard ratios for all cause mortality by quintile of total white cell count for
complete case analysis in PREDICT
Hazard ratios were adjusted for age, sex, total:HDL cholesterol ratio, systolic blood pressure, ethnicity, dia-
betes and smoking. P values *** <0.001, ** <0.01, * <0.05
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Multiple adjustment
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Hazard ratio
Hazard ratio
(95% CI)
1.09 (0.92, 1.30)
0.91 (0.76, 1.09)
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1.21 (1.03, 1.42) *
1.64 (1.41, 1.90) ***
Figure 9.10: Multiply adjusted hazard ratios for all cause mortality by quintile of total white
cell count, by method of multiple imputation in CALIBER
Hazard ratios were adjusted for age, sex, total:HDL cholesterol ratio, systolic blood pressure, ethnicity, dia-
betes and smoking. P values *** <0.001, ** <0.01, * <0.05
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1.88 (1.80, 1.96) ***
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Hazard ratio
Hazard ratio
(95% CI)
1.02 (0.97, 1.07)
0.87 (0.83, 0.92) ***
1 (reference)
1.20 (1.14, 1.25) ***
1.90 (1.82, 1.99) ***
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9.5 Discussion
Total leukocyte count had a J-shaped relationship with all-cause mortality in two cohorts
in different countries. Individuals in the second quintile of white cell count (5.35 to 6.25
×109/L) had the lowest mortality risk, and those in the highest quintile had the highest
risk (Figure 9.3 on page 222). Mortality risk was increased at ’high normal’ levels of
total white cell count below the upper limit of laboratory reference ranges. The validity of
these findings are increased by the fact that they were observed in two populations with
different ethnic compositions looked after by different healthcare systems. This was the
first collaborative study between the CALIBER programme in England and PREDICT in
New Zealand, and paves the way for future studies to improve electronic health record
research by international collaboration.
The strength of the association between white cell count and mortality was strongest
close to the time of white cell count measurement, suggesting that it reflects the patient’s
acute medical state. However, there was a significant but weaker association which per-
sisted for several years after measurement, suggesting that the white cell count is also a
useful long-term prognostic marker (Figure 9.4 on page 222).
These findings corroborate previous studies which have found an association between
total white cell count and mortality or cardiovascular events [253, 262, 263]. Total white
cell count is a marker of inflammation, and there are a number of putative biological
mechanisms which may explain the inflammation. One potential source is periodontitis
[264], which is linked to higher white cell count [265,266]. Cigarette smoking and diabetes
are both associated with higher white cell count and dental disease [267, 268]. The
increased risk of mortality observed in the lowest quintile of may be because of frailty
or malnutrition, which were not recorded in our dataset.
The main strengths of this study were the fact that two cohorts were available in differ-
ent countries. Both cohorts were large and population based, avoiding the selection bias
inherent in many bespoke cohorts with low response rates. The studies differed in the
method of patient selection and timing of white cell count measurement relative to study
entry. In CALIBER the study population consisted of all patients undergoing a full blood
count; this meant there was no missing white cell count data but some covariate data
were missing. In PREDICT the study population consisted of all individuals undergoing
cardiovascular risk assessment in primary care, with complete recording of cardiovascu-
lar risk factors.
9.5.1 Limitations
A limitation of both studies is that white cell count was measured only when it was thought
to be clinically necessary, so the probability that a patient has a white cell count depends
on a range of factors such as the patient’s health-seeking behaviour and the doctor’s
tolerance of uncertainty or propensity to investigate a patient, as well as the patient’s
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clinical condition. Replication of this study in a bespoke investigator-led cohort such as
UK Biobank [169] would address these issues.
Other weaknesses of the study relate to the variation in time from recording of white
cell count to cardiovascular assessment (in PREDICT), and the amount of missing data.
Complete case analysis assumes there is no selection bias caused by the removal of pa-
tients with incomplete records. Multiple imputation relies on the missingness mechanism
being Missing at Random, i.e. whether a value is missing is independent of the value
itself conditional on all observed covariates [187, 193]. However, analyses in the two co-
horts (with different types of information missing) and analyses using different methods
for handling missing data yielded similar results.
Finally, as this is an observational study it is can be used to demonstrate association
but not causation. It is possible, though unlikely, that residual confounding may account
for the association observed between total white cell count and mortality.
9.5.2 Conclusions
This collaborative study yielded similar results in cohorts based on routine electronic
health records in England and New Zealand. In both countries total white cell count had
a ‘J’-shaped relationship with overall mortality, with similar hazard ratios. Replication of
studies in different countries can be challenging but also extremely useful for generalising
study results to a wider population.
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The Discussion of this thesis is divided into two sections. Firstly, I discuss the use of
electronic health record databases for research, and how national initiatives such as the
Farr Institute can facilitate their use for patient benefit. Secondly, I discuss the clinical and
research implications of the association of differential leukocyte counts with incidence of
cardiovascular diseases, and what lessons can be learned for similar studies investigating
biomarkers in electronic health records.
10.1 Using large electronic health record databases for research
10.1.1 Using linked general practice records for research
The work in this thesis illustrates the process of preparing raw structured clinical data for
statistical analysis. Patient data are increasingly being collected electronically worldwide
[269], creating a rich resource for research, but there is much work involved in creating a
research-ready dataset from clinical data.
A primary hurdle is the gathering of data from multiple sources. For the work in this
thesis I benefited from the resource built up by the Clinical Practice Research Datalink
(CPRD), which has been collecting pseudonymised research data from general practices
for many years [4]. Individual hospitals can have hundreds of incompatible information
systems, but over 90% of general practices in England use one of 3 clinical software sys-
tems [132]. All these general practice systems share a terminology system for recording
medical information, the Read codes [136]. The completeness and quality of information
recorded in GP systems has been improving over time, and most practices are now pa-
perless. A key advantage of general practice databases over other clinical data sources
for research is that healthy people are registered with a general practice, providing a
meaningful follow-up period and denominator for the calculation of incidence and preva-
lence (although prison, army and homeless populations are not included).
There are a number of limitations to the general practice data in CPRD which I encoun-
tered, some of which may be overcome with new initiatives.
Population coverage The current coverage of CPRD is 6.9% of the population of the
UK [129]. While this has been adequate for many studies on disease epidemiology when
used alone or linked to national datasets (such as CALIBER), it is of limited use when
linking to detailed datasets which do not cover the entire population, such as UK Biobank
[169] or local hospital datasets. In such cases the overlap between CPRD and the second
data source may be too small to be useful. The incomplete coverage of CPRD also means
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it is impossible to use it to calculate estimates of morbidity for small areas, which would
be immensely useful for local healthcare planning and service evaluation.
There are other projects which collect primary care data from all general practices,
including the National Diabetes Audit [11], but only a limited subset of information is ex-
tracted. There are other research databases in the UK (QResearch, www.qresearch.org
and ResearchOne, www.researchone.org) which collect data from other GP systems,
and if used in combination with CPRD they could significantly increase coverage. For an
individual researcher it is prohibitively expensive and time-consuming to seek access to
multiple primary care datasets when a single dataset suffices for most projects, and there
is no unified portal or access scheme. Studies that have used more than one general
practice database have generally done so only for the purpose of validation of risk pre-
diction algorithms [270]. Wider collaborations may need higher level facilitation, such as
Public Health England’s Burden of Disease project or the Farr Institute. In the longer term,
national projects such as the care.data programme www.hscic.gov.uk/gpes/caredata
will compile a single uniform dataset from all general practices for audit and research.
Recommendation:
• Improve the population coverage of general practice databases.
The Read terminology. Read codes have the advantage that they are used throughout
general practice and convey much of the meaning of clinical entries without requiring a
detailed information model. However, the Read terminology does have limitations which
need to be taken into account in interpreting the data [136]. Read codes were devel-
oped for clinical use to enable information to be stored more efficiently; therefore they
encode clinical statements that a general practitioner might want to record, but unlike
ICD-10 they are not strictly hierarchical (there are broad chapters but many terms are in
unordered lists) and there are many synonymous terms giving a wide variety of ways that
the same diagnosis can be coded. There is no consistent way to record relationships
between terms, or qualifiers such as laterality or negation. Read will be superseded by
SNOMED-CT (a combination of Read Clinical Terms Version 3 and SNOMED) but this
change in terminology system will not, on its own, solve this problem [271]. SNOMED-
CT contains far too many terms to be used for data entry as is; it is often better to use
information models to store contextual information (as described in section 10.1.2) rather
than construct complicated multi-part codes.
A suggested solution is to develop and curate subsets of the terminology in use (e.g.
SNOMED-CT in the NHS, possibly others such as ICD-11 or ICD-10-CM elsewhere).
These subsets should be developed for particular clinical use cases in different settings,
such as in general practice or a cancer multidisciplinary team meeting, and curated by the
relevant professional group. This will facilitate data entry at the point of care. In parallel,
information models (archetypes), as described later (section 10.1.2), should be devel-
oped by clinical groups in order to standardise data collection for clinical care, research
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and audit across healthcare sites and clinical systems.
Recommendations:
• Develop terminology subsets for data entry in different situations.
• Develop better user interfaces (possibly with real-time natural language process-
ing) to encourage appropriate coding.
Lack of secondary care linkages. Secondary care records (e.g. hospital inpatient,
outpatient, and mental health records) contain rich information on diseases and inves-
tigations which is not captured in administrative sources or disease registries, but this
has not yet been linked to primary care for research purposes; even for clinical care
the integration between GP and hospital data is operational in only a few sites. Lack
of standardisation of data formats in different hospitals is one of the problems, and can
only be addressed in the long term by using open information models such as openEHR
archetypes [272].
Recommendations:
• Develop hospital research databases linked to primary care.
• Encourage standardisation of secondary care information systems.
Information models used in general practice systems. CPRD primarily records clin-
ical ‘events’ such as diagnoses, prescriptions or laboratory results. Although this is suited
to events related to a single time point, such as tests or prescriptions, it is unclear how
chronic conditions should be recorded; there is no structured way for representing onset,
duration or exacerbations. A problem-orientated medical record, in which problems or di-
agnoses are recorded once in a specific part of the record, may help, as long as doctors
use the system in the way it is intended. Event-based records in CPRD are sometimes
misused by repeatedly recording a diagnosis for a consultation related to that diagnosis
(e.g. myocardial infarction).
Although clinical terminologies are standardised, the information models (archetypes)
which describe how data elements are organised to describe clinical entities, are cre-
ated ad hoc by system manufacturers. The openEHR programme seeks to standardise
information models used in electronic health record systems in order to facilitate interop-
erability and ensure the integrity of patient data [272]. Clinical professional groups should
be closely involved in specifying the information structures for storing clinical information
in their domain (see section 10.1.2).
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Recommendation:
• Clinical professional groups should be involved in specifying information struc-
tures for storing clinical information in their domain.
Lack of free text in primary care research databases. Much of the electronic informa-
tion in healthcare records is stored as free text rather than in a structured form [273], and
is difficult to access for research. There has been intense interest in developing computer
algorithms to extract coded information from free text [274]. Natural language processing
can be used to classify patients [275] or assign diagnostic codes [276], but the results
are not reliable enough to be used in clinical practice. Ideally, real-time natural language
processing could be used to assist data entry by clinicians, as recommended in the NHS
Common User Interface guidelines [277]. This would allow clinicians to select appropriate
diagnosis codes without having to be intimately familiar with the terminology. The codes
can be verified by the clinician at the point of data entry, improving the accuracy of the
records. There are a few examples of such systems (e.g. http://clinithink.com/), but
they are not yet in general use.
There is a potential risk of identifying patients in research databases if names and
addresses are included in the free text. Free text is collected by CPRD but not routinely
made available to researchers (except in limited quantities after anonymisation), and is
not collected by other primary care research databases. Natural language processing
tools may be able to tap into this resource, extracting useful information for research from
large databases without compromising patient confidentiality [276].
However, it is possible that CPRD may not be permitted to collect free text at all in
the future. If this occurs it will limit the potential for using free text for case validation or
extracting further information about clinical events in general practice databases.
Potential solutions:
• Individual patient consent for free text data extraction – this may be possible for
disease cohorts or with concerted effort in a small set of practices.
• Encode as much data as possible, using software that facilitates coding at the
point of data entry.
• Provide a mechanism for natural language processing to take place on the raw
patient records with only anonymised data (extracted codes) being extracted for
the research database. This would require liaison with the GP system supplier.
Patients moving between practices. As patient data in CPRD were pseudonymised
at the practice level, individuals would not be recognised as being the same person if they
subsequently re-registered at another practice. At the current level of coverage of CPRD
(6.9%) this is not too much of a problem, but if research is performed using much larger
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proportions of the population, it will be important to ensure that patients are not double
counted.
Recommendation:
• Link patients between healthcare providers to compile a longitudinal view in re-
search databases.
Documentation of the process of data generation. Conversion of raw clinical data
to a research-ready format requires knowledge of the clinical domain as well as the
health system and health informatics. It is essential to understand what information is
unlikely to be captured as well as what is recorded. The phenotyping process used by
the CALIBER group [179] brings these disciplines together along with an exploration of
the data. Publication of phenotyping algorithms will help to make research more efficient,
by reducing duplication of effort, and will hopefully improve the quality of research. If
researchers are able to explore the user interface of electronic health record systems
used in practice, it may help them understand why information is captured in a certain
way. Although CALIBER has its own data portal for publication of phenotyping algorithms
(https://caliberresearch.org/portal), a more general repository of variable defini-
tions and methods for a range of healthcare datasets would be desirable.
Recommendation:
• The Farr should set up a repository of variable definitions and methods for repro-
ducible EHR research.
Problems with data linkage. When performing research using identifiable clinical data
(without explicit patient consent), specific approval from the Confidentiality Advisory
Group of the Health Research Authority [144] is required, and researchers must show
that it is not practical to seek consent. Identifiable data should be used for the specific
parts of the project for which pseudonymised data would not be sufficient. This com-
monly means that identifiers are used for linkage but are then removed and replaced by
pseudo-identifiers for analysis.
A potential solution which does not involve extraction of identifiers from the original data
location is to run pseudonymisation software separately in the two datasets to be linked,
using an encryption algorithm with a study-specific key (‘salt’) which is accessible to a
minimum number of people or stored within an encryption service, and is not provided
to researchers using the linked data. Examples of pseudonymisation software include
OpenPseudonymiser (www.openpseudonymiser.org). This approach may be suitable if
both datasets have strong identifiers (e.g. different databases within a single hospital
trust) but there is no possibility to detect or quantify the quality of links or linkage error.
The linkage in CALIBER was deterministic with CPRD as the denominator population
and other datasets providing additional information (for example, deaths are recorded
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in CPRD but the death registry provides additional information such as a more precise
date of death and the cause of death; see subsection 3.4.1). When using linked datasets
without a denominator, and existence of a patient in a particular dataset is itself of interest,
mismatches and missed matches can be more of a problem. If the probability of a match
varies by the factor under investigation this can bias the results; for example in a study
comparing ethnic groups, Hispanic people were less likely to be matched by name than
White people [17].
The datasets used in CALIBER have a strong identifier, the NHS number, but linkage
to other health and social care datasets may have to use probabilistic methods because
a unique identifier is not available. This is particularly the case for research involving
marginalised or migrant groups.
Recommendation:
• The Farr Institute should develop best practice guidance for data linkage and han-
dling uncertainty in the linkage process.
10.1.2 Improving health record design to facilitate research
Developments in electronic health record systems should seek to improve the quality of
information entered (by having an intuitive user interface which makes it easy to enter
data correctly) and make it easy to share and extract information (using standardised
information models).
Although the terminologies in clinical use (e.g. ICD-10, Read) are standardised, they
can be difficult to use in practice without being narrowed down to a small subset for
a clinical use case, or without intelligent user interfaces which suggest the appropriate
term to the user. Terms require additional data elements to convey clinical information in
full, such as whether a diagnosis is confirmed or suspected. No structured information
system can represent all the nuances of meaning so there will always be a need for
unstructured free text to convey clinical narrative faithfully.
Even for information that is intrinsically structured, such as clinical measurements or
scores, the format of the information can vary between information systems. For example,
a blood pressure can be recorded as text (e.g. ‘120/76’), a sequence of two numbers,
or two numbers with labels such as ‘Systolic’ and ‘Diastolic’, or ‘SYS’ and ‘DIA’. The
myriad of ways of recording even a simple clinical measurement such as blood pressure
makes it difficult to share health records or to extract usable research data from multiple
incompatible EHR systems. The costs of data migration are huge, and loss of information
or incorrect translation can be harmful to patient care.
This situation has arisen because the way clinical information is recorded in EHR sys-
tems is determined largely by the system vendor. These information models are not
developed in an open and transparent way and may have little clinical input. In the cur-
rent situation it may be too expensive, difficult and disruptive for a healthcare provider to
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switch from an inadequate EHR system (‘vendor lock-in’).
There are a number of initiatives to try to resolve this problem [278]. One key area of
work is in healthcare information standards; there are now commonly used standards for
the structure of electronic clinical documents and inter-system messages such as Health
Level 7 (HL7) versions 2 and 3, HL7 Clinical Document Architecture and Fast Healthcare
Interoperable Resources (www.hl7.org.uk). However, although these standards dictate
the format of the document (e.g. how a laboratory request message should be organ-
ised), they do not specify how the clinical information within the document is structured.
Standardised documents containing non-standardised clinical information are a slight im-
provement but still present significant barriers to interoperability.
Therefore clinically-led standardised information models for EHR are essential. Open-
EHR ‘archetypes’ fulfil this role, and are described in the next section [279].
Archetypes
Archetypes are ‘re-usable formal models of a domain concept’ [278], or formal ways of
representing an information model, which can make it easier for clinicians and system de-
velopers to understand the information how the data need to be organised [279] (Figure
10.2 on page 237). For example, an archetype for blood pressure contains data ele-
ments for systolic and diastolic pressures (with units and allowable minima and maxima),
body site, patient position and device details (see Figure 10.1 on page 236). Not all of
these data elements need to be used in a particular instance, but because all these extra
elements exist in the archetype, they will be clearly defined if they are used in the future.
OpenEHR archetypes contain certain administrative data elements by default, such as
the time and date, and identity of the healthcare provider entering the data. This means
that archetype designers can focus on the clinical information rather than the administra-
tive overhead.
The advantage of recording blood pressure using an archetype is that blood pressure
readings can easily be retrieved in the future, whether from ward observations, admission
clerkings or clinic notes.
The CPRD uses information models called ‘entity types’. These fulfil the function of
archetypes but are specific to the GP system Vision, and would have to be mapped
individually if records are to be combined between clinical system. If all GP systems use
archetypes, the information can be easily retrieved and combined. It also becomes much
easier to compile a research database.
By separating the user application from the information model and the physical
database, the openEHR archetype model permits EHR systems to be developed in a
more flexible way and reduces vendor lock-in. This should improve the quality of health-
care information systems and enable more efficient care, as well as providing better data
for answering research questions [279]. It should also give more power to clinicians to
shape the data structures of EHR systems so that they faithfully represent cinical prac-
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Figure 10.1: Mindmap of the openEHR blood pressure archetype
OpenEHR blood pressure archetype, openEHR-EHR-OBSERVATION.blood_pressure.v1
http://openehr.org/ckm/
tice and facilitate audit and research, as suggested in the schematic Figure 10.2 on page
237.
10.1.3 Data science
The work in this thesis involved the development of ‘big data’ approaches to EHR. The
open source statistical package R has a well-documented application programming in-
terface and packaging system, so it is possible for individuals to contribute packages to
perform functions that are not well supported in base R. Packages that fulfil strict require-
ments (such as my CALIBERrfimpute package [147]) can be published on the Compre-
hensive R Archive Network http://cran.r-project.org/.
EHR research should seek to emulate the wide range of tools and methods published
in bioinformatics. The Farr can use its position as the institute leading EHR research in
the UK to set up a methods repository for EHR research. This will enable researchers to
share their methods in a way that ensures they receive appropriate credit, and that their
methods can be readily reused.
Throughout the work described in this thesis I sought to apply good software engineer-
ing practices to data management and analysis programs, to yield re-usable methods and
ensure that analyses could be replicated. I used the Git version control system [280] to
require me to document changes to my code, and allow me to revert to a previous version
at any time, even when the program code is distributed among multiple files. For functions
that were frequently used, I formally documented and packaged them into R packages,
as described in section 4.3. This required an initial investment of time in making the meth-
ods generally applicable, and in testing them with data in different formats. However, it
made subsequent work much quicker, and particularly facilitated rapid exploration of new
datasets.
Another initiative in reproducible research is to combine documentation and code into
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Figure 10.2: Schematic showing how openEHR archetypes can bridge the gap between
clinical practice and big data
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1. A need to capture certain types of clinical information is established among a clinical community.
For example, this might relate to a new type of investigation being introduced, and it is important to
evaluate how the outcome of the investigation correlates with outcomes.
2. Clinicians and information modellers develop an archetype for the data elements that could be
recorded in this new investigation.
3. The archetype can be reviewed more widely among clinicians and the clinical modelling community,
to make sure that it is unambiguous, well structured and well documented.
4. Templates are limited versions of archetype which include only the data elements required in a par-
ticular setting, and are designed to be easy to convert into data entry forms.
5. Operational templates can be used to create forms and data structures automatically on openEHR
systems.
6. For non-openEHR systems, the template can provide a guide for developers implementing a new data
entry form.
7. A common information model between hospitals allows standardised datasets to be extracted for audit
and research.
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a hybrid document that can carry out an analysis and produce a report. I applied this to
the simulation study in the CALIBERrfimpute package [147]. The vignette contains both
documentation and code, and when it is re-run by the user, a formatted report is gener-
ated with tables and graphs generated from the new data. However, for large analysis
it was essential to split the tasks into several steps in order to save time and be able to
selectively re-run specific parts of the analysis.
Some computing tasks could be very time-consuming, and I tried to take advantage
of the parallel processing capabilities of the CALIBER high performance cluster to per-
form some tasks at the same time, such as multiple imputation of different subsets of the
cohort. Tasks that require the dataset to be considered as a whole, such as fitting statis-
tical models, have generally not been optimised for parallel processing in most statistical
software packages. There is much scope for software development to optimise statistical
methods for large datasets.
10.1.4 Machine learning
‘Machine learning’ covers a broad range of techniques which involve a computer program
learning a set of rules from a dataset, and then applying it to new data. This can take the
form of a prediction model, as an alternative to a conventional statistical model. The Ran-
dom Forest algorithm, which I used for my novel multiple imputation method, is a machine
learning method (section 4.4); some investigators have used it instead of Cox models for
modelling survival [281, 282], but this is still uncommon. Machine learning methods can
be good at building predictive models from large complex healthcare datasets with many
data values per patient, whereas conventional statistical models can only include a limited
number of predictor variables.
Machine learning approaches have the disadvantage that the models can be complex
and difficult for humans to understand. Statisticians may be unfamiliar with these meth-
ods, and there is no mathematical theory that can prove how these models will behave,
instead simulation studies are required to learn how the method will perform in different
situations. Machine learning methods may also be computationally intensive, but this
disadvantage is becoming less important as computing power increases.
10.1.5 Validation and replication of studies
It is good practice to replicate epidemiological studies to show that the conclusions ap-
ply more generally, to different populations looked after by different healthcare systems.
There have been few examples of replication of studies in electronic health records from
different countries. This may arise because of the lack of comparable datasets in differ-
ent countries and the requirement for international collaborations. However, international
replication of studies increases the quality and utility of the research.
As it is generally not possible for entire electronic health record datasets to be trans-
ferred between countries, international replication generates additional challenges of en-
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suring that analyses are comparable. Sharing analysis code is essential, and meta-
analysis techniques may be required to combine results from individual analyses. Publi-
cation of phenotypes, dataset descriptions and analysis scripts will facilitate replication of
studies.
In this thesis I was able to carry out a replication study in New Zealand data looking
at a simple outcome (all cause mortality) (chapter 9). Further work will be required to
harmonise the definitions of cardiovascular diseases in England and New Zealand for
more detailed studies (for example the coding systems are different; England uses the
original WHO version of ICD-10 but New Zealand uses the Australian Modification).
10.2 Differential leukocyte count and onset of cardiovascular diseases
I found that counts of different leukocyte subtypes in peripheral blood had widely differ-
ing associations with specific initial presentations of cardiovascular disease. Neutrophil
counts within the normal range had strong monotonic positive associations with myocar-
dial infarction, unheralded coronary death, heart failure, and ventricular arrhythmia / sud-
den cardiac death, but no association with stable or unstable angina. Neutrophil counts
were moderately associated with cerebral infarction but not with intracerebral haemor-
rhage, stable angina or unstable angina. Monocytes showed similar associations with
cardiovascular diseases to neutrophils, but less strong. Low counts of lymphocytes were
associated with increased heart failure, unheralded coronary death and other death (sec-
tion 7.6). Low eosinophil counts were associated with increased short-term incidence
of heart failure, unheralded coronary death and ventricular arrhythmia or sudden cardiac
death (section 8.6).
A recommendation arising from this thesis is that the components of the leukocyte dif-
ferential should be tested in predictive models for cardiovascular diseases [30, 47]. The
total leukocyte count is included in a prognostic model for patients with stable coronary
disease [283], but incorporating components of the differential count may enable more ac-
curate predictions. I investigated leukocyte counts in isolation, but the power of predictive
models may be increased by combining them in various ways. For example, a combina-
tion of high neutrophil count and low lymphocyte count has been found to be a particularly
strong predictor of poor prognosis in many diseases, including cancers [284–286], pul-
monary embolism [287] and heart failure [288].
10.2.1 Utility of biomarkers in electronic health records for research
The differential leukocyte count is one of many commonly performed clinical measure-
ments which can be researched at scale in electronic health record datasets. Leukocyte
counts can be performed for a range of diverse indications, and a strength of electronic
health record datasets over bespoke cohort data collections is the longitudinal record of
all the important clinical events. This allowed the patient state to be classified, addressing
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potential concerns that the predictive value of the leukocyte differential may be affected
by the indication for the test.
Statistical methods used for analysis should allow for variation in the timing of covariate
recording; in this study I used multiple imputation to fill in missing values using measure-
ments outside the desired time window as auxiliary variables, as described in subsec-
tion 7.4.7. This would incorporate the within-person correlation of repeat measurements
but also model changes over time and associations with other variables, and make more
complete use of the available data.
However, studies do need to take into account the population in which the test is per-
formed, and the likely frequency with which it is performed. Selection bias can limit the
generalisability of results from investigating a test that is performed in a limited group of
patients. This would be the case for glucose and HbA1c tests – they are generally only
performed in patients that the GP suspects of having diabetes, and would be unrepresen-
tative of these measurements in the general population. This is less of a problem when
studying a population with pre-existing disease, where the test is routinely recommended
in patients with that condition.
Bespoke cohort studies can overcome this type of selection bias if tests are performed
in all participants. Such studies may also incorporate information that is not collected
clinically, such as genotype information or a comprehensive biomarker assay [169].
However, bespoke studies or surveys with low response rates can be subject to another
source of selection bias – independent factors that each increase the probability of a per-
son’s agreeing to participate will be over-represented in the cohort, and the combination
of such factors will also be over-represented [20]. For example, if diabetic individuals
and older individuals are particularly enthusiastic about entering a research cohort, there
may be a relative deficit of young non-diabetic people in the cohort. If the cohort is used
to make inferences about the general population, it could give a misleading impression
that diabetes is common in young people. This is why, unlike population-based cohorts
such as CALIBER, consented cohorts with low response rates cannot be used to obtain
unbiased estimates of population disease incidence or prevalence [20].
10.2.2 Combining phenotype and genotype information
Large cohorts with detailed genotype and phenotype information will allow new insights
into the causal relevance of epidemiological findings. Mendelian randomisation studies
take advantage of the random association of chromosomes during meiosis, so presence
of an allele associated with a higher level of a biomarker is independent of potential con-
founders. The allele can therefore be used as an instrumental variable to assess whether
higher level of the biomarker is causally related to an outcome, or merely a marker of an
underlying condition [289]. This may be helpful for validation of drug targets. For example,
Mendelian randomisation studies found that CRP is not causally related to cardiovascular
disease [52], so drugs acting on CRP itself may not be clinically useful. CRP is increased
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by interleukin-6, which is thought to be causally relevant [290]. Mendelian randomisa-
tion studies using SNPs for genes associated with neutrophil count [56,237] may help to
determine whether the neutrophil count itself is causal in atherosclerotic disease.
Genetic studies have typically required large consortia to obtain sufficient statistical
power by combining the results of many studies, but large cohorts with genetic information
are now being gathered in the UK, and will hopefully accelerate these studies in the future.
The UK Biobank (500 000 participants with 100 000 SNP assay) and Genomics England
(100 000 whole genome sequences, www.genomicsengland.co.uk) have been set up for
genetic studies from the outset, and there are other large cohorts such as 50 000 blood
donors in the INTERVAL study (a clinical trial of reducing the interval between blood
donations) with long term storage of blood samples and participant consent for genetic
analyses and linkage to EHR [291].
10.2.3 Clinical and research implications
The strong and diverse associations of leukocyte subtypes with initial presentation of
cardiovascular diseases suggests that clinicians should be aware of the significance of
these ‘routine’ tests, and should treat measurements such as the neutrophil count as a
continuous measurement. In the same way as doctors inform patients that reducing salt
in their diet will reduce their blood pressure, they can also say that stopping smoking and
exercising regularly will reduce the inflammation in their body. In clinical trials, smoking
cessation reduced the mean neutrophil count by 1.0× 109/L [239], and moderate regular
exercise (8 kcal per kg body weight per week) reduced the mean neutrophil count by
0.1× 109/L in overweight postmenopausal women [240].
Differential leukocyte counts should be investigated for incorporation into better risk
prediction models and clinical decision support algorithms. If these tools run in the elec-
tronic health record itself, they can make use of rich clinical information in the system, in-
cluding repeated measures (for example, I found that the mean of two neutrophil counts
was more strongly associated with cardiovascular diseases, see Figure 7.9 on page
173). It will likely be more cost-effective to make better use of existing information in the
patient record than to carry out additional testing for a novel biomarker.
This thesis provides evidence for the importance of inflammation in the development
of atherosclerotic diseases, and therefore the importance of public health measures to
combat the causes of this inflammation (such as obesity [292], smoking [239], physical
inactivity [240] and air pollution [229]). Inflammatory pathways are under investigation
as potential therapeutic targets for cardiovascular diseases; the results of the trials of
anti-inflammatory agents such as methotrexate (CIRT) [233] and canakinumab, a hu-
man monoclonal antibody that selectively neutralizes interleukin-1β (CANTOS) [234], are
awaited.
Finally, this thesis has brought to light the limitations of electronic health record data
and the need for better systems that enable information to be recorded easily, accurately,
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and contemporaneously. Clinicians will be more willing to enter high quality information if
they see a benefit in making it easier to look after their patients. Efforts to improve user
interfaces and standardise the clinical content of electronic health records are extremely
important [273], both for clinical care and research utility of the data.
10.3 Conclusion
A set of tools were developed to assist the process of converting raw electronic health
records into a research-ready format. Counts of leukocyte subtypes are differentially
associated with the short and long term risk of different initial presentations of cardiovas-
cular diseases. Leukocyte counts should be investigated for use in cardiovascular risk
prediction models, and inflammatory pathways should be further developed as therapeu-
tic targets for cardiovascular diseases, both directly (using medication) and indirectly (by
eliminating factors that cause or contribute to inflammation).
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